<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006501" GROUP_ID="HAEMATOL" ID="021806101220465057" MERGED_FROM="" MODIFIED="2008-08-12 10:04:31 +0200" MODIFIED_BY="Nicole Skoetz" REVIEW_NO="1" REVMAN_SUB_VERSION="5.0.15" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="2.2">
<COVER_SHEET MODIFIED="2008-08-12 10:04:31 +0200" MODIFIED_BY="Nicole Skoetz">
<TITLE>Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation</TITLE>
<CONTACT>
<PERSON ID="603E1C0082E26AA20178986B1C03D221" MODIFIED="2008-07-21 16:32:48 +0200" MODIFIED_BY="Nicole Skoetz" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Pia</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Raanani</LAST_NAME>
<SUFFIX/>
<POSITION>Head of Hemato-Oncology</POSITION>
<EMAIL_1>praanani@012.net.il</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Institute of Hematology</DEPARTMENT>
<ORGANISATION>Rabin Medical Center</ORGANISATION>
<ADDRESS_1>Institute of Hematology, Rabin Medical Center, Campus Beilinson</ADDRESS_1>
<ADDRESS_2/>
<CITY>Petah-Tikva</CITY>
<ZIP>49100</ZIP>
<REGION/>
<COUNTRY CODE="IL">Israel</COUNTRY>
<PHONE_1>+972-3-5462621</PHONE_1>
<PHONE_2/>
<FAX_1>+972-3- 9240145</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2008-07-21 16:32:38 +0200" MODIFIED_BY="Nicole Skoetz">
<PERSON ID="603E1C0082E26AA20178986B1C03D221" MODIFIED="2008-07-21 16:32:01 +0200" MODIFIED_BY="Nicole Skoetz" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Pia</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Raanani</LAST_NAME>
<SUFFIX/>
<POSITION>Head of Hemato-Oncology</POSITION>
<EMAIL_1>praanani@012.net.il</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Institute of Hematology</DEPARTMENT>
<ORGANISATION>Rabin Medical Center</ORGANISATION>
<ADDRESS_1>Institute of Hematology, Rabin Medical Center, Campus Beilinson</ADDRESS_1>
<ADDRESS_2/>
<CITY>Petah-Tikva</CITY>
<ZIP>49100</ZIP>
<REGION/>
<COUNTRY CODE="IL">Israel</COUNTRY>
<PHONE_1>+972-3-5462621</PHONE_1>
<PHONE_2/>
<FAX_1>+972-3- 9240145</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13692" MODIFIED="2008-07-21 16:32:19 +0200" MODIFIED_BY="Nicole Skoetz" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Anat</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Gafter-Gvili</LAST_NAME>
<SUFFIX/>
<POSITION>Physician</POSITION>
<EMAIL_1>gn44@bezeqint.net</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Medicine E</DEPARTMENT>
<ORGANISATION>Beilinson Campus, Rabin Medical Center</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2>Kaplan</ADDRESS_2>
<CITY>Petah-Tiqva</CITY>
<ZIP>49100</ZIP>
<REGION/>
<COUNTRY CODE="IL">Israel</COUNTRY>
<PHONE_1>+972 3 9376508</PHONE_1>
<PHONE_2/>
<FAX_1>+972 3 9276512</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="12314" MODIFIED="2008-07-21 16:32:25 +0200" MODIFIED_BY="Nicole Skoetz" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Mical</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Paul</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>pil1pel@zahav.net.il</EMAIL_1>
<EMAIL_2>mica@zahav.net.il; MichalP2@clalit.org.il; paulm@post.tau.ac.il</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Infectious Diseases Unit and Department of Medicine E</DEPARTMENT>
<ORGANISATION>Rabin Medical Center</ORGANISATION>
<ADDRESS_1>Beilinson Campus</ADDRESS_1>
<ADDRESS_2/>
<CITY>Petah-Tikva</CITY>
<ZIP>49100</ZIP>
<REGION/>
<COUNTRY CODE="IL">Israel</COUNTRY>
<PHONE_1>+972 3 937 7512</PHONE_1>
<PHONE_2/>
<FAX_1>+972 3 937 7513</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="603E1DC582E26AA20178986BD1541BEE" MODIFIED="2008-07-21 16:32:28 +0200" MODIFIED_BY="Nicole Skoetz" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Isaac</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Ben-Bassat</LAST_NAME>
<SUFFIX/>
<POSITION>Professor in Hematology</POSITION>
<EMAIL_1>benbasat@post.tau.ac.il</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Institute of Hematology</DEPARTMENT>
<ORGANISATION>Sheba Medical Center, Tel-Hashomer</ORGANISATION>
<ADDRESS_1>Institute of Hematology, Sheba Medical Center</ADDRESS_1>
<ADDRESS_2/>
<CITY>Tel-Hashomer</CITY>
<ZIP>52621</ZIP>
<REGION/>
<COUNTRY CODE="IL">Israel</COUNTRY>
<PHONE_1>+972-3- 5302564</PHONE_1>
<PHONE_2/>
<FAX_1>+972-3-5340167</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="12295" MODIFIED="2008-07-21 16:32:35 +0200" MODIFIED_BY="Nicole Skoetz" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Leonard</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Leibovici</LAST_NAME>
<SUFFIX/>
<POSITION>Head</POSITION>
<EMAIL_1>leibovic@post.tau.ac.il</EMAIL_1>
<EMAIL_2>leibovici@clalit.org.il</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Medicine E</DEPARTMENT>
<ORGANISATION>Beilinson Campus, Rabin Medical Center</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2>Kaplan</ADDRESS_2>
<CITY>Petah-Tiqva</CITY>
<ZIP>49100</ZIP>
<REGION/>
<COUNTRY CODE="IL">Israel</COUNTRY>
<PHONE_1>+972 3 9376501</PHONE_1>
<PHONE_2>+972 3 9376506</PHONE_2>
<FAX_1>+972 3 9376505</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="798DD99282E26AA200C1C7C4D8B3CCA8" MODIFIED="2008-07-21 16:32:38 +0200" MODIFIED_BY="Nicole Skoetz" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Ofer</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Shpilberg</LAST_NAME>
<SUFFIX/>
<POSITION>Head</POSITION>
<EMAIL_1>ofers2@clalit.org.il</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Institute of Hematology</DEPARTMENT>
<ORGANISATION>Rabin Medical Center</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Petah-Tikva</CITY>
<ZIP>49100</ZIP>
<REGION/>
<COUNTRY CODE="IL">Israel</COUNTRY>
<PHONE_1>972-3-937790-5/-6</PHONE_1>
<PHONE_2/>
<FAX_1>972-3-9240145</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-08-12 10:04:31 +0200" MODIFIED_BY="Nicole Skoetz">
<UP_TO_DATE>
<DATE DAY="22" MONTH="7" YEAR="2008"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="30" MONTH="4" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="" YEAR=""/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2007"/>
</DATES>
<WHATS_NEW MODIFIED="2008-07-21 16:37:23 +0200" MODIFIED_BY="Nicole Skoetz"/>
<HISTORY MODIFIED="2008-08-12 10:02:19 +0200" MODIFIED_BY="Nicole Skoetz"/>
<SOURCES_OF_SUPPORT MODIFIED="2008-08-11 15:28:04 +0200" MODIFIED_BY="Nicole Skoetz">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-08-11 15:33:48 +0200" MODIFIED_BY="Nicole Skoetz">
<SUMMARY MODIFIED="2008-08-11 15:29:17 +0200" MODIFIED_BY="Nicole Skoetz">
<TITLE MODIFIED="2008-08-11 15:29:17 +0200" MODIFIED_BY="Nicole Skoetz">The role of prophylactic immunoglobulins in hematological malignancies</TITLE>
<SUMMARY_BODY>
<P>Patients with hematological malignancies are prone to infections due to defects in their immune system. One of the main defects is a reduction in the level of immunoglobulins. For many years, the notion was that administration of pooled immunoglobulins from healthy donors might reverse this defect. However, randomized controlled trials showed different results in terms of prolongation of survival, reduction of infections and side effects of treatments. We conducted a systematic review assessing the role of administration of immunoglobulins from healthy donors as prophylaxis in patients with hematological malignancies. Our review showed that in the context of bone marrow transplantation the administration of immunoglobulins did not have an effect on survival or other outcomes. On the other hand, in patients with lymphoproliferative disorders like chronic lymphocytic leukemia or multiple myeloma, it reduced substantially the rate of infections. Despite their high cost, prophylactic immunoglobulins might prove cost-effective in this population.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-06-25 20:08:07 +0200" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND>
<P>Patients undergoing hematopoietic stem cell transplantation (HSCT) and those with lymphoproliferative disorders (LPD) have a higher incidence of infections due to secondary hypogammaglobulinemia. One approach is the prophylactic administration of intravenous immunoglobulins (IVIG). Randomized controlled trials (RCTs) showed conflicting results in terms of type, schedule, dose and hematological patients benefiting from IVIG. We therefore performed a systematic review and meta-analysis to evaluate the role of IVIG in these patients.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine whether prophylaxis with IVIG reduces mortality or affects other outcomes in patients with hematological malignancies.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-06-16 17:29:22 +0200" MODIFIED_BY="[Empty name]">
<P>PubMed (January 1966 to December 2007), CENTRAL (The Cochrane Library, up to 2007, issue 1), LILACS and conference proceedings published between 2002-2007 were searched. The terms "immunoglobulins" or "gammaglobulins" or specific gammaglobulins and similar and the terms "hematologic neoplasms" or "hematologic malignancies" or "transplant" or "autotransplant" or "allotransplant" or "bone marrow transplant" or "peripheral stem cell transplant" and similar were selected. References of all included trials and reviews identified were scanned for additional trials.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All RCTs comparing prophylaxis of IVIG with placebo, no treatment or another immunoglobulin preparation, different administration schedules or doses for patients with hematological malignancies were included. One author screened all abstracts identified through the search strategy and two reviewers independently inspected each reference identified by the search and applied inclusion criteria. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2008-06-25 20:08:07 +0200" MODIFIED_BY="[Empty name]">
<P>For each trial, results were expressed as relative risks (RR) with 95% confidence intervals (CI) for dichotomous data and weighted mean differences for continuous data. We conducted meta-analysis, where enough similar trials were available, using the fixed- effects model, unless significant heterogeneity was present. We performed sensitivity analyses to assess the effect of individual methodological quality measures on effect estimates, including allocation generation, concealment and blinding.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Forty trials were included: thirty included HSCT patients and ten included patients LPD. When polyvalent immunoglobulins or hyperimmune cytomegalovirus (CMV)-IVIG was compared to control for HSCT, there was no difference in all-cause mortality. Polyvalent immunoglobulins significantly reduced the risk for interstitial pneumonitis but increased the risk for veno-occlusive disease and adverse events. In LPD, no benefit in terms of mortality IVIG could be demonstrated but there was a decrease in clinically and microbiologically documented infections.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>In patients undergoing HSCT, routine prophylaxis with IVIG is not supported. Its use may be considered in LPD patients with hypogammaglobulinemia and recurrent infections, for reduction of clinically documented infections.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-08-11 15:33:48 +0200" MODIFIED_BY="Nicole Skoetz">
<BACKGROUND MODIFIED="2008-06-25 20:08:07 +0200" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2008-06-25 20:08:07 +0200" MODIFIED_BY="[Empty name]">
<P>Bone marrow transplantation (BMT) and hematopoietic stem cell transplantation (HSCT) compromise the immune system of patients due to the need for high doses of chemoradiotherapy prior to infusion of the donor stem cells. Multiple immunological deficiencies, including T- and B-cell abnormalities and hypogammaglobulinemia (low immunoglobulin levels) predispose patients to a high risk of developing a variety of infections. This period of immunological incompetence usually lasts from six to 12 months. In some subsets of patients [those with chronic graft-versus-host disease (GVHD); recipients of unrelated transplants and older patients] persistent T- and B-cell abnormalities may be seen for years, despite normal serum immunoglobulin levels (<LINK REF="REF-Siadak-1994" TYPE="REFERENCE">Siadak 1994</LINK>). These abnormalities are less prominent in autologous transplantations. Due to the deficient immune function, BMT recipients are highly susceptible to bacterial, viral and fungal infections. In particular, cytomegalovirus (CMV) is a serious problem for these immunocompromised patients.<BR/>Patients with secondary hypogammaglobulinemia due to underlying low-grade B-cell lymphoproliferative disorders (LPD) have a higher incidence of serious bacterial infections, in particular those caused by encapsulated bacteria, when compared with an age-matched population (<LINK REF="REF-Besa-1992" TYPE="REFERENCE">Besa 1992</LINK>; <LINK REF="REF-Jim-1956" TYPE="REFERENCE">Jim 1956</LINK>). Infections are the major cause of morbidity and mortality in chronic lymphocytic leukemia (CLL) (<LINK REF="STD-Jurlander-1994" TYPE="STUDY">Jurlander 1994</LINK>). The incidence varies, but up to 65% of patients die from infection-related events (<LINK REF="REF-Hansen-1973" TYPE="REFERENCE">Hansen 1973</LINK>). Factors underlying the increased susceptibility to infections are many and complex. A major factor is the decreased capacity to produce potent immunoglobulins, often reflected by a certain degree of hypogammaglobulinemia seen in the majority of patients during their disease (<LINK REF="REF-Fairley-1961" TYPE="REFERENCE">Fairley 1961</LINK>; <LINK REF="STD-Jurlander-1994" TYPE="STUDY">Jurlander 1994</LINK>; <LINK REF="REF-Rozman-1988" TYPE="REFERENCE">Rozman 1988</LINK>).<BR/>Life threatening infections cause significant morbidity and mortality in patients with multiple myeloma (MM) with a fatality rate of 30% (<LINK REF="REF-Chapel-1994a" TYPE="REFERENCE">Chapel 1994a</LINK>; <LINK REF="REF-Perri-1981" TYPE="REFERENCE">Perri 1981</LINK>; <LINK REF="REF-Twomey-1973" TYPE="REFERENCE">Twomey 1973</LINK>). Since in MM patients host-defense defects are multifactorial, infections associated with the initial phase of the disease and relapse are of viral, fungal, and bacterial etiology (<LINK REF="REF-Perri-1981" TYPE="REFERENCE">Perri 1981</LINK>; Chapel 1994b; <LINK REF="REF-Savage-1982" TYPE="REFERENCE">Savage 1982</LINK>). Infections in patients in stable or plateau phase are those typical of depressed humoral immunity, predominantly due to Streptococcus pneumoniae or Haemophilus influenza (<LINK REF="REF-Chapel-1994a" TYPE="REFERENCE">Chapel 1994a</LINK>; <LINK REF="REF-Espersen-1984" TYPE="REFERENCE">Espersen 1984</LINK>; <LINK REF="REF-Savage-1982" TYPE="REFERENCE">Savage 1982</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2008-05-27 13:21:46 +0200" MODIFIED_BY="Nicole Skoetz">
<P>Since the defective immune response among hematological cancer patients is due in part to immunoglobulin deficiency, one approach for prevention of infections is the administration of intravenous immunoglobulins (IVIG). Polyvalent human immunoglobulin preparations were one of the first plasma proteins prepared in a purified state as a therapeutic drug. Since the early 1980s safer IVIG preparations became available. IVIG is prepared from pooled human plasma. IVIG contains concentrated IgG with normal plasma ratios of IgG1 and IgG2 but lower percentages of IgG3 and IgG4 and only trace amounts of IgA and IgM. Hyperimmune IVIG is purified from donor plasma selected for high titer toward a specific pathogen like CMV.<BR/>Several large controlled trials showed that administration of IVIG prevented infection in patients undergoing BMT (<LINK REF="STD-Cordonnier-2003" TYPE="STUDY">Cordonnier 2003</LINK>; <LINK REF="STD-Sullivan-1990" TYPE="STUDY">Sullivan 1990</LINK>; <LINK REF="REF-Winston-1987a" TYPE="REFERENCE">Winston 1987a</LINK>), especially CMV infection, and interstitial pneumonia (<LINK REF="STD-Cordonnier-2003" TYPE="STUDY">Cordonnier 2003</LINK>) and reduced the incidence of acute graft versus host disease (GVHD) (<LINK REF="STD-Sullivan-1990" TYPE="STUDY">Sullivan 1990</LINK>; <LINK REF="REF-Sullivan-1996a" TYPE="REFERENCE">Sullivan 1996a</LINK>; <LINK REF="STD-Cordonnier-2003" TYPE="STUDY">Cordonnier 2003</LINK>; <LINK REF="STD-Abdel_x002d_Mageed-1999" TYPE="STUDY">Abdel-Mageed 1999</LINK>; <LINK REF="REF-Pirofsky-1984" TYPE="REFERENCE">Pirofsky 1984</LINK>; <LINK REF="REF-Winston-1990" TYPE="REFERENCE">Winston 1990</LINK>; <LINK REF="REF-Bass-1993" TYPE="REFERENCE">Bass 1993</LINK>; <LINK REF="REF-Winston-1987a" TYPE="REFERENCE">Winston 1987a</LINK>; <LINK REF="REF-Winston-1987b" TYPE="REFERENCE">Winston 1987b</LINK>; <LINK REF="REF-Wingard-1990" TYPE="REFERENCE">Wingard 1990</LINK>; <LINK REF="STD-Bowden-1986" TYPE="STUDY">Bowden 1986</LINK>; <LINK REF="REF-Graham_x002d_Pole-1988" TYPE="REFERENCE">Graham-Pole 1988</LINK>; <LINK REF="STD-Petersen-1987" TYPE="STUDY">Petersen 1987</LINK>; <LINK REF="STD-Wolff-1993" TYPE="STUDY">Wolff 1993</LINK>; Nasman Bjork 1999). However an improvement in survival was reported in only a few studies (<LINK REF="REF-Graham_x002d_Pole-1988" TYPE="REFERENCE">Graham-Pole 1988</LINK>; <LINK REF="STD-Wolff-1993" TYPE="STUDY">Wolff 1993</LINK>; <LINK REF="REF-Guglielmo-1994" TYPE="REFERENCE">Guglielmo 1994</LINK>) and the type, schedule, dose and patients benefiting form IVIG have not been established.<BR/>Criteria have been suggested for the use of IVIG among patients with LPD. These include: low levels of protective antibodies to encapsulated organisms, viruses, or bacterial toxins; poor or absent antibody response to immunization or infection; severe hypogammaglobulinemia (serum IgG &lt; 200 mg/dL); and increased rate, severity, and duration of infections, especially infections of the respiratory system or with encapsulated organisms such as Pneumococcus, Haemophilus influenzae, and Meningococcus (<LINK REF="REF-Chapel-1994a" TYPE="REFERENCE">Chapel 1994a</LINK>; <LINK REF="REF-Chapel-1994b" TYPE="REFERENCE">Chapel 1994b</LINK>). However, these criteria are not based on empirical evidence and are not practiced universally.<BR/>IVIG exposes patients to the potential transmission of new pathogens. It is very expensive in high doses and is not always well tolerated. The incidence of adverse effects is reported to be between 1% and 15%, although fewer than 5% of patients experience clinically significant reactions.</P>
</INTERVENTION>
<IMPORTANCE MODIFIED="2008-05-27 13:22:10 +0200" MODIFIED_BY="Nicole Skoetz">
<P>A meta-analysis of 12 randomized controlled trials of IVIG prophylaxis in patients undergoing BMT showed a significant reduction in overall mortality, CMV pneumonia and non-CMV interstitial pneumonia in patients receiving IVIG prophylaxis (<LINK REF="REF-Bass-1993" TYPE="REFERENCE">Bass 1993</LINK>). Another meta-analysis of 18 randomized controlled trials supported the use of IVIG in the prevention of symptomatic CMV disease in transplant recipients including both bone marrow and solid organ transplant recipients (<LINK REF="REF-Glowacki-1993" TYPE="REFERENCE">Glowacki 1993</LINK>; <LINK REF="REF-Glowacki-1994" TYPE="REFERENCE">Glowacki 1994</LINK>). More than 2300 patients were enrolled in the trials included in a systematic review by Sokos at al. based on MEDLINE search and references of all relevant studies and review articles (<LINK REF="REF-Sokos-2002" TYPE="REFERENCE">Sokos 2002</LINK>). The authors summarized their review by stating that trials examining the utility of IVIG in HSCT show variability in terms of trial design, patients and treatments. According to their search, the role of IVIG in the prevention of CMV infection as well as prophylaxis for GVHD is uncertain.<BR/>Despite the controversy about the benefit of IVIG in BMT, this agent has been given as part of most transplantation protocols for many years and a National Institutes of Health (NIH) consensus panel endorsed the use of IVIG after allogeneic BMT (<LINK REF="STD-Sullivan-1990" TYPE="STUDY">Sullivan 1990</LINK>; <LINK REF="REF-Winston-1987a" TYPE="REFERENCE">Winston 1987a</LINK>; <LINK REF="STD-Bowden-1986" TYPE="STUDY">Bowden 1986</LINK>; <LINK REF="REF-Graham_x002d_Pole-1988" TYPE="REFERENCE">Graham-Pole 1988</LINK>; <LINK REF="STD-Petersen-1987" TYPE="STUDY">Petersen 1987</LINK>; <LINK REF="STD-Winston-2001" TYPE="STUDY">Winston 2001</LINK>; <LINK REF="REF-Consensus-IVIG-1990" TYPE="REFERENCE">Consensus IVIG 1990</LINK>; <LINK REF="STD-Winston-1993" TYPE="STUDY">Winston 1993</LINK>; <LINK REF="STD-Condie-1984" TYPE="STUDY">Condie 1984</LINK>).<BR/>No recent meta-analysis assessed the compiled evidence available to date. The effect of IVIG on overall survival among bone marrow transplant patients and other hemato-oncological patients is unclear. We therefore performed a systematic review and meta-analysis of IVIG prophylaxis in hematological malignancies.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES>
<P>To determine whether the prophylactic administration of IVIG reduces mortality in patients with hematological malignancies and hematopoietic stem cell transplantation or affect other patient-related outcomes, including the incidence of infections, hospitalization, GVHD and others in patients with hematological malignancies and hematopoietic stem cell transplantation.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-06-25 20:08:07 +0200" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2008-06-25 20:08:07 +0200" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>Randomized controlled trials. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Patients with hematological malignancies - CLL or MM, and patients undergoing BMT or HSCT given IVIG for prophylaxis (and not as treatment of suspected or documented infections). We conducted separate analyses for patients with CLL or MM and patients following allogeneic and autologous HSCT.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-06-16 17:29:50 +0200" MODIFIED_BY="[Empty name]">
<P>Administration of intravenous or intramuscular immunoglobulins ( polyclonal or monoclonal), hyperimmune immunoglobulin preparations or monoclonal antibodies vs. placebo, no treatment or another immunoglobulin preparation, administration schedule or dose. Pooled immunoglobulins were assessed separately from specific hyperimmune immunoglobulin preparations.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-06-25 20:08:07 +0200" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-05-27 13:24:09 +0200" MODIFIED_BY="Nicole Skoetz">
<UL>
<LI>All cause mortality</LI>
<LI>Clinically documented infections, applying standard definitions (<LINK REF="REF-Consensus-IVIG-1990" TYPE="REFERENCE">Consensus IVIG 1990</LINK>).</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-06-25 20:08:07 +0200" MODIFIED_BY="[Empty name]">
<UL>
<LI>Microbiologically documented infections</LI>
<UL>
<LI>CMV infections as defined in each study.</LI>
<LI>Other herpesvirus infections</LI>
<LI>Bacterial infections</LI>
</UL>
<LI>Bacteremia</LI>
<LI>Infection-related mortality</LI>
<LI>Acute and chronic GVHD, veno-occlusive disease and interstitial pneumonia in allogeneic bone marrow transplants</LI>
<LI>Disease relapse</LI>
<LI>Adverse events (side effects) and complications - i.e.</LI>
<UL>
<LI>Immediate adverse events: allergic reaction, anaphylaxis, fever and chills</LI>
<LI>Delayed adverse events: renal, pulmonary, aseptic meningitis, arthritis, cerebral infarction, hyperviscosity, hemolysis, and leukopenia</LI>
<LI>Late adverse events: transmission of infectious agents</LI>
</UL>
</UL>
<P>For patients with CLL/MM we planned to extract outcomes at end of follow up, since the nature of the disease and its treatment mandate a prolonged follow up. For patients following HSCT we planned to assess the main outcomes at 100 days post transplantation (time of engraftment and recovery from the procedure) and at the longest available follow-up. In addition, we tried to extract survival data as time to event data.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-06-16 18:00:44 +0200" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2008-06-16 18:00:44 +0200" MODIFIED_BY="[Empty name]">
<P>We conducted a comprehensive search strategy to identify both published and unpublished trials, with no restriction on language or study years. We searched PubMed ; CENTRAL ; LILACS; references of all included studies and major reviews (for search strategy see Appendix 1).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-05-27 13:29:12 +0200" MODIFIED_BY="Nicole Skoetz">
<P>In addition, we searched conference proceedings published between 2002-2007 for recently conducted, unpublished trials:</P>
<UL>
<LI>Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); </LI>
<LI>European Congress of Clinical Microbiology and Infectious Diseases (available at http://www.akm.ch/eccmid2001-2004/);</LI>
<LI>
Annual Meeting of the American Society of Hematology (available at http://www.hematology.org/) </LI>
<LI>and the annual Meeting of the European Hematology Association (available at http://www.ehaweb.org/).</LI>
</UL>
<P>We searched the following trial databases for ongoing and unpublished trials: </P>
<UL>
<LI>UKCCCR Register of Cancer Trials (http://www.ctu.mrc.ac.uk/ukcccr/home.html); </LI>
<LI>PDQ (Physician Data Query) database of the National Cancer Institute (http://www.cancer.gov/search/clinical_trials/); </LI>
<LI>and the National Institutes of Health database (http://clinicaltrials.gov/).</LI>
</UL>
<P>We searched the web for new drug application (NDA) documents of the US Food and Drug Administration, which may include unpublished studies.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-06-25 20:08:07 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Study selection<BR/>
</B>One author screened all abstracts identified through our search strategy and selected articles for full-text inspection (PR). Two authors applied inclusion criteria to all retrieved articles (PR, AGG).</P>
<P>
<B>Quality assessment </B>
<BR/>We used an individual component approach, since the use of composite scales has yielded conflicting results. We assessed: allocation concealment (A-adequate, B - unclear, C- inadequate, D - not used), allocation generation (same), blinding, intention to treat analysis, and predetermination of outcome assessment time. We used the definitions detailed in the Cochrane handbook to determine allocation concealment and generation.</P>
<P>
<B>Data collection<BR/>
</B>Data from included trials were independently extracted by two reviewers into a data extraction sheet (PR, AGG). Differences in the data extracted were resolved by discussion with a third reviewer (MP, LL, OS or IB). Justification for excluding studies from the review was documented. The first or corresponding author of each included study was contacted for clarifications and further information. Authors of all included trials, and trials in assessment for inclusion, were contacted for clarifications and further information. Data regarding all-cause mortality and randomization methods were requested primarily.</P>
<P>
<B>We extracted the following data from included studies (see table of: "Characteristics of included studies") :</B>
</P>
<P>
<U>Characteristics of trials:</U>
</P>
<UL>
<LI>Study years (years during which the study was conducted)</LI>
<LI>Location (where the study was conducted)</LI>
<LI>Setting of trial: outpatient, inpatient, isolation precautions</LI>
<LI>Multi-center vs. single institute</LI>
<LI>Publication status</LI>
<LI>Duration of follow up: duration of planned IVIG treatment, planned duration of follow up after intervention, actual follow-up in study</LI>
</UL>
<P>
<U>Methodological quality assessment:</U>
</P>
<UL>
<LI>Allocation concealment:</LI>
<UL>
<LI>adequate (A) for example centralized (e.g. allocation by a central office unaware of subject characteristics) or pharmacy-controlled randomization, pre-numbered or coded identical containers which are administered serially to participants, on-site computer system combined with allocations kept in a locked unreadable computer file that can be accessed only after the characteristics of an enrolled participant have been entered, sequentially numbered, sealed, opaque envelopes</LI>
<LI>unclear (B)</LI>
<LI>inadequate (C) for example non-concealed table, non-opaque envelopes, date of birth, date of admission, hospital numbers or alternation</LI>
</UL>
<LI>Allocation generation:</LI>
<UL>
<LI>adequate (A) for example computer generated, random number table</LI>
<LI>unclear (B)</LI>
<LI>inadequate (C) for example date of birth, date of admission, hospital numbers or alternation</LI>
</UL>
<LI>Blinding:</LI>
<UL>
<LI>caregiver</LI>
<LI>patient</LI>
<LI>outcome assessor</LI>
</UL>
</UL>
<P>
<U>Characteristics of participants and treatment:</U>
</P>
<UL>
<LI>Number of participants in each group</LI>
<LI>Underlying hematological malignancy</LI>
<LI>Disease status</LI>
</UL>
<P>
<U>Bone marrow transplantation:</U>
</P>
<UL>
<LI>none</LI>
<LI>autologous</LI>
<LI>allogeneic - sibling, unrelated donor, haplo-identical</LI>
<LI>syngeneic</LI>
<LI>myeloablative vs. non-myeloablative</LI>
<LI>T-cell depletion performed</LI>
<LI>Type of graft</LI>
<LI>CMV status of donor and recipient</LI>
</UL>
<P>
<U>Lymphoproliferative disorders</U>
</P>
<UL>
<LI>Stage of disease</LI>
<LI>Time from diagnosis</LI>
<LI>Paraprotein levels</LI>
<LI>Age and percentage of children &lt;16 years</LI>
<LI>Baseline immunoglobulin levels</LI>
<LI>Chemotherapy protocol used in study</LI>
<LI>Steroid use</LI>
<LI>Prophylaxis measures used in study other than the intervention and isolation precautions including: G-CSF, antibacterial, antifungal, anti-Pneumocystis jirovecii and antiviral prophylaxis and type</LI>
</UL>
<P>
<U>Characteristics of interventions:</U>
</P>
<UL>
<LI>Type of immunoglobulin</LI>
<LI>Dose of immunoglobulin</LI>
<LI>Schedule of administration</LI>
<LI>Total duration of intervention</LI>
</UL>
<P>Characteristics of outcome measures as defined above. Outcomes were extracted preferentially by intention-to-treat, including all individuals randomized in the outcome assessment. Where impossible, data by available case analysis were extracted. In the main analysis all studies were combined. Secondary, per-protocol analyses were conducted, using the protocol definitions used in each study. We compared the effect estimate obtained from intention to treat studies to that obtained from studies reporting an available case analysis. For trials of IVIG prophylaxis post HSCT we planned to assess all-cause mortality at two time points, since they reflect different causes for death: mortality at three to four months post SCT - as this is a composite of infections, acute rejection, treatment-related mortality and mortality at one to two years post SCT - as this is composite of disease-related mortality, chronic rejection and the above. This was done whenever possible, but in practice, the trials reported on mortality only at a single time point most commonly and this point in time varied between the trials.</P>
<P>
<U>Data synthesis</U>
<BR/>Results for dichotomous data were expressed as relative risks (RR) with 95% confidence intervals (CI) and pooled using a fixed effect model, unless significant heterogeneity was present. In this case we considered the appropriateness of a meta-analysis and pooled trials using a random effects model. As we did not obtain data from the primary studies on time to event data, hazard ratios for mortality or continuous outcomes, we did not perform these meta-analyses. The number of patients needed to treat (NNT) was calculated as 1/risk difference. The major comparisons were between immunoglobulin vs. placebo / no treatment and pooled vs. monoclonal immunoglobulins.</P>
<P>We assessed for heterogeneity in the results of the trials using a chi-squared test of heterogeneity (P &lt; 0.1) and the I<SUP>2</SUP> measure of inconsistency. We searched for reasons for heterogeneity assessing the following patient subgroups:</P>
<UL>
<LI>Different IVIG doses and administration schedules</LI>
<LI>Use of antifungal prophylaxis.</LI>
</UL>
<P>Although pre-planned, we did not perform subgroup analyses of children, adults, according to CMV sero-status of bone marrow transplant recipients, or according to CMV screening or pre-emptive treatment since we did not have enough participants for each subgroup or the necessary data.</P>
<P>We performed sensitivity analyses to assess the effect of individual methodological quality measures on effect estimates, including allocation generation, concealment and blinding. We visually examined funnel plots for mortality and clinically documented infections (1/standard error plotted against RR) in order to estimate potential selection bias (publication or other).</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-08-11 15:33:48 +0200" MODIFIED_BY="Nicole Skoetz">
<STUDY_DESCRIPTION MODIFIED="2008-07-21 22:26:32 +0200" MODIFIED_BY="[Empty name]">
<P>The computerized search strategy identified 855 studies, (including 8 abstracts from conference proceedings) not all relevant for the present review. These were screened for randomized or quasi-randomized controlled trials according to protocol and their references were searched in order to identify additional references. 73 studies were considered for this review, including 8 abstracts from conference proceedings (for QUORUM diagram see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
<P>We excluded 28 studies for the following reasons (Table of excluded studies): The design of 23 was incompatible with inclusion criteria (13 non-randomised controlled trials, 2 review articles, 1 meta-analysis, 1 phase I study which was not a RCT, 3 retrospective studies and 3 reports of subcategories of other studies (<LINK REF="STD-Aulitzky-1991" TYPE="STUDY">Aulitzky 1991</LINK>; <LINK REF="STD-Bunch-1988" TYPE="STUDY">Bunch 1988</LINK>; <LINK REF="STD-Chapel-1992" TYPE="STUDY">Chapel 1992</LINK>; <LINK REF="STD-Chapel-1993" TYPE="STUDY">Chapel 1993</LINK>; <LINK REF="STD-Cortez-2002" TYPE="STUDY">Cortez 2002</LINK>; <LINK REF="STD-Elfenbein-1989" TYPE="STUDY">Elfenbein 1989</LINK>; <LINK REF="STD-Esperou-2004" TYPE="STUDY">Esperou 2004</LINK>; <LINK REF="STD-Fehir-1989" TYPE="STUDY">Fehir 1989</LINK>; <LINK REF="STD-Gamm-1994" TYPE="STUDY">Gamm 1994</LINK>; <LINK REF="STD-Gerein-1989" TYPE="STUDY">Gerein 1989</LINK>; <LINK REF="STD-Graham-Pole-1988" TYPE="STUDY">Graham Pole 1988</LINK>; <LINK REF="STD-Jurlander-1994" TYPE="STUDY">Jurlander 1994</LINK>; <LINK REF="STD-Klaesson-1995" TYPE="STUDY">Klaesson 1995</LINK>; <LINK REF="STD-Messori-1994" TYPE="STUDY">Messori 1994</LINK>; <LINK REF="STD-Nasman--Bjork-1999" TYPE="STUDY">Nasman Bjork 1999</LINK>; , <LINK REF="STD-Nurnberger-1988" TYPE="STUDY">Nurnberger 1988</LINK>; <LINK REF="STD-Petersen-1987" TYPE="STUDY">Petersen 1987</LINK>; <LINK REF="STD-Rand-1991" TYPE="STUDY">Rand 1991</LINK>; <LINK REF="STD-Spitzer-1992" TYPE="STUDY">Spitzer 1992</LINK>; <LINK REF="STD-Sullivan-1996" TYPE="STUDY">Sullivan 1996</LINK>; <LINK REF="STD-Sullivan-1998" TYPE="STUDY">Sullivan 1998</LINK>; <LINK REF="STD-Terada-1980" TYPE="STUDY">Terada 1980</LINK>; <LINK REF="STD-Vu-Van-1985" TYPE="STUDY">Vu Van 1985</LINK>), 3 studies were excluded since they reported on immunoglobulin prophylaxis in patients treated for acute leukemia or solid tumors (<LINK REF="STD-Bode-1986" TYPE="STUDY">Bode 1986</LINK>, <LINK REF="STD-Collins-1991" TYPE="STUDY">Collins 1991</LINK>, <LINK REF="STD-Gimesi-1992" TYPE="STUDY">Gimesi 1992</LINK>), 1 study reported on patients with primary hypogammaglobulinemia who received standard-dose immunoglobulin therapy (<LINK REF="STD-Eijkhout-2001" TYPE="STUDY">Eijkhout 2001</LINK>) and 1 study reported on the results of oral and not parenterally administered immunoglobulins (<LINK REF="STD-Copelan-1994" TYPE="STUDY">Copelan 1994</LINK> ).</P>
<P>Five reports were identified as duplicate publications and were considered under their primary reference (<LINK REF="REF-O_x0027_Reilly-1983" TYPE="REFERENCE">O'Reilly 1983</LINK>; <LINK REF="REF-Griffiths-1989" TYPE="REFERENCE">Griffiths 1989</LINK>; <LINK REF="REF-Kubaneck-1985" TYPE="REFERENCE">Kubaneck 1985</LINK>; <LINK REF="REF-Jackson-1993" TYPE="REFERENCE">Jackson 1993</LINK>; <LINK REF="REF-Winston-1985" TYPE="REFERENCE">Winston 1985</LINK>).<BR/>Forty trials were included in our review. Of them 18 studies were multicenter studies (<LINK REF="STD-Cordonnier-2003" TYPE="STUDY">Cordonnier 2003</LINK>; <LINK REF="STD-Winston-2001" TYPE="STUDY">Winston 2001</LINK>; <LINK REF="STD-Ruutu-1997" TYPE="STUDY">Ruutu 1997</LINK>; <LINK REF="STD-Abdel_x002d_Mageed-1999" TYPE="STUDY">Abdel-Mageed 1999</LINK>; <LINK REF="STD-Boeckh-2001" TYPE="STUDY">Boeckh 2001</LINK>; <LINK REF="STD-Sklenar-1993" TYPE="STUDY">Sklenar 1993</LINK>; <LINK REF="STD-Salmon-1967" TYPE="STUDY">Salmon 1967</LINK>; <LINK REF="STD-Chapel-1994c" TYPE="STUDY">Chapel 1994c</LINK>; <LINK REF="STD-Wolff-1993" TYPE="STUDY">Wolff 1993</LINK>; <LINK REF="STD-Molica-1996" TYPE="STUDY">Molica 1996</LINK>; <LINK REF="STD-Chapel-1994" TYPE="STUDY">Chapel 1994</LINK>; <LINK REF="STD-Cooperative-CLL-1988" TYPE="STUDY">Cooperative CLL 1988</LINK>; <LINK REF="STD-Condie-1984" TYPE="STUDY">Condie 1984</LINK>; <LINK REF="STD-Boughton-1995" TYPE="STUDY">Boughton 1995</LINK>; <LINK REF="STD-Ringden-1987" TYPE="STUDY">Ringden 1987</LINK>; <LINK REF="STD-Jacobsen-1985" TYPE="STUDY">Jacobsen 1985</LINK>; <LINK REF="STD-Graham-Pole-1990" TYPE="STUDY">Graham Pole 1990</LINK>; <LINK REF="STD-Sullivan-2000" TYPE="STUDY">Sullivan 2000</LINK>) and 22 were single center trials (<LINK REF="STD-Zikos-1998" TYPE="STUDY">Zikos 1998</LINK>; <LINK REF="STD-Winston-1982" TYPE="STUDY">Winston 1982</LINK>; <LINK REF="STD-Meyers-1983" TYPE="STUDY">Meyers 1983</LINK>; <LINK REF="STD-Winston-1993" TYPE="STUDY">Winston 1993</LINK>; <LINK REF="STD-Poynton-1992" TYPE="STUDY">Poynton 1992</LINK>; <LINK REF="STD-Filipovich-1992" TYPE="STUDY">Filipovich 1992</LINK>; <LINK REF="STD-Peltier-1992" TYPE="STUDY">Peltier 1992</LINK>;<LINK REF="STD-Feinstein-1999" TYPE="STUDY">Feinstein 1999</LINK>; <LINK REF="STD-Musto-1995" TYPE="STUDY">Musto 1995</LINK>; <LINK REF="STD-Bowden-1991" TYPE="STUDY">Bowden 1991</LINK>; <LINK REF="STD-Winston-1987" TYPE="STUDY">Winston 1987</LINK>; <LINK REF="STD-Bordigoni-1987" TYPE="STUDY">Bordigoni 1987</LINK>; <LINK REF="STD-Winston-1984" TYPE="STUDY">Winston 1984</LINK>; <LINK REF="STD-Sullivan-1990" TYPE="STUDY">Sullivan 1990</LINK>; <LINK REF="STD-Lum-1994" TYPE="STUDY">Lum 1994</LINK>; <LINK REF="STD-Hargreaves-1992" TYPE="STUDY">Hargreaves 1992</LINK>; <LINK REF="STD-Serrano-1999" TYPE="STUDY">Serrano 1999</LINK>; <LINK REF="STD-Raiola-2002" TYPE="STUDY">Raiola 2002</LINK>; <LINK REF="STD-Ustun-1998" TYPE="STUDY">Ustun 1998</LINK>; <LINK REF="STD-Bowden-1986" TYPE="STUDY">Bowden 1986</LINK>; <LINK REF="STD-Gluck-1990" TYPE="STUDY">Gluck 1990</LINK>; <LINK REF="STD-Emanuel-1992" TYPE="STUDY">Emanuel 1992</LINK>). These studies randomized 4682 patients, mostly adults, and were published between the years 1967 to 2003.</P>
<P>4223 patients were included in the 30 studies assessing patients receiving prophylaxis after bone marrow or peripheral stem cell transplantation and 459 patients were included in the 10 studies assessing patients with lymphoproliferative disorders. One trial included multiple myeloma patients without specifying either the total number of patients or the number in each arm, therefore we could not include it in the analyses (Gluck 1990).</P>
<P>Of the 30 studies assessing immunoglobulin prophylaxis post transplant, 24 included patients undergoing allogeneic transplantation only (<LINK REF="STD-Cordonnier-2003" TYPE="STUDY">Cordonnier 2003</LINK>; <LINK REF="STD-Winston-2001" TYPE="STUDY">Winston 2001</LINK>; <LINK REF="STD-Ruutu-1997" TYPE="STUDY">Ruutu 1997</LINK>; <LINK REF="STD-Zikos-1998" TYPE="STUDY">Zikos 1998</LINK>; <LINK REF="STD-Abdel_x002d_Mageed-1999" TYPE="STUDY">Abdel-Mageed 1999</LINK>; <LINK REF="STD-Winston-1982" TYPE="STUDY">Winston 1982</LINK>; <LINK REF="STD-Meyers-1983" TYPE="STUDY">Meyers 1983</LINK>; <LINK REF="STD-Boeckh-2001" TYPE="STUDY">Boeckh 2001</LINK>; <LINK REF="STD-Winston-1993" TYPE="STUDY">Winston 1993</LINK>; <LINK REF="STD-Feinstein-1999" TYPE="STUDY">Feinstein 1999</LINK>; <LINK REF="STD-Bowden-1991" TYPE="STUDY">Bowden 1991</LINK>; <LINK REF="STD-Winston-1987" TYPE="STUDY">Winston 1987</LINK>; <LINK REF="STD-Condie-1984" TYPE="STUDY">Condie 1984</LINK>; <LINK REF="STD-Winston-1984" TYPE="STUDY">Winston 1984</LINK>; <LINK REF="STD-Ringden-1987" TYPE="STUDY">Ringden 1987</LINK>; <LINK REF="STD-Jacobsen-1985" TYPE="STUDY">Jacobsen 1985</LINK>; <LINK REF="STD-Lum-1994" TYPE="STUDY">Lum 1994</LINK>; <LINK REF="STD-Graham-Pole-1990" TYPE="STUDY">Graham Pole 1990</LINK>; <LINK REF="STD-Serrano-1999" TYPE="STUDY">Serrano 1999</LINK>; <LINK REF="STD-Raiola-2002" TYPE="STUDY">Raiola 2002</LINK>; <LINK REF="STD-Sullivan-2000" TYPE="STUDY">Sullivan 2000</LINK>; <LINK REF="STD-Ustun-1998" TYPE="STUDY">Ustun 1998</LINK>; <LINK REF="STD-Bowden-1986" TYPE="STUDY">Bowden 1986</LINK>; <LINK REF="STD-Emanuel-1992" TYPE="STUDY">Emanuel 1992</LINK>), 5 included patients who either received allogeneic or autologous transplant (<LINK REF="STD-Poynton-1992" TYPE="STUDY">Poynton 1992</LINK>; <LINK REF="STD-Filipovich-1992" TYPE="STUDY">Filipovich 1992</LINK>; <LINK REF="STD-Peltier-1992" TYPE="STUDY">Peltier 1992</LINK>; <LINK REF="STD-Bordigoni-1987" TYPE="STUDY">Bordigoni 1987</LINK>; <LINK REF="STD-Sullivan-1990" TYPE="STUDY">Sullivan 1990</LINK>) and 1 evaluated IVIG post-autologous transplantation only (<LINK REF="STD-Wolff-1993" TYPE="STUDY">Wolff 1993</LINK>). Among these studies, 18 evaluated the use of polyvalent immunoglobulins (<LINK REF="STD-Cordonnier-2003" TYPE="STUDY">Cordonnier 2003</LINK>; <LINK REF="STD-Winston-2001" TYPE="STUDY">Winston 2001</LINK>; <LINK REF="STD-Abdel_x002d_Mageed-1999" TYPE="STUDY">Abdel-Mageed 1999</LINK>; <LINK REF="STD-Winston-1993" TYPE="STUDY">Winston 1993</LINK>; <LINK REF="STD-Poynton-1992" TYPE="STUDY">Poynton 1992</LINK>; <LINK REF="STD-Filipovich-1992" TYPE="STUDY">Filipovich 1992</LINK>; <LINK REF="STD-Peltier-1992" TYPE="STUDY">Peltier 1992</LINK>; <LINK REF="STD-Wolff-1993" TYPE="STUDY">Wolff 1993</LINK>; <LINK REF="STD-Feinstein-1999" TYPE="STUDY">Feinstein 1999</LINK>; <LINK REF="STD-Winston-1987" TYPE="STUDY">Winston 1987</LINK>; <LINK REF="STD-Winston-1984" TYPE="STUDY">Winston 1984</LINK>; <LINK REF="STD-Sullivan-1990" TYPE="STUDY">Sullivan 1990</LINK>; <LINK REF="STD-Lum-1994" TYPE="STUDY">Lum 1994</LINK>; <LINK REF="STD-Graham-Pole-1990" TYPE="STUDY">Graham Pole 1990</LINK>; <LINK REF="STD-Raiola-2002" TYPE="STUDY">Raiola 2002</LINK>; <LINK REF="STD-Sullivan-2000" TYPE="STUDY">Sullivan 2000</LINK>; <LINK REF="STD-Ustun-1998" TYPE="STUDY">Ustun 1998</LINK>; <LINK REF="STD-Emanuel-1992" TYPE="STUDY">Emanuel 1992</LINK>), 9 evaluated hyperimmune CMV immunoglobulins (CMV-IVIG) (<LINK REF="STD-Ruutu-1997" TYPE="STUDY">Ruutu 1997</LINK>; <LINK REF="STD-Winston-1982" TYPE="STUDY">Winston 1982</LINK>; <LINK REF="STD-Meyers-1983" TYPE="STUDY">Meyers 1983</LINK>; <LINK REF="STD-Boeckh-2001" TYPE="STUDY">Boeckh 2001</LINK>; <LINK REF="STD-Bowden-1991" TYPE="STUDY">Bowden 1991</LINK>; <LINK REF="STD-Bordigoni-1987" TYPE="STUDY">Bordigoni 1987</LINK>; <LINK REF="STD-Ringden-1987" TYPE="STUDY">Ringden 1987</LINK>; <LINK REF="STD-Serrano-1999" TYPE="STUDY">Serrano 1999</LINK>; <LINK REF="STD-Bowden-1986" TYPE="STUDY">Bowden 1986</LINK>) and 3 compared between polyvalent immunoglobulins and hyperimmune CMV-IVIG (<LINK REF="STD-Zikos-1998" TYPE="STUDY">Zikos 1998</LINK>; <LINK REF="STD-Condie-1984" TYPE="STUDY">Condie 1984</LINK>; <LINK REF="STD-Jacobsen-1985" TYPE="STUDY">Jacobsen 1985</LINK>). Among the 18 studies evaluating polyvalent immunoglobulins administration, immunoglobulins were compared to placebo in 1 study (<LINK REF="STD-Sullivan-2000" TYPE="STUDY">Sullivan 2000</LINK>), to no intervention in 10 trials (<LINK REF="STD-Winston-1993" TYPE="STUDY">Winston 1993</LINK>; <LINK REF="STD-Poynton-1992" TYPE="STUDY">Poynton 1992</LINK>; <LINK REF="STD-Wolff-1993" TYPE="STUDY">Wolff 1993</LINK>; <LINK REF="STD-Feinstein-1999" TYPE="STUDY">Feinstein 1999</LINK>; <LINK REF="STD-Winston-1987" TYPE="STUDY">Winston 1987</LINK>; <LINK REF="STD-Winston-1984" TYPE="STUDY">Winston 1984</LINK>; <LINK REF="STD-Sullivan-1990" TYPE="STUDY">Sullivan 1990</LINK>; <LINK REF="STD-Lum-1994" TYPE="STUDY">Lum 1994</LINK>; <LINK REF="STD-Ustun-1998" TYPE="STUDY">Ustun 1998</LINK>; <LINK REF="STD-Emanuel-1992" TYPE="STUDY">Emanuel 1992</LINK>), different products and different doses were compared in 2 (<LINK REF="STD-Filipovich-1992" TYPE="STUDY">Filipovich 1992</LINK>; <LINK REF="STD-Peltier-1992" TYPE="STUDY">Peltier 1992</LINK>) and in 3 studies respectively (<LINK REF="STD-Winston-2001" TYPE="STUDY">Winston 2001</LINK>; <LINK REF="STD-Abdel_x002d_Mageed-1999" TYPE="STUDY">Abdel-Mageed 1999</LINK>; <LINK REF="STD-Graham-Pole-1990" TYPE="STUDY">Graham Pole 1990</LINK>), in 1 study both different doses and placebo were compared (<LINK REF="STD-Cordonnier-2003" TYPE="STUDY">Cordonnier 2003</LINK>) and in 1 study both different products and different doses were evaluated (<LINK REF="STD-Raiola-2002" TYPE="STUDY">Raiola 2002</LINK>). Among the 9 studies reporting on hyperimmune CMV-IVIG, immunoglobulins were compared to no intervention in 8 trials (<LINK REF="STD-Ruutu-1997" TYPE="STUDY">Ruutu 1997</LINK>; <LINK REF="STD-Winston-1982" TYPE="STUDY">Winston 1982</LINK>; <LINK REF="STD-Meyers-1983" TYPE="STUDY">Meyers 1983</LINK>; <LINK REF="STD-Bowden-1991" TYPE="STUDY">Bowden 1991</LINK>; <LINK REF="STD-Bordigoni-1987" TYPE="STUDY">Bordigoni 1987</LINK>; <LINK REF="STD-Ringden-1987" TYPE="STUDY">Ringden 1987</LINK>; <LINK REF="STD-Serrano-1999" TYPE="STUDY">Serrano 1999</LINK>; <LINK REF="STD-Bowden-1986" TYPE="STUDY">Bowden 1986</LINK>) and to placebo in 1 trial (<LINK REF="STD-Boeckh-2001" TYPE="STUDY">Boeckh 2001</LINK>). 8 trials included only patients who underwent allogeneic transplantation (<LINK REF="STD-Ruutu-1997" TYPE="STUDY">Ruutu 1997</LINK>; <LINK REF="STD-Winston-1982" TYPE="STUDY">Winston 1982</LINK>; <LINK REF="STD-Meyers-1983" TYPE="STUDY">Meyers 1983</LINK>; <LINK REF="STD-Boeckh-2001" TYPE="STUDY">Boeckh 2001</LINK>; <LINK REF="STD-Bowden-1991" TYPE="STUDY">Bowden 1991</LINK>; <LINK REF="STD-Ringden-1987" TYPE="STUDY">Ringden 1987</LINK>; <LINK REF="STD-Serrano-1999" TYPE="STUDY">Serrano 1999</LINK>; <LINK REF="STD-Bowden-1986" TYPE="STUDY">Bowden 1986</LINK>) and in 1 trial either allogeneic or autologous transplant patients were randomized (<LINK REF="STD-Bordigoni-1987" TYPE="STUDY">Bordigoni 1987</LINK>).</P>
<P>Among the 10 studies of LPD, 4 evaluated patients with CLL (<LINK REF="STD-Boughton-1995" TYPE="STUDY">Boughton 1995</LINK>; <LINK REF="STD-Chapel-1994c" TYPE="STUDY">Chapel 1994c</LINK>; <LINK REF="STD-Cooperative-CLL-1988" TYPE="STUDY">Cooperative CLL 1988</LINK>; <LINK REF="STD-Molica-1996" TYPE="STUDY">Molica 1996</LINK>), 4 MM patients (<LINK REF="STD-Chapel-1994" TYPE="STUDY">Chapel 1994</LINK>; <LINK REF="STD-Musto-1995" TYPE="STUDY">Musto 1995</LINK>; <LINK REF="STD-Salmon-1967" TYPE="STUDY">Salmon 1967</LINK>; <LINK REF="STD-Hargreaves-1992" TYPE="STUDY">Hargreaves 1992</LINK>), 1 both CLL and MM patients (<LINK REF="STD-Sklenar-1993" TYPE="STUDY">Sklenar 1993</LINK>) and 1 both MM and low risk non-Hodgkin lymphoma (<LINK REF="STD-Gluck-1990" TYPE="STUDY">Gluck 1990</LINK> ). All studies used polyvalent immunoglobulins. In 5 studies immunoglobulins were compared to placebo (<LINK REF="STD-Salmon-1967" TYPE="STUDY">Salmon 1967</LINK>; <LINK REF="STD-Chapel-1994" TYPE="STUDY">Chapel 1994</LINK>; <LINK REF="STD-Cooperative-CLL-1988" TYPE="STUDY">Cooperative CLL 1988</LINK>; <LINK REF="STD-Boughton-1995" TYPE="STUDY">Boughton 1995</LINK>; <LINK REF="STD-Hargreaves-1992" TYPE="STUDY">Hargreaves 1992</LINK>), in 3 to no intervention (<LINK REF="STD-Molica-1996" TYPE="STUDY">Molica 1996</LINK>; <LINK REF="STD-Musto-1995" TYPE="STUDY">Musto 1995</LINK>; <LINK REF="STD-Gluck-1990" TYPE="STUDY">Gluck 1990</LINK>) and in 2, different doses of immunoglobulins were compared (<LINK REF="STD-Sklenar-1993" TYPE="STUDY">Sklenar 1993</LINK>; <LINK REF="STD-Chapel-1994c" TYPE="STUDY">Chapel 1994c</LINK>). Two studies in the LPD group were crossover studies (<LINK REF="STD-Molica-1996" TYPE="STUDY">Molica 1996</LINK>; <LINK REF="STD-Musto-1995" TYPE="STUDY">Musto 1995</LINK>). These studies were not included in the meta-analysis since data for the first randomization was not available separately and the combined data could not be used for meta-analysis. One study comparing various products was composed of two phases: in phase I - 21 patients were randomized to receive one of 3 polyvalent immunoglobulins products weekly and in phase II - 32 patients were randomized to receive the various polyvalent immunoglobulins products every other week. Since the only outcome evaluated in this study was immunoglobulin levels, it was not included in our analyzes (<LINK REF="STD-Peltier-1992" TYPE="STUDY">Peltier 1992</LINK>).</P>
<P>Thirty-two studies consisted of 2 arms. 5 studies had 3 arms (<LINK REF="STD-Winston-2001" TYPE="STUDY">Winston 2001</LINK>; <LINK REF="STD-Boeckh-2001" TYPE="STUDY">Boeckh 2001</LINK>; <LINK REF="STD-Sklenar-1993" TYPE="STUDY">Sklenar 1993</LINK>; <LINK REF="STD-Peltier-1992" TYPE="STUDY">Peltier 1992</LINK>; <LINK REF="STD-Condie-1984" TYPE="STUDY">Condie 1984</LINK>) and 3 studies had 4 arms (<LINK REF="STD-Cordonnier-2003" TYPE="STUDY">Cordonnier 2003</LINK>; <LINK REF="STD-Filipovich-1992" TYPE="STUDY">Filipovich 1992</LINK>; <LINK REF="STD-Bowden-1986" TYPE="STUDY">Bowden 1986</LINK>). This was mainly due to the use of 3-4 doses or products of immunoglobulins. Of these, 5 studies involved transplant patients receiving polyvalent immunoglobulins (<LINK REF="STD-Cordonnier-2003" TYPE="STUDY">Cordonnier 2003</LINK>; <LINK REF="STD-Winston-2001" TYPE="STUDY">Winston 2001</LINK>; <LINK REF="STD-Sklenar-1993" TYPE="STUDY">Sklenar 1993</LINK>; <LINK REF="STD-Filipovich-1992" TYPE="STUDY">Filipovich 1992</LINK>; <LINK REF="STD-Peltier-1992" TYPE="STUDY">Peltier 1992</LINK>) and 3 involved transplant patients receiving hyperimmune CMV-IVIG (<LINK REF="STD-Boeckh-2001" TYPE="STUDY">Boeckh 2001</LINK>; <LINK REF="STD-Condie-1984" TYPE="STUDY">Condie 1984</LINK>; <LINK REF="STD-Bowden-1986" TYPE="STUDY">Bowden 1986</LINK>). None of the studies dealing with lymphoproliferative disorders had more than two arms.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>Generation of randomization sequence was described as adequate in 11 studies (classified as A). In the remaining 29 studies it was not specified (classified as B).<BR/>Allocation concealment was adequate by description in 9 studies (classified as A, table of included studies). In the remaining 31 studies allocation concealment was not clear (classified as B, table of included studies). <BR/>13 studies were conducted in a double-blinded fashion. All remaining trials were open.<BR/>15 studies reported results per protocol, (<LINK REF="STD-Abdel_x002d_Mageed-1999" TYPE="STUDY">Abdel-Mageed 1999</LINK>; <LINK REF="STD-Bowden-1986" TYPE="STUDY">Bowden 1986</LINK>; <LINK REF="STD-Bowden-1991" TYPE="STUDY">Bowden 1991</LINK>; <LINK REF="STD-Chapel-1994" TYPE="STUDY">Chapel 1994</LINK>; <LINK REF="STD-Cooperative-CLL-1988" TYPE="STUDY">Cooperative CLL 1988</LINK>; <LINK REF="STD-Feinstein-1999" TYPE="STUDY">Feinstein 1999</LINK>; <LINK REF="STD-Graham-Pole-1990" TYPE="STUDY">Graham Pole 1990</LINK>; <LINK REF="STD-Meyers-1983" TYPE="STUDY">Meyers 1983</LINK>; <LINK REF="STD-Poynton-1992" TYPE="STUDY">Poynton 1992</LINK>; <LINK REF="STD-Salmon-1967" TYPE="STUDY">Salmon 1967</LINK>; <LINK REF="STD-Sullivan-1990" TYPE="STUDY">Sullivan 1990</LINK>; <LINK REF="STD-Winston-1982" TYPE="STUDY">Winston 1982</LINK>; <LINK REF="STD-Winston-1984" TYPE="STUDY">Winston 1984</LINK>; <LINK REF="STD-Winston-1987" TYPE="STUDY">Winston 1987</LINK>; <LINK REF="STD-Winston-2001" TYPE="STUDY">Winston 2001</LINK>). In 3 studies it was unknown whether patients were excluded after randomization (<LINK REF="STD-Gluck-1990" TYPE="STUDY">Gluck 1990</LINK>; <LINK REF="STD-Hargreaves-1992" TYPE="STUDY">Hargreaves 1992</LINK>). In the remaining 12 studies analysis was performed by intention to treat.<BR/>21 studies reported that patients gave their consent to participate in the research. Approval of the ethics committee was reported in 18 of them. <BR/> </P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-08-11 15:33:48 +0200" MODIFIED_BY="Nicole Skoetz">
<P>
<B>
<U>BONE MARROW TRANSPLANTATION AND HEMATOPOIETIC STEM CELL TRANSPLANTATION<BR/>
</U>
</B>
<BR/>For patients undergoing transplantation (30 studies) prophylaxis was initiated in most studies during conditioning (26 studies) or immediately after transplant (4 studies) and was administered either weekly (15 trials), bi-weekly (6 trials) or by using a different schedule (9 trials). In most studies immunoglobulin prophylaxis was given for 3 months and the maximum period of administration was 1 year (see table of included studies). In 24 out of the 30 studies, immunoglobulins were administered in the setting of hospitalization in isolation precaution conditions for at least part of the treatment period (<LINK REF="STD-Cordonnier-2003" TYPE="STUDY">Cordonnier 2003</LINK>; <LINK REF="STD-Zikos-1998" TYPE="STUDY">Zikos 1998</LINK>; <LINK REF="STD-Winston-1982" TYPE="STUDY">Winston 1982</LINK>; <LINK REF="STD-Meyers-1983" TYPE="STUDY">Meyers 1983</LINK>; <LINK REF="STD-Boeckh-2001" TYPE="STUDY">Boeckh 2001</LINK>; <LINK REF="STD-Winston-1993" TYPE="STUDY">Winston 1993</LINK>; <LINK REF="STD-Poynton-1992" TYPE="STUDY">Poynton 1992</LINK>; <LINK REF="STD-Filipovich-1992" TYPE="STUDY">Filipovich 1992</LINK>; <LINK REF="STD-Wolff-1993" TYPE="STUDY">Wolff 1993</LINK>; <LINK REF="STD-Feinstein-1999" TYPE="STUDY">Feinstein 1999</LINK>; <LINK REF="STD-Bowden-1991" TYPE="STUDY">Bowden 1991</LINK>; <LINK REF="STD-Winston-1987" TYPE="STUDY">Winston 1987</LINK>; <LINK REF="STD-Bordigoni-1987" TYPE="STUDY">Bordigoni 1987</LINK>; <LINK REF="STD-Condie-1984" TYPE="STUDY">Condie 1984</LINK>; <LINK REF="STD-Winston-1984" TYPE="STUDY">Winston 1984</LINK>; <LINK REF="STD-Ringden-1987" TYPE="STUDY">Ringden 1987</LINK>; <LINK REF="STD-Jacobsen-1985" TYPE="STUDY">Jacobsen 1985</LINK>; <LINK REF="STD-Sullivan-1990" TYPE="STUDY">Sullivan 1990</LINK>; <LINK REF="STD-Lum-1994" TYPE="STUDY">Lum 1994</LINK>; <LINK REF="STD-Serrano-1999" TYPE="STUDY">Serrano 1999</LINK>; <LINK REF="STD-Raiola-2002" TYPE="STUDY">Raiola 2002</LINK>; <LINK REF="STD-Bowden-1986" TYPE="STUDY">Bowden 1986</LINK>; <LINK REF="STD-Emanuel-1992" TYPE="STUDY">Emanuel 1992</LINK>; <LINK REF="STD-Abdel_x002d_Mageed-1999" TYPE="STUDY">Abdel-Mageed 1999</LINK>) and the remaining 6 studies did not report on the trial setting (<LINK REF="STD-Winston-2001" TYPE="STUDY">Winston 2001</LINK>; <LINK REF="STD-Ruutu-1997" TYPE="STUDY">Ruutu 1997</LINK>; <LINK REF="STD-Peltier-1992" TYPE="STUDY">Peltier 1992</LINK>; <LINK REF="STD-Graham-Pole-1990" TYPE="STUDY">Graham Pole 1990</LINK>; <LINK REF="STD-Sullivan-2000" TYPE="STUDY">Sullivan 2000</LINK>; <LINK REF="STD-Ustun-1998" TYPE="STUDY">Ustun 1998</LINK>).</P>
<P>I<B>.<U>Polyvalent immunoglobulins versus placebo or no intervention (control)</U>
</B>
</P>
<P>
<B>Primary outcome measures<BR/>
</B>
<I>
<BR/>1.<B>All cause mortality<BR/>
</B>
</I>Eight trials including 1418 patients, out of 12 trials that compared polyvalent immunoglobulins to control reported this outcome (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). The time of follow up for mortality reporting was heterogeneous in these studies. This comparison includes 5 trials which reported mortality at 100 - 200 days) and 3 trials which reported mortality at more than 2 years (comparison 1.3). Overall, there was no difference in the risk for all-cause mortality between polyvalent immunoglobulins and placebo or no intervention, RR 0.99 (95% CI 0.88 to 1.12). There was no statistical evidence of heterogeneity (P = 0.4, I<SUP>2 </SUP>= 3.3%) (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).<BR/>Since there was variability in the time point for reporting mortality, and since some trials reported mortality at 2 different time points, we also divided these analyses to two graphs. The first, (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> ) with 4 trials including 881 participants reported mortality at 100 days (RR 1.03, 95% CI 0.83 to 1.26) with no statistical evidence of heterogeneity (P = 0.12, I<SUP>2 </SUP>= 48%). The second, (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>) with 5 trials including 737 patients reported mortality at 1-2 years with borderline heterogeneity (RR 1.07, 95% CI 0.94 to 1.21) (P = 0.09, I<SUP>2 </SUP>= 51%).<BR/>We separated the trials according to type of transplant, whether allogeneic or autologous. Our analysis of mortality according to transplant type did not yield a difference in mortality between polyvalent immunoglobulins and control for the allo-BMT only group, RR 1.07 (95% CI 0.79 to 1.44) and for the allo-BMT and auto-BMT group, RR 0.95 (95% CI 0.81 to 1.10) (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>). We also divided the trials according to the use of antifungal prophylaxis. Again, there was no difference in mortality rate between polyvalent immunoglobulins and control in trials in which the patients received or did not receive antifungal prophylaxis RR 1.07 (95% CI 0.74 to 1.53) and RR 0.88 (95% CI 0.76 to 1.02), respectively) (<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>). We analyzed separately trials in which the polyvalent immunoglobulins dose was above 500mg/kg, and there was no difference in mortality for patients given high-dose polyvalent immunoglobulins vs. control, RR 1.06 (95% CI 0.91 to 1.23) (<LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>)</P>
<P>
<I>Sensitivity Analysis<BR/>
</I>There was no difference in all cause mortality between trials of adequate randomization generation (RR 1.40, 95% CI 0.88 to 2.22) (<LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>) and those in which randomization generation was not clear (RR 0.93, 95% CI 0.83 to 1.05). There was also no difference in all cause mortality between trials which were blinded (RR 0.94, 95% CI 0.76 to 1.17)) and those not blinded (RR 0.99, 95% CI 0.86 to 1.14) (<LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK>). Only one trial reporting all cause mortality of transplant patients receiving polyvalent immunoglobulins had adequate allocation concealment (<LINK REF="STD-Cordonnier-2003" TYPE="STUDY">Cordonnier 2003</LINK>), thus we did not conduct sensitivity analysis.<BR/>We conducted sensitivity analysis for mortality also according to ITT versus per protocol. There was no difference in all cause mortality between trials which were analyzed by ITT (RR 1.04, 95% CI 0.87 to 1.24) or per protocol (RR 0.91, 95% CI 0.79 to 1.06) (<LINK REF="FIG-23" TYPE="FIGURE">Figure 23</LINK>).We did not perform sensitivity analysis according to allocation concealment because only one trial was of adequate allocation concealment (<LINK REF="STD-Cordonnier-2003" TYPE="STUDY">Cordonnier 2003</LINK>)</P>
<P>The funnel plot for mortality was difficult to interpret due to the small number of studies (additional figures: <LINK REF="FIG-61" TYPE="FIGURE">Figure 61</LINK>).</P>
<P>2<I>
<B>.Clinically documented infections<BR/>
</B>
</I>Five trials which reported clinically documented infections included 688 participants. Polyvalent immunoglobulins administration did not result in a reduction in the occurrence of clinically documented infections, RR 1.00 (95% CI 0.90 to 1.10). There was no evidence for heterogeneity in these comparisons (P = 0.97, I<SUP>2 </SUP>= 0%) (<LINK REF="FIG-10" TYPE="FIGURE">Figure 10</LINK>).</P>
<P>
<I>Sensitivity Analysis</I>
<BR/>There was no difference in clinically documented infections between trials of adequate randomization generation (RR 0.99, 95% CI 0.86 to 1.14) (<LINK REF="FIG-25" TYPE="FIGURE">Figure 25</LINK>) and those in which randomization generation was not clear (RR 1.00, 95% CI 0.86 to 1.17). There was also no difference in a clinically documented infections between trials which were blinded (RR 1.01, 95% CI 0.91 to 1.12) and those not blinded (RR 0.99, 95% CI 0.86 to 1.15), (<LINK REF="FIG-26" TYPE="FIGURE">Figure 26</LINK>).</P>
<P>
<B>Secondary outcome measures<BR/>
</B>
<BR/>3<I>
<B>.Microbiologically documented infections (bacterial)<BR/>
</B>
</I>Seven trials that reported this outcome included 1186 participants. Polyvalent immunoglobulins prophylaxis did not result in a decrease in the occurrence of microbiologically documented bacterial infections, when analyzed per patient, RR 1.00 (95% CI 0.88 to 1.15 ) (<LINK REF="FIG-11" TYPE="FIGURE">Figure 11</LINK>), or as episode per patient-months, RR 0.97 (95% CI 0.82 to 1.16) (<LINK REF="FIG-12" TYPE="FIGURE">Figure 12</LINK>).</P>
<P>4<I>
<B>.CMV infection and interstitial pneumonitis<BR/>
</B>
</I>Six trials which reported CMV infections included 986 participants. There was no statistically significant difference in the occurrence of CMV infections when analyzed per patient RR 0.84 (95% CI 0.66 to 1.07) (<LINK REF="FIG-13" TYPE="FIGURE">Figure 13</LINK>) (<LINK REF="FIG-22" TYPE="FIGURE">Figure 22</LINK>) (<LINK REF="FIG-24" TYPE="FIGURE">Figure 24</LINK>) or as episodes per patient months RR 0.70 (95% CI 0.49 to 1.02) (<LINK REF="FIG-14" TYPE="FIGURE">Figure 14</LINK>). Polyvalent immunoglobulins significantly reduced the risk for developing interstitial pneumonitis by 36% (RR 0.64, 95% CI 0.45 to 0.89), 7 trials, 990 patients (<LINK REF="FIG-15" TYPE="FIGURE">Figure 15</LINK>) (<LINK REF="FIG-22" TYPE="FIGURE">Figure 22</LINK>) (<LINK REF="FIG-24" TYPE="FIGURE">Figure 24</LINK>). It should be noted that sensitivity analysis revealed that the significant reduction in interstitial pneumonitis was only in trials of unclear randomization generation (RR 0.52, 95% CI 0.36 to 0.76) and in trials of adequate randomization the effect was not significant (RR 1.66, 95% CI 0.57 to 4.85) (<LINK REF="FIG-29" TYPE="FIGURE">Figure 29</LINK>). In addition, the significant reduction remained only for trials which were double blind (RR 0.58, 95% CI 0.41 to 0.82) (<LINK REF="FIG-30" TYPE="FIGURE">Figure 30</LINK>), as opposed to non-blinded trials (RR 1.56, 95% CI 0.47 to 5.19).</P>
<P>5.<I>
<B>Infection related mortality<BR/>
</B>
</I>Three trials which compared polyvalent immunoglobulins to placebo or no intervention included 275 participants. Polyvalent immunoglobulins administration did not result in a decrease in the risk of infection-related death, RR 0.64 (95% CI 0.28 to 1.49) (<LINK REF="FIG-16" TYPE="FIGURE">Figure 16</LINK>). Although there was a 36% reduction in risk, the 95% confidence was too wide to conclude on benefit.</P>
<P>6.<I>
<B>Acute GVHD<BR/>
</B>
</I>Seven trials that reported this outcome included 989 participants. Polyvalent immunoglobulins prophylaxis did not result in a decrease in the occurrence of acute GVHD, RR 0.93 (95% CI 0.83 to 1.04) (<LINK REF="FIG-17" TYPE="FIGURE">Figure 17</LINK>).</P>
<P>7.<I>
<B>Veno-occlusive disease (VOD)<BR/>
</B>
</I>Four trials including 447 patients reported the occurrence of VOD. When compared to control, polyvalent immunoglobulins prophylaxis resulted in a significantly increased risk for developing VOD, RR 2.73 (95% CI 1.11 to 6.71), (<LINK REF="FIG-18" TYPE="FIGURE">Figure 18</LINK>) (<LINK REF="FIG-24" TYPE="FIGURE">Figure 24</LINK>). We separated the trials according to type of transplant, whether allogeneic or autologous. Our analysis of VOD according to transplant type showed increased risk for both groups: the allogeneic only group, RR 2.04 (95% CI 0.76 to 5.49) and the autologous only group, RR 11.8 (95% CI 0.66 to 210.03) (<LINK REF="FIG-20" TYPE="FIGURE">Figure 20</LINK>). However, these results were not statistically significant, Moreover, since the autologous group included only one trial these results should be interpreted with caution (<LINK REF="STD-Wolff-1993" TYPE="STUDY">Wolff 1993</LINK>).<BR/>In addition we conducted sensitivity analysis according randomization generation. It should be noted that trials of adequate randomization yielded a significant increase in VOD (RR 3.35, 95% CI 1.19 to 9.47), while for trials of unclear randomization this effect was not significant (<LINK REF="FIG-27" TYPE="FIGURE">Figure 27</LINK>).<BR/>Sensitivity analysis according to blinding did not affect results (<LINK REF="FIG-28" TYPE="FIGURE">Figure 28</LINK>).</P>
<P>8.<I>
<B>Adverse events<BR/>
</B>
</I>Five trials, which included 728 patients (<LINK REF="STD-Winston-1984" TYPE="STUDY">Winston 1984</LINK>, <LINK REF="STD-Winston-1987" TYPE="STUDY">Winston 1987</LINK>, <LINK REF="STD-Sullivan-1990" TYPE="STUDY">Sullivan 1990</LINK>, <LINK REF="STD-Winston-1993" TYPE="STUDY">Winston 1993</LINK>, <LINK REF="STD-Cordonnier-2003" TYPE="STUDY">Cordonnier 2003</LINK>) reported adverse events, with a significant increase for developing adverse events: RR 8.12 (95% CI 3.15 to 20.97) (<LINK REF="FIG-19" TYPE="FIGURE">Figure 19</LINK>). Only one trial was double-blind and reported adverse events in the control group (<LINK REF="STD-Cordonnier-2003" TYPE="STUDY">Cordonnier 2003</LINK>), while the remaining open trials did not report adverse events in the control group. Adverse events were not common (4 of 18 cases (<LINK REF="STD-Winston-1984" TYPE="STUDY">Winston 1984</LINK>), 9 of 38 cases (<LINK REF="STD-Winston-1987" TYPE="STUDY">Winston 1987</LINK>), 14 of 184 cases (<LINK REF="STD-Sullivan-1990" TYPE="STUDY">Sullivan 1990</LINK>), 7 of 27 cases (<LINK REF="STD-Winston-1993" TYPE="STUDY">Winston 1993</LINK>), 27 of 150 cases (<LINK REF="STD-Cordonnier-2003" TYPE="STUDY">Cordonnier 2003</LINK>). Adverse events did not require discontinuation of treatment. They included mainly early adverse events: fever, chills, nausea and vomiting, headaches, myalgias, rash and hypotension without anaphylaxis.</P>
<P>9. <I>
<B>Fungal Infections<BR/>
</B>
</I>Five trials reported this outcome. Polyvalent immunoglobulins prophylaxis did not result in a decrease in the occurrence of fungal infections, RR 0.95 (95% CI 0.72 to 1.25) (<LINK REF="FIG-31" TYPE="FIGURE">Figure 31</LINK>).</P>
<P>10. <I>
<B>Bacteremia</B>
</I>
<BR/>Four trials reported this outcome. Polyvalent immunoglobulins prophylaxis did not result in a decrease in the occurrence of bacteremia, RR 1.03 (95% CI 0.93 to 1.13) (<LINK REF="FIG-32" TYPE="FIGURE">Figure 32</LINK>).</P>
<P>
<U>
<B>II.Hyperimmune CMV-IVIG versus placebo or no intervention (control)<BR/>
</B>
</U>
<B>
<BR/>Primary outcome measures </B>
</P>
<P>
<I>
<B>1.All cause mortality</B>
</I>
</P>
<P>Four trials including 288 patients out of nine trials which compared hyperimmune CMV-IVIG to control reported this outcome. There was no difference in the risk for all-cause mortality between hyperimmune CMV-IVIG and placebo or no intervention, RR 0.86 (95% CI 0.63 to 1.16) (<LINK REF="FIG-21" TYPE="FIGURE">Figure 21</LINK>). There was no statistical evidence of heterogeneity (P = 0.68, I<SUP>2 </SUP>= 0%) (comparison 2.1). Mortality was assessed in these studies between 62 days and 5 years after randomization.<BR/>Three trials including 234 participants reported mortality at 100 days, RR 0.89 (95% CI 0.64 to 1.24) (<LINK REF="FIG-33" TYPE="FIGURE">Figure 33</LINK>). Again, there was no statistical evidence of heterogeneity (P = 0.48, I<SUP>2 </SUP>= 0%).<BR/>
<BR/>

<BR/>
2.<I>
<B>Clinically documented infections<BR/>
</B>
</I>There were no data on this outcome</P>
<P>
<B>Secondary outcome measures<BR/>
<I>
<BR/>3.CMV infection and interstitial pneumonitis<BR/>
</I>
</B>Eight trials which reported CMV infections included 553 participants and five trials reported on interstitial pneumonitis in 345 patients. Hyperimmune CMV-IVIG prophylaxis did not result in a decrease in the occurrence of CMV infections, RR 1.02 (95% CI 0.82 to 1.26) (<LINK REF="FIG-34" TYPE="FIGURE">Figure 34</LINK>) or interstitial pneumonitis (RR 0.95 (95% CI 0.58 to 1.56) (<LINK REF="FIG-35" TYPE="FIGURE">Figure 35</LINK>).</P>
<P>
<I>
<B>4.Infection related mortality<BR/>
</B>
</I>Three trials which compared polyvalent immunoglobulins CMV-IVIG to placebo or no intervention included 234 participants. Hyperimmune CMV-IVIG administration did not result in a statistically significant decrease in the risk of infection-related death, RR 0.67 (95% CI 0.34 to 1.32) (<LINK REF="FIG-36" TYPE="FIGURE">Figure 36</LINK>).</P>
<P>
<I>
<B>5.Acute GVHD<BR/>
</B>
</I>Five trials that reported this outcome included 342 participants. Hyperimmune CMV-IVIG prophylaxis did not result in a decrease in the occurrence of acute GVHD, RR 1.02 (95% CI 0.72 to 1.44) (<LINK REF="FIG-37" TYPE="FIGURE">Figure 37</LINK>).</P>
<P>
<I>
<B>6.Adverse events<BR/>
</B>
</I>Only one study including 54 patients reported adverse effects for hyperimmune CMV-IVIG as compared to control. Therefore, meta-analysis could not be done.</P>
<P>7. <I>
<B>Fungal Infections<BR/>
</B>
</I>Two trials reported this outcome. Hyperimmune CMV-IVIG prophylaxis did not result in a decrease in the occurrence of fungal infections, RR 1.02 (95% CI 0.54 to 1.93) (<LINK REF="FIG-38" TYPE="FIGURE">Figure 38</LINK>).</P>
<P>8. <I>
<B>Bacteremia<BR/>
</B>
</I>Only one trial reported this outcome. Therefore, meta-analysis could not be done.
<BR/>

</P>
<P>
<U>
<B>III.IVIG or anti CMV-IVIG versus placebo or no intervention (control)<BR/>
</B>
</U>
<B>
<BR/>Primary outcome measures<BR/>
</B>
<BR/>We pooled all trials that assessed IVIG, whether polyvalent immunoglobulins or specific hyperimmune CMV-IVIG.<BR/>
<I>
<B>
<BR/>1.All cause mortality<BR/>
</B>
</I>Twelve trials including 1706 patients which compared polyvalent immunoglobulins or specific hyperimmune CMV-IVIG to control reported this outcome. Pooling all trials showed no difference in mortality, RR 0.97 (95% CI 0.87 to 1.09) (<LINK REF="FIG-39" TYPE="FIGURE">Figure 39</LINK>). Importantly, there was no statistical evidence of heterogeneity (P = 0.54, I<SUP>2 </SUP>= 0%).</P>
<P>
<I>
<B>2. All-cause Mortality - 100d (3-4 mo)</B>
</I>
<BR/>Eight trials including 1178 patients which compared polyvalent immunoglobulins or specific hyperimmune CMV-IVIG to control reported this outcome. Pooling all trials showed no difference in mortality, RR 0.96 (95% CI 0.82 to 1.14) (<LINK REF="FIG-40" TYPE="FIGURE">Figure 40</LINK>). Importantly, there was no statistical evidence of heterogeneity (P = 0.26, I<SUP>2 </SUP>= 20.8%).</P>
<P>
<I>
<B>3. CMV infection and interstitial pneumonitis<BR/>
</B>
</I>Thirteen trials including 1511 patients which compared polyvalent immunoglobulins or specific hyperimmune CMV-IVIG to control reported this outcome. Pooling all trials showed no difference in CMV infections, RR 0.90 (95% CI 0.76 to 1.06) (<LINK REF="FIG-41" TYPE="FIGURE">Figure 41</LINK>). Importantly, there was no statistical evidence of heterogeneity (P = 0.11, I<SUP>2</SUP> = 33.6%). Polyvalent immunoglobulins or hyperimmune anti CMV-IVIG significantly reduced the risk for developing interstitial pneumonitis by 38% (RR 0.72 (95% CI 0.55 to 0.95) (<LINK REF="FIG-42" TYPE="FIGURE">Figure 42</LINK>). Importantly, there was no statistical evidence of heterogeneity (P = 0.25, I<SUP>2 </SUP>= 19.6%).</P>
<P>
<I>
<B>4. Infection-related Mortality<BR/>
</B>
</I>Six trials including 509 patients which compared polyvalent immunoglobulins or specific hyperimmune CMV-IVIG to control reported this outcome. Pooling all trials showed no difference in infection related mortality, RR 0.66 (95% CI 0.39 to 1.12) (<LINK REF="FIG-43" TYPE="FIGURE">Figure 43</LINK>). Importantly, there was no statistical evidence of heterogeneity (P = 0.5, I<SUP>2 </SUP>= 0%).</P>
<P>
<I>
<B>5. Acute GVHD</B>
</I>
<BR/>Twelve trials including 1331 patients which compared polyvalent immunoglobulins or specific hyperimmune CMV-IVIG to control reported this outcome. Pooling all trials showed no difference in acute GVHD, RR 0.94 (95% CI 0.84 to 1.05) (<LINK REF="FIG-44" TYPE="FIGURE">Figure 44</LINK>). Importantly, there was no statistical evidence of heterogeneity (P = 0.54, I<SUP>2 </SUP>= 0%).</P>
<P>
<I>
<B>6. Adverse Events<BR/>
</B>
</I>Six trials, which included 782 patients reported adverse effects, with a significant increase for developing adverse effects: RR 8.02 (95% CI 3.25 to 19.78) (<LINK REF="FIG-45" TYPE="FIGURE">Figure 45</LINK>). Importantly, there was no statistical evidence of heterogeneity (P = 0.74, I<SUP>2 </SUP>= 0%).<BR/>
<I>
<B>
<BR/>
</B>
</I>
<BR/>I<U>
<B>V.Polyvalent immunoglobulins versus hyperimmune CMV-IVIG</B>
</U>
<BR/>
<B>
<BR/>Primary outcome measures</B>
</P>
<P>
<I>
<B>1.All cause mortality<BR/>
</B>
</I>Three trials including 212 patients which compared polyvalent immunoglobulins to hyperimmune CMV-IVIG reported all cause mortality. Mortality was higher with polyvalent IVIG without statistical significance, RR 1.46 (95% CI 0.92 to 2.32) (<LINK REF="FIG-46" TYPE="FIGURE">Figure 46</LINK>). There was no statistical evidence of heterogeneity (P = 0.99, I<SUP>2 </SUP>= 0%). Mortality was assessed in these studies between 110 days and 4 years after randomization.<BR/>
<B>
<BR/>
<I>2.Clinically documented infections<BR/>
</I>
</B>One trial that reported clinically documented infections included 128 participants. Therefore, meta-analysis could not be done.<BR/>
<B>
<BR/>Secondary outcome measures</B>
</P>
<P>
<I>
<B>3.CMV infection and interstitial pneumonitis<BR/>
</B>
</I>Three trials which reported CMV infections included 212 participants. Polyvalent immunoglobulins prophylaxis was associated with an increased risk to develop CMV infection as compared to hyperimmune CMV-IVIG prophylaxis, RR 1.42 (95% CI 1.07 to 1.89) (<LINK REF="FIG-47" TYPE="FIGURE">Figure 47</LINK>) although there was no difference between them regarding the occurrence of interstitial pneumonitis RR 0.83 (95% CI 0.40 to 1.75) (<LINK REF="FIG-48" TYPE="FIGURE">Figure 48</LINK>).</P>
<P>
<I>
<B>4.Infection related mortality<BR/>
</B>
</I>Two trials which compared polyvalent immunoglobulins to hyperimmune CMV-IVIG included 177 participants. Results of the comparison favored hyperimmune CMV-IVIG without statistical significance, RR 3.28 (95% CI 0.95 to 11.26) (<LINK REF="FIG-49" TYPE="FIGURE">Figure 49</LINK>).</P>
<P>
<I>
<B>5.Acute GVHD<BR/>
</B>
</I>Two trials which compared polyvalent immunoglobulins to hyperimmune CMV-IVIG included 163 participants. Results of the comparison favored hyperimmune CMV-IVIG without statistical significance, RR 1.23 (95% CI 0.87 to 1.75) (<LINK REF="FIG-50" TYPE="FIGURE">Figure 50</LINK>).</P>
<P>
<I>
<B>6.Adverse events<BR/>
</B>
</I>No studies comparing between polyvalent immunoglobulins and hyperimmune CMV-IVIG prophylaxis reported this outcome</P>
<P>
<U>
<B>V.Polyvalent immunoglobulins 250 mg/kg versus polyvalent immunoglobulins 500 mg/kg</B>
</U>
</P>
<P>
<U>
<B>Primary outcome measures </B>
</U>
</P>
<P>
<I>
<B>1.All cause mortality<BR/>
</B>
</I>One trial including 412 patients which compared these 2 doses of immunoglobulins reported all cause mortality. Therefore, meta-analysis could not be done.</P>
<P>
<I>
<B>2.Clinically documented infections<BR/>
</B>
</I>Two trials that reported clinically documented infections included 509 participants. There was a slight decrease in the occurrence of clinically documented infections with the lower dose, RR 0.89 (95% CI 0.81 to 0.97) (<LINK REF="FIG-51" TYPE="FIGURE">Figure 51</LINK>).<BR/>
<BR/>
<U>
<B>Secondary outcome measures<BR/>
</B>
</U>
<BR/>
<I>
<B>3.Microbiologically documented infections<BR/>
</B>
</I>Two trials that reported this outcome included 509 participants. There was a slight increase in the occurrence of microbiologically documented infections with the lower dose, RR 1.28 (95% CI 1.04 to 1.57) (<LINK REF="FIG-52" TYPE="FIGURE">Figure 52</LINK>).<BR/>This discrepancy between clinically and microbiologically documented infections could stem either from the small number of trials (only two for each comparison) or from the different definitions, i.e. there is not necessarily overlap between the two outcomes.</P>
<P>
<I>
<B>4.CMV infection and Interstitial pneumonitis<BR/>
</B>
</I>One trial which reported CMV infections included 412 participants. Therefore, meta-analysis could not be done.<BR/>Two studies which reported interstitial pneumonitis included 509 participants. There was no difference in the occurrence of interstitial pneumonitis between the two doses, RR 0.98 (95% CI 0.33 to 2.92) (<LINK REF="FIG-53" TYPE="FIGURE">Figure 53</LINK>).</P>
<P>
<I>
<B>5.Infection related mortality<BR/>
</B>
</I>One trial which compared polyvalent immunoglobulins to hyperimmune CMV-IVIG included 412 participants. Therefore, meta-analysis could not be done.</P>
<P>
<I>
<B>6.Acute GVHD<BR/>
</B>
</I>Three trials which reported acute GVHD included 841 participants. There was a higher rate of acute GVHD with polyvalent immunoglobulins at a dose of 250 mg/kg as compared to 500 mg/kg, RR 1.32 (95% CI 1.13 to 1.55) (<LINK REF="FIG-54" TYPE="FIGURE">Figure 54</LINK>).</P>
<P>
<U>
<B>II.LYMPHOPROLIFERATIVE DISORDERS </B>
</U>
</P>
<P>For patients with LPD (10 trials) polyvalent immunoglobulins were administered for a maximal period of two years. They were administered every two weeks in one trial (<LINK REF="STD-Salmon-1967" TYPE="STUDY">Salmon 1967</LINK>), every three weeks in three trials (<LINK REF="STD-Sklenar-1993" TYPE="STUDY">Sklenar 1993</LINK>, <LINK REF="STD-Cooperative-CLL-1988" TYPE="STUDY">Cooperative CLL 1988</LINK>, <LINK REF="STD-Boughton-1995" TYPE="STUDY">Boughton 1995</LINK>) or every four weeks in five trials (<LINK REF="STD-Chapel-1994c" TYPE="STUDY">Chapel 1994c</LINK>, <LINK REF="STD-Molica-1996" TYPE="STUDY">Molica 1996</LINK>, <LINK REF="STD-Musto-1995" TYPE="STUDY">Musto 1995</LINK>, <LINK REF="STD-Chapel-1994" TYPE="STUDY">Chapel 1994</LINK>, <LINK REF="STD-Gluck-1990" TYPE="STUDY">Gluck 1990</LINK>) (see table of included studies). In one trial the schedule of immunoglobulins administration was not mentioned (<LINK REF="STD-Hargreaves-1992" TYPE="STUDY">Hargreaves 1992</LINK>).</P>
<P>
<U>
<B>I.Polyvalent immunoglobulins versus placebo or no intervention (control)<BR/>
</B>
</U>
<B>
<BR/>Primary outcome measures<BR/>
<I>
<BR/>1.All cause mortality<BR/>
</I>
</B>Two out of seven trials which compared polyvalent immunoglobulins to control included 163 patients and reported this outcome. There was no difference in the risk for all-cause mortality between immunoglobulins and control, RR 1.36 (95% CI 0.58 to 3.19) There was no statistical evidence of heterogeneity (P = 0.60, I<SUP>2 </SUP>= 0%) (<LINK REF="FIG-55" TYPE="FIGURE">Figure 55</LINK>). The time period during which mortality was assessed in these studies was 1 year.</P>
<P>
<I>
<B>2.Clinically documented infections<BR/>
</B>
</I>Three trials that reported clinically documented infections included 205 participants. Immunoglobulins significantly reduced the risk for developing clinically documented infections by 51%, RR 0.49 (95% CI 0.39 to 0.61) There was no statistical evidence of heterogeneity (P = 0.80, I<SUP>2 </SUP>= 0%) (<LINK REF="FIG-56" TYPE="FIGURE">Figure 56</LINK>). The corresponding NNT was 2 patients (95% CI 2 to 3).</P>
<P>
<B>Secondary outcome measures<BR/>
</B>
<BR/>
<I>
<B>3.Microbiologically documented infections and bacteremia<BR/>
</B>
</I>Three trials that reported this outcome included 205 participants. There was a significant reduction in the occurrence of microbiologically documented infections with the use of immunoglobulins as compared to control, RR 0.71 (95% CI 0.53 to 0.95) (<LINK REF="FIG-57" TYPE="FIGURE">Figure 57</LINK>). Two studies which included 124 patients, reported the occurrence of bacteremia. There was no difference in reduction in the occurrence of bacteremia RR 0.65 (95% CI 0.14 to 3.07) (<LINK REF="FIG-58" TYPE="FIGURE">Figure 58</LINK>).</P>
<P>
<I>
<B>4.Infection related mortality<BR/>
</B>
</I>Only one trial compared polyvalent immunoglobulins to control included 82 participants. Therefore, meta-analysis could not be done.</P>
<P>
<I>
<B>5.Adverse events<BR/>
</B>
</I>Three trials, which included 205 patients, reported adverse events. When compared to placebo or no intervention, polyvalent immunoglobulins caused a significant increase in adverse events, RR 2.37 (95% CI 1.74 to 3.24) (<LINK REF="FIG-59" TYPE="FIGURE">Figure 59</LINK>). When data of the same studies were analyzed according to adverse events requiring discontinuation of prophylaxis, there was no statistically significant difference between polyvalent immunoglobulins and control RR 5.43 (95% CI 0.70 to 42.24) (<LINK REF="FIG-60" TYPE="FIGURE">Figure 60</LINK>).<BR/>Side effects were common (16 of 41 cases (<LINK REF="STD-Cooperative-CLL-1988" TYPE="STUDY">Cooperative CLL 1988</LINK>), 39 of 41 cases (<LINK REF="STD-Chapel-1994" TYPE="STUDY">Chapel 1994</LINK>), 21 of 24 cases (<LINK REF="STD-Boughton-1995" TYPE="STUDY">Boughton 1995</LINK>) but occurred also in the control arm in most studies. In a few cases adverse effects required discontinuation of treatment. These included mainly early side effects- fever, chills, nausea and vomiting, headaches, myalgias, rash and hypotension without anaphylaxis.</P>
<P>6.<I>
<B> Fungal Infections<BR/>
</B>
</I>One trial reported this outcome. Therefore, meta-analysis could not be done.</P>
<P>7. <I>
<B>Bacteremia<BR/>
</B>
</I>One trial reported this outcome. Therefore, meta-analysis could not be done.</P>
<P>Two trials were cross-over studies and were not included in our meta-analysis (<LINK REF="STD-Musto-1995" TYPE="STUDY">Musto 1995</LINK>, <LINK REF="STD-Molica-1996" TYPE="STUDY">Molica 1996</LINK>). No washout period was reported in these two trials. The first trial reported on 25 patients with multiple myeloma with low levels of immunoglobulins or a recent history of recurrent infections (<LINK REF="STD-Musto-1995" TYPE="STUDY">Musto 1995</LINK>). Patients received polyvalent immunoglobulins every 4 to 6 weeks or no treatment for 12 months and were then switched to observation or polyvalent immunoglobulins for another year. A total of 30 serious infections occurred in 250 patient-months during the observation period compared with 10 infections in 261 patient-months during the IVIG period. The second study enrolled 42 CLL patients with hypogammaglobulinemia and/or a history of at least one severe infection during the previous 6 months (<LINK REF="STD-Molica-1996" TYPE="STUDY">Molica 1996</LINK>). Patients received immunoglobulins every 4 to 6 weeks or no treatment for 6 months and were then switched to observation or immunoglobulins for another 12 months. The incidence of infections was significantly lower among the patients who completed the first 6 months of immunoglobulins as compared to observation. Similarly, the rate of infections was significantly lower among the patients who completed the 12 months of immunoglobulins as compared to observation.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-07-22 21:30:00 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>
<U>
<BR/>BONE MARROW AND STEM CELL TRANSPLANTATION<BR/>
</U>
</B>
<U>
<BR/>
</U>Our review included 30 trials evaluating the use of immunoglobulins as prophylaxis in patients undergoing BMT or PBSCT. We demonstrated that prophylaxis with polyvalent immunoglobulins or specific hyperimmune CMV- IVIG did not have an effect on mortality. Polyvalent immunoglobulins were associated with a decrease in interstitial pneumonitis. Polyvalent immunoglobulins or hyperimmune CMV-IVIG had no influence on the other (infection-related) outcomes or GVHD. The administration of polyvalent immunoglobulins increased the risk for VOD.</P>
<P>Our results are different from those of the meta-analysis conducted by <LINK REF="REF-Bass-1993" TYPE="REFERENCE">Bass 1993</LINK> which showed a reduction of all cause mortality with the use of immunoglobulins. When we checked the three studies that indicated that immunoglobulin reduced mortality in Bass' review we found that one of them was excluded from our analysis since it reported on the total number of deaths in the study but not separately on the number in the two arms (<LINK REF="STD-Graham-Pole-1990" TYPE="STUDY">Graham Pole 1990</LINK>); and one described two pilot studies compared to historical controls (<LINK REF="STD-Vu-Van-1985" TYPE="STUDY">Vu Van 1985</LINK>). The third study compared polyvalent immunoglobulins to hyperimmune CMV-IVIG and therefore was not included in our analysis comparing polyvalent immunoglobulins to placebo/ no treatment (<LINK REF="STD-Condie-1984" TYPE="STUDY">Condie 1984</LINK>).<BR/>We found a borderline influence on the occurrence of CMV infections with the use of polyvalent immunoglobulins and no effect at all with the use of hyperimmune CMV-IVIG. Similarly, <LINK REF="REF-Bass-1993" TYPE="REFERENCE">Bass 1993</LINK> also found only a borderline significant reduction in symptomatic CMV infections with the use of immunoglobulins but when analyzed separately they found the rate of fatal CMV infections to be significantly reduced by the administration of immunoglobulins. Unlike us and Bass, <LINK REF="REF-Glowacki-1994" TYPE="REFERENCE">Glowacki 1994</LINK> in their meta-analysis showed a clear significant beneficial effect of immunoglobulins in terms of CMV infections. This difference might have been attributed to the difference in the study populations (bone marrow and solid organ recipients).</P>
<P>The most significant beneficial outcome in our review was the reduction of 36% in the occurrence of interstitial pneumonitis by polyvalent immunoglobulins, RR 0.64 (95% CI 0.45 to 0.89). This could not be confirmed with the use of hyperimmune CMV-IVIG. Interestingly, a direct comparison between them did not yield any difference regarding the occurrence of interstitial pneumonitis, RR 0.83 (95% CI 0.40 to 1.75). This could be explained by the small number of trials. Our data did not allow us to separate between CMV and non-CMV interstitial pneumonitis. <LINK REF="REF-Bass-1993" TYPE="REFERENCE">Bass 1993</LINK> analyzed separately the occurrence of CMV and of non-CMV interstitial pneumonia and found a reduction in both with IVIG.</P>
<P>We could not show such an effect of immunoglobulin therapy in prevention and treatment of GVHD in our meta-analysis. This applied to prophylaxis with polyvalent immunoglobulins as well as hyperimmune CMV-IVIG and for various preparations or doses. Concerns about increased incidence of hepatic VOD in patients receiving IVIG have been raised. This was mainly due to the study published by Cordonnier et al. (<LINK REF="STD-Cordonnier-2003" TYPE="STUDY">Cordonnier 2003</LINK>). An interesting finding in our meta-analysis was that pooled IVIG prophylaxis resulted in a significantly increased risk for developing VOD, RR 2.73 (95% CI 1.11 to 6.71) (<LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK>), although these results should be interpreted cautiously due to the small number of studies evaluating this outcome. Several possibilities might explain this increased risk. One explanation is attack of liver cells by of the immunoglobulins which contain high levels of antibodies in a similar way to another antibody, Gemtuzumab ozogamicin, which is associated with VOD through receptor mediated targeting of CD33 cells in the liver (<LINK REF="REF-Wadleigh-2003" TYPE="REFERENCE">Wadleigh 2003</LINK>). Another mechanism suggested is through induction of hyperviscosity affecting the circulation in the small hepatic venules by pooled IVIG. The last option explaining this result is through the effects of cytokines triggered by immunoglobulin administration (<LINK REF="STD-Cordonnier-2003" TYPE="STUDY">Cordonnier 2003</LINK>).</P>
<P>The number of trials comparing between different doses of IVIG in our meta-analysis was small. When the dose of 500 mg/kg was compared to 250 mg/kg there was no difference in all cause mortality, infection related mortality, the occurrence of CMV infections, interstitial pneumonitis and VOD. Slight changes were noted regarding the rate of clinically documented infections, microbiologically documented infections and the rate of acute GVHD but the number of trials and the differences were too small to draw any conclusions. The lack of effect on mortality and of difference between the different preparations and doses of polyvalent immunoglobulins do not support a biological effect of immunoglobulins in the context of transplant.</P>
<P>Adverse effects associated with IVIG infusion can be divided into three types - immediate, delayed and late. Usually fewer than 5% of patients experience clinically significant reactions in routine practice. In our review the absolute risk for adverse events with IVIG was higher (49/415, 11.8% unadjusted) and as expected the five studies assessing side effects showed a significant increase for developing adverse effects with IVIG as compared to control: RR 8.12 (95% CI 3.15 to 20.97).</P>
<P>In summary, since IVIG are associated with side effects, a higher rate of VOD and are highly expensive, current information does not support their use as routine prophylaxis for patients undergoing HSCT.<BR/>
<BR/>
<U>
<B>LPD: CLL AND MULTIPLE MYELOMA</B>
</U>
</P>
<P>Only few randomized controlled studies evaluated the role of polyvalent immunoglobulins in MM and CLL in our systematic review. We therefore combined trials regarding both LPDs. There was lack of evidence of effect of prophylaxis with pooled IVIG on all cause mortality assessed after one year of treatment. Only two small studies reported on this outcome. The most significant finding was that polyvalent immunoglobulins reduced the risk for developing clinically documented infections by 51%, with a small number of patients needed to treat (NNT 2, 95% CI 2 to 3). All 3 trials evaluating this outcome and included in the analysis favored treatment with IVIG over control (<LINK REF="STD-Cooperative-CLL-1988" TYPE="STUDY">Cooperative CLL 1988</LINK>; <LINK REF="STD-Chapel-1994" TYPE="STUDY">Chapel 1994</LINK>; <LINK REF="STD-Boughton-1995" TYPE="STUDY">Boughton 1995</LINK>). We also found a reduction in the occurrence of microbiologically documented infections with the use of polyvalent immunoglobulins as compared to control, RR 0.71 (95% CI 0.53 to 0.95). We did not have enough data to do subgroup analysis according to immunoglobulin levels or previous infections. Therefore, conclusions as to which patients might benefit most from IVIG prophylaxis cannot be drawn. The trials included in our meta-analysis included patients with hypogammaglobulinemia and recurrent infections and thus our results apply to these patients. Our findings support the recommendations of the NIH consensus paper stating that in hypogammaglobulinemia associated with CLL, polyvalent immunoglobulins can decrease the number of infections significantly although it has no effect on mortality. However, since the number of patients in these trials is rather small, only three trials including 205 patients actually registering the endpoints of clinically and microbiologically documented infections, conclusions regarding the benefit with regard to these outcomes should be regarded with some scepticism. Furthermore, conclusions concerning all cause mortality should be regarded even more cautiously since this outcome was evaluated in only two trials including 163 patients.</P>
<P>
<B>Limitations of this review</B>
</P>
<P>The major limitation is that the majority of the studies are old, with many of them reporting on patients treated in the 80's and 90's. The techniques and supportive treatments for patients undergoing transplantation for hematological malignancies have changed considerably during the last two decades which might have influence on the results. These changes include modifications of transplant regimens - i.e. myeloablative vs. reduced intensity conditioning, the use of bone marrow vs. stem cell grafts, detection, prevention and treatment of infections, mainly gancyclovir for CMV and prophylaxis and treatment for bacterial infections and prevention and treatment of complications associated with BMT, mainly GVHD and VOD. In addition, in most studies the donors were HLA- matched siblings while the growing number of matched unrelated, haploidentical and cord blood transplants are not reflected in the older studies and could modify our results.<BR/>The other limitation of our study is the relatively small number of prospective, randomized, controlled trials reported for the group of LPDs. Only two trials reported on all cause mortality in LPD.<BR/>Most studies were of uncertain methodological quality with unclear randomization generation and allocation concealment. However, when we performed a sensitivity analysis of all cause mortality by randomization generation there was no difference in all cause mortality between trials of adequate randomization generation and those in which randomization generation was not clear.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-06-25 20:08:08 +0200" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2008-06-25 20:08:08 +0200" MODIFIED_BY="[Empty name]">
<P>In patients undergoing HSCT, current information does not support the use of IVIG as routine prophylaxis, for the following reasons: prophylaxis with polyvalent immunoglobulins or hyperimmune CMV-IVIG does not affect overall survival. The only outcome for which pooled IVIG was protective was interstitial pneumonitis. It was not proven as protective against acute GVHD, clinically documented infections, CMV infections or bacterial infections and was associated with a higher rate of VOD. Hyperimmune CMV-IVIG did not affect any of the outcomes examined including all cause mortality, interstitial pneumonia, CMV infections, acute GVHD or VOD. Since these agents are associated with significant side effects, a higher rate of VOD and are highly expensive, current information does not support their use as routine prophylaxis for patients undergoing transplant. This is even more so, in view of the modern transplant techniques and the use of gancyclovir and broad spectrum antibiotic for prophylaxis and treatment.<BR/>The use of IVIG may be considered in patients with hypogammaglobulinemia associated with CLL or MM and recurrent infections. This is since IVIG can decrease the number of infections significantly. Since the absolute risk reduction of clinically documented infections was high and the number needed to treat was small (2 patients), it might prove cost effective to use prophylactic IVIG in these patients especially in view of the costs of antibiotics, hospitalization days, loss of working days and other prophylactic measures.<BR/>
</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-06-25 20:08:08 +0200" MODIFIED_BY="[Empty name]">
<P>Among HSCT recipients trials comparing polyclonal or hyperimmune anti-CMV IVIG are probably not warranted. More controlled trials on IVIG prophylaxis are needed in LPD patients with hypogammaglobulinemia and / or recurrent infections in order to assess the effect on overall survival and the best schedule of IVIG administration.<BR/>Future trials should adhere more to adequate randomization, allocation concealment and blinding, Data on all-cause mortality should be reported, even if not as a primary outcome.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We thank the authors who responded to our requests: Prof. M. Boeckh, Prof. P Bordigoni, Prof. C. Cordonnier, Prof. H. Chapel, Prof. J. Englund, Prof. Stefan Gluck, Prof. L.G. Lum, Prof. S. Molica, Prof. P. Musto, Prof. K. Sullivan, Prof. S.N. Wolff </P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>No potential conflict of interest</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Pia Raanani - Conception and design, provision of study material, protocol development, searching for trials, data extraction, analysis and interpretation of data, writing of review and final approval, clinical and scientific advice</P>
<P>Anat Gafter-Gvili - Provision of study material, protocol development, searching for trials, data extraction, eligibility and quality assessment, analysis and interpretation of data, writing of review and final approval, methodological advice</P>
<P>Mical Paul - Provision of study material, protocol development, data extraction, eligibility and quality assessment, analysis and interpretation of data, writing of review and final approval, methodological advice</P>
<P>Isaac Ben-Bassat -Protocol development, writing of review and final approval, clinical and scientific advice</P>
<P>Leonard Leibovici - Conception and design, protocol development, writing of review and final approval, clinical and scientific advice</P>
<P>Ofer Shpilberg - Conception and design, protocol development, writing of review and final approval, clinical and scientific advice</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-07-21 17:16:22 +0200" MODIFIED_BY="Nicole Skoetz">
<STUDIES MODIFIED="2008-07-21 17:16:22 +0200" MODIFIED_BY="Nicole Skoetz">
<INCLUDED_STUDIES MODIFIED="2008-07-21 17:16:22 +0200" MODIFIED_BY="Nicole Skoetz">
<STUDY DATA_SOURCE="PUB" ID="STD-Abdel_x002d_Mageed-1999" MODIFIED="2008-06-25 20:27:49 +0200" MODIFIED_BY="[Empty name]" NAME="Abdel-Mageed 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-06-25 20:27:49 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Abdel-Mageed A, Graham-Pole J, Del Rosario ML, Longmate J, Ochoa S, Amylon M, Elfenbein GJ, Janiec J, Jansen J, Lazarus HM</AU>
<TI>Comparison of two doses of intravenous immunoglobulin after allogeneic bone marrow transplants</TI>
<SO>Bone marrow transplantation</SO>
<YR>1999</YR>
<VL>23</VL>
<NO>9</NO>
<PG>929-32</PG>
<IDENTIFIERS MODIFIED="2008-06-25 20:27:49 +0200" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boeckh-2001" MODIFIED="2008-06-25 20:35:53 +0200" MODIFIED_BY="[Empty name]" NAME="Boeckh 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-06-25 20:35:53 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boeckh,M.; Bowden,R.A.; Storer,B.; Chao,N.J.; Spielberger,R.; Tierney,D.K.; Gallez-Hawkins,G.; Cunningham,T.; Blume,K.G.; Levitt,D.; Zaia,J.A</AU>
<TI>Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation</TI>
<SO>Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation</SO>
<YR>2001</YR>
<VL>1</VL>
<NO>7</NO>
<PG>343-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bordigoni-1987" MODIFIED="2008-06-25 20:50:27 +0200" MODIFIED_BY="[Empty name]" NAME="Bordigoni 1987" YEAR="1987">
<REFERENCE MODIFIED="2008-06-25 20:50:27 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bordigoni,P.; Janot,C.; Aymard,J.P.; Witz,F.; Bene,M.C.; Legras,B.; Schoonemann,F.; Olive,D.; Streiff,F</AU>
<TI>[Clinical and biological evaluation of the preventive role of anti-cytomegalovirus specific immunoglobulins in bone marrow grafts. Randomized study of 60 patients]</TI>
<TO>Evaluation clinique et biologique du role prphylatctyque des immunoglobulines specifiques anto-cytomegalovirus dans les greffes medullaires</TO>
<SO>Nouvelle revue fran?aise d'hematologie</SO>
<YR>1987</YR>
<VL>29</VL>
<NO>5</NO>
<PG>289-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boughton-1995" MODIFIED="2008-06-25 20:39:27 +0200" MODIFIED_BY="[Empty name]" NAME="Boughton 1995" YEAR="1995">
<REFERENCE MODIFIED="2008-06-25 20:39:27 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boughton,B.J.; Jackson,N.; Lim,S.; Smith,N</AU>
<TI>Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinaemia</TI>
<SO>Clinical and laboratory haematology</SO>
<YR>1995</YR>
<VL>17</VL>
<NO>1</NO>
<PG>75-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bowden-1986" MODIFIED="2008-06-25 20:39:59 +0200" MODIFIED_BY="[Empty name]" NAME="Bowden 1986" YEAR="1986">
<REFERENCE MODIFIED="2008-06-25 20:39:59 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bowden RA, Sayers M, Flournoy N, Newton B, Banaji M, Thomas ED, Meyers JD</AU>
<TI>ytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation</TI>
<SO>The New England journal of medicine</SO>
<YR>1986</YR>
<VL>314</VL>
<NO>16</NO>
<PG>1006-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bowden-1991" MODIFIED="2008-06-25 20:42:31 +0200" MODIFIED_BY="[Empty name]" NAME="Bowden 1991" YEAR="1991">
<REFERENCE MODIFIED="2008-06-25 20:42:31 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bowden,R.A.; Fisher,L.D.; Rogers,K.; Cays,M.; Meyers,J.D</AU>
<TI>Cytomegalovirus (CMV)-specific intravenous immunoglobulin for the prevention of primary CMV infection and disease after marrow transplant</TI>
<SO>The Journal of infectious diseases</SO>
<YR>1991</YR>
<VL>164</VL>
<NO>3</NO>
<PG>483-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chapel-1994" MODIFIED="2008-06-25 20:42:22 +0200" MODIFIED_BY="[Empty name]" NAME="Chapel 1994" YEAR="1994">
<REFERENCE MODIFIED="2008-06-25 20:42:22 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chapel,H.M.; Lee,M.; Hargreaves,R.; Pamphilon,D.H.; Prentice,A.G</AU>
<TI>Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma</TI>
<SO>Lancet</SO>
<YR>1994</YR>
<VL>343</VL>
<NO>8905</NO>
<PG>1059-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chapel-1994c" MODIFIED="2008-06-25 20:42:11 +0200" MODIFIED_BY="[Empty name]" NAME="Chapel 1994c" YEAR="1994">
<REFERENCE MODIFIED="2008-06-25 20:42:11 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chapel,H.; Dicato,M.; Gamm,H.; Brennan,V.; Ries,F.; Bunch,C.; Lee,M</AU>
<TI>Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: a comparison of two dose regimes</TI>
<SO>British journal of haematology</SO>
<YR>1994</YR>
<VL>88</VL>
<PG>209-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Condie-1984" MODIFIED="2008-07-21 17:15:55 +0200" MODIFIED_BY="Nicole Skoetz" NAME="Condie 1984" YEAR="1984">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Condie RM, O'Reilly RJ</AU>
<TI>Prevention of cytomegalovirus infection by prophylaxis with an intravenous, hyperimmune, native, unmodified cytomegalovirus globulin. Randomized trial in bone marrow transplant recipients</TI>
<SO>The American journal of Medicine</SO>
<YR>1984</YR>
<VL>76</VL>
<NO>3A</NO>
<PG>134-141</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-07-21 17:15:55 +0200" MODIFIED_BY="Nicole Skoetz" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Reilly, R.J.; Reich, L.; Gold, J.; Kirkpatrick, D.; Dinsmore, R.; Kapoor, N.; Condie, R.</AU>
<TI>A randomized trial of intravenous hyperimmune globulin for the prevention of CMV infections following marrow transplantation: preliminary results</TI>
<SO>Transplantation proceedings</SO>
<YR>1983</YR>
<VL>XV</VL>
<NO>1</NO>
<PG>1405-1411</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cooperative-CLL-1988" MODIFIED="2008-06-25 20:45:51 +0200" MODIFIED_BY="[Empty name]" NAME="Cooperative CLL 1988" YEAR="1988">
<REFERENCE MODIFIED="2008-06-25 20:45:41 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia</AU>
<TI>Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia</TI>
<SO>The New England journal of medicine</SO>
<YR>1988</YR>
<VL>319</VL>
<NO>14</NO>
<PG>902-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-06-25 20:45:51 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Griffiths,H.; Brennan,V.; Lea,J.; Bunch,C.; Lee,M.; Chapel,H</AU>
<TI>Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors</TI>
<SO>Blood</SO>
<YR>1989</YR>
<VL>73</VL>
<NO>2</NO>
<PG>366-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cordonnier-2003" NAME="Cordonnier 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cordonnier C, Chevret S, Legrand M, Rafi H, Dhedin N, Lehmann B, Bassompierre F, Gluckman E</AU>
<TI>Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial</TI>
<SO>Annals of internal medicine</SO>
<YR>2003</YR>
<VL>139</VL>
<NO>1</NO>
<PG>8-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Emanuel-1992" NAME="Emanuel 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Emanuel D, Taylor J, Brochstein J, Kernan N, Boulad F, Small T.Gillo A, Laver J, Castro-Malaspina H, Young J, Papadopoulos E, Carabasi M, Childs B, Flomenberg M, O'Reilly R</AU>
<TI>The use of intravenous immune globulin as prophylaxis for the infectious complications of allogeneic marrow transplantation</TI>
<SO>Blood</SO>
<YR>1992</YR>
<VL>80</VL>
<NO>suppl 1</NO>
<PG>271a</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feinstein-1999" MODIFIED="2008-06-25 20:46:42 +0200" MODIFIED_BY="[Empty name]" NAME="Feinstein 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-06-25 20:46:42 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feinstein,L.C.; Seidel,K.; Jocum,J.; Bowden,R.A.; Anasetti,C.; Deeg,H.J.; Flowers,M.E.; Kansu,E.; Martin,P.J.; Nash,R.A.; Storek,J.; Etzioni,R.; Applebaum,F.R.; Hansen,J.A.; Storb,R.; Sullivan,K.M</AU>
<TI>Reduced dose intravenous immunoglobulin does not decrease transplant-related complications in adults given related donor marrow allografts</TI>
<SO>Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation</SO>
<YR>1999</YR>
<VL>5</VL>
<NO>6</NO>
<PG>369-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Filipovich-1992" MODIFIED="2008-06-25 20:46:54 +0200" MODIFIED_BY="[Empty name]" NAME="Filipovich 1992" YEAR="1992">
<REFERENCE MODIFIED="2008-06-25 20:46:54 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Filipovich,A.H.; Peltier,M.H.; Bechtel,M.K.; Dirksen,C.L.; Strauss,S.A.; Englund,J.A</AU>
<TI>Circulating cytomegalovirus (CMV) neutralizing activity in bone marrow transplant recipients: comparison of passive immunity in a randomized study of four intravenous IgG products administered to CMV-seronegative patients</TI>
<SO>Blood</SO>
<YR>1992</YR>
<VL>80</VL>
<PG>2656-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gluck-1990" MODIFIED="2008-07-21 17:16:22 +0200" MODIFIED_BY="Nicole Skoetz" NAME="Gluck 1990" YEAR="1990">
<REFERENCE MODIFIED="2008-07-21 17:16:22 +0200" MODIFIED_BY="Nicole Skoetz" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Gluck, S., Schnutenhaus, W., Schneider, W.</AU>
<TI>Prophylactic intravenous immunoglobulin (IVIG) application to patients with recurrent infections and secondary antibody deficiency due to B-cell neoplasia</TI>
<SO>Blut</SO>
<YR>1990</YR>
<VL>61</VL>
<NO>2-3</NO>
<PG>140</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Graham-Pole-1990" NAME="Graham Pole 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Graham Pole,J.; Amylon, M; Elfenbein,G.; Gallo,J.; Klempere,M.; Janssen,J.; Lazarus, H.; Pick, T.; Fand, K.; Spruce, W.</AU>
<TI>Preventing systemic infections with IVIG: a randomized multicenter trial</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>1990</YR>
<VL>5</VL>
<NO>suppl 2</NO>
<PG>132</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hargreaves-1992" MODIFIED="2008-06-25 20:47:36 +0200" MODIFIED_BY="[Empty name]" NAME="Hargreaves 1992" YEAR="1992">
<REFERENCE MODIFIED="2008-06-25 20:47:36 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Hagreaves R.M.; Lea J.R.; Holt J; Bunch C; Reid C; Griffiths H; Chapel,H.</AU>
<TI>Infection, immune response and intravenous immunoglobulin infection prophylaxis in myeloma</TI>
<SO>British journal of cancer</SO>
<YR>1992</YR>
<VL>66</VL>
<NO>suppl XVII Abstract O40</NO>
<PG>11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jacobsen-1985" MODIFIED="2008-06-25 20:48:52 +0200" MODIFIED_BY="[Empty name]" NAME="Jacobsen 1985" YEAR="1985">
<REFERENCE MODIFIED="2008-06-25 20:48:22 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jacobsen,N.; Schafer,U.; Ostendorf,P.; Kubaneck,B.; Wolf,H</AU>
<TI>Intravenous hyperimmune globulin prophylaxis against cytomegalovirus interstitial pneumonitis after allogenic bone marrow transplantation</TI>
<SO>The Tokai journal of experimental and clinical medicine</SO>
<YR>1985</YR>
<VL>10</VL>
<NO>2-3</NO>
<PG>193-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-06-25 20:48:52 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kubaneck B ; Ernst P; Ostendorf P; Schafer U ; Wolf H</AU>
<TI>Preliminary data of a controlled trial of interavenous hyperimmune globulin in the prevention of cytomegalovirus infection in bone marrow transplant recipients</TI>
<SO>Transplantation proceedings</SO>
<YR>1985</YR>
<VL>XVII</VL>
<PG>468-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lum-1994" MODIFIED="2008-06-25 20:49:25 +0200" MODIFIED_BY="[Empty name]" NAME="Lum 1994" YEAR="1994">
<REFERENCE MODIFIED="2008-06-25 20:49:25 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lum L, Bitonti O, Galoforo S, Walker A, Lum C, Abella E, Babington R, Karenes C, Momim F, Uberti J, Ratanatharathorn V, Sensenbrenner L</AU>
<TI>Intravenous gammaglobulin (IVIG) does not alter immune parameters in a randomized trial after bone marrow transplantation (BMT)</TI>
<SO>Experimental hematology</SO>
<YR>1994</YR>
<VL>22</VL>
<PG>680</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meyers-1983" MODIFIED="2008-06-25 20:52:01 +0200" MODIFIED_BY="[Empty name]" NAME="Meyers 1983" YEAR="1983">
<REFERENCE MODIFIED="2008-06-25 20:52:01 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meyers,J.D.; Leszczynski,J.; Zaia,J.A.; Flournoy,N.; Newton,B.; Snydman,D.R.; Wright,G.G.; Levin,M.J.; Thomas,E.D</AU>
<TI>Prevention of cytomegalovirus infection by cytomegalovirus immune globulin after marrow transplantation</TI>
<SO>Annals of internal medicine</SO>
<YR>1983</YR>
<VL>98</VL>
<PG>442-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Molica-1996" MODIFIED="2008-06-25 20:52:14 +0200" MODIFIED_BY="[Empty name]" NAME="Molica 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-06-25 20:52:14 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Molica S; Musto P; Chiurazzi F; Specchia G; Brugiatelli M; Cicoira L; Levato D; Nobile F; Carotenuto M; Liso V; Rotoli B</AU>
<TI>Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study</TI>
<SO>Haematologica</SO>
<YR>1996</YR>
<VL>81</VL>
<NO>2</NO>
<PG>121-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Musto-1995" MODIFIED="2008-06-25 20:52:45 +0200" MODIFIED_BY="[Empty name]" NAME="Musto 1995" YEAR="1995">
<REFERENCE MODIFIED="2008-06-25 20:52:45 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Musto,P.; Brugiatelli,M.; Carotenuto,M</AU>
<TI>Prophylaxis against infections with intravenous immunoglobulins in multiple myeloma</TI>
<SO>British journal of haematology</SO>
<YR>1995</YR>
<VL>89</VL>
<NO>4</NO>
<PG>945-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peltier-1992" MODIFIED="2008-06-25 20:53:17 +0200" MODIFIED_BY="[Empty name]" NAME="Peltier 1992" YEAR="1992">
<REFERENCE MODIFIED="2008-06-25 20:53:17 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peltier MK, Filipovich AH, Bechtel M, Dirksen CL, Englund JA</AU>
<TI>Randomized double-blinded comparison of three intravenous immunoglobulin products in bone marrow transplantation</TI>
<SO>Seminars in hematology</SO>
<YR>1992</YR>
<VL>29</VL>
<PG>112-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poynton-1992" MODIFIED="2008-06-25 20:54:20 +0200" MODIFIED_BY="[Empty name]" NAME="Poynton 1992" YEAR="1992">
<REFERENCE MODIFIED="2008-06-25 20:53:49 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jackson,S.K.; Parton,J.; Barnes,R.A.; Poynton,C.H.; Fegan,C</AU>
<TI>Effect of IgM-enriched intravenous immunoglobulin (Pentaglobin) on endotoxaemia and anti-endotoxin antibodies in bone marrow transplantation</TI>
<SO>European journal of clinical investigation</SO>
<YR>1993</YR>
<VL>23</VL>
<NO>9</NO>
<PG>540-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-06-25 20:54:20 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Poynton CH, Jackson S, Fegan C, Barnes RA, Whittaker JA</AU>
<TI>Use of IgM enriched intravenous immunoglobulin (Pentaglobin) in bone marrow transplantation</TI>
<SO>Bone marrow transplantation</SO>
<YR>1992</YR>
<VL>9</VL>
<PG>451-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raiola-2002" NAME="Raiola 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Raiola AM; Di Grazia C; Dominietto A; Bregante S; Gualandi F; Lamparelli T; Occhini D; Van Lint MT; Bacigalupo A</AU>
<TI>Prevention of graft versus host disease with IgM enriched immunoglobulins: a preliminary analysis of a randomized study [abstract]</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>2002</YR>
<VL>29</VL>
<NO>Suppl 2</NO>
<PG>S188</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ringden-1987" MODIFIED="2008-06-25 20:54:41 +0200" MODIFIED_BY="[Empty name]" NAME="Ringden 1987" YEAR="1987">
<REFERENCE MODIFIED="2008-06-25 20:54:41 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ringden,O.; Pihlstedt,P.; Volin,L.; Nikoskelainen,J.; Lonnqvist,B.; Ruutu,P.; Ruutu,T.; Toivanen,A.; Wahren,B</AU>
<TI>Failure to prevent cytomegalovirus infection by cytomegalovirus hyperimmune plasma: a randomized trial by the Nordic Bone Marrow Transplantation Group</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>1987</YR>
<VL>2</VL>
<NO>3</NO>
<PG>299-305</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ruutu-1997" MODIFIED="2008-06-25 20:54:59 +0200" MODIFIED_BY="[Empty name]" NAME="Ruutu 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-06-25 20:54:59 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ruutu T., Ljungman P., Brinch L., Lenhoff S., Lonnqvist B., Ringden O., Ruutu P. Volin L., Albrechtsen D.; Sallerfors B., Ebeling F., Myllyla G.</AU>
<TI>No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group</TI>
<SO>Bone marrow transplantation</SO>
<YR>1997</YR>
<VL>19</VL>
<NO>3</NO>
<PG>233-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salmon-1967" MODIFIED="2008-06-25 20:55:26 +0200" MODIFIED_BY="[Empty name]" NAME="Salmon 1967" YEAR="1967">
<REFERENCE MODIFIED="2008-06-25 20:55:26 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Salmon,S.E.; Samal,B.A.; Hayes,D.M.; Hosley,H.; Miller,S.P.; Schilling,A</AU>
<TI>Role of gamma globulin for immunoprophylaxis in multiple myeloma</TI>
<SO>The New England journal of medicine</SO>
<YR>1967</YR>
<VL>277</VL>
<PG>1336-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Serrano-1999" NAME="Serrano 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>J. Serrano, M. Falcon, J.A. Castillejo, J.A. Navarro, A. Pascual, I. Gracia-Rubio, C. Martin, P. Gomez, F. Martinez, A. Torres</AU>
<TI>A randomized trial to determine the utility of intravenous hyperimmune immunoglobulin in antimicrobial prophylaxis and its immunomodulatory effect in allogeneic bone marrow transplantation hyperimmune immunoglobulin in antimicrobial prophylaxis and its immunomodulatory effect in allogeneic bone marrow transplantation</TI>
<SO>Transplantology (Madrid)</SO>
<YR>1999</YR>
<VL>10</VL>
<NO>1</NO>
<PG>1-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sklenar-1993" NAME="Sklenar 1993" YEAR="1993">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sklenar,I.; Schiffman,G.; Jonsson,V.; Verhoef,G.; Birgens,H.; Boogaerts,M.; Ferrant,A.; Christensen,B.E.; Hasle,H.; Drivsholm,A</AU>
<TI>Effect of various doses of intravenous polyclonal IgG on in vivo levels of 12 pneumococcal antibodies in patients with chronic lymphocytic leukaemia and multiple myeloma</TI>
<SO>Oncology</SO>
<YR>1993</YR>
<VL>50</VL>
<PG>466-477</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sullivan-1990" MODIFIED="2008-06-25 20:55:46 +0200" MODIFIED_BY="[Empty name]" NAME="Sullivan 1990" YEAR="1990">
<REFERENCE MODIFIED="2008-06-25 20:55:46 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sullivan, K.M.;Kopecky, K.J,; Jocom ,J.; Fisher, L.; Buckner ,CD; Meyers, J.D.; Counts, G.W.; Bowden, R.A.; Peterson, F.B.; Witherspoon, R.P.</AU>
<TI>Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation</TI>
<SO>The New England journal of Medicine</SO>
<YR>1990</YR>
<VL>323</VL>
<NO>11</NO>
<PG>705-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sullivan-2000" NAME="Sullivan 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sullivan, K.; Seidel,K.; Jocom, J.; Anasetti, C.; Hnasen, J.; Storb, R.; Messner, H.; Ndemanee, A.; Goldman, J.; Kolb, H.; Beatty, P.; Gluckman, E</AU>
<TI>Intravenous immunoglobulin (IVIG) prophylaxis in unrelated ddonor bone marrow transplantation(BMT): a phase III double-blind, Placebo-controlled multi-institutional trial</TI>
<SO>ASCO annual meeting abstract book</SO>
<YR>2000</YR>
<PG>abstract 181</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ustun-1998" NAME="Ustun 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ustun, C.; Ozcan, M.; Beksac, M.; Ilhan, O.; Cakir Gurman, G.; Akan, H.; Demirer, T.; Arat, M.; Celebi, H.; Konuk, N.; et al.</AU>
<TI>Clinical effects of intravenous immune globulin (IVIG)treatment in patients with allogenetic peripheral stem cell transplantation</TI>
<SO>Blood</SO>
<YR>1998</YR>
<VL>92</VL>
<NO>10 Suppl1 (Pt 2)</NO>
<PG>355b, abstract 4528</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Winston-1982" MODIFIED="2008-06-25 20:56:49 +0200" MODIFIED_BY="[Empty name]" NAME="Winston 1982" YEAR="1982">
<REFERENCE MODIFIED="2008-06-25 20:56:49 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Winston,D.J.; Pollard,R.B.; Ho,W.G.; Gallagher,J.G.; Rasmussen,L.E.; Huang,S.N.; Lin,C.H.; Gossett,T.G.; Merigan,T.C.; Gale,R.P</AU>
<TI>Cytomegalovirus immune plasma in bone marrow transplant recipients</TI>
<SO>Annals of internal medicine</SO>
<YR>1982</YR>
<VL>97</VL>
<NO>1</NO>
<PG>11-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Winston-1984" MODIFIED="2008-06-25 20:58:52 +0200" MODIFIED_BY="[Empty name]" NAME="Winston 1984" YEAR="1984">
<REFERENCE MODIFIED="2008-06-25 20:58:52 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Winston,D.J.; Ho,W.G.; Lin,C.H.; Budinger,M.D.; Champlin,R.E.; Gale,R.P</AU>
<TI>Intravenous immunoglobulin for modification of cytomegalovirus infections associated with bone marrow transplantation. Preliminary results of a controlled trial</TI>
<SO>The American journal of medicine</SO>
<YR>1984</YR>
<VL>76</VL>
<NO>3A</NO>
<PG>128-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Winston-1987" MODIFIED="2008-06-25 21:00:43 +0200" MODIFIED_BY="[Empty name]" NAME="Winston 1987" YEAR="1987">
<REFERENCE MODIFIED="2008-06-25 21:00:08 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Winston DJ, Ho WG, Lin GH et al. Winston DJ, Ho WG, Lin GH et al. [Use of a polyvalent intravenous immunoglobulin or specific cytomegalovirus hyperimmunoglobulin for modification of cytomegalovirus infections and prevention of interstitial pneumonias following bone marrow transplantation]. Immun Infekt. 1985;13:296-301. Winston DJ, Ho WG, Lin GH et al.</AU>
<TI>Use of a polyvalent intravenous immunoglobulin or specific cytomegalovirus hyperimmunoglobulin for modification of cytomegalovirus infections and prevention of interstitial pneumonias following bone marrow transplantation</TI>
<SO>Immunitat und Infektion</SO>
<YR>1985</YR>
<VL>13</VL>
<PG>296-301</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-06-25 21:00:43 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Winston,D.J.; Ho,W.G.; Lin,C.H.; Bartoni,K.; Budinger,M.D.; Gale,R.P.; Champlin,R.E</AU>
<TI>Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation</TI>
<SO>Annals of internal medicine</SO>
<YR>1987</YR>
<VL>106</VL>
<NO>1</NO>
<PG>12-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Winston-1993" MODIFIED="2008-06-25 21:00:55 +0200" MODIFIED_BY="[Empty name]" NAME="Winston 1993" YEAR="1993">
<REFERENCE MODIFIED="2008-06-25 21:00:55 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Winston, D.J., Ho, W.G., Bartoni,K., Champlin, R.E</AU>
<TI>Intravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients</TI>
<SO>Bone marrow transplantation</SO>
<YR>1993</YR>
<VL>12</VL>
<NO>3</NO>
<PG>283-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Winston-2001" MODIFIED="2008-06-25 21:01:04 +0200" MODIFIED_BY="[Empty name]" NAME="Winston 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-06-25 21:01:04 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Winston, D..J, Antin, J.H., Wolff, S.N., Bierer, B.E., Small, T., Miller, K.B,. Linker, C., Kaizer, H., Lazarus, H.M., Petersen, F.B., Cowan, M.J., Ho, W.G., Wingard, J.R., Schiller,G.J., Territo, M.C., Jiao, J., Petrarca, M.A., Tonetta, S.A.</AU>
<TI>A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation</TI>
<SO>Bone marrow transplantation</SO>
<YR>2001</YR>
<VL>28</VL>
<NO>2</NO>
<PG>187-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolff-1993" MODIFIED="2008-06-25 21:01:16 +0200" MODIFIED_BY="[Empty name]" NAME="Wolff 1993" YEAR="1993">
<REFERENCE MODIFIED="2008-06-25 21:01:16 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wolff SN, Fay JW, Herzig RH, Greer JP, Dummer S, Brown RA, Collins RH, Stevens DA, Herzig GP</AU>
<TI>High-dose weekly intravenous immunoglobulin to prevent infections in patients undergoing autologous bone marrow transplantation or severe myelosuppressive therapy. A study of the American Bone Marrow Transplant Group</TI>
<SO>Annals of internal medicine</SO>
<YR>1993</YR>
<VL>118</VL>
<NO>12</NO>
<PG>937-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zikos-1998" MODIFIED="2008-06-25 21:01:25 +0200" MODIFIED_BY="[Empty name]" NAME="Zikos 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-06-25 21:01:25 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zikos,P.; Van Lint,M.T.; Lamparelli,T.; Gualandi,F.; Occhini,D.; Mordini,N.; Berisso,G.; Bregante,S.; Bacigalupo,A</AU>
<TI>A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIgG) vs. Cytomegalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT)</TI>
<SO>Haematologica</SO>
<YR>1998</YR>
<VL>83</VL>
<NO>2</NO>
<PG>132-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-06-26 19:27:51 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Aulitzky-1991" MODIFIED="2008-06-26 19:14:51 +0200" MODIFIED_BY="[Empty name]" NAME="Aulitzky 1991" YEAR="1991">
<REFERENCE MODIFIED="2008-06-26 19:14:51 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aulitzky,W.E.; Schulz,T.F.; Tilg,H.; Niederwieser,D.; Larcher,K.; Ostberg,L.; Scriba,M.; Martindale,J.; Stern,A.C.; Grass,P</AU>
<TI>Human monoclonal antibodies neutralizing cytomegalovirus (CMV) for prophylaxis of CMV disease: report of a phase I trial in bone marrow transplant recipients</TI>
<SO>The Journal of infectious diseases</SO>
<YR>1991</YR>
<VL>163</VL>
<NO>6</NO>
<PG>1344-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bode-1986" MODIFIED="2008-06-26 19:15:22 +0200" MODIFIED_BY="[Empty name]" NAME="Bode 1986" YEAR="1986">
<REFERENCE MODIFIED="2008-06-26 19:15:22 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bode,U.; Erps,M.; Liappis,N</AU>
<TI>Immunoglobulin administration as infection prevention in oncologic patients</TI>
<TO>Immunglobulingabe als infektionprophylaxe onkologischer patienten?</TO>
<SO>Klinische P?diatrie</SO>
<YR>1986</YR>
<VL>198</VL>
<NO>6</NO>
<PG>476-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bunch-1988" MODIFIED="2008-06-26 19:15:35 +0200" MODIFIED_BY="[Empty name]" NAME="Bunch 1988" YEAR="1988">
<REFERENCE MODIFIED="2008-06-26 19:15:35 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bunch, C.</AU>
<TI>Immunoglobulin replacement in chronic lymphocytic leukaemia</TI>
<SO>Nouvelle Revue Francaise d'Hematologie</SO>
<YR>1988</YR>
<VL>30</VL>
<NO>5-6</NO>
<PG>419-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chapel-1992" MODIFIED="2008-06-26 19:16:04 +0200" MODIFIED_BY="[Empty name]" NAME="Chapel 1992" YEAR="1992">
<REFERENCE MODIFIED="2008-06-26 19:16:04 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-06-26 19:16:04 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chapel HM, Lee M.</AU>
<TI>Immunoglobulin replacement in patients with chronic lymphocytic leukemia (CLL):kinetics of immunoglobulin metabolism</TI>
<SO>Journal of clinical immunology</SO>
<YR>1992</YR>
<VL>12</VL>
<NO>1</NO>
<PG>17-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chapel-1993" MODIFIED="2008-06-26 19:16:14 +0200" MODIFIED_BY="[Empty name]" NAME="Chapel 1993" YEAR="1993">
<REFERENCE MODIFIED="2008-06-26 19:16:14 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chapel,H.M.; Hargreaves,R.; Lee,M.; Pamphilon,D</AU>
<TI>Intravenous immunoglobulin therapy in patients with multiple myeloma</TI>
<SO>Immunodeficiency</SO>
<YR>1993</YR>
<VL>4</VL>
<NO>1-4</NO>
<PG>77-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Collins-1991" MODIFIED="2008-06-26 19:16:41 +0200" MODIFIED_BY="[Empty name]" NAME="Collins 1991" YEAR="1991">
<REFERENCE MODIFIED="2008-06-26 19:16:41 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Collins, P.W.; Slocombe, G.; Wainwright, A.; Newland, A.C.</AU>
<TI>A pilot study using intravenous immunoglobulin for the prevention of infection during remission induction in acute leukaemia</TI>
<SO>Leukemia &amp; lymphoma</SO>
<YR>1991</YR>
<VL>6</VL>
<PG>25-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Collins, P.W.; Solocombe, G.; Wainwright, A.; Newland, A.C.</AU>
<TI>Intravenous immunoglobulin for infection prophylaxis in acute leukemia</TI>
<SO>British Journal of Haemaology</SO>
<YR>1991</YR>
<VL>77</VL>
<NO>Suppl 1</NO>
<PG>75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Copelan-1994" MODIFIED="2008-06-26 19:17:09 +0200" MODIFIED_BY="[Empty name]" NAME="Copelan 1994" YEAR="1994">
<REFERENCE MODIFIED="2008-06-26 19:17:09 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Copelan,E.A.; Bechtel,T.P.; Klein,J.P.; Klein,J.L.; Tutschka,P.; Kapoor,N.; Featheringham,N.C.; Avalos,B.R</AU>
<TI>Controlled trial of orally administered immunoglobulin following bone marrow transplantation</TI>
<SO>Bone marrow transplantation</SO>
<YR>1994</YR>
<VL>13</VL>
<PG>87-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cortez-2002" MODIFIED="2008-06-26 19:17:41 +0200" MODIFIED_BY="[Empty name]" NAME="Cortez 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-06-26 19:17:41 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cortez,K.; Murphy,B.R.; Almeida,K.N.; Beeler,J.; Levandowski,R.A.; Gill,V.J.; Childs,R.W.; Barrett,A.J.; Smolskis,M.; Bennett,J.E</AU>
<TI>Immune-globulin prophylaxis of respiratory syncytial virus infection in patients undergoing stem-cell transplantation</TI>
<SO>The Journal of infectious diseases</SO>
<YR>2002</YR>
<VL>186</VL>
<PG>834-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eijkhout-2001" MODIFIED="2008-06-26 19:18:21 +0200" MODIFIED_BY="[Empty name]" NAME="Eijkhout 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-06-26 19:18:21 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eijkhout,H.W.; Der Meer,J.W.; Kallenberg,C.G.; Weening,R.S.; van Dissel,J.T.; Sanders,L.A.; Strengers,P.F.; Nienhuis,H.; Schellekens,P.T</AU>
<TI>The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial</TI>
<SO>Annals of internal medicine</SO>
<YR>2001</YR>
<VL>135</VL>
<PG>165-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elfenbein-1989" MODIFIED="2008-06-26 19:19:06 +0200" MODIFIED_BY="[Empty name]" NAME="Elfenbein 1989" YEAR="1989">
<REFERENCE MODIFIED="2008-06-26 19:19:06 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Elfenbein,G.; Krischer,J.; Babington,R.; Hong,R.; Jansen,J.; Lazarus,H.; Winton,E.; Rand,K.</AU>
<TI>Interim results of a multicenter trial to prevent cytomegalovirus pneumonia after allogeneic bone marrow transplantation</TI>
<SO>Transplantation proceedings</SO>
<YR>1989</YR>
<VL>21</VL>
<NO>1</NO>
<PG>3099-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Esperou-2004" MODIFIED="2008-06-26 19:19:18 +0200" MODIFIED_BY="[Empty name]" NAME="Esperou 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-06-26 19:19:18 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Esperou,H.; Brunot,A.; Roudot-Thoraval,F.; Buzyn,A.; Dhedin,N.; Rio,B.; Chevret,S.; Bassompierre,F.; Gluckman,E.; Cordonnier,C.; Durand-Zaleski,I</AU>
<TI>Predicting the costs of allogeneic sibling stem-cell transplantation: results from a prospective, multicenter, French study</TI>
<SO>Transplantation</SO>
<YR>2004</YR>
<VL>77</VL>
<PG>1854-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fehir-1989" MODIFIED="2008-06-26 19:19:46 +0200" MODIFIED_BY="[Empty name]" NAME="Fehir 1989" YEAR="1989">
<REFERENCE MODIFIED="2008-06-26 19:19:46 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fehir,K.M.; Decker,W.A.; Samo,T.; Young,J.B.; Lederer,E.; Lawrence,E.C</AU>
<TI>Immune globulin (GAMMAGARD) prophylaxis of CMV infections in patients undergoing organ transplantation and allogeneic bone marrow transplantation</TI>
<SO>Transplantation proceedings</SO>
<YR>1989</YR>
<VL>21</VL>
<NO>1 Pt 3</NO>
<PG>3107-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gamm-1994" MODIFIED="2008-06-26 19:20:08 +0200" MODIFIED_BY="[Empty name]" NAME="Gamm 1994" YEAR="1994">
<REFERENCE MODIFIED="2008-06-26 19:20:08 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gamm,H.; Huber,C.; Chapel,H.; Lee,M.; Ries,F.; Dicato,M.A.</AU>
<TI>Intravenous immune globulin in chronic lymphocytic leukaemia</TI>
<SO>Clinical and experimental immunology</SO>
<YR>1994</YR>
<VL>97 Suppl 1</VL>
<PG>17-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gerein-1989" MODIFIED="2008-06-26 19:20:43 +0200" MODIFIED_BY="[Empty name]" NAME="Gerein 1989" YEAR="1989">
<REFERENCE MODIFIED="2008-06-26 19:20:43 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gerein,V.; Kropp,H.; Schwabe,D.; Gussetis,E.; Langer,B.; Kornhuber,B</AU>
<TI>[Prevention of cytomegalic inclusion disease in leukemia patients with a cytomegalovirus hyperimmune globulin preparation]</TI>
<TO>Zytomegalie-prophylaxe bei leukamierpatienten mit einem zytomegalie-hyperimmunglobulinpraparat</TO>
<SO>Klinische P?diatrie</SO>
<YR>1989</YR>
<VL>201</VL>
<NO>4</NO>
<PG>323-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gimesi-1992" MODIFIED="2008-06-26 19:20:53 +0200" MODIFIED_BY="[Empty name]" NAME="Gimesi 1992" YEAR="1992">
<REFERENCE MODIFIED="2008-06-26 19:20:53 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gimesi, A.; Eibl, M.; Koos, R.; Somlo, P.; Magyarossy, E.; Kardos, G.; Fazekas, E.; Schmidt, M.; Borsi, J.; Schuler, D.</AU>
<TI>Immunoglobulin prophylaxis during intensive treatment of acute lymphoblastic leukemia in children</TI>
<SO>Acta Paediatrica Hungarica</SO>
<YR>1992</YR>
<VL>32</VL>
<NO>2</NO>
<PG>115-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Graham-Pole-1988" MODIFIED="2008-06-26 19:21:25 +0200" MODIFIED_BY="[Empty name]" NAME="Graham Pole 1988" YEAR="1988">
<REFERENCE MODIFIED="2008-06-26 19:21:25 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Graham-Pole,J.; Camitta,B.; Casper,J.; Elfenbein,G.; Gross,S.; Herzig,R.; Koch,P.; Mahoney,D.; Marcus,R.; Munoz,L.; Munoz,L; Pick,T; Spruce,W; Steuber,P.; Weiner,R</AU>
<TI>Intravenous immunoglobulin may lessen all forms of infection in patients receiving allogeneic bone marrow transplantation for acute lymphoblastic leukemia: a pediatric oncology group study</TI>
<SO>Bone marrow transplantation</SO>
<YR>1988</YR>
<VL>3</VL>
<PG>559-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jurlander-1994" MODIFIED="2008-06-26 19:21:38 +0200" MODIFIED_BY="[Empty name]" NAME="Jurlander 1994" YEAR="1994">
<REFERENCE MODIFIED="2008-06-26 19:21:38 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jurlander J, Geisler CH, Hansen MM</AU>
<TI>Treatment of hypogammaglobulinaemia in chronic lymphocytic leukaemia by low-dose intravenous gammaglobulin</TI>
<SO>European journal of haematology</SO>
<YR>1994</YR>
<VL>53</VL>
<NO>2</NO>
<PG>114-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klaesson-1995" MODIFIED="2008-06-26 19:23:10 +0200" MODIFIED_BY="[Empty name]" NAME="Klaesson 1995" YEAR="1995">
<REFERENCE MODIFIED="2008-06-26 19:23:10 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klaesson,S.; Ringden,O.; Markling,L.; Tammik,L</AU>
<TI>Intravenous immunoglobulin: immune modulatory effects in vitro and clinical effects in allogeneic bone marrow transplant recipients</TI>
<SO>Transplantation proceedings</SO>
<YR>1995</YR>
<VL>27</VL>
<NO>6</NO>
<PG>3536-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Messori-1994" MODIFIED="2008-06-26 19:23:38 +0200" MODIFIED_BY="[Empty name]" NAME="Messori 1994" YEAR="1994">
<REFERENCE MODIFIED="2008-06-26 19:23:38 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Messori,A.; Rampazzo,R.; Scroccaro,G.; Martini,N</AU>
<TI>Efficacy of hyperimmune anti-cytomegalovirus immunoglobulins for the prevention of cytomegalovirus infection in recipients of allogeneic bone marrow transplantation: a meta-analysis</TI>
<SO>Bone marrow transplantation</SO>
<YR>1994</YR>
<VL>13</VL>
<NO>2</NO>
<PG>163-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nasman--Bjork-1999" NAME="Nasman  Bjork 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nasman B, I, Fesel C, Brissac C, Lundkvist I</AU>
<TI>Prophylactic intravenous immunoglobulin treatment influences serum immunoglobulin M repertoire development after allogeneic bone marrow transplantation</TI>
<SO>Scandinavian journal of immunology</SO>
<YR>1999</YR>
<VL>50</VL>
<NO>1</NO>
<PG>73-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nurnberger-1988" NAME="Nurnberger 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nurenberger, W.; Willers, R.; Schroten, H.; Bunning, G.; Gobel, U.; Whan, V</AU>
<TI>Preventive long term intravenous immunoglobulin infusion in children with acute lymphatic leukemia. II. Zymosan opsonization is decreased and is not increased by IgG infusions</TI>
<TO>Prophylaktische Langzeit-i.v.-Immunoglobulin-Infusion bei Kindern mot akuter lymphatischer Leulamie. II. Die Zymosan-Opsonisierung ist erniedrigt und wird durch IgG-infusionen nicht gesteigert</TO>
<SO>Monatsschroft Kinderheilkunde: Organ der Deutschen Gesellschaft fur Kinderheilkunde</SO>
<YR>1988</YR>
<VL>136</VL>
<NO>4</NO>
<PG>181-185</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Petersen-1987" MODIFIED="2008-06-26 19:24:08 +0200" MODIFIED_BY="[Empty name]" NAME="Petersen 1987" YEAR="1987">
<REFERENCE MODIFIED="2008-06-26 19:24:08 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Petersen FB, Bowden RA, Thornquist M, Meyers JD, Buckner CD, Counts GW, Nelson N, Newton BA, Sullivan KM, McIver J</AU>
<TI>The effect of prophylactic intravenous immune globulin on the incidence of septicemia in marrow transplant recipients</TI>
<SO>Bone marrow transplantation</SO>
<YR>1987</YR>
<VL>2</VL>
<NO>2</NO>
<PG>141-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rand-1991" MODIFIED="2008-06-26 19:24:53 +0200" MODIFIED_BY="[Empty name]" NAME="Rand 1991" YEAR="1991">
<REFERENCE MODIFIED="2008-06-26 19:24:53 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rand,K.H.; Gibbs,K.; Derendorf,H.; Graham-Pole,J</AU>
<TI>Pharmacokinetics of intravenous immunoglobulin (Gammagard) in bone marrow transplant patients</TI>
<SO>Journal of clinical pharmacology</SO>
<YR>1991</YR>
<VL>31</VL>
<NO>12</NO>
<PG>1151-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spitzer-1992" MODIFIED="2008-06-26 19:25:18 +0200" MODIFIED_BY="[Empty name]" NAME="Spitzer 1992" YEAR="1992">
<REFERENCE MODIFIED="2008-06-26 19:25:18 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spitzer,T.R.; Cottler-Fox,M.; Sullivan,P.; Lynch,M.; Tefft,M.C.; Pickle,L.W.; Cirenza,E.; Cahill,R.; Deeg,H.J.; Sacher,R</AU>
<TI>Continuous infusion intravenous immunoglobulin is associated with a reduced incidence of infection and achieves higher serum immunoglobulin G levels than intermittent infusion following bone marrow transplantation</TI>
<SO>Seminars in hematology</SO>
<YR>1992</YR>
<VL>29</VL>
<NO>3 Suppl 2</NO>
<PG>123-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sullivan-1996" MODIFIED="2008-06-26 19:25:40 +0200" MODIFIED_BY="[Empty name]" NAME="Sullivan 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-06-26 19:25:40 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sullivan,K.M.; Storek,J.; Kopecky,K.J.; Jocom,J.; Longton,G.; Flowers,M.; Siadak,M.; Nims,J.; Witherspoon,R.P.; Anasetti,C.; Appelbaum,F.R.; Bowden,R.A.; Buckner,C.D.; Crawford,S.W.; Deeg,H.J.; Hansen,J.A.; McDonald,G.B.; Sanders,J.E.; Storb,R</AU>
<TI>A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery</TI>
<SO>Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation</SO>
<YR>1996</YR>
<VL>2</VL>
<NO>1</NO>
<PG>44-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sullivan-1998" MODIFIED="2008-06-26 19:26:03 +0200" MODIFIED_BY="[Empty name]" NAME="Sullivan 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-06-26 19:26:03 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sullivan,K.M.; Kansu,E.; Storer,B.; Jocom,J.; Emerson,G.; Reagan,T.; Emerson,V.; Siadak,M.F.; Davis,C.; Appelbaum,F.R.; Buckner,C.D.; Hansen,J.A.; Shulman,H.M.; Storb,R.; McDonald,G.B</AU>
<TI>Intravenous immunoglobulin and the risk of hepatic veno-occlusive disease after bone marrow transplantation</TI>
<SO>Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation</SO>
<YR>1998</YR>
<VL>4</VL>
<NO>1</NO>
<PG>20-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Terada-1980" MODIFIED="2008-06-26 19:26:55 +0200" MODIFIED_BY="[Empty name]" NAME="Terada 1980" YEAR="1980">
<REFERENCE MODIFIED="2008-06-26 19:26:55 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Terada,H.; Matsuno,K.</AU>
<TI>Clinical effects of gamma globulin in severe infections associated with leukemia and malignant lymphoma</TI>
<SO>[Rinsho ketsueki] The Japanese journal of clinical hematology</SO>
<YR>1980</YR>
<VL>21</VL>
<NO>9</NO>
<PG>1328 - 32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vu-Van-1985" MODIFIED="2008-06-26 19:27:51 +0200" MODIFIED_BY="[Empty name]" NAME="Vu Van 1985" YEAR="1985">
<REFERENCE MODIFIED="2008-06-26 19:27:51 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vu Van, H.; Fiere, D.; Chomel, J.; Thouvenot, D.; Guyotat, D.; Dutou, L.; Ginestet, C.; Lacroze, M.; Aymard, M.</AU>
<TI>Prophylaxis against cytomegalovirus infection after BMT with gammaglobulins</TI>
<SO>Experimental hematology (suppl.17)</SO>
<YR>1985</YR>
<VL>13</VL>
<PG>105</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-06-26 19:38:39 +0200" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-06-26 19:38:39 +0200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Bass-1993" MODIFIED="2008-06-26 19:31:14 +0200" MODIFIED_BY="[Empty name]" NAME="Bass 1993" TYPE="JOURNAL_ARTICLE">
<AU>Bass EB, Powe NR, Goodman SN, Graziano SL, Griffiths RI, Kickler TS, Wingard JR</AU>
<TI>Efficacy of immune globulin in preventing complications of bone marrow transplantation: a meta-analysis.</TI>
<SO>Bone marrow transplantation</SO>
<YR>1993</YR>
<VL>12</VL>
<NO>3</NO>
<PG>273-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Besa-1992" NAME="Besa 1992" TYPE="JOURNAL_ARTICLE">
<AU>Besa EC</AU>
<TI>Recent advances in the treatment of chronic lymphocytic leukemia: defining the role of intravenous immunoglobulin</TI>
<SO>Seminars in hematology</SO>
<YR>1992</YR>
<VL>29</VL>
<NO>3 Suppl 2</NO>
<PG>14-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chapel-1994a" MODIFIED="2008-06-26 19:31:26 +0200" MODIFIED_BY="[Empty name]" NAME="Chapel 1994a" TYPE="JOURNAL_ARTICLE">
<AU>Chapel HM, Lee M, Hargreaves R, Pamphilon DH, Prentice AG</AU>
<TI>Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma</TI>
<SO>Lancet</SO>
<YR>1994</YR>
<VL>343</VL>
<NO>8905</NO>
<PG>1059-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chapel-1994b" MODIFIED="2008-06-26 19:31:34 +0200" MODIFIED_BY="[Empty name]" NAME="Chapel 1994b" TYPE="JOURNAL_ARTICLE">
<AU>Chapel HM, Lee M</AU>
<TI>The use of intravenous immune globulin in multiple myeloma</TI>
<SO>Clinical and experimental immunology</SO>
<YR>1994</YR>
<VL>97 Suppl 1</VL>
<PG>21-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Consensus-IVIG-1990" MODIFIED="2008-06-26 19:31:42 +0200" MODIFIED_BY="[Empty name]" NAME="Consensus IVIG 1990" TYPE="JOURNAL_ARTICLE">
<AU>No authors listed</AU>
<TI>Consensus on IVIG</TI>
<SO>Lancet</SO>
<YR>1990</YR>
<VL>336</VL>
<NO>8713</NO>
<PG>470-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Espersen-1984" MODIFIED="2008-06-26 19:31:51 +0200" MODIFIED_BY="[Empty name]" NAME="Espersen 1984" TYPE="JOURNAL_ARTICLE">
<AU>Espersen F, Birgens HS, Hertz JB, Drivsholm A</AU>
<TI>Current patterns of bacterial infection in myelomatosis</TI>
<SO>Scandinavian journal of infectious diseases</SO>
<YR>1984</YR>
<VL>16</VL>
<NO>2</NO>
<PG>169-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fairley-1961" MODIFIED="2008-06-26 19:32:01 +0200" MODIFIED_BY="[Empty name]" NAME="Fairley 1961" TYPE="JOURNAL_ARTICLE">
<AU>Fairley GH, Scott RB</AU>
<TI>Hypogammaglobulinaemia in chronic lymphatic leukaemia</TI>
<SO>British medical journal</SO>
<YR>1961</YR>
<VL>5257</VL>
<PG>920-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glowacki-1993" MODIFIED="2008-06-26 19:32:09 +0200" MODIFIED_BY="[Empty name]" NAME="Glowacki 1993" TYPE="JOURNAL_ARTICLE">
<AU>Glowacki LS, Smaill FM</AU>
<TI>Meta-analysis of immune globulin prophylaxis in transplant recipients for the prevention of symptomatic cytomegalovirus disease</TI>
<SO>Transplantation proceedings</SO>
<YR>1993</YR>
<VL>25</VL>
<NO>1 Pt 2</NO>
<PG>1408-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glowacki-1994" NAME="Glowacki 1994" TYPE="JOURNAL_ARTICLE">
<AU>Glowacki LS, Smaill FM</AU>
<TI>Use of immune globulin to prevent symptomatic cytomegalovirus disease in transplant recipients--a meta-analysis</TI>
<SO>Clinical transplantation</SO>
<YR>1994</YR>
<VL>8</VL>
<NO>1</NO>
<PG>10-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Graham_x002d_Pole-1988" MODIFIED="2008-06-26 19:32:24 +0200" MODIFIED_BY="[Empty name]" NAME="Graham-Pole 1988" TYPE="JOURNAL_ARTICLE">
<AU>Graham-Pole J, Camitta B, Casper J, Elfenbein G, Gross S, Herzig R, Koch P, Mahoney D, Marcus R, Munoz L</AU>
<TI>Intravenous immunoglobulin may lessen all forms of infection in patients receiving allogeneic bone marrow transplantation for acute lymphoblastic leukemia: a pediatric oncology group study</TI>
<SO>Bone marrow transplantation</SO>
<YR>1988</YR>
<VL>3</VL>
<NO>6</NO>
<PG>559-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Griffiths-1989" MODIFIED="2008-06-26 19:32:31 +0200" MODIFIED_BY="[Empty name]" NAME="Griffiths 1989" TYPE="JOURNAL_ARTICLE">
<AU>Griffiths,H.; Brennan,V.; Lea,J.; Bunch,C.; Lee,M.; Chapel,H</AU>
<TI>Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors</TI>
<SO>Blood</SO>
<YR>1989</YR>
<VL>73</VL>
<NO>2</NO>
<PG>366-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guglielmo-1994" NAME="Guglielmo 1994" TYPE="JOURNAL_ARTICLE">
<AU>Guglielmo BJ, Wong-Beringer A, Linker CA</AU>
<TI>Immune globulin therapy in allogeneic bone marrow transplant: a critical review</TI>
<SO>Bone marrow transplantation</SO>
<YR>1994</YR>
<VL>13</VL>
<NO>5</NO>
<PG>499-510</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hansen-1973" NAME="Hansen 1973" TYPE="JOURNAL_ARTICLE">
<AU>Hansen MM</AU>
<TI>Chronic lymphocytic leukaemia. Clinical studies based on 189 cases followed for a long time</TI>
<SO>Scandinavian journal of haematology. Supplementum</SO>
<YR>1973</YR>
<VL>18</VL>
<PG>3-286</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jackson-1993" MODIFIED="2008-06-26 19:35:53 +0200" MODIFIED_BY="[Empty name]" NAME="Jackson 1993" TYPE="JOURNAL_ARTICLE">
<AU>Jackson,S.K.; Parton,J.; Barnes,R.A.; Poynton,C.H.; Fegan,C</AU>
<TI>Effect of IgM-enriched intravenous immunoglobulin (Pentaglobin) on endotoxaemia and anti-endotoxin antibodies in bone marrow transplantation</TI>
<SO>European journal of clinical investigation</SO>
<YR>1993</YR>
<VL>23</VL>
<NO>9</NO>
<PG>540-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jim-1956" MODIFIED="2008-06-26 19:36:07 +0200" MODIFIED_BY="[Empty name]" NAME="Jim 1956" TYPE="JOURNAL_ARTICLE">
<AU>Jim RT, Reinhard EH</AU>
<TI>Agammaglobulinemia and chronic lymphocytic leukemia</TI>
<SO>Annals of internal medicine</SO>
<YR>1956</YR>
<VL>44</VL>
<NO>4</NO>
<PG>790-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kubaneck-1985" MODIFIED="2008-06-26 19:36:16 +0200" MODIFIED_BY="[Empty name]" NAME="Kubaneck 1985" TYPE="JOURNAL_ARTICLE">
<AU>Kubaneck B ; Ernst P; Ostendorf P; Schafer U ; Wolf H</AU>
<TI>Preliminary data of a controlled trial of interavenous hyperimmune globulin in the prevention of cytomegalovirus infection in bone marrow transplant recipients</TI>
<SO>Transplantation proceedings</SO>
<YR>1985</YR>
<VL>XVII</VL>
<PG>468-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Reilly-1983" MODIFIED="2008-06-26 19:36:24 +0200" MODIFIED_BY="[Empty name]" NAME="O'Reilly 1983" TYPE="JOURNAL_ARTICLE">
<AU>O'Reilly, R.J.; Reich, L.; Gold, J.; Kirkpatrick, D.; Dinsmore, R.; Kapoor, N.; Condie, R.</AU>
<TI>A randomized trial of intravenous hyperimmune globulin for the prevenetion of CMV infections following marrow transplantation: preliminary results</TI>
<SO>Transplantation proceedings</SO>
<YR>1983</YR>
<VL>XV</VL>
<NO>1</NO>
<PG>1405-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Perri-1981" MODIFIED="2008-06-26 19:36:31 +0200" MODIFIED_BY="[Empty name]" NAME="Perri 1981" TYPE="JOURNAL_ARTICLE">
<AU>Perri RT, Hebbel RP, Oken MM</AU>
<TI>Influence of treatment and response status on infection risk in multiple myeloma</TI>
<SO>The American journal of medicine</SO>
<YR>1981</YR>
<VL>71</VL>
<NO>6</NO>
<PG>935-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pirofsky-1984" NAME="Pirofsky 1984" TYPE="JOURNAL_ARTICLE">
<AU>Pirofsky B</AU>
<TI>Intravenous immune globulin therapy in hypogammaglobulinemia. A review</TI>
<SO>The American journal of medicine</SO>
<YR>1984</YR>
<VL>76</VL>
<NO>3A</NO>
<PG>53-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rozman-1988" MODIFIED="2008-06-26 19:36:46 +0200" MODIFIED_BY="[Empty name]" NAME="Rozman 1988" TYPE="JOURNAL_ARTICLE">
<AU>Rozman C, Montserrat E, Vinolas N</AU>
<TI>Serum immunoglobulins in B-chronic lymphocytic leukemia. Natural history and prognostic significance</TI>
<SO>Cancer</SO>
<YR>1988</YR>
<VL>61</VL>
<NO>2</NO>
<PG>279-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Savage-1982" NAME="Savage 1982" TYPE="JOURNAL_ARTICLE">
<AU>Savage DG, Lindenbaum J, Garrett TJ</AU>
<TI>Biphasic pattern of bacterial infection in multiple myeloma</TI>
<SO>Annals of internal medicine</SO>
<YR>1982</YR>
<VL>96</VL>
<NO>1</NO>
<PG>47-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Siadak-1994" MODIFIED="2008-06-26 19:36:58 +0200" MODIFIED_BY="[Empty name]" NAME="Siadak 1994" TYPE="JOURNAL_ARTICLE">
<AU>Siadak MF, Kopecky K, Sullivan KM</AU>
<TI>Reduction in transplant-related complications in patients given intravenous immuno globulin after allogeneic marrow transplantation</TI>
<SO>Clinical and experimental immunology</SO>
<YR>1994</YR>
<VL>97</VL>
<NO>Suppl 1</NO>
<PG>53-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sokos-2002" MODIFIED="2008-06-26 19:37:07 +0200" MODIFIED_BY="[Empty name]" NAME="Sokos 2002" TYPE="JOURNAL_ARTICLE">
<AU>Sokos DR, Berger M, Lazarus HM</AU>
<TI>Intravenous immunoglobulin: appropriate indications and uses in hematopoietic stem cell transplantation</TI>
<SO>Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.</SO>
<YR>2002</YR>
<VL>8</VL>
<NO>3</NO>
<PG>117-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sullivan-1996a" MODIFIED="2008-06-26 19:37:13 +0200" MODIFIED_BY="[Empty name]" NAME="Sullivan 1996a" TYPE="JOURNAL_ARTICLE">
<AU>Sullivan KM</AU>
<TI>Immunomodulation in allogeneic marrow transplantation: use of intravenous immune globulin to suppress acute graft-versus-host disease</TI>
<SO>Clinical and experimental immunology</SO>
<YR>1996</YR>
<VL>104 Suppl 1</VL>
<PG>43-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Twomey-1973" MODIFIED="2008-06-26 19:37:22 +0200" MODIFIED_BY="[Empty name]" NAME="Twomey 1973" TYPE="JOURNAL_ARTICLE">
<AU>Twomey JJ</AU>
<TI>Infections complicating multiple myeloma and chronic lymphocytic leukemia</TI>
<SO>Archives of internal medicine</SO>
<YR>1973</YR>
<VL>132</VL>
<NO>4</NO>
<PG>562-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wadleigh-2003" MODIFIED="2008-06-26 19:37:30 +0200" MODIFIED_BY="[Empty name]" NAME="Wadleigh 2003" TYPE="JOURNAL_ARTICLE">
<AU>Wadleigh M, Richardson PG, Zahrieh D, Lee SJ, Cutler C, Ho V, Alyea EP, Antin JH, Stone RM, Soiffer RJ, DeAngelo DJ.</AU>
<TI>Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation</TI>
<SO>Blood</SO>
<YR>2003</YR>
<VL>102</VL>
<NO>5</NO>
<PG>1578-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wingard-1990" MODIFIED="2008-06-26 19:37:37 +0200" MODIFIED_BY="[Empty name]" NAME="Wingard 1990" TYPE="JOURNAL_ARTICLE">
<AU>Wingard JR</AU>
<TI>Advances in the management of infectious complications after bone marrow transplantation</TI>
<SO>Bone marrow transplantation</SO>
<YR>1990</YR>
<VL>6</VL>
<NO>6</NO>
<PG>371-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Winston-1985" MODIFIED="2008-06-26 19:38:00 +0200" MODIFIED_BY="[Empty name]" NAME="Winston 1985" TYPE="JOURNAL_ARTICLE">
<AU>Winston DJ, Ho WG, Lin GH et al. Winston DJ, Ho WG, Lin GH et al. [Use of a polyvalent intravenous immunoglobulin or specific cytomegalovirus hyperimmunoglobulin for modification of cytomegalovirus infections and prevention of interstitial pneumonias following bone marrow transplantation]. Immun Infekt. 1985;13:296-301. Winston DJ, Ho WG, Lin GH et al.</AU>
<TI>Use of a polyvalent intravenous immunoglobulin or specific cytomegalovirus hyperimmunoglobulin for modification of cytomegalovirus infections and prevention of interstitial pneumonias following bone marrow transplantation</TI>
<SO>Immunit?t und Infektion</SO>
<YR>1985</YR>
<VL>13</VL>
<PG>296-301</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Winston-1987a" MODIFIED="2008-06-26 19:38:31 +0200" MODIFIED_BY="[Empty name]" NAME="Winston 1987a" TYPE="JOURNAL_ARTICLE">
<AU>Winston DJ, Ho WG, Lin CH, Bartoni K, Budinger MD, Gale RP, Champlin RE</AU>
<TI>Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation</TI>
<SO>Annals of internal medicine</SO>
<YR>1987</YR>
<VL>106</VL>
<NO>1</NO>
<PG>12-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Winston-1987b" MODIFIED="2008-06-26 19:38:39 +0200" MODIFIED_BY="[Empty name]" NAME="Winston 1987b" TYPE="JOURNAL_ARTICLE">
<AU>Winston DJ, Ho WG, Lin CH, Bartoni K, Budinger MD, Gale RP, Champlin RE</AU>
<TI>Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation</TI>
<SO>Annals of internal medicine</SO>
<YR>1987</YR>
<VL>106</VL>
<NO>1</NO>
<PG>12-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Winston-1990" NAME="Winston 1990" TYPE="JOURNAL_ARTICLE">
<AU>Winston DJ, Ho WG, Champlin RE</AU>
<TI>Cytomegalovirus infections after allogeneic bone marrow transplantation</TI>
<SO>Reviews of infectious diseases</SO>
<YR>1990</YR>
<VL>12 Suppl 7</VL>
<PG>S776-S792</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-07-22 21:54:03 +0200" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-07-22 21:54:03 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-07-21 22:26:32 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Abdel_x002d_Mageed-1999">
<CHAR_METHODS MODIFIED="2008-07-21 22:26:32 +0200" MODIFIED_BY="[Empty name]">
<P>Randomization generation: not specified;<BR/>Allocation concealment: unclear; Blinding: none; Excluded: 18 pts.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>350 patients with acute leukemia or CML who had allogeneic stem cell transplantation from sibling donors; <BR/>Multi-center - 10 centers, USA<BR/>Setting: hospitalization in isolation precautions with laminar air flow</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-21 22:26:32 +0200" MODIFIED_BY="[Empty name]">
<P>IV polyvalent Immunoglobulin in 2 doses. The trial included 2 arms: (50 mg/kg; 250 mg/kg; 500 mg/kg ) Schedule: weekly from day -8 to day +111 posttransplant (18 doses)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-21 22:26:32 +0200" MODIFIED_BY="[Empty name]">
<P>All cause mortality; CDI; CMV infections; relapse;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-21 22:26:32 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Boeckh-2001">
<CHAR_METHODS MODIFIED="2008-07-21 22:26:32 +0200" MODIFIED_BY="[Empty name]">
<P>Randomization generation: computer generated;<BR/>Allocation concealment: sealed envelopes; Blinding: double blind<BR/>Excluded: none<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-21 22:26:32 +0200" MODIFIED_BY="[Empty name]">
<P>179 patients who had myeloablative allogeneic stem cell transplantation from sibling donors and unrelated donors;<BR/>Multi-center - 3 centers, USA;<BR/>Setting: hospitalization in isolation precautions and then outpatients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-21 22:26:32 +0200" MODIFIED_BY="[Empty name]">
<P>IV anti CMV specific monoclonal ab (MSL-109) in 2 doses. The trial included 2 arms: 60 mg/kg and 15 mg/kg.<BR/>Schedule: every 14 days from day -1 to day +84 post-ransplant<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-21 22:26:32 +0200" MODIFIED_BY="[Empty name]">
<P>All cause mortality; MDI; bacterial infections; fungal infections; bacteremia; CMV disease; hospitalization; IRM; acute GVHD; engraftment; relapse; adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-21 22:26:32 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bordigoni-1987">
<CHAR_METHODS MODIFIED="2008-07-21 22:26:32 +0200" MODIFIED_BY="[Empty name]">
<P>Randomization generation: random numbers;<BR/>Allocation concealment: opaque envelopes;<BR/>Blinding: none; Excluded:none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-21 22:26:32 +0200" MODIFIED_BY="[Empty name]">
<P>60 patients who had myeloablative allogeneic and autologous bone marrow transplantation;<BR/>Single center, France, Europe;<BR/>Setting: hospitalization in isolation precautions and then outpatients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-21 22:26:32 +0200" MODIFIED_BY="[Empty name]">
<P>IV anti CMV IgG (Nancy) enriched plasma 4 ml/kg<BR/>vs control. The trial included 2 arms: anti CMV IgG (Nancy) enriched plasma and control;<BR/>Schedule: day -7, -3, 0 and then every 15 days to day 90 posttransplant<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-21 22:26:32 +0200" MODIFIED_BY="[Empty name]">
<P>All cause mortality; CMV infection; IRM; IP; engraftment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-21 22:26:32 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Boughton-1995">
<CHAR_METHODS MODIFIED="2008-07-21 22:26:32 +0200" MODIFIED_BY="[Empty name]">
<P>Randomization generation: not specified;<BR/>Allocation concealment: central - from a reference center;<BR/>Blinding: double blind<BR/>Excluded: none<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-21 22:26:32 +0200" MODIFIED_BY="[Empty name]">
<P>42 patients with CLL; Multi-center - 20 centers in UK, Europe;<BR/>Setting: outpatients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>IV polyvalent Immunoglobulin (Sandoglobulin) vs placebo. The trial included 2 arms: IVIG 18 and placebo<BR/>Schedule: every 3 weeks for 12 months<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-21 22:26:32 +0200" MODIFIED_BY="[Empty name]">
<P>All cause mortality; CDI; MDI; bacterial infections; viral infections; bacteremia; immunoglobulin levels; adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-22 21:38:42 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bowden-1986">
<CHAR_METHODS MODIFIED="2008-07-22 21:38:42 +0200" MODIFIED_BY="[Empty name]">
<P>Randomization generation: protocol registrar using a table of random permutations;<BR/>Allocation concealment: adequate measures to conceal allocation protocol registrar;<BR/>Blinding: none;<BR/>Excluded: 2 pts.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-21 22:26:32 +0200" MODIFIED_BY="[Empty name]">
<P>99 patients who had myeloablative allogeneic bone marrow transplantation, all recipients CMV negative;<BR/>single center, USA;<BR/>Setting: hospitalization in isolation precautions and then outpatients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-21 22:26:32 +0200" MODIFIED_BY="[Empty name]">
<P>CMV immune globulin vs. control. The trial included 4 arms: CMV immune globulin (150 mg/kg) + seronegative blood products vs. seronegative blood products alone vs. CMV immune globulin alone (150 mg/kg) vs. control;</P>
<P>Schedule: days -5, -1 , +6 ,+20, +34 - dose of 150 mg/kg; days +48; +62 - dose of 100 mg/kg posttransplant<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-21 22:26:32 +0200" MODIFIED_BY="[Empty name]">
<P>All cause mortality; CMV infection; CMV disease;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-21 22:26:32 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bowden-1991">
<CHAR_METHODS MODIFIED="2008-07-21 22:26:32 +0200" MODIFIED_BY="[Empty name]">
<P>Randomization generation: adequate-protocol registrar using assignment from a table of random permutations;<BR/>Allocation concealment:: unclear; Blinding: none; Excluded: 3 pts.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-21 22:26:32 +0200" MODIFIED_BY="[Empty name]">
<P>123 patients who had myeloablative allogeneic bone marrow transplantation for ALL, AML, CML, aplastic anemia, lymphoma and other; Single center: USA; Setting: hospitalization in isolation precautions and then outpatients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-21 22:26:32 +0200" MODIFIED_BY="[Empty name]">
<P>CMV IVIG vs placebo. The trial included 2 arms: CMV IVIG (Cutter Biological) 200 mg/kg vs. placebo; Schedule: days -8; -6 pretransplant; +1; +7; +14; +21; +28; +42; +56; +70 posttransplant (10 doses)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-21 22:26:32 +0200" MODIFIED_BY="[Empty name]">
<P>All cause mortality; CMV infection; CMV disease; hospitalization; IRM; acute GVHD; IP</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-21 22:26:32 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chapel-1994">
<CHAR_METHODS MODIFIED="2008-07-21 22:26:32 +0200" MODIFIED_BY="[Empty name]">
<P>Randomization generation: randomization table for each study site;<BR/>Allocation concealment: randomization code kept by pharmacy;<BR/>Blinding: double blind<BR/>Excluded: 1 pt.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-21 22:26:32 +0200" MODIFIED_BY="[Empty name]">
<P>83 multiple myeloma plateau phase patients;<BR/>Multi-center -9 centers, UK, Europe;<BR/>Setting: Outpatients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-21 22:26:32 +0200" MODIFIED_BY="[Empty name]">
<P>IVIG polyvalent Immunoglobulin (Gammagard) vs placebo. The trial included 2 arms: IVIG 0.4 g/kg vs. placebo<BR/>Schedule: every 4 weeks for 12 months<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-21 22:26:32 +0200" MODIFIED_BY="[Empty name]">
<P>All cause mortality; CDI; MDI; bacterial infections; bacteremia;<BR/>IRM; adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-22 21:53:17 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chapel-1994c">
<CHAR_METHODS MODIFIED="2008-07-21 22:26:32 +0200" MODIFIED_BY="[Empty name]">
<P>Randomization generation: table of random numbers;<BR/>Allocation concealment: allocated centrally;<BR/>Blinding: double blind<BR/>Excluded: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-22 21:53:17 +0200" MODIFIED_BY="[Empty name]">
<P>34 B-CLL patients;<BR/>Multi-center- USA + Europe<BR/>Setting: outpatients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>IVIG polyvalent Immunoglobulin (Gammagard) in 2 doses. The trial included 2 arms: (250 mg/kg; 500 mg/kg ) Schedule: every 4 weeks for 1 year<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-21 22:26:32 +0200" MODIFIED_BY="[Empty name]">
<P>All cause mortality; CDI; MDI; bacterial infections; fungal infections; viral infection; immunoglobulin levels; adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-21 22:26:32 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Condie-1984">
<CHAR_METHODS MODIFIED="2008-07-21 22:26:32 +0200" MODIFIED_BY="[Empty name]">
<P>Randomization generation: not specified;<BR/>Allocation concealment: unclear;<BR/>Blinding: none; Excluded: none<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>55 patients who had myeloablative allogeneic myeloablative bone marrow transplantation for acute leukemia (AML + ALL) ; <BR/>Multi-center - 2 centers; USA;<BR/>Setting: hospitalization in isolation precautions and then outpatients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-21 22:26:32 +0200" MODIFIED_BY="[Empty name]">
<P>Hyperimmune CMV IVIG vs.<BR/>CMV deficient IVIG vs. control. The trial included 3 arms: Hyperimmune CMV IVIG 200 mg/kg vs. CMV deficient IVIG 200 mg/kg vs. control - not randomized, matched control;<BR/>Schedule: posttransplant days: +25; +50; +75<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-21 22:26:32 +0200" MODIFIED_BY="[Empty name]">
<P>All cause mortality; CMV infection; CMV disease; acute GVHD; IP</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-21 22:26:32 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cooperative-CLL-1988">
<CHAR_METHODS MODIFIED="2008-07-21 22:26:32 +0200" MODIFIED_BY="[Empty name]">
<P>Randomization generation: table of random numbers;<BR/>Allocation concealment: allocated centrally; Blinding: double blind; Excluded: 3 pts.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>84 CLL patients; <BR/>Multi-center - 10 centers, USA &amp; Europe<BR/>Setting: outpatient</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-21 22:26:32 +0200" MODIFIED_BY="[Empty name]">
<P>IVIG polyvalent Immunoglobulin (Gammagard) vs placebo. The trial included 2 arms: IVIG 0.4 g/kg vs. placebo;<BR/>Schedule: every 4 weeks for 12 months<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-21 22:26:32 +0200" MODIFIED_BY="[Empty name]">
<P>All cause mortality; CDI; MDI; bacterial infections; IRM; adverse events bacteremia;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-21 22:26:32 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cordonnier-2003">
<CHAR_METHODS MODIFIED="2008-07-21 22:26:32 +0200" MODIFIED_BY="[Empty name]">
<P>Randomization generation: computer generated;<BR/>Allocation concealment: central randomization;<BR/>Blinding: double blind<BR/>Excluded:none<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>200 patients who had myeloablative allogeneic stem cell transplantation from HLA identical sibling donors; <BR/>Multi-center - 19 centers; France,Europe<BR/>Setting: hospitalization in isolation precautions and then outpatients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>IV polyvalent Immunoglobulin vs placebo. The trial included 4 arms: IVIG in 3 different doses (50 mg/kg; 250 mg/kg; 500 mg/kg ) and placebo<BR/>Schedule: 16 weekly doses from -7d to day 100 post-transplant<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-21 22:26:32 +0200" MODIFIED_BY="[Empty name]">
<P>All cause mortality; CDI; MDI; bacterial infections; fungal infections; viral infections; CMV infections; CMV disease;<BR/>TRM; acute GVHD; chronic GVHD; VOD; IP; engraftment; relapse; adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-22 21:53:44 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Emanuel-1992">
<CHAR_METHODS MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>Randomization generation: not specified;<BR/>Allocation concealment: unclear;<BR/>Blinding: none;<BR/>Excluded: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-06-25 20:06:18 +0200" MODIFIED_BY="[Empty name]">
<P>92 patients who had myeloablative allogeneic bone marrow transplantation<BR/>single center; USA; Setting: hospitalization in isolation precautions and then outpatients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-22 21:53:44 +0200" MODIFIED_BY="[Empty name]">
<P>IV polyvalent Immunoglobulin (Gammagard) vs control. The trial included 2 arms: IVIG 500 mg/kg then 250 mg/kg and control; Schedule: 500 mg/kg every 2 weeks from day -7 to day +100 then 250 mg/kg from day +100 to day +180<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>All cause mortality; MDI; bacterial infections; CMV infections; CMV disease; IP; engraftment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Feinstein-1999">
<CHAR_METHODS MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>Randomization generation: not specified;<BR/>Allocation concealment: unclear;<BR/>Blinding: none<BR/>Excluded: 19 pts.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>260 patients who had myeloablative allogeneic bone marrow transplantation from HLA identical sibling donors; <BR/>single center, USA; Setting: hospitalization in isolation precautions and then outpatients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>IV polyvalent Immunoglobulin (Gamimmune) vs control. The trial included 2 arms: IVIG 500 mg/kg and control; Schedule: daily from days -6 to -1 then every 3rd day posttransplant from day +3 to day +90</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>All cause mortality; CDI; MDI; bacterial infections; fungal infections; viral infections; CMV infections; hospitalization; acute GVHD; engraftment; immunoglobulin levels; adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Filipovich-1992">
<CHAR_METHODS MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>Randomization generation: not specified;<BR/>Allocation concealment: database personnel and pharmacy personnel;<BR/>Blinding: double blind<BR/>Excluded: none<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>42 patients who had autoBMT and alloBMT for acute leukemia, CML, other malignancy or non-malignant disease; Single center, USA;<BR/>Setting: inpatient<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>IVIG polyvalent immunoglobulin products at a dose of 500 mg/kg. The trial included 4 arms: Gamimmune, Gammagard, Sandoglobulin, immune Globulin Intravenous; Schedule: every other week for 3 doses (week -1 to week +3);</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>CMV infections; immunoglobulin levels</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gluck-1990">
<CHAR_METHODS MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>Randomization generation: not specific;<BR/>Allocation concealment: unclear;<BR/>Blinding: none;<BR/>Excluded: unknown</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Unknown number of patients with multiple myeloma and low risk non-Hodgkin lymphoma; single center, Europe, Germany; Setting: outpatients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>IV polyvalent Immunoglobulin vs placebo. The trial included 2 arms: IVIG (IVIG 0.5 -0.7 g/kg) and placebo<BR/>Schedule: monthly for 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-06-25 20:08:08 +0200" MODIFIED_BY="[Empty name]">
<P>Descriptive results on outcomes and not the exact numbers of patients who developed infections in each arm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Graham-Pole-1990">
<CHAR_METHODS MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>Randomization generation: not specified;<BR/>Allocation concealment: unclear;<BR/>Blinding: none<BR/>Excluded: 57 pts.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>150 patients who had alloBMT from HLA matched and mismatched donors; <BR/>Multi-center - 8 centers; USA; Setting: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>IV polyvalent Immunoglobulin in 2 doses. The trial included 2 arms: 2 different doses (250 mg/kg; 500 mg/kg);<BR/>Schedule: weekly from 1 week before to 16 weeks after BMT posttransplant<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Authors reported on the total number of deaths in the study but not separately on the numbers in the 2 arms</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hargreaves-1992">
<CHAR_METHODS MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>Randomization generation: table of random numbers;<BR/>Allocation concealment: allocated centrally;<BR/>Blinding: double blind<BR/>Excluded: unknown<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>39 patients with multiple myeloma patients; single center, UK, Europe; Setting: outpatients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>IVIG polyvalent immunoglobulin (Gammagard) vs. placebo. The trial included 2 arms: IVIG and placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Authors reported on the total rate of infections in both the treatment and the placebo arms</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jacobsen-1985">
<CHAR_METHODS MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>Randomization generation: not specified; Allocation concealment: unclear; Blinding: none; Excluded: none<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>49 patients who had myeloablative allogeneic bone marrow transplantation for ALL, AML, AUL, CML, lymphoma, SAA; <BR/>Multi-center - 4 centers; Germany, Europe<BR/>Setting: hospitalization in isolation precautions and then outpatients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hyperimmune CMV IVIG vs. control IG. The trial included 2 arms: Hyperimmune CMV IVIG 0.1 G protein/kg vs. control IG 0.1 G protein/kg; Schedule: day -7; day +13; day +33; day +53 ; day +79; day + 93</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>All cause mortality; CMV disease; IRM; acute GVHD; IP</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lum-1994">
<CHAR_METHODS MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>Randomization generation: not specified; Allocation concealment: unclear;<BR/>Blinding: none; Excluded:none<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-06-25 20:08:08 +0200" MODIFIED_BY="[Empty name]">
<P>54 patients who had myeloablative allogeneic bone marrow transplantation;<BR/>single center, USA; Setting: hospitalization in isolation precautions and then outpatients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>IVIG polyvalent immunoglobulin vs. control. The trial included 2 arms: IVIG 400 mg/kg vs. control;Schedule: 10 weekly infusions from day +14 to day +79</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>All cause mortality; IRM; acute GVHD; chronic GVHD</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Meyers-1983">
<CHAR_METHODS MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>Randomization generation: not specified; Allocation concealment: unclear;<BR/>Blinding: none;<BR/>Excluded: 6 pts.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-06-25 20:08:08 +0200" MODIFIED_BY="[Empty name]">
<P>68 patients with myeloablative allogeneitic BMT for acute leukemia and CML; Sincle-center USA; Setting: hospitalization in isolation precautions and then outpatients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>IM anti-CMV hyperimmune globulin vs. control. The trial included 2 arms: anti-CMV hyperimmune globulin and control; Schedule: on days -4 and -2 before BMT, then weekly to day +77 posttransplant</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>CMV infections; IRM; immunoglobulin levels</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-22 21:48:26 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Molica-1996">
<CHAR_METHODS MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>Randomization generation:not specified; Allocation concealment: unclear; Blinding: none; Excluded: none<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-06-25 20:08:08 +0200" MODIFIED_BY="[Empty name]">
<P>42 CLL patients;<BR/>single center, Italy, Europe<BR/>Setting: Outpatients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-22 21:48:26 +0200" MODIFIED_BY="[Empty name]">
<P>IV polyvalent Immunoglobulin (Vena-N) vs. control. The trial included 4 arms: Patients were randomly allocated to receive an<BR/>infusion of IVIG every 4 weeks for at least 6 months<BR/>or no treatment. Then they were switched to<BR/>observation or IVIG for another 12 months;<BR/>finally, they received IVIG or no therapy for 6<BR/>more months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>All cause mortality; CDI; MDI; IRM</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Musto-1995">
<CHAR_METHODS MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>Randomization generation:not specified; Allocation concealment: unclear; blinding: none; Excluded: none<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-06-17 20:18:56 +0200" MODIFIED_BY="[Empty name]">
<P>25 Multiple myeloma patients </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>IV polyvalent Immunoglobulin (Vena-N) vs. control. The trial included 8 arms: IVIG then no therapy then IVIG; IVIG then no therapy then no therapy; IVIG then IVIG then IVIG; IVIG then IVIG then no therapy; No therapy then no therapy then IVIG;<BR/>No therapy then no therapy then no therapy<BR/>No therapy then IVIG then IVIG<BR/>No therapy then IVIG then no therapy<BR/>Schedule: every 4 weeks for 6 months, then 4 weeks for 12 months then 4 weeks for 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>All cause mortality; CDI; IRM</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Peltier-1992">
<CHAR_METHODS MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>Randomization generation:not specified;<BR/>Allocation concealment: unclear ;<BR/>Blinding: double blind<BR/>Excluded: none<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>53 CMV - seronegative patients who had undergone AutoBMT and AlloBMT for acute leukemia, CML, other malignancy or non-malignant disease; <BR/>Single - center USA; Setting: not mentioned</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>IVIG polyvalent immunoglobulin products at a dose of 500 mg/kg. The trial included 3 arms: Gammagard, Sandoglobulin, Gamimmune; Schedule: weekly starting the week before BMT, total 6 doses</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>No relevant outcomes (immunoglobulin levels)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Poynton-1992">
<CHAR_METHODS MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>Randomization generation: not specified; Allocation concealment: unclear;<BR/>Blinding: none;<BR/>Excluded: 9 pts.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>72 patients who had autologous or allogeneic bone marrow transplantation;<BR/>Single center; UK, Europe<BR/>Setting: hospitalization in isolation precautions and then outpatients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>IgM and IgA enriched IVIG Immunoglobulin vs control. The trial included 2 arms: IgM and IgA enriched IVIG and control;<BR/>Schedule: days 0, +3, +7, then weekly until neutrophil &gt; 0.5 x 10<SUP>9</SUP>/l</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>All cause mortality; CDI; MDI; bacterial infections; fungal infections; bacteremia; CMV disease; hospitalization; antibiotics; IRM; VOD; engraftment; relapse; immunoglobulin levels;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Raiola-2002">
<CHAR_METHODS MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>Randomization generation:not specified;<BR/>Allocation concealment:: unclear;<BR/>Blinding: none Excluded:none<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>89 patients who had allogenetic alternative donor bone marrow transplantation</P>
<P>Single center - Italy, Europe;</P>
<P>Setting: hospitalization in isolation precautions and then outpatients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>IVIG polyvalent immunoglobulin (Pentaglobulin) in 2 doses. The trial included 2 arms: IVIG 200 mg/kg and 400 mg/kg; Schedule: every 2 weeks from day -7 to day +100<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>All cause mortality; IRM; GVHD; relapse</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ringden-1987">
<CHAR_METHODS MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>Randomization generation: not specified;<BR/>Allocation concealment:: unclear;<BR/>Blinding: none; Excluded:none<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>54 patients who had allogenetic myeloablative bone marrow transplantation;</P>
<P>Multi center; 5 centers Scandinavia Europe;</P>
<P>Setting: hospitalization in isolation precautions and then outpatients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>CMV hyperimmune plasma vs control. The trial included 2 arms: CMV hyperimmune plasma 30 ml/kg and control;</P>
<P>Schedule: 4 times 2 days period (each period total 30 ml/kg): days 3 &amp; 4; days 25 &amp; 26; days 50 &amp; 51; days 75 &amp; 76</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>All cause mortality; CMV infection; CMV disease; IRM; acute GVHD; chronic GVHD; IP; immunoglobulin levels; adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ruutu-1997">
<CHAR_METHODS MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>Randomization generation: not specified;<BR/>Allocation concealment: unclear; Blinding: none; Excluded: none<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>28 patients who had myeloablative allogeneic bone marrow transplantation from HLA identical sibling or unrelated donors; <BR/>Multi-center - number not mentioned; Scandinavia, Europe<BR/>Setting: not specified</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>Anti-CMV hyperimmune globulin<BR/>vs control. The trial included 2 arms: anti-CMV hyperimmune globulin 400 mg/kg<BR/>and control<BR/>Schedule: 0.4g/kg on day -8, then 0.2g/kg on day -1,+7,+14,+21,+28,+35,+42,+56,+70<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>All cause mortality; CMV infections; CMV disease; acute GVHD; chronic GVHD; IP</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Salmon-1967">
<CHAR_METHODS MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>Randomization generation: adequate-randomized card selection;<BR/>Allocation concealment: unclear;<BR/>Blinding: double blind<BR/>Excluded: 7 pts<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>48 patients with active multiple myeloma; multi-center- 5 centers; USA (ECOG); Setting: outpatients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Cohn fraction II gamma globulin IM vs placebo. The trial included 2 arms: 20 ml of Cohn fraction II gamma globulin 16.5% and 10 ml of Human serum albumin 5%<BR/>Schedule: every 2 weeks for at least 6 weeks<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>All cause mortality; CDI; bacterial infections; IRM; adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Serrano-1999">
<CHAR_METHODS MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>Randomization generation: not specified;<BR/>Allocation concealment: unclear;<BR/>Blinding: none;<BR/>Excluded:none<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>92 patients who had myeloablative allogeneic bone marrow transplantation from HLA identical sibling donors; single center, Spain, Europe;<BR/>Setting: hospitalization in isolation precautions and then outpatients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hyperimmune CMV IVIG vs control. The trial included 2 arms: Hyperimmune CMV IVIG at a dose of 150 mg/kg and control.<BR/>Schedule: every 2 weeks from day 2 to day +86, then monthly till 1 yr post BMT<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>All cause mortality; CDI; bacterial infections; fungal infections; bacteremia; CMV infection; CMV disease; IRM; acute GVHD; chronic GVHD; IP; engraftment; relapse; immunoglobulin levels </P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-22 21:31:27 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sklenar-1993">
<CHAR_METHODS MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>Randomization generation: not specified;<BR/>Allocation concealment: unclear;<BR/>Blinding: only patient blinded<BR/>Excluded: none<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>62 CLL and multiple myeloma patients;<BR/>Multi-center - 10 centers, USA and Europe;<BR/>Setting: Outpatients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-22 21:31:27 +0200" MODIFIED_BY="[Empty name]">
<P>IV polyvalent Immunoglobulin in 3 doses. The trial included 3 arms: (100 mg/kg; 400 mg/kg; 800 mg/kg ) Schedule: every 3 weeks total 6 doses (week 0, 3, 6, 9, 12, 15)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>All cause mortality; immunoglobulin levels; adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sullivan-1990">
<CHAR_METHODS MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>Randomization generation: not specified;<BR/>Allocation concealment: unclear; Blinding: none; Excluded: 14 pts.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>383 patients who had myeloablative allogeneic BMT or autologous BMT or syngeneic BMT for SAA or acute leukemia or CML or lymphoma;<BR/>single center - USA; Setting: hospitalization in isolation precautions and then outpatients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>IV polyvalent Immunoglobulin (Gamimune N) vs control. The trial included 2 arms: IVIG 500 mg/kg and control;<BR/>Schedule: 15 weekly infusions from day -7 to day +90<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>All cause mortality; CDI; MDI; bacterial infections; fungal infections; viral infections; bacteremia; acute GVHD; IP; relapse; immunoglobulin levels; adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sullivan-2000">
<CHAR_METHODS MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>Randomization generation: not specified;<BR/>Allocation concealment: unclear; Blinding: double blind; Excluded: none<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>497 patients who had myeloablative allogeneic BMT from unrelated donor; Multi-center- USA and Europe; Setting: hospitalization in isolation precautions and then outpatients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>IV polyvalent immunoglobulin (Gammagard) vs. placebo. The trial included 2 arms: IVIG 500 mg/kg and placebo; Schedule: day -7 and -1 and then weekly from day +6 to day +90<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>All cause mortality; TRM; relapse</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ustun-1998">
<CHAR_METHODS MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>Randomization generation: not specified;<BR/>Allocation concealment: unclear;<BR/>Blinding: none;<BR/>Excluded: none<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>14 patients who had alloSCT from HLA identical siblings for acute leukemia, CML, MDS; single center- Turkey, Europe; Setting: not mentioned</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>IV polyvalent Immunoglobulin<BR/>vs control. The trial included 2 arms: IVIG 0.5 g/kg and control;<BR/>Schedule: day -4 then weekly until ANC&gt;0.5 x10(9)/l<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>All cause mortality; CDI; acute GVHD; VOD; engraftment;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Winston-1982">
<CHAR_METHODS MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>Randomization generation:not specified;<BR/>Allocation concealment: unclear;<BR/>Blinding: none Excluded: 6 pts<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>54 patients who had myeloablative allogeneic bone marrow transplantation from HLA identical sibling donors; single center; USA<BR/>Setting: hospitalization in isolation precautions and then outpatients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>Anti-CMV hyperimmune plasma at a dose of 10 ml/kg vs. control; Schedule: before conditioning, then on day +3; +30; +45; +60; +75; +90; +120<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>All cause mortality; CMV infection; CMV disease; IRM; TRM; acute GVHD; IP; relapse; adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Excluded patients died (ITT)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-22 21:54:03 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Winston-1984">
<CHAR_METHODS MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>Randomization generation: not specified; Allocation concealment: unclear;<BR/>Blinding: none<BR/>Excluded: 5 pts.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-06-25 20:08:08 +0200" MODIFIED_BY="[Empty name]">
<P>41 patients who had myeloablative allogeneic BMT for acute leukemia in remission or relapse and aplastic anemia from HLA identical sibling donors;<BR/>Single-center, USA; setting: hospitalization in isolation precautions and then outpatients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-22 21:54:03 +0200" MODIFIED_BY="[Empty name]">
<P>IV polyvalent Immunoglobulin 5% in 10% maltose vs control. The trial included 2 arms: IVIG 5% in 10% maltose 20 cc/kg<BR/>and control;<BR/>Schedule: before initiation of conditioning and then every week until day +120</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>All cause mortality; viral infections; CMV infections; CMV disease; acute GVHD; IP; adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Results from an ongoing study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-06-25 20:08:08 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Winston-1987">
<CHAR_METHODS>
<P>Randomization generation: not specified; allocation concealment: unclear;<BR/>Blinding: none<BR/>Excluded: 14 pts.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>89 patients who had alloBMT T- cell depleted from sibling for acute leukemia in remission or relapse and for aplastic anemia; Single-center, USA; setting: hospitalization in isolation precautions and then outpatients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-06-25 20:08:08 +0200" MODIFIED_BY="[Empty name]">
<P>IV polyvalent Immunoglobulinvs control. The trial included 2 arms: IVIG 20 cc/kg and control; Schedule: before initiation of conditioning and then every week until day +120</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>all cause mortality; CMV infection; CMV disease; acute GVHD; IP; adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-06-25 20:05:29 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Winston-1993">
<CHAR_METHODS>
<P>Randomization generation: not specified; allocation concealment: unclear;<BR/>Blinding: none<BR/>Excluded: none<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>51 patients who had myeloablative allogeneic BMT for acute leukemia nd aplastic anemia and CML and MDS from HLA sibling or unrelated donors; <BR/>Single-center, USA; setting: hospitalization in isolation precautions and then outpatients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-06-25 20:05:24 +0200" MODIFIED_BY="[Empty name]">
<P>IV polyvalent ImmunoglobulinI(Sandoglobulin)<BR/>vs control. The trial included 2 arms: IVIG 1 g/kg and control;<BR/>Schedule: before initiation of conditioning and then every week until day +120</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-06-25 20:05:29 +0200" MODIFIED_BY="[Empty name]">
<P>all cause mortality ; bacterial infections; fungal infections; viral infections; bacteremia; CMV infections; CMV disease; IRM; acute GVHD; IP; relapse; adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>in both arms seronegative blood products were administered</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Winston-2001">
<CHAR_METHODS>
<P>Randomization generation: not specified; allocation concealment: unclear; <BR/>Blinding: double blind<BR/>Excluded: 9 pts.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>627 patients with acute leukemia, CML, lymphoma, aplastic anemia<BR/>who had myeloablative allogeneic bone marrow transplantation from sibling or matched unrelated donors; <BR/>Multi-center - 13 centers; USA<BR/>Setting: not specified</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>IV polyvalent Immunoglobulin in 3 doses. The trial included 3 arms: 100 mg/kg; 250 mg/kg; 500 mg/kg Schedule: day -2, then weekly from day 0 to day +90, then monthly from day +90 to day +360 <BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>all cause mortality; CDI; MDI; bacterial infections; fungal infections; viral infections;<BR/>bacteremia; CMV infection; CMV disease; IRM; TRM; acute GVHD; chronic GVHD; VOD; IP; relapse; adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-06-25 20:08:08 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wolff-1993">
<CHAR_METHODS>
<P>Randomization generation:computer generated;<BR/>allocation concealment: unclear- computer generated scheme at each study center; <BR/>Blinding: none; Excluded:none<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-06-25 20:06:47 +0200" MODIFIED_BY="[Empty name]">
<P>170 patients who had myeloablative autologous BMT or myelosuppressive Rx. for acute leukemia or other disease;<BR/>Multi-center - 3 centers; USA; setting: hospitalization in isolation precautions</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-06-25 20:08:08 +0200" MODIFIED_BY="[Empty name]">
<P>IV polyvalent immunoglobulin (Sandoglobulin) vs. control. The trial included 2 arms: IIVIG Sandoglobulin 500 mg/kg and control;<BR/>Schedule: weekly dose beginning at start of chemotherapy and discontinued when severe side effects occurred or when neutropenia resolved (&gt;500 PMNs)<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>all cause mortality; CDI; fungal infections; bacteremia; IRM; TRM; VOD; IP; adverse event</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Zikos-1998">
<CHAR_METHODS>
<P>Randomization generation: not specified; allocation concealment: unclear; <BR/>Blinding: none; Excluded:none<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>128 patients who had myeloablative allogeneic BMT + peripheral stem cell transplant from from HLA identical sibling donor for acute leukemia or CML or SAA and others; single - center - Italy, Europe<BR/>Setting: hospitalization in isolation precautions and then outpatients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>anti-CMV hyperimmune globulin ( CMV IgG) vs. polyvalent Immunoglobulin. The trial included arms: anti-CMV hyperimmune globulin 100mg/kg (CMV IgG) and polyvalent Immunoglobulin (IVIG) 400 mg/kg<BR/>Schedule: weekly from day -7 to day +100d<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>all cause mortality; CDI; fungal infections; CMV infections; CMV disease; IRM; TRM; acute GVHD; chronic GVHD; IP;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>CDI=clinically documented infections; MDI=microbiologically documented infections (all pathogens included, ie bacterial, fungal, viral, other); IRM=infection related mortality; TRM=transplant related mortality; GVHD=graft versus host disease; VOD=veno-occlusive disease; IP=interstitial pneumonia</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Aulitzky-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Phase I study. The safety and pharmacokinetics of two neutralizing human IgG1 monoclonal antibodies to CMV in BMT recipients was assessed in an open phase I trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bode-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Children with leukemia (ALL) and solid tumors reported together as a single cohort (not CLL or MM or BMT)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bunch-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Reports the study by the cooperative CLL group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chapel-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT. The study describes the kinetics of immunoglobulin levels in 15 patients given IVIG in a different RCT included in this review (see reference Co-operative group for the study of CLL)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chapel-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Collins-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Reports a study of immunoglobulin prophylaxis in patients with acute leukemia (not CLL or MM or BMT)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Copelan-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Oral and not parenteral immunoglobulins. This is a controlled trial of orally administered immunoglobulin following bone marrow transplantation where 72 patients were randomized to oral Ig vs. placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cortez-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT. Also the intervention was the administration of RSV (respiratory syncitial virus) immunoglobulins and not polyvalent IG or anti CMV IG</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Eijkhout-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>This is a crossover study dealing with 43 patients with primary hypogammaglobulinemia who received standard-dose immunoglobulin therapy for 9 months, followed by a 3-month washout period, and high-dose intravenous immunoglobulin therapy for 9 months, or vice versa.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Elfenbein-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-07-21 17:12:35 +0200" MODIFIED_BY="Nicole Skoetz" STUDY_ID="STD-Esperou-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-07-21 17:12:35 +0200" MODIFIED_BY="Nicole Skoetz">
<P>This is a subcategory of <LINK REF="STD-Cordonnier-2003" TYPE="STUDY">Cordonnier 2003</LINK> dealing with costs only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fehir-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT. This is a publication reporting on Immune globulin (GAMMAGARD) prophylaxis of CMV infections in patients undergoing organ transplantation and allogeneic bone marrow transplantation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gamm-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-07-21 22:26:33 +0200" MODIFIED_BY="[Empty name]">
<P>The study itself is not an RCT and quotes the RCT by Chapel 1994 (which is already included in the review)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gerein-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>All pts. received first hyperimmune CMVIG and only those who became negative were randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gimesi-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Reports a study of immunoglobulin prophylaxis in children with acute lymphoblastic leukemia (not CLL or MM or BMT)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-07-21 17:14:28 +0200" MODIFIED_BY="Nicole Skoetz" STUDY_ID="STD-Graham-Pole-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-07-21 17:14:28 +0200" MODIFIED_BY="Nicole Skoetz">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jurlander-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>No RCT. 15 patients with CLL and hypogammaglobulinaemia and a history of recurrent infections received a fixed dose of 10 grams of gammaglobulin intravenously every 3 weeks.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Klaesson-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT. Forty-five recipients of bone marrow from HLA-identical siblings were given intravenous immune globulin once a week during the first 3 months after transplantation. Fifty-three consecutive previously transplanted HLA-identical siblings were included as controls.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-06-25 20:08:08 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Messori-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-06-25 20:08:08 +0200" MODIFIED_BY="[Empty name]">
<P>Not RCT, meta-analysis. This is an analysis of the RCT's published on the effectiveness of hyperimmune immunoglobulins for prevention of CMV infection or disease in CMV-seronegative recipients of allogeneic bone marrow transplantation (BMT). The clinical trials were identified by searching a number of computerized literature databases, by reviewing bibliographies of the paper examined and by consulting experts.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nasman--Bjork-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective study. Sera obtained from 13 IVIG-treated and 31 non-IVIG-treated patients before and at different time points after BMT, ranging from 3 days to 3 years, and from 18 healthy controls, were analyzed using a quantitative immunoblot system.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nurnberger-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Petersen-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>This report represents a retrospective analysis of bacterial and fungal bacteremia of the same patients from another RCT (see reference Meyers in included studies)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rand-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>No RCT. The pharmacokinetics of an IVIG, Gammagard were measured in 31 CMV antibody negative BMT patients as part of a multicenter efficacy trial of 2 weekly dose regimens.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Spitzer-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT. Historical controls. Continuous infusion intravenous immunoglobulin was compared to intermittent infusion following bone marrow transplantation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-07-21 17:14:57 +0200" MODIFIED_BY="Nicole Skoetz" STUDY_ID="STD-Sullivan-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-07-21 17:14:57 +0200" MODIFIED_BY="Nicole Skoetz">
<P>includes 383 pts. from <LINK REF="STD-Sullivan-1990" TYPE="STUDY">Sullivan 1990</LINK> &amp; 94 pts. from <LINK REF="STD-Bowden-1986" TYPE="STUDY">Bowden 1986</LINK>. Outcomes reported only for 100 pts</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sullivan-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective analysis. A retrospective analysis of two randomized clinical trials conducted Iin one center to determine the effect of IVIg infusions on the development and severity of VOD. Patients were randomized to receive or not to receive IVIG prophylaxis after allogeneic BMT. To determine the relationship of IVIG to the development and severity of VOD, a single observer reviewed data displays created for each patient for grading VOD without knowledge of patient IVIG use.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Terada-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vu-Van-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT, a description of 2 pilot studies compared to a historical control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Abdel_x002d_Mageed-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Boeckh-2001">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Bordigoni-1987">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Boughton-1995">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Bowden-1986">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bowden-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Chapel-1994">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Chapel-1994c">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Condie-1984">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Cooperative-CLL-1988">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Cordonnier-2003">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Emanuel-1992">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Feinstein-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Filipovich-1992">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Gluck-1990">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Graham-Pole-1990">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Hargreaves-1992">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Jacobsen-1985">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lum-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Meyers-1983">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Molica-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Musto-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Peltier-1992">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Poynton-1992">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Raiola-2002">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ringden-1987">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ruutu-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Salmon-1967">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Serrano-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sklenar-1993">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sullivan-1990">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sullivan-2000">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ustun-1998">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Winston-1982">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Winston-1984">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Winston-1987">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Winston-1993">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Winston-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wolff-1993">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Zikos-1998">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-08-11 15:34:16 +0200" MODIFIED_BY="Nicole Skoetz">
<COMPARISON ID="CMP-001" MODIFIED="2008-06-25 17:58:05 +0200" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Polyvalent immunoglobulins vs. placebo / no intervention - HSCT</NAME>
<DICH_OUTCOME CHI2="7.237151089200917" CI_END="1.1201187551781742" CI_START="0.8820847875302138" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9940018682929863" ESTIMABLE="YES" EVENTS_1="300" EVENTS_2="273" I2="3.276856960396851" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.04926406908491527" LOG_CI_START="-0.054489667717709155" LOG_EFFECT_SIZE="-0.0026127993163969463" METHOD="MH" MODIFIED="2008-06-25 17:41:38 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.40461277362558135" P_Q="0.0" P_Z="0.921365056281286" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="756" TOTAL_2="662" WEIGHT="99.99999999999997" Z="0.09871437341501813">
<NAME>All-cause Mortality</NAME>
<GROUP_LABEL_1>Polyvalent IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.2658338530924166" CI_END="1.153048487885952" CI_START="0.8659324596996624" DF="2.0" EFFECT_SIZE="0.9992307607695325" ESTIMABLE="YES" EVENTS_1="146" EVENTS_2="144" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.06184757058918029" LOG_CI_START="-0.06251598041179264" LOG_EFFECT_SIZE="-3.3420491130615174E-4" MODIFIED="2008-06-25 17:41:36 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8755378298734714" P_Z="0.9915951526558159" STUDIES="3" TAU2="0.0" TOTAL_1="239" TOTAL_2="235" WEIGHT="51.74444538657731" Z="0.010534108817966065">
<NAME>2 years and more</NAME>
<DICH_DATA CI_END="1.7956645992446418" CI_START="0.6392948795428534" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="13" LOG_CI_END="0.25422522080559784" LOG_CI_START="-0.19429877405071144" LOG_EFFECT_SIZE="0.029963223377443202" ORDER="6" O_E="0.0" SE="0.263465214808178" STUDY_ID="STD-Lum-1994" TOTAL_1="28" TOTAL_2="26" VAR="0.0694139194139194" WEIGHT="4.813420896371873"/>
<DICH_DATA CI_END="1.1452298351980588" CI_START="0.8383914163838789" EFFECT_SIZE="0.9798728813559322" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="118" LOG_CI_END="0.058892653611788165" LOG_CI_START="-0.07655317672986092" LOG_EFFECT_SIZE="-0.008830261559036367" ORDER="7" O_E="0.0" SE="0.07956155121035804" STUDY_ID="STD-Sullivan-1990" TOTAL_1="184" TOTAL_2="185" VAR="0.0063300404309984265" WEIGHT="42.01648130609466"/>
<DICH_DATA CI_END="1.7732552129951322" CI_START="0.674958343971265" EFFECT_SIZE="1.0940170940170941" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="13" LOG_CI_END="0.24877124525633185" LOG_CI_START="-0.17072302945291837" LOG_EFFECT_SIZE="0.03902410790170677" ORDER="8" O_E="0.0" SE="0.2464130134943632" STUDY_ID="STD-Winston-1993" TOTAL_1="27" TOTAL_2="24" VAR="0.06071937321937323" WEIGHT="4.914543184110779"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.922973685328866" CI_END="1.200490651413916" CI_START="0.8137710421283358" DF="4.0" EFFECT_SIZE="0.9883949253544492" ESTIMABLE="YES" EVENTS_1="154" EVENTS_2="129" I2="42.22136062026667" ID="CMP-001.01.02" LOG_CI_END="0.07935878242290184" LOG_CI_START="-0.08949776848571984" LOG_EFFECT_SIZE="-0.005069493031409011" MODIFIED="2008-06-25 17:41:38 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.14001529457725226" P_Z="0.906316481331049" STUDIES="5" TAU2="0.0" TOTAL_1="517" TOTAL_2="427" WEIGHT="48.25555461342267" Z="0.11768597318815802">
<NAME>100-200 days</NAME>
<DICH_DATA CI_END="1.7431481714047472" CI_START="0.6296112326755309" EFFECT_SIZE="1.0476190476190477" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="14" LOG_CI_END="0.24133430465929537" LOG_CI_START="-0.2009275324827214" LOG_EFFECT_SIZE="0.02020338608828699" MODIFIED="2008-06-25 17:40:52 +0200" MODIFIED_BY="[Empty name]" ORDER="1" O_E="0.0" SE="0.25978679236862195" STUDY_ID="STD-Cordonnier-2003" TOTAL_1="150" TOTAL_2="50" VAR="0.06748917748917749" WEIGHT="7.49782870396388"/>
<DICH_DATA CI_END="1.258328438015756" CI_START="0.40795117345534293" EFFECT_SIZE="0.7164750957854407" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="18" LOG_CI_END="0.09979401169835539" LOG_CI_START="-0.3893918133019193" LOG_EFFECT_SIZE="-0.14479890080178195" MODIFIED="2008-06-25 17:41:38 +0200" MODIFIED_BY="[Empty name]" ORDER="2" O_E="0.0" SE="0.2873501751140487" STUDY_ID="STD-Poynton-1992" TOTAL_1="29" TOTAL_2="34" VAR="0.08257012313807446" WEIGHT="5.916653943264015"/>
<DICH_DATA CI_END="1.163219761020434" CI_START="0.7305092071417054" EFFECT_SIZE="0.921814919251474" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="94" LOG_CI_END="0.06566177146306576" LOG_CI_START="-0.13637430596426628" LOG_EFFECT_SIZE="-0.03535626725060022" ORDER="3" O_E="0.0" SE="0.11867699197552743" STUDY_ID="STD-Sullivan-2000" TOTAL_1="249" TOTAL_2="248" VAR="0.014084228424359403" WEIGHT="33.629238027206775"/>
<DICH_DATA CI_END="63.149196457537265" CI_START="0.1425196281959308" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8003678287428493" LOG_CI_START="-0.8461253193035243" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="4" O_E="0.0" SE="1.5545631755148024" STUDY_ID="STD-Ustun-1998" TOTAL_1="7" TOTAL_2="7" VAR="2.4166666666666665" WEIGHT="0.17851973104675906"/>
<DICH_DATA CI_END="13.606525523365265" CI_START="1.1379764111245112" EFFECT_SIZE="3.934959349593496" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" LOG_CI_END="1.1337472406573357" LOG_CI_START="0.05613325975269332" LOG_EFFECT_SIZE="0.5949402502050145" ORDER="5" O_E="0.0" SE="0.6329957866586224" STUDY_ID="STD-Wolff-1993" TOTAL_1="82" TOTAL_2="88" VAR="0.4006836659275683" WEIGHT="1.0333142079412407"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.809290940782868" CI_END="1.2627607489459105" CI_START="0.8342716095510568" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0263943893557694" ESTIMABLE="YES" EVENTS_1="143" EVENTS_2="111" I2="48.358585745135436" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.1013210740270137" LOG_CI_START="-0.07869253530279625" LOG_EFFECT_SIZE="0.01131426936210873" METHOD="MH" MODIFIED="2008-06-25 17:58:05 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.12126658755932462" P_Q="0.0" P_Z="0.8053908051791137" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="488" TOTAL_2="393" WEIGHT="100.0" Z="0.2463764883519376">
<NAME>All cause mortality 100 days</NAME>
<GROUP_LABEL_1>Polyvalent IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7431481714047472" CI_START="0.6296112326755309" EFFECT_SIZE="1.0476190476190477" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="14" LOG_CI_END="0.24133430465929537" LOG_CI_START="-0.2009275324827214" LOG_EFFECT_SIZE="0.02020338608828699" MODIFIED="2008-06-25 17:57:03 +0200" MODIFIED_BY="[Empty name]" ORDER="364" O_E="0.0" SE="0.25978679236862195" STUDY_ID="STD-Cordonnier-2003" TOTAL_1="150" TOTAL_2="50" VAR="0.06748917748917749" WEIGHT="17.709077433010695"/>
<DICH_DATA CI_END="1.163219761020434" CI_START="0.7305092071417054" EFFECT_SIZE="0.921814919251474" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="94" LOG_CI_END="0.06566177146306576" LOG_CI_START="-0.13637430596426628" LOG_EFFECT_SIZE="-0.03535626725060022" MODIFIED="2008-06-25 17:57:34 +0200" MODIFIED_BY="[Empty name]" ORDER="365" O_E="0.0" SE="0.11867699197552743" STUDY_ID="STD-Sullivan-2000" TOTAL_1="249" TOTAL_2="248" VAR="0.014084228424359403" WEIGHT="79.42869912753632"/>
<DICH_DATA CI_END="63.149196457537265" CI_START="0.1425196281959308" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8003678287428493" LOG_CI_START="-0.8461253193035243" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2008-06-25 17:57:47 +0200" MODIFIED_BY="[Empty name]" ORDER="366" O_E="0.0" SE="1.5545631755148024" STUDY_ID="STD-Ustun-1998" TOTAL_1="7" TOTAL_2="7" VAR="2.4166666666666665" WEIGHT="0.42164470078596894"/>
<DICH_DATA CI_END="13.606525523365265" CI_START="1.1379764111245112" EFFECT_SIZE="3.934959349593496" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" LOG_CI_END="1.1337472406573357" LOG_CI_START="0.05613325975269332" LOG_EFFECT_SIZE="0.5949402502050145" MODIFIED="2008-06-25 17:58:05 +0200" MODIFIED_BY="[Empty name]" ORDER="367" O_E="0.0" SE="0.6329957866586224" STUDY_ID="STD-Wolff-1993" TOTAL_1="82" TOTAL_2="88" VAR="0.4006836659275683" WEIGHT="2.4405787386670204"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.155899652560464" CI_END="1.2143653767084144" CI_START="0.9415950584023255" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.069317744079617" ESTIMABLE="YES" EVENTS_1="266" EVENTS_2="186" I2="50.95574773600556" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.08434937637186142" LOG_CI_START="-0.026135829385345314" LOG_EFFECT_SIZE="0.029106773493258065" METHOD="MH" MODIFIED="2008-06-25 17:50:10 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.08603153021869625" P_Q="0.0" P_Z="0.30175117719451794" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="418" TOTAL_2="319" WEIGHT="100.00000000000003" Z="1.0326853692668216">
<NAME>All-cause Mortality at 1-2years and more</NAME>
<GROUP_LABEL_1>Polyvalent IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0532393936215105" CI_START="1.1162164407233806" EFFECT_SIZE="1.5138888888888888" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="24" LOG_CI_END="0.31243958807865363" LOG_CI_START="0.04774841494005673" LOG_EFFECT_SIZE="0.18009400150935514" ORDER="14" O_E="0.0" SE="0.1554809053440502" STUDY_ID="STD-Cordonnier-2003" TOTAL_1="150" TOTAL_2="50" VAR="0.0241743119266055" WEIGHT="18.228048126412205"/>
<DICH_DATA CI_END="1.7956645992446418" CI_START="0.6392948795428534" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="13" LOG_CI_END="0.25422522080559784" LOG_CI_START="-0.19429877405071144" LOG_EFFECT_SIZE="0.029963223377443202" ORDER="15" O_E="0.0" SE="0.263465214808178" STUDY_ID="STD-Lum-1994" TOTAL_1="28" TOTAL_2="26" VAR="0.0694139194139194" WEIGHT="6.8261414794383155"/>
<DICH_DATA CI_END="1.258328438015756" CI_START="0.40795117345534293" EFFECT_SIZE="0.7164750957854407" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="18" LOG_CI_END="0.09979401169835539" LOG_CI_START="-0.3893918133019193" LOG_EFFECT_SIZE="-0.14479890080178195" ORDER="16" O_E="0.0" SE="0.2873501751140487" STUDY_ID="STD-Poynton-1992" TOTAL_1="29" TOTAL_2="34" VAR="0.08257012313807446" WEIGHT="8.390688820094509"/>
<DICH_DATA CI_END="1.1452298351980588" CI_START="0.8383914163838789" EFFECT_SIZE="0.9798728813559322" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="118" LOG_CI_END="0.058892653611788165" LOG_CI_START="-0.07655317672986092" LOG_EFFECT_SIZE="-0.008830261559036367" ORDER="17" O_E="0.0" SE="0.07956155121035804" STUDY_ID="STD-Sullivan-1990" TOTAL_1="184" TOTAL_2="185" VAR="0.0063300404309984265" WEIGHT="59.58557376101503"/>
<DICH_DATA CI_END="1.7732552129951322" CI_START="0.674958343971265" EFFECT_SIZE="1.0940170940170941" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="13" LOG_CI_END="0.24877124525633185" LOG_CI_START="-0.17072302945291837" LOG_EFFECT_SIZE="0.03902410790170677" ORDER="18" O_E="0.0" SE="0.2464130134943632" STUDY_ID="STD-Winston-1993" TOTAL_1="27" TOTAL_2="24" VAR="0.06071937321937323" WEIGHT="6.969547813039962"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.498021304533356" CI_END="1.1760199744304005" CI_START="0.8938381979902207" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.025266587159347" ESTIMABLE="YES" EVENTS_1="212" EVENTS_2="179" I2="23.05349943202339" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.070414698195249" LOG_CI_START="-0.048741089794366234" LOG_EFFECT_SIZE="0.01083680420044141" METHOD="MH" NO="4" P_CHI2="0.2607277307310506" P_Q="0.0" P_Z="0.7214633032849154" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="500" TOTAL_2="407" WEIGHT="99.99999999999999" Z="0.35650380562677564">
<NAME>All-cause Mortality - by type of HSCT</NAME>
<GROUP_LABEL_1>Polyvalent IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.015343287284534966" CI_END="1.4375127490723785" CI_START="0.792742003824121" DF="2.0" EFFECT_SIZE="1.0675095958455634" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="40" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.15761170506756758" LOG_CI_START="-0.10086812989068712" LOG_EFFECT_SIZE="0.028371787588440237" NO="1" P_CHI2="0.992357708452065" P_Z="0.6670013726484945" STUDIES="3" TAU2="0.0" TOTAL_1="205" TOTAL_2="100" WEIGHT="26.02388467448302" Z="0.4302670795139141">
<NAME>allogeneic transplant</NAME>
<DICH_DATA CI_END="1.7431481714047472" CI_START="0.6296112326755309" EFFECT_SIZE="1.0476190476190477" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="14" LOG_CI_END="0.24133430465929537" LOG_CI_START="-0.2009275324827214" LOG_EFFECT_SIZE="0.02020338608828699" ORDER="19" O_E="0.0" SE="0.25978679236862195" STUDY_ID="STD-Cordonnier-2003" TOTAL_1="150" TOTAL_2="50" VAR="0.06748917748917749" WEIGHT="11.327352647430203"/>
<DICH_DATA CI_END="1.7956645992446418" CI_START="0.6392948795428534" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="13" LOG_CI_END="0.25422522080559784" LOG_CI_START="-0.19429877405071144" LOG_EFFECT_SIZE="0.029963223377443202" ORDER="20" O_E="0.0" SE="0.263465214808178" STUDY_ID="STD-Lum-1994" TOTAL_1="28" TOTAL_2="26" VAR="0.0694139194139194" WEIGHT="7.2718807119305"/>
<DICH_DATA CI_END="1.7732552129951322" CI_START="0.674958343971265" EFFECT_SIZE="1.0940170940170941" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="13" LOG_CI_END="0.24877124525633185" LOG_CI_START="-0.17072302945291837" LOG_EFFECT_SIZE="0.03902410790170677" ORDER="21" O_E="0.0" SE="0.2464130134943632" STUDY_ID="STD-Winston-1993" TOTAL_1="27" TOTAL_2="24" VAR="0.06071937321937323" WEIGHT="7.4246513151223175"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.1248730700615321" CI_END="1.1024295616372717" CI_START="0.8141031658174684" DF="1.0" EFFECT_SIZE="0.9473602251623544" ESTIMABLE="YES" EVENTS_1="126" EVENTS_2="136" I2="11.10108094726647" ID="CMP-001.04.02" LOG_CI_END="0.04235085032172371" LOG_CI_START="-0.08932055640533067" LOG_EFFECT_SIZE="-0.023484853041803477" NO="2" P_CHI2="0.2888716084921733" P_Z="0.48445417833286686" STUDIES="2" TAU2="0.0" TOTAL_1="213" TOTAL_2="219" WEIGHT="72.41503479259381" Z="0.6991565942568934">
<NAME>autologous and allo transplant</NAME>
<DICH_DATA CI_END="1.258328438015756" CI_START="0.40795117345534293" EFFECT_SIZE="0.7164750957854407" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="18" LOG_CI_END="0.09979401169835539" LOG_CI_START="-0.3893918133019193" LOG_EFFECT_SIZE="-0.14479890080178195" ORDER="22" O_E="0.0" SE="0.2873501751140487" STUDY_ID="STD-Poynton-1992" TOTAL_1="29" TOTAL_2="34" VAR="0.08257012313807446" WEIGHT="8.938591204774854"/>
<DICH_DATA CI_END="1.1452298351980588" CI_START="0.8383914163838789" EFFECT_SIZE="0.9798728813559322" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="118" LOG_CI_END="0.058892653611788165" LOG_CI_START="-0.07655317672986092" LOG_EFFECT_SIZE="-0.008830261559036367" ORDER="23" O_E="0.0" SE="0.07956155121035804" STUDY_ID="STD-Sullivan-1990" TOTAL_1="184" TOTAL_2="185" VAR="0.0063300404309984265" WEIGHT="63.476443587818956"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="13.606525523365265" CI_START="1.137976411124511" DF="0.0" EFFECT_SIZE="3.934959349593496" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" I2="0.0" ID="CMP-001.04.03" LOG_CI_END="1.1337472406573357" LOG_CI_START="0.05613325975269324" LOG_EFFECT_SIZE="0.5949402502050145" NO="3" P_CHI2="1.0" P_Z="0.030452509570562086" STUDIES="1" TAU2="0.0" TOTAL_1="82" TOTAL_2="88" WEIGHT="1.5610805329231539" Z="2.164154296469287">
<NAME>autologous alone</NAME>
<DICH_DATA CI_END="13.606525523365265" CI_START="1.1379764111245112" EFFECT_SIZE="3.934959349593496" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" LOG_CI_END="1.1337472406573357" LOG_CI_START="0.05613325975269332" LOG_EFFECT_SIZE="0.5949402502050145" ORDER="24" O_E="0.0" SE="0.6329957866586224" STUDY_ID="STD-Wolff-1993" TOTAL_1="82" TOTAL_2="88" VAR="0.4006836659275683" WEIGHT="1.5610805329231539"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.942327977983341" CI_END="1.0449217117176917" CI_START="0.7932503324427937" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9104309392791702" ESTIMABLE="YES" EVENTS_1="197" EVENTS_2="186" I2="49.63693250784575" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.01908375318136618" LOG_CI_START="-0.1005897372193048" LOG_EFFECT_SIZE="-0.04075299201896929" METHOD="MH" NO="5" P_CHI2="0.09371383202186423" P_Q="0.0" P_Z="0.18191823854139444" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="428" TOTAL_2="330" WEIGHT="100.0" Z="1.3348720147127957">
<NAME>All cause mortality -by use of antifungal prophylaxis</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.01557026227977976" CI_END="1.529817057396492" CI_START="0.7427910088588505" DF="1.0" EFFECT_SIZE="1.0659898477157361" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="27" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.18463949897866014" LOG_CI_START="-0.1291333618340074" LOG_EFFECT_SIZE="0.027753068572326376" NO="1" P_CHI2="0.9006970463692333" P_Z="0.7288047887229396" STUDIES="2" TAU2="0.0" TOTAL_1="177" TOTAL_2="74" WEIGHT="18.07620650812634" Z="0.3467158677863203">
<NAME>Use of oral polyene</NAME>
<DICH_DATA CI_END="1.7431481714047472" CI_START="0.6296112326755309" EFFECT_SIZE="1.0476190476190477" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="14" LOG_CI_END="0.24133430465929537" LOG_CI_START="-0.2009275324827214" LOG_EFFECT_SIZE="0.02020338608828699" ORDER="25" O_E="0.0" SE="0.25978679236862195" STUDY_ID="STD-Cordonnier-2003" TOTAL_1="150" TOTAL_2="50" VAR="0.06748917748917749" WEIGHT="10.919129819629617"/>
<DICH_DATA CI_END="1.7732552129951322" CI_START="0.674958343971265" EFFECT_SIZE="1.0940170940170941" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="13" LOG_CI_END="0.24877124525633185" LOG_CI_START="-0.17072302945291837" LOG_EFFECT_SIZE="0.03902410790170677" ORDER="26" O_E="0.0" SE="0.2464130134943632" STUDY_ID="STD-Winston-1993" TOTAL_1="27" TOTAL_2="24" VAR="0.06071937321937323" WEIGHT="7.1570766884967245"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.397793382506985" CI_END="1.0150263373865513" CI_START="0.7562012327262684" DF="2.0" EFFECT_SIZE="0.8761073950043677" ESTIMABLE="YES" EVENTS_1="137" EVENTS_2="159" I2="72.96491133789635" ID="CMP-001.05.02" LOG_CI_END="0.006477311247507253" LOG_CI_START="-0.12136261900498321" LOG_EFFECT_SIZE="-0.057442653878738" NO="2" P_CHI2="0.024750899628197764" P_Z="0.07817891172353855" STUDIES="3" TAU2="0.0" TOTAL_1="251" TOTAL_2="256" WEIGHT="81.92379349187365" Z="1.761351598931012">
<NAME>no antifungal prophylaxis</NAME>
<DICH_DATA CI_END="1.258328438015756" CI_START="0.40795117345534293" EFFECT_SIZE="0.7164750957854407" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="18" LOG_CI_END="0.09979401169835539" LOG_CI_START="-0.3893918133019193" LOG_EFFECT_SIZE="-0.14479890080178195" ORDER="27" O_E="0.0" SE="0.2873501751140487" STUDY_ID="STD-Poynton-1992" TOTAL_1="29" TOTAL_2="34" VAR="0.08257012313807446" WEIGHT="8.616456184197522"/>
<DICH_DATA CI_END="1.1452298351980588" CI_START="0.8383914163838789" EFFECT_SIZE="0.9798728813559322" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="118" LOG_CI_END="0.058892653611788165" LOG_CI_START="-0.07655317672986092" LOG_EFFECT_SIZE="-0.008830261559036367" ORDER="28" O_E="0.0" SE="0.07956155121035804" STUDY_ID="STD-Sullivan-1990" TOTAL_1="184" TOTAL_2="185" VAR="0.0063300404309984265" WEIGHT="61.18883640309672"/>
<DICH_DATA CI_END="0.8135903187173477" CI_START="0.26653864225888546" EFFECT_SIZE="0.465675057208238" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="23" LOG_CI_END="-0.08959422792288477" LOG_CI_START="-0.5742398188954811" LOG_EFFECT_SIZE="-0.331917023409183" ORDER="29" O_E="0.0" SE="0.2846832191716696" STUDY_ID="STD-Winston-1987" TOTAL_1="38" TOTAL_2="37" VAR="0.08104453527794489" WEIGHT="12.118500904579411"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.21187251013121" CI_END="1.2261254606565477" CI_START="0.9081553026514834" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0552309409845964" ESTIMABLE="YES" EVENTS_1="142" EVENTS_2="134" I2="61.62607592353311" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.08853491070695861" LOG_CI_START="-0.04183987690049079" LOG_EFFECT_SIZE="0.023347516903233938" METHOD="MH" NO="6" P_CHI2="0.07383409420637066" P_Q="0.0" P_Z="0.4826912053321871" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="293" TOTAL_2="297" WEIGHT="100.0" Z="0.7019806988535257">
<NAME>All-cause Mortality - high dose IVIG</NAME>
<GROUP_LABEL_1>Polyvalent IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1452298351980588" CI_START="0.8383914163838789" EFFECT_SIZE="0.9798728813559322" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="118" LOG_CI_END="0.058892653611788165" LOG_CI_START="-0.07655317672986092" LOG_EFFECT_SIZE="-0.008830261559036367" ORDER="30" O_E="0.0" SE="0.07956155121035804" STUDY_ID="STD-Sullivan-1990" TOTAL_1="184" TOTAL_2="185" VAR="0.0063300404309984265" WEIGHT="87.59941749747955"/>
<DICH_DATA CI_END="1.7732552129951322" CI_START="0.674958343971265" EFFECT_SIZE="1.0940170940170941" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="13" LOG_CI_END="0.24877124525633185" LOG_CI_START="-0.17072302945291837" LOG_EFFECT_SIZE="0.03902410790170677" ORDER="31" O_E="0.0" SE="0.2464130134943632" STUDY_ID="STD-Winston-1993" TOTAL_1="27" TOTAL_2="24" VAR="0.06071937321937323" WEIGHT="10.24624401691308"/>
<DICH_DATA CI_END="13.606525523365265" CI_START="1.1379764111245112" EFFECT_SIZE="3.934959349593496" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" LOG_CI_END="1.1337472406573357" LOG_CI_START="0.05613325975269332" LOG_EFFECT_SIZE="0.5949402502050145" ORDER="32" O_E="0.0" SE="0.6329957866586224" STUDY_ID="STD-Wolff-1993" TOTAL_1="82" TOTAL_2="88" VAR="0.4006836659275683" WEIGHT="2.154338485607365"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.121181006094389" CI_END="1.0939871647173753" CI_START="0.863915781313457" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9721691088250567" ESTIMABLE="YES" EVENTS_1="305" EVENTS_2="284" I2="23.25555215576914" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.03901222663624394" LOG_CI_START="-0.0635285925831083" LOG_EFFECT_SIZE="-0.01225818297343218" METHOD="MH" NO="7" P_CHI2="0.24407265855136584" P_Q="0.0" P_Z="0.6393516298637663" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="770" TOTAL_2="675" WEIGHT="99.99999999999997" Z="0.46860552366827385">
<NAME>All-cause Mortality -sensitivity analysis by randomization generation</NAME>
<GROUP_LABEL_1>Polyvalent IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.9046290708606675" CI_END="2.218601529347215" CI_START="0.8800870434651887" DF="1.0" EFFECT_SIZE="1.397341211225997" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="17" I2="74.3893726688979" ID="CMP-001.07.01" LOG_CI_END="0.34607930802499104" LOG_CI_START="-0.05547437259169414" LOG_EFFECT_SIZE="0.14530246771664845" NO="1" P_CHI2="0.04815331561419489" P_Z="0.15606568356592995" STUDIES="2" TAU2="0.0" TOTAL_1="232" TOTAL_2="138" WEIGHT="8.215289240612925" Z="1.41842855556479">
<NAME>randomization generation A</NAME>
<DICH_DATA CI_END="1.7431481714047472" CI_START="0.6296112326755309" EFFECT_SIZE="1.0476190476190477" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="14" LOG_CI_END="0.24133430465929537" LOG_CI_START="-0.2009275324827214" LOG_EFFECT_SIZE="0.02020338608828699" ORDER="33" O_E="0.0" SE="0.25978679236862195" STUDY_ID="STD-Cordonnier-2003" TOTAL_1="150" TOTAL_2="50" VAR="0.06748917748917749" WEIGHT="7.220232050464832"/>
<DICH_DATA CI_END="13.606525523365265" CI_START="1.1379764111245112" EFFECT_SIZE="3.934959349593496" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" LOG_CI_END="1.1337472406573357" LOG_CI_START="0.05613325975269332" LOG_EFFECT_SIZE="0.5949402502050145" ORDER="34" O_E="0.0" SE="0.6329957866586224" STUDY_ID="STD-Wolff-1993" TOTAL_1="82" TOTAL_2="88" VAR="0.4006836659275683" WEIGHT="0.9950571901480945"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.060557391206483" CI_END="1.0543293142475283" CI_START="0.8276050453012989" DF="5.0" EFFECT_SIZE="0.934113622575066" ESTIMABLE="YES" EVENTS_1="250" EVENTS_2="267" I2="0.0" ID="CMP-001.07.02" LOG_CI_END="0.022976281675876155" LOG_CI_START="-0.08217687042312913" LOG_EFFECT_SIZE="-0.02960029437362651" NO="2" P_CHI2="0.5407306486320822" P_Z="0.2698327351170213" STUDIES="6" TAU2="0.0" TOTAL_1="538" TOTAL_2="537" WEIGHT="91.78471075938705" Z="1.1034478709581235">
<NAME>randomization generation B</NAME>
<DICH_DATA CI_END="1.7956645992446418" CI_START="0.6392948795428534" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="13" LOG_CI_END="0.25422522080559784" LOG_CI_START="-0.19429877405071144" LOG_EFFECT_SIZE="0.029963223377443202" ORDER="35" O_E="0.0" SE="0.263465214808178" STUDY_ID="STD-Lum-1994" TOTAL_1="28" TOTAL_2="26" VAR="0.0694139194139194" WEIGHT="4.635210699063842"/>
<DICH_DATA CI_END="1.258328438015756" CI_START="0.40795117345534293" EFFECT_SIZE="0.7164750957854407" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="18" LOG_CI_END="0.09979401169835539" LOG_CI_START="-0.3893918133019193" LOG_EFFECT_SIZE="-0.14479890080178195" ORDER="36" O_E="0.0" SE="0.2873501751140487" STUDY_ID="STD-Poynton-1992" TOTAL_1="29" TOTAL_2="34" VAR="0.08257012313807446" WEIGHT="5.697598080638915"/>
<DICH_DATA CI_END="1.1452298351980588" CI_START="0.8383914163838789" EFFECT_SIZE="0.9798728813559322" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="118" LOG_CI_END="0.058892653611788165" LOG_CI_START="-0.07655317672986092" LOG_EFFECT_SIZE="-0.008830261559036367" ORDER="37" O_E="0.0" SE="0.07956155121035804" STUDY_ID="STD-Sullivan-1990" TOTAL_1="184" TOTAL_2="185" VAR="0.0063300404309984265" WEIGHT="40.4608796695554"/>
<DICH_DATA CI_END="1.163219761020434" CI_START="0.7305092071417054" EFFECT_SIZE="0.921814919251474" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="94" LOG_CI_END="0.06566177146306576" LOG_CI_START="-0.13637430596426628" LOG_EFFECT_SIZE="-0.03535626725060022" ORDER="38" O_E="0.0" SE="0.11867699197552743" STUDY_ID="STD-Sullivan-2000" TOTAL_1="249" TOTAL_2="248" VAR="0.014084228424359403" WEIGHT="32.38416237868733"/>
<DICH_DATA CI_END="1.1376372913410278" CI_START="0.23721093899940981" EFFECT_SIZE="0.5194805194805194" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="0.05600381963585647" LOG_CI_START="-0.6248652873248954" LOG_EFFECT_SIZE="-0.2844307338445195" ORDER="39" O_E="0.0" SE="0.3999458837851816" STUDY_ID="STD-Winston-1984" TOTAL_1="21" TOTAL_2="20" VAR="0.15995670995670996" WEIGHT="3.8742708563469828"/>
<DICH_DATA CI_END="1.7732552129951322" CI_START="0.674958343971265" EFFECT_SIZE="1.0940170940170941" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="13" LOG_CI_END="0.24877124525633185" LOG_CI_START="-0.17072302945291837" LOG_EFFECT_SIZE="0.03902410790170677" ORDER="40" O_E="0.0" SE="0.2464130134943632" STUDY_ID="STD-Winston-1993" TOTAL_1="27" TOTAL_2="24" VAR="0.06071937321937323" WEIGHT="4.732589075094596"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.121181006094389" CI_END="1.0939871647173753" CI_START="0.8639157813134568" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9721691088250566" ESTIMABLE="YES" EVENTS_1="305" EVENTS_2="284" I2="23.25555215576914" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.03901222663624394" LOG_CI_START="-0.06352859258310842" LOG_EFFECT_SIZE="-0.01225818297343223" METHOD="MH" NO="8" P_CHI2="0.24407265855136584" P_Q="0.0" P_Z="0.6393516298637649" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="770" TOTAL_2="675" WEIGHT="99.99999999999997" Z="0.46860552366827574">
<NAME>All-cause Mortality -sensitivity analysis by double blinding</NAME>
<GROUP_LABEL_1>Polyvalent IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.2011639176961157" CI_END="1.1675967486472465" CI_START="0.7644358403874869" DF="1.0" EFFECT_SIZE="0.9447501266397667" ESTIMABLE="YES" EVENTS_1="131" EVENTS_2="108" I2="0.0" ID="CMP-001.08.01" LOG_CI_END="0.06729287695786985" LOG_CI_START="-0.11665895934907354" LOG_EFFECT_SIZE="-0.024683041195601853" NO="1" P_CHI2="0.6537830113468299" P_Z="0.5988992471492194" STUDIES="2" TAU2="0.0" TOTAL_1="399" TOTAL_2="298" WEIGHT="39.60439442915216" Z="0.5259841134890814">
<NAME>double blinding</NAME>
<DICH_DATA CI_END="1.7431481714047472" CI_START="0.6296112326755309" EFFECT_SIZE="1.0476190476190477" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="14" LOG_CI_END="0.24133430465929537" LOG_CI_START="-0.2009275324827214" LOG_EFFECT_SIZE="0.02020338608828699" ORDER="41" O_E="0.0" SE="0.25978679236862195" STUDY_ID="STD-Cordonnier-2003" TOTAL_1="150" TOTAL_2="50" VAR="0.06748917748917749" WEIGHT="7.220232050464831"/>
<DICH_DATA CI_END="1.163219761020434" CI_START="0.7305092071417054" EFFECT_SIZE="0.921814919251474" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="94" LOG_CI_END="0.06566177146306576" LOG_CI_START="-0.13637430596426628" LOG_EFFECT_SIZE="-0.03535626725060022" ORDER="42" O_E="0.0" SE="0.11867699197552743" STUDY_ID="STD-Sullivan-2000" TOTAL_1="249" TOTAL_2="248" VAR="0.014084228424359403" WEIGHT="32.38416237868733"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.890851299931729" CI_END="1.1369463099934025" CI_START="0.8623056539830932" DF="5.0" EFFECT_SIZE="0.9901490955318424" ESTIMABLE="YES" EVENTS_1="174" EVENTS_2="176" I2="43.7624156413639" ID="CMP-001.08.02" LOG_CI_END="0.05573995648707895" LOG_CI_START="-0.06433876629921736" LOG_EFFECT_SIZE="-0.004299404906069228" NO="2" P_CHI2="0.11349785296906312" P_Z="0.8883814292273366" STUDIES="6" TAU2="0.0" TOTAL_1="371" TOTAL_2="377" WEIGHT="60.39560557084782" Z="0.1403525716349837">
<NAME>no blinding</NAME>
<DICH_DATA CI_END="1.7956645992446418" CI_START="0.6392948795428534" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="13" LOG_CI_END="0.25422522080559784" LOG_CI_START="-0.19429877405071144" LOG_EFFECT_SIZE="0.029963223377443202" ORDER="43" O_E="0.0" SE="0.263465214808178" STUDY_ID="STD-Lum-1994" TOTAL_1="28" TOTAL_2="26" VAR="0.0694139194139194" WEIGHT="4.635210699063841"/>
<DICH_DATA CI_END="1.258328438015756" CI_START="0.40795117345534293" EFFECT_SIZE="0.7164750957854407" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="18" LOG_CI_END="0.09979401169835539" LOG_CI_START="-0.3893918133019193" LOG_EFFECT_SIZE="-0.14479890080178195" ORDER="44" O_E="0.0" SE="0.2873501751140487" STUDY_ID="STD-Poynton-1992" TOTAL_1="29" TOTAL_2="34" VAR="0.08257012313807446" WEIGHT="5.697598080638914"/>
<DICH_DATA CI_END="1.1452298351980588" CI_START="0.8383914163838789" EFFECT_SIZE="0.9798728813559322" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="118" LOG_CI_END="0.058892653611788165" LOG_CI_START="-0.07655317672986092" LOG_EFFECT_SIZE="-0.008830261559036367" ORDER="45" O_E="0.0" SE="0.07956155121035804" STUDY_ID="STD-Sullivan-1990" TOTAL_1="184" TOTAL_2="185" VAR="0.0063300404309984265" WEIGHT="40.460879669555396"/>
<DICH_DATA CI_END="1.1376372913410278" CI_START="0.23721093899940981" EFFECT_SIZE="0.5194805194805194" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="0.05600381963585647" LOG_CI_START="-0.6248652873248954" LOG_EFFECT_SIZE="-0.2844307338445195" ORDER="46" O_E="0.0" SE="0.3999458837851816" STUDY_ID="STD-Winston-1984" TOTAL_1="21" TOTAL_2="20" VAR="0.15995670995670996" WEIGHT="3.874270856346982"/>
<DICH_DATA CI_END="1.7732552129951322" CI_START="0.674958343971265" EFFECT_SIZE="1.0940170940170941" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="13" LOG_CI_END="0.24877124525633185" LOG_CI_START="-0.17072302945291837" LOG_EFFECT_SIZE="0.03902410790170677" ORDER="47" O_E="0.0" SE="0.2464130134943632" STUDY_ID="STD-Winston-1993" TOTAL_1="27" TOTAL_2="24" VAR="0.06071937321937323" WEIGHT="4.732589075094595"/>
<DICH_DATA CI_END="13.606525523365265" CI_START="1.1379764111245112" EFFECT_SIZE="3.934959349593496" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" LOG_CI_END="1.1337472406573357" LOG_CI_START="0.05613325975269332" LOG_EFFECT_SIZE="0.5949402502050145" ORDER="48" O_E="0.0" SE="0.6329957866586224" STUDY_ID="STD-Wolff-1993" TOTAL_1="82" TOTAL_2="88" VAR="0.4006836659275683" WEIGHT="0.9950571901480942"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.4866501220310464" CI_END="1.1049650368771882" CI_START="0.8996776632637042" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9970518353454656" ESTIMABLE="YES" EVENTS_1="267" EVENTS_2="181" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.043348536363632506" LOG_CI_START="-0.04591306182795531" LOG_EFFECT_SIZE="-0.0012822627321613998" METHOD="MH" NO="9" P_CHI2="0.9747875188902902" P_Q="0.0" P_Z="0.9550943443430039" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="388" TOTAL_2="300" WEIGHT="100.0" Z="0.056310638049748084">
<NAME>Clinically documented infections</NAME>
<GROUP_LABEL_1>Polyvalent IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1197236422163708" CI_START="0.9063572887417918" EFFECT_SIZE="1.0074074074074073" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="45" LOG_CI_END="0.04911084814310333" LOG_CI_START="-0.04270056839268063" LOG_EFFECT_SIZE="0.003205139875211354" ORDER="49" O_E="0.0" SE="0.05393048054696102" STUDY_ID="STD-Cordonnier-2003" TOTAL_1="150" TOTAL_2="50" VAR="0.002908496732026141" WEIGHT="33.49676609132128"/>
<DICH_DATA CI_END="1.1457727361680978" CI_START="0.8483793519680012" EFFECT_SIZE="0.9859259259259259" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="90" LOG_CI_END="0.05909848393504327" LOG_CI_START="-0.07140990997570523" LOG_EFFECT_SIZE="-0.006155713020331018" ORDER="50" O_E="0.0" SE="0.07666127661014252" STUDY_ID="STD-Feinstein-1999" TOTAL_1="120" TOTAL_2="121" VAR="0.005876951331496785" WEIGHT="44.47703381420252"/>
<DICH_DATA CI_END="6.41946023225646" CI_START="0.38066311635842387" EFFECT_SIZE="1.5632183908045978" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.80749851280288" LOG_CI_START="-0.4194592012996821" LOG_EFFECT_SIZE="0.194019655751599" ORDER="51" O_E="0.0" SE="0.7207210348024826" STUDY_ID="STD-Poynton-1992" TOTAL_1="29" TOTAL_2="34" VAR="0.5194388100067613" WEIGHT="1.370590781867114"/>
<DICH_DATA CI_END="2.4775917649219226" CI_START="0.40361774452035826" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.3940297488328639" LOG_CI_START="-0.39402974883286385" LOG_EFFECT_SIZE="0.0" ORDER="52" O_E="0.0" SE="0.46291004988627577" STUDY_ID="STD-Ustun-1998" TOTAL_1="7" TOTAL_2="7" VAR="0.2142857142857143" WEIGHT="1.9849935461523718"/>
<DICH_DATA CI_END="1.3573826675095535" CI_START="0.6833484518054647" EFFECT_SIZE="0.9631019387116948" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="39" LOG_CI_END="0.13270229936184452" LOG_CI_START="-0.16535778518138775" LOG_EFFECT_SIZE="-0.016327742909771636" ORDER="53" O_E="0.0" SE="0.17508196908190843" STUDY_ID="STD-Wolff-1993" TOTAL_1="82" TOTAL_2="88" VAR="0.03065369589759834" WEIGHT="18.67061576645672"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.55827022558451" CI_END="1.1460674872298784" CI_START="0.8753817949060199" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.001621991598988" ESTIMABLE="YES" EVENTS_1="256" EVENTS_2="208" I2="29.892374956059367" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="0.059210192211270656" LOG_CI_START="-0.05780248954158301" LOG_EFFECT_SIZE="7.038513348438379E-4" METHOD="MH" NO="10" P_CHI2="0.19998679174206113" P_Q="0.0" P_Z="0.9811883923174458" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="638" TOTAL_2="548" WEIGHT="99.99999999999999" Z="0.023579038546917525">
<NAME>Microbiologically documented infections - bacterial</NAME>
<GROUP_LABEL_1>Polyvalent IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7143907515092733" CI_START="0.8570028924740436" EFFECT_SIZE="1.2121212121212122" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="22" LOG_CI_END="0.23410981518535737" LOG_CI_START="-0.06701771228520755" LOG_EFFECT_SIZE="0.08354605145007493" ORDER="54" O_E="0.0" SE="0.17688380024151104" STUDY_ID="STD-Cordonnier-2003" TOTAL_1="150" TOTAL_2="50" VAR="0.03128787878787878" WEIGHT="15.214322527017137"/>
<DICH_DATA CI_END="4.873664934818431" CI_START="0.8207375873181608" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="6" LOG_CI_END="0.687855668065473" LOG_CI_START="-0.08579567673751061" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="55" O_E="0.0" SE="0.45444662957319293" STUDY_ID="STD-Emanuel-1992" TOTAL_1="46" TOTAL_2="46" VAR="0.2065217391304348" WEIGHT="2.766240459457661"/>
<DICH_DATA CI_END="1.1457727361680978" CI_START="0.8483793519680012" EFFECT_SIZE="0.9859259259259259" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="90" LOG_CI_END="0.05909848393504327" LOG_CI_START="-0.07140990997570523" LOG_EFFECT_SIZE="-0.006155713020331018" ORDER="56" O_E="0.0" SE="0.07666127661014252" STUDY_ID="STD-Feinstein-1999" TOTAL_1="120" TOTAL_2="121" VAR="0.005876951331496785" WEIGHT="41.321434249160085"/>
<DICH_DATA CI_END="1.3687057364993827" CI_START="0.29117972144415594" EFFECT_SIZE="0.6312997347480106" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="13" LOG_CI_END="0.13631008746828222" LOG_CI_START="-0.535838873766844" LOG_EFFECT_SIZE="-0.1997643931492809" ORDER="57" O_E="0.0" SE="0.3948236270205315" STUDY_ID="STD-Poynton-1992" TOTAL_1="29" TOTAL_2="34" VAR="0.15588569645364775" WEIGHT="5.517844726008139"/>
<DICH_DATA CI_END="1.0875620749683386" CI_START="0.44550447461421794" EFFECT_SIZE="0.6960702341137124" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="39" LOG_CI_END="0.03645405463525665" LOG_CI_START="-0.35114792958332575" LOG_EFFECT_SIZE="-0.15734693747403455" ORDER="58" O_E="0.0" SE="0.22767932419076092" STUDY_ID="STD-Sullivan-1990" TOTAL_1="184" TOTAL_2="185" VAR="0.051837874663961614" WEIGHT="17.93183517350332"/>
<DICH_DATA CI_END="2.874053590926599" CI_START="0.7259501909335501" EFFECT_SIZE="1.4444444444444444" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" LOG_CI_END="0.45849486192858596" LOG_CI_START="-0.13909317619356215" LOG_EFFECT_SIZE="0.15970084286751188" ORDER="59" O_E="0.0" SE="0.3510261717014463" STUDY_ID="STD-Winston-1993" TOTAL_1="27" TOTAL_2="24" VAR="0.12321937321937323" WEIGHT="3.90528064864611"/>
<DICH_DATA CI_END="1.5668104755865655" CI_START="0.6868701755017389" EFFECT_SIZE="1.0373983739837398" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="30" LOG_CI_END="0.19501646654842927" LOG_CI_START="-0.16312534065693815" LOG_EFFECT_SIZE="0.01594556294574557" ORDER="60" O_E="0.0" SE="0.21037427038297035" STUDY_ID="STD-Wolff-1993" TOTAL_1="82" TOTAL_2="88" VAR="0.04425733363916712" WEIGHT="13.343042216207543"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.735825609869641" CI_END="1.1583175161556944" CI_START="0.817698712666997" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9732187533232931" ESTIMABLE="YES" EVENTS_1="244" EVENTS_2="202" I2="0.0" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="0.0638276238238496" LOG_CI_START="-0.08740668597304982" LOG_EFFECT_SIZE="-0.01178953107460011" METHOD="MH" NO="11" P_CHI2="0.4489633892951257" P_Q="0.0" P_Z="0.7599247919360295" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2062" TOTAL_2="1480" WEIGHT="100.00000000000001" Z="0.30557955178112295">
<NAME>Microbiologically documented infections - patient months</NAME>
<GROUP_LABEL_1>Polyvalent IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9074278707275283" CI_START="0.7702717651461191" EFFECT_SIZE="1.2121212121212122" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="22" LOG_CI_END="0.2804481241171966" LOG_CI_START="-0.11335602121704673" LOG_EFFECT_SIZE="0.08354605145007493" ORDER="61" O_E="0.0" SE="0.23132250433129287" STUDY_ID="STD-Cordonnier-2003" TOTAL_1="900" TOTAL_2="300" VAR="0.05351010101010101" WEIGHT="15.647160614697217"/>
<DICH_DATA CI_END="1.27244315693999" CI_START="0.763924051232677" EFFECT_SIZE="0.9859259259259259" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="90" LOG_CI_END="0.10463839047544174" LOG_CI_START="-0.11694981651610376" LOG_EFFECT_SIZE="-0.006155713020331018" ORDER="62" O_E="0.0" SE="0.13016200966614866" STUDY_ID="STD-Feinstein-1999" TOTAL_1="360" TOTAL_2="363" VAR="0.016942148760330577" WEIGHT="42.49700355557147"/>
<DICH_DATA CI_END="1.5116705859257529" CI_START="0.2636416682334541" EFFECT_SIZE="0.6312997347480106" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="13" LOG_CI_END="0.17945716265906758" LOG_CI_START="-0.5789859489576294" LOG_EFFECT_SIZE="-0.1997643931492809" ORDER="63" O_E="0.0" SE="0.44551323811759974" STUDY_ID="STD-Poynton-1992" TOTAL_1="87" TOTAL_2="102" VAR="0.19848204533802913" WEIGHT="5.674824003598703"/>
<DICH_DATA CI_END="1.1207854259558805" CI_START="0.4322984218017403" EFFECT_SIZE="0.6960702341137124" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="39" LOG_CI_END="0.04952247500069103" LOG_CI_START="-0.3642163499487601" LOG_EFFECT_SIZE="-0.15734693747403455" ORDER="64" O_E="0.0" SE="0.2430322338155215" STUDY_ID="STD-Sullivan-1990" TOTAL_1="552" TOTAL_2="555" VAR="0.05906466667336231" WEIGHT="18.441984819096202"/>
<DICH_DATA CI_END="3.2846097954834352" CI_START="0.6352108417734704" EFFECT_SIZE="1.4444444444444444" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" LOG_CI_END="0.5164837837180469" LOG_CI_START="-0.19708209798302326" LOG_EFFECT_SIZE="0.15970084286751188" ORDER="65" O_E="0.0" SE="0.41915213111928984" STUDY_ID="STD-Winston-1993" TOTAL_1="81" TOTAL_2="72" VAR="0.17568850902184235" WEIGHT="4.016383473291264"/>
<DICH_DATA CI_END="1.5668104755865655" CI_START="0.6868701755017389" EFFECT_SIZE="1.0373983739837398" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="30" LOG_CI_END="0.19501646654842927" LOG_CI_START="-0.16312534065693815" LOG_EFFECT_SIZE="0.01594556294574557" ORDER="66" O_E="0.0" SE="0.21037427038297035" STUDY_ID="STD-Wolff-1993" TOTAL_1="82" TOTAL_2="88" VAR="0.04425733363916712" WEIGHT="13.722643533745154"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.080695275465663" CI_END="1.066430346801584" CI_START="0.6609937682730591" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8395855010260268" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="96" I2="1.5882722952375279" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="0.02793249505260472" LOG_CI_START="-0.17980263494307513" LOG_EFFECT_SIZE="-0.07593506994523518" METHOD="MH" NO="12" P_CHI2="0.4061118943496991" P_Q="0.0" P_Z="0.15189145758416941" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="543" TOTAL_2="443" WEIGHT="100.0" Z="1.4328823657249115">
<NAME>CMV infections</NAME>
<GROUP_LABEL_1>Polyvalent IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4080965589264984" CI_START="0.6140017241774663" EFFECT_SIZE="0.9298245614035088" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="19" LOG_CI_END="0.14863243717192903" LOG_CI_START="-0.21183040931533378" LOG_EFFECT_SIZE="-0.031598986071702355" ORDER="67" O_E="0.0" SE="0.21173766034648542" STUDY_ID="STD-Cordonnier-2003" TOTAL_1="150" TOTAL_2="50" VAR="0.04483283680900363" WEIGHT="27.0326621208816"/>
<DICH_DATA CI_END="2.371723402122864" CI_START="0.7210196475976105" EFFECT_SIZE="1.3076923076923077" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="13" LOG_CI_END="0.3750640388506784" LOG_CI_START="-0.14205290070780402" LOG_EFFECT_SIZE="0.11650556907143717" ORDER="68" O_E="0.0" SE="0.3037570500667868" STUDY_ID="STD-Emanuel-1992" TOTAL_1="46" TOTAL_2="46" VAR="0.09226834546527643" WEIGHT="12.330687984963538"/>
<DICH_DATA CI_END="1.0720598207282825" CI_START="0.08535554474734167" EFFECT_SIZE="0.3025" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="0.030219019580024386" LOG_CI_START="-1.068768261603049" LOG_EFFECT_SIZE="-0.5192746210115123" ORDER="69" O_E="0.0" SE="0.6455505690417155" STUDY_ID="STD-Feinstein-1999" TOTAL_1="120" TOTAL_2="121" VAR="0.4167355371900826" WEIGHT="9.445787157329233"/>
<DICH_DATA CI_END="1.1567742386182183" CI_START="0.5072949958791901" EFFECT_SIZE="0.7660455486542443" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="42" LOG_CI_END="0.0632486083127206" LOG_CI_START="-0.29473942168175477" LOG_EFFECT_SIZE="-0.11574540668451712" ORDER="70" O_E="0.0" SE="0.21028394088808292" STUDY_ID="STD-Sullivan-1990" TOTAL_1="184" TOTAL_2="185" VAR="0.044219335795422754" WEIGHT="39.72964634054543"/>
<DICH_DATA CI_END="1.5500603737061573" CI_START="0.4128871435309164" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.1903486139488756" LOG_CI_START="-0.3841686399649884" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="71" O_E="0.0" SE="0.3374742788552765" STUDY_ID="STD-Winston-1984" TOTAL_1="18" TOTAL_2="18" VAR="0.1138888888888889" WEIGHT="9.485144603818105"/>
<DICH_DATA CI_END="6.007403904090159" CI_START="0.1408928071947561" EFFECT_SIZE="0.92" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7786868324501918" LOG_CI_START="-0.8511111777590813" LOG_EFFECT_SIZE="-0.03621217265444471" ORDER="72" O_E="0.0" SE="0.9573514188271905" STUDY_ID="STD-Winston-1993" TOTAL_1="25" TOTAL_2="23" VAR="0.9165217391304348" WEIGHT="1.9760717924621054"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.9668404166693598" CI_END="1.0163812422623173" CI_START="0.4878558381150436" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7041644145995252" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="64" I2="0.0" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="0.007056641367370942" LOG_CI_START="-0.3117084934905157" LOG_EFFECT_SIZE="-0.15232592606157241" METHOD="MH" NO="13" P_CHI2="0.5793175753128958" P_Q="0.0" P_Z="0.06104258792944592" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1041" TOTAL_2="1041" WEIGHT="99.99999999999999" Z="1.8731868472723376">
<NAME>CMV infections - patient months</NAME>
<GROUP_LABEL_1>Polyvalent IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0900999705340506" CI_START="0.08394298915095855" EFFECT_SIZE="0.3025" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="0.03746632790430268" LOG_CI_START="-1.076015569927327" LOG_EFFECT_SIZE="-0.5192746210115123" ORDER="73" O_E="0.0" SE="0.6540647786105872" STUDY_ID="STD-Feinstein-1999" TOTAL_1="360" TOTAL_2="363" VAR="0.42780073461891643" WEIGHT="15.577686389036094"/>
<DICH_DATA CI_END="1.1948734316703253" CI_START="0.49111961740805693" EFFECT_SIZE="0.7660455486542443" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="42" LOG_CI_END="0.07732190458262612" LOG_CI_START="-0.3088127179516604" LOG_EFFECT_SIZE="-0.11574540668451712" ORDER="74" O_E="0.0" SE="0.22681738867384804" STUDY_ID="STD-Sullivan-1990" TOTAL_1="552" TOTAL_2="555" VAR="0.05144612780482345" WEIGHT="65.52084656704493"/>
<DICH_DATA CI_END="1.8712241976778183" CI_START="0.34202208414910273" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.272125824903065" LOG_CI_START="-0.46594585091917784" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="75" O_E="0.0" SE="0.43354695589170383" STUDY_ID="STD-Winston-1984" TOTAL_1="54" TOTAL_2="54" VAR="0.18796296296296297" WEIGHT="15.642593415657078"/>
<DICH_DATA CI_END="6.354231237041905" CI_START="0.13320258083557343" EFFECT_SIZE="0.92" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8030630152037513" LOG_CI_START="-0.8754873605126408" LOG_EFFECT_SIZE="-0.03621217265444471" ORDER="76" O_E="0.0" SE="0.9859887996541737" STUDY_ID="STD-Winston-1993" TOTAL_1="75" TOTAL_2="69" VAR="0.9721739130434783" WEIGHT="3.2588736282618913"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.045981204469274" CI_END="0.8906194408358923" CI_START="0.45498115165668074" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6365650468564413" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="72" I2="14.8450751444782" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="-0.05030782912889014" LOG_CI_START="-0.3420065943342017" LOG_EFFECT_SIZE="-0.19615721173154593" METHOD="MH" NO="14" P_CHI2="0.31661602588143445" P_Q="0.0" P_Z="0.008388617573326325" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="543" TOTAL_2="447" WEIGHT="100.0" Z="2.6360143830641567">
<NAME>Interstitial Pneumonitis</NAME>
<GROUP_LABEL_1>Polyvalent IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.191402094443973" CI_START="0.4661078148828928" EFFECT_SIZE="1.5555555555555556" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="3" LOG_CI_END="0.7152846679917867" LOG_CI_START="-0.33151361551396036" LOG_EFFECT_SIZE="0.19188552623891314" ORDER="77" O_E="0.0" SE="0.6148944934663492" STUDY_ID="STD-Cordonnier-2003" TOTAL_1="150" TOTAL_2="50" VAR="0.3780952380952381" WEIGHT="6.107279249012674"/>
<DICH_DATA CI_END="3.2229063532708806" CI_START="0.3102789502354341" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.508247686570799" LOG_CI_START="-0.508247686570799" LOG_EFFECT_SIZE="0.0" ORDER="78" O_E="0.0" SE="0.5970944139166224" STUDY_ID="STD-Emanuel-1992" TOTAL_1="46" TOTAL_2="46" VAR="0.35652173913043483" WEIGHT="6.785865832236304"/>
<DICH_DATA CI_END="0.9479000001178588" CI_START="0.3330386636908239" EFFECT_SIZE="0.5618606138107417" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="34" LOG_CI_END="-0.023237476678540606" LOG_CI_START="-0.4775053447133569" LOG_EFFECT_SIZE="-0.25037141069594876" ORDER="79" O_E="0.0" SE="0.2668391943458639" STUDY_ID="STD-Sullivan-1990" TOTAL_1="184" TOTAL_2="185" VAR="0.07120315563914972" WEIGHT="46.01883647313856"/>
<DICH_DATA CI_END="1.042546606978355" CI_START="0.15347035703634673" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.018095479186391133" LOG_CI_START="-0.8139754965304663" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="80" O_E="0.0" SE="0.4887626099538393" STUDY_ID="STD-Winston-1984" TOTAL_1="18" TOTAL_2="18" VAR="0.23888888888888885" WEIGHT="13.571731664472608"/>
<DICH_DATA CI_END="0.8529126852017203" CI_START="0.18846465705144" EFFECT_SIZE="0.40092879256965946" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="17" LOG_CI_END="-0.0690954263659058" LOG_CI_START="-0.7247700814617587" LOG_EFFECT_SIZE="-0.3969327539138322" ORDER="81" O_E="0.0" SE="0.3851465380451917" STUDY_ID="STD-Winston-1987" TOTAL_1="38" TOTAL_2="37" VAR="0.14833785576819633" WEIGHT="23.37956974733148"/>
<DICH_DATA CI_END="7.533035597908136" CI_START="0.25280645169509575" EFFECT_SIZE="1.38" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8769700197276257" LOG_CI_START="-0.5972118469251526" LOG_EFFECT_SIZE="0.13987908640123647" ORDER="82" O_E="0.0" SE="0.8659417257897716" STUDY_ID="STD-Winston-1993" TOTAL_1="25" TOTAL_2="23" VAR="0.749855072463768" WEIGHT="2.827444096765127"/>
<DICH_DATA CI_END="23.226535498709673" CI_START="0.19834131861072427" EFFECT_SIZE="2.1463414634146343" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.365984434681748" LOG_CI_START="-0.7025868038208817" LOG_EFFECT_SIZE="0.33169881543043317" ORDER="83" O_E="0.0" SE="1.2150889850892173" STUDY_ID="STD-Wolff-1993" TOTAL_1="82" TOTAL_2="88" VAR="1.476441241685144" WEIGHT="1.3092729370432399"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.5191896385233936" CI_END="1.4914842096109595" CI_START="0.2766812431267061" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6423906173186319" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" I2="43.1687346965714" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="0.17361865983342947" LOG_CI_START="-0.5580202817071924" LOG_EFFECT_SIZE="-0.19220081093688143" METHOD="MH" NO="15" P_CHI2="0.17211463615166978" P_Q="0.0" P_Z="0.30312217163126365" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="137" TOTAL_2="138" WEIGHT="100.0" Z="1.0297611180794821">
<NAME>Infection-related Mortality</NAME>
<GROUP_LABEL_1>Polyvalent IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1025707802411278" CI_START="0.14763268194458018" EFFECT_SIZE="0.5571428571428572" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.3227506246605525" LOG_CI_START="-0.8308174906360677" LOG_EFFECT_SIZE="-0.2540334329877576" ORDER="84" O_E="0.0" SE="0.6776116211794992" STUDY_ID="STD-Lum-1994" TOTAL_1="28" TOTAL_2="26" VAR="0.4591575091575092" WEIGHT="41.786642320387664"/>
<DICH_DATA CI_END="1.4165296650786792" CI_START="0.022311525872526987" EFFECT_SIZE="0.17777777777777778" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.15122567398181586" LOG_CI_START="-1.651470727548616" LOG_EFFECT_SIZE="-0.7501225267834001" ORDER="85" O_E="0.0" SE="1.0589127897500796" STUDY_ID="STD-Winston-1993" TOTAL_1="27" TOTAL_2="24" VAR="1.1212962962962962" WEIGHT="42.6645129573706"/>
<DICH_DATA CI_END="11.407509778352972" CI_START="0.40383762688634794" EFFECT_SIZE="2.1463414634146343" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0571908497158287" LOG_CI_START="-0.3937932188549624" LOG_EFFECT_SIZE="0.33169881543043317" ORDER="86" O_E="0.0" SE="0.8523152243654598" STUDY_ID="STD-Wolff-1993" TOTAL_1="82" TOTAL_2="88" VAR="0.7264412416851441" WEIGHT="15.54884472224173"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.90261761890155" CI_END="1.0444262595715519" CI_START="0.8269627770285627" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9293554971144492" ESTIMABLE="YES" EVENTS_1="277" EVENTS_2="247" I2="44.96734445131804" I2_Q="0.0" ID="CMP-001.16" LOG_CI_END="0.018877782572252158" LOG_CI_START="-0.08251403832522" LOG_EFFECT_SIZE="-0.03181812787648393" METHOD="MH" NO="16" P_CHI2="0.09143326518948891" P_Q="0.0" P_Z="0.2186497479004239" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="545" TOTAL_2="444" WEIGHT="99.99999999999997" Z="1.2301265356790367">
<NAME>Acute GVHD</NAME>
<GROUP_LABEL_1>Polyvalent IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1756305614022722" CI_START="0.6352653604555504" EFFECT_SIZE="0.8641975308641975" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="27" LOG_CI_END="0.07027086735961569" LOG_CI_START="-0.1970448250884016" LOG_EFFECT_SIZE="-0.06338697886439294" ORDER="87" O_E="0.0" SE="0.15702256097798384" STUDY_ID="STD-Cordonnier-2003" TOTAL_1="150" TOTAL_2="50" VAR="0.02465608465608465" WEIGHT="15.548317660434606"/>
<DICH_DATA CI_END="1.0368240423622626" CI_START="0.731416965135806" EFFECT_SIZE="0.8708333333333333" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="88" LOG_CI_END="0.015705059267452543" LOG_CI_START="-0.13583497046855658" LOG_EFFECT_SIZE="-0.06006495560055201" ORDER="88" O_E="0.0" SE="0.089015363602177" STUDY_ID="STD-Feinstein-1999" TOTAL_1="120" TOTAL_2="121" VAR="0.007923734957227778" WEIGHT="33.64381629920382"/>
<DICH_DATA CI_END="2.7408529251926943" CI_START="0.5200365162717657" EFFECT_SIZE="1.1938775510204083" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.43788573182153046" LOG_CI_START="-0.2839661597141969" LOG_EFFECT_SIZE="0.07695978605366682" ORDER="89" O_E="0.0" SE="0.4240193743125776" STUDY_ID="STD-Lum-1994" TOTAL_1="28" TOTAL_2="26" VAR="0.1797924297924298" WEIGHT="2.7868955294423254"/>
<DICH_DATA CI_END="1.401990695259398" CI_START="0.9336724913275977" EFFECT_SIZE="1.1441154422788606" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="87" LOG_CI_END="0.14674513131187475" LOG_CI_START="-0.029805436567057274" LOG_EFFECT_SIZE="0.05846984737240875" ORDER="90" O_E="0.0" SE="0.10370667751149037" STUDY_ID="STD-Sullivan-1990" TOTAL_1="184" TOTAL_2="185" VAR="0.010755074960472264" WEIGHT="33.309574640601845"/>
<DICH_DATA CI_END="4.334593955143529" CI_START="0.05767552914693294" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6369484210048898" LOG_CI_START="-1.2390084123328524" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="91" O_E="0.0" SE="1.1019463300386796" STUDY_ID="STD-Ustun-1998" TOTAL_1="7" TOTAL_2="7" VAR="1.2142857142857144" WEIGHT="0.7678181560708447"/>
<DICH_DATA CI_END="1.3206325080361108" CI_START="0.425932268497982" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.12078198344656102" LOG_CI_START="-0.37065945666316086" LOG_EFFECT_SIZE="-0.12493873660829993" ORDER="92" O_E="0.0" SE="0.28867513459481287" STUDY_ID="STD-Winston-1984" TOTAL_1="18" TOTAL_2="18" VAR="0.08333333333333331" WEIGHT="4.606908936425068"/>
<DICH_DATA CI_END="0.8701151238792503" CI_START="0.31968610382828855" EFFECT_SIZE="0.5274122807017544" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="24" LOG_CI_END="-0.06042328260232113" LOG_CI_START="-0.49527624130684766" LOG_EFFECT_SIZE="-0.2778497619545844" ORDER="93" O_E="0.0" SE="0.2554347804999005" STUDY_ID="STD-Winston-1987" TOTAL_1="38" TOTAL_2="37" VAR="0.06524692708903235" WEIGHT="9.33666877782147"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.4878094472405414" CI_END="6.707699152648129" CI_START="1.10907487872122" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.7275154672745034" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.17" LOG_CI_END="0.8265735758072136" LOG_CI_START="0.044960868347217575" LOG_EFFECT_SIZE="0.4357672220772156" METHOD="MH" NO="17" P_CHI2="0.47749848666934147" P_Q="0.0" P_Z="0.028855809143928192" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="268" TOTAL_2="179" WEIGHT="100.0" Z="2.185450806422882">
<NAME>VOD</NAME>
<GROUP_LABEL_1>Polyvalent IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.821345722213828" CI_START="0.7639744941851261" EFFECT_SIZE="2.4444444444444446" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="3" LOG_CI_END="0.8932814831685563" LOG_CI_START="-0.1169211404027935" LOG_EFFECT_SIZE="0.3881801713828814" ORDER="94" O_E="0.0" SE="0.5933980216694459" STUDY_ID="STD-Cordonnier-2003" TOTAL_1="150" TOTAL_2="50" VAR="0.3521212121212121" WEIGHT="65.52914360143276"/>
<DICH_DATA CI_END="9.196087501391645" CI_START="0.01644553380754024" EFFECT_SIZE="0.3888888888888889" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9636030949581328" LOG_CI_START="-1.7839520251362313" LOG_EFFECT_SIZE="-0.4101744650890492" ORDER="95" O_E="0.0" SE="1.6139274781606219" STUDY_ID="STD-Poynton-1992" TOTAL_1="29" TOTAL_2="34" VAR="2.604761904761905" WEIGHT="20.162813415825465"/>
<DICH_DATA CI_END="63.149196457537265" CI_START="0.1425196281959308" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8003678287428493" LOG_CI_START="-0.8461253193035243" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="96" O_E="0.0" SE="1.5545631755148024" STUDY_ID="STD-Ustun-1998" TOTAL_1="7" TOTAL_2="7" VAR="2.4166666666666665" WEIGHT="7.281015955714751"/>
<DICH_DATA CI_END="210.03210045415952" CI_START="0.6624048799437582" EFFECT_SIZE="11.795180722891565" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.3222856756134767" LOG_CI_START="-0.1788764767593484" LOG_EFFECT_SIZE="1.071704599427064" ORDER="97" O_E="0.0" SE="1.4691950292561289" STUDY_ID="STD-Wolff-1993" TOTAL_1="82" TOTAL_2="88" VAR="2.1585340339909176" WEIGHT="7.027027027027027"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.7826306494346964" CI_END="20.969793141788898" CI_START="3.146032219814103" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RR" EFFECT_SIZE="8.122293079352943" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.18" LOG_CI_END="1.321594146353626" LOG_CI_START="0.4977631660990351" LOG_EFFECT_SIZE="0.9096786562263307" METHOD="MH" NO="18" P_CHI2="0.5948349436660892" P_Q="0.0" P_Z="1.501925348337399E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="415" TOTAL_2="313" WEIGHT="99.99999999999997" Z="4.328405817313193">
<NAME>Adverse Events</NAME>
<GROUP_LABEL_1>Polyvalent IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="13.761098541212323" CI_START="0.8074290782698115" EFFECT_SIZE="3.3333333333333335" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="2" LOG_CI_END="1.1386531047819934" LOG_CI_START="-0.09289561422131816" LOG_EFFECT_SIZE="0.5228787452803376" ORDER="98" O_E="0.0" SE="0.7234178138070235" STUDY_ID="STD-Cordonnier-2003" TOTAL_1="150" TOTAL_2="50" VAR="0.5233333333333333" WEIGHT="59.69976038175078"/>
<DICH_DATA CI_END="485.1818815553855" CI_START="1.7521603689061844" EFFECT_SIZE="29.156756756756756" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="0" LOG_CI_END="2.6859045743721146" LOG_CI_START="0.2435738530556026" LOG_EFFECT_SIZE="1.4647392137138586" ORDER="99" O_E="0.0" SE="1.4346371554333703" STUDY_ID="STD-Sullivan-1990" TOTAL_1="184" TOTAL_2="185" VAR="2.0581837677499526" WEIGHT="9.923140764262257"/>
<DICH_DATA CI_END="155.8552614005574" CI_START="0.5197129649144481" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.192721467881129" LOG_CI_START="-0.2842364490024794" LOG_EFFECT_SIZE="0.9542425094393249" ORDER="100" O_E="0.0" SE="1.4549773415168654" STUDY_ID="STD-Winston-1984" TOTAL_1="18" TOTAL_2="18" VAR="2.116959064327485" WEIGHT="9.949960063625129"/>
<DICH_DATA CI_END="307.0366023917386" CI_START="1.1162334414534598" EFFECT_SIZE="18.512820512820515" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" LOG_CI_END="2.487190151598393" LOG_CI_START="0.04775502948788675" LOG_EFFECT_SIZE="1.2674725905431399" ORDER="101" O_E="0.0" SE="1.4329362661263156" STUDY_ID="STD-Winston-1987" TOTAL_1="38" TOTAL_2="37" VAR="2.053306342780027" WEIGHT="10.079180324191688"/>
<DICH_DATA CI_END="91.34475988701922" CI_START="0.23320193927135308" EFFECT_SIZE="4.615384615384615" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9606836385257036" LOG_CI_START="-0.6322678423720901" LOG_EFFECT_SIZE="0.6642078980768068" ORDER="102" O_E="0.0" SE="1.5231125351961998" STUDY_ID="STD-Winston-1993" TOTAL_1="25" TOTAL_2="23" VAR="2.319871794871795" WEIGHT="10.347958466170134"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.4878094472405414" CI_END="6.707699152648126" CI_START="1.1090748787212195" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.7275154672745026" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.19" LOG_CI_END="0.8265735758072134" LOG_CI_START="0.0449608683472174" LOG_EFFECT_SIZE="0.4357672220772154" METHOD="MH" NO="19" P_CHI2="0.47749848666934147" P_Q="0.0" P_Z="0.02885580914392828" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="268" TOTAL_2="179" WEIGHT="100.0" Z="2.185450806422881">
<NAME>VOD according to type of transplant</NAME>
<GROUP_LABEL_1>Polyvalent IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.208986546224706" CI_END="5.488967613914523" CI_START="0.7597882132423119" DF="2.0" EFFECT_SIZE="2.042168674698795" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="4" I2="0.0" ID="CMP-001.19.01" LOG_CI_END="0.7394906683586406" LOG_CI_START="-0.1193074480325866" LOG_EFFECT_SIZE="0.310091610163027" NO="1" P_CHI2="0.5463514662112985" P_Z="0.1569533236388343" STUDIES="3" TAU2="0.0" TOTAL_1="186" TOTAL_2="91" WEIGHT="92.97297297297297" Z="1.4153929223354222">
<NAME>allo</NAME>
<DICH_DATA CI_END="7.821345722213828" CI_START="0.7639744941851261" EFFECT_SIZE="2.4444444444444446" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="3" LOG_CI_END="0.8932814831685563" LOG_CI_START="-0.1169211404027935" LOG_EFFECT_SIZE="0.3881801713828814" ORDER="103" O_E="0.0" SE="0.5933980216694459" STUDY_ID="STD-Cordonnier-2003" TOTAL_1="150" TOTAL_2="50" VAR="0.3521212121212121" WEIGHT="65.52914360143275"/>
<DICH_DATA CI_END="9.196087501391645" CI_START="0.01644553380754024" EFFECT_SIZE="0.3888888888888889" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9636030949581328" LOG_CI_START="-1.7839520251362313" LOG_EFFECT_SIZE="-0.4101744650890492" ORDER="104" O_E="0.0" SE="1.6139274781606219" STUDY_ID="STD-Poynton-1992" TOTAL_1="29" TOTAL_2="34" VAR="2.604761904761905" WEIGHT="20.16281341582546"/>
<DICH_DATA CI_END="63.149196457537265" CI_START="0.1425196281959308" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8003678287428493" LOG_CI_START="-0.8461253193035243" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="105" O_E="0.0" SE="1.5545631755148024" STUDY_ID="STD-Ustun-1998" TOTAL_1="7" TOTAL_2="7" VAR="2.4166666666666665" WEIGHT="7.28101595571475"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="210.03210045415952" CI_START="0.6624048799437582" DF="0.0" EFFECT_SIZE="11.795180722891565" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" I2="0.0" ID="CMP-001.19.02" LOG_CI_END="2.3222856756134767" LOG_CI_START="-0.1788764767593484" LOG_EFFECT_SIZE="1.071704599427064" NO="2" P_CHI2="1.0" P_Z="0.09303105127067521" STUDIES="1" TAU2="0.0" TOTAL_1="82" TOTAL_2="88" WEIGHT="7.027027027027026" Z="1.6796211432755352">
<NAME>auto</NAME>
<DICH_DATA CI_END="210.03210045415952" CI_START="0.6624048799437582" EFFECT_SIZE="11.795180722891565" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.3222856756134767" LOG_CI_START="-0.1788764767593484" LOG_EFFECT_SIZE="1.071704599427064" ORDER="106" O_E="0.0" SE="1.4691950292561289" STUDY_ID="STD-Wolff-1993" TOTAL_1="82" TOTAL_2="88" VAR="2.1585340339909176" WEIGHT="7.027027027027026"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="14.758836448878185" CI_END="0.9189789370787412" CI_START="0.6220350799439078" CI_STUDY="95" CI_TOTAL="95" DF="12.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7560668863219326" ESTIMABLE="YES" EVENTS_1="169" EVENTS_2="168" I2="18.692777431569706" I2_Q="0.0" ID="CMP-001.20" LOG_CI_END="-0.03669444249343687" LOG_CI_START="-0.20618512238882192" LOG_EFFECT_SIZE="-0.12143978244112939" METHOD="MH" NO="20" P_CHI2="0.25489079865608266" P_Q="0.0" P_Z="0.004975407483434972" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1086" TOTAL_2="890" WEIGHT="200.00000000000006" Z="2.8086216896634695">
<NAME>CMV Infections and Interstitial pneumonitis</NAME>
<GROUP_LABEL_1>polyvalent IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.080695275465664" CI_END="1.066430346801584" CI_START="0.6609937682730591" DF="5.0" EFFECT_SIZE="0.8395855010260267" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="96" I2="1.5882722952375452" ID="CMP-001.20.01" LOG_CI_END="0.02793249505260472" LOG_CI_START="-0.17980263494307513" LOG_EFFECT_SIZE="-0.07593506994523523" NO="1" P_CHI2="0.40611189434969897" P_Z="0.1518914575841691" STUDIES="6" TAU2="0.0" TOTAL_1="543" TOTAL_2="443" WEIGHT="100.00000000000001" Z="1.4328823657249126">
<NAME>CMV infections</NAME>
<DICH_DATA CI_END="1.4080965589264984" CI_START="0.6140017241774663" EFFECT_SIZE="0.9298245614035088" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="19" LOG_CI_END="0.14863243717192903" LOG_CI_START="-0.21183040931533378" LOG_EFFECT_SIZE="-0.031598986071702355" ORDER="107" O_E="0.0" SE="0.21173766034648542" STUDY_ID="STD-Cordonnier-2003" TOTAL_1="150" TOTAL_2="50" VAR="0.04483283680900363" WEIGHT="27.0326621208816"/>
<DICH_DATA CI_END="2.371723402122864" CI_START="0.7210196475976105" EFFECT_SIZE="1.3076923076923077" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="13" LOG_CI_END="0.3750640388506784" LOG_CI_START="-0.14205290070780402" LOG_EFFECT_SIZE="0.11650556907143717" ORDER="108" O_E="0.0" SE="0.3037570500667868" STUDY_ID="STD-Emanuel-1992" TOTAL_1="46" TOTAL_2="46" VAR="0.09226834546527643" WEIGHT="12.330687984963538"/>
<DICH_DATA CI_END="1.0720598207282825" CI_START="0.08535554474734167" EFFECT_SIZE="0.3025" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="0.030219019580024386" LOG_CI_START="-1.068768261603049" LOG_EFFECT_SIZE="-0.5192746210115123" ORDER="109" O_E="0.0" SE="0.6455505690417155" STUDY_ID="STD-Feinstein-1999" TOTAL_1="120" TOTAL_2="121" VAR="0.4167355371900826" WEIGHT="9.445787157329233"/>
<DICH_DATA CI_END="1.1567742386182183" CI_START="0.5072949958791901" EFFECT_SIZE="0.7660455486542443" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="42" LOG_CI_END="0.0632486083127206" LOG_CI_START="-0.29473942168175477" LOG_EFFECT_SIZE="-0.11574540668451712" ORDER="110" O_E="0.0" SE="0.21028394088808292" STUDY_ID="STD-Sullivan-1990" TOTAL_1="184" TOTAL_2="185" VAR="0.044219335795422754" WEIGHT="39.72964634054543"/>
<DICH_DATA CI_END="1.5500603737061573" CI_START="0.4128871435309164" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.1903486139488756" LOG_CI_START="-0.3841686399649884" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="111" O_E="0.0" SE="0.3374742788552765" STUDY_ID="STD-Winston-1984" TOTAL_1="18" TOTAL_2="18" VAR="0.1138888888888889" WEIGHT="9.485144603818105"/>
<DICH_DATA CI_END="6.007403904090159" CI_START="0.1408928071947561" EFFECT_SIZE="0.92" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7786868324501918" LOG_CI_START="-0.8511111777590813" LOG_EFFECT_SIZE="-0.03621217265444471" ORDER="112" O_E="0.0" SE="0.9573514188271905" STUDY_ID="STD-Winston-1993" TOTAL_1="25" TOTAL_2="23" VAR="0.9165217391304348" WEIGHT="1.9760717924621054"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.045981204469275" CI_END="0.8906194408358926" CI_START="0.4549811516566809" DF="6.0" EFFECT_SIZE="0.6365650468564416" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="72" I2="14.84507514447821" ID="CMP-001.20.02" LOG_CI_END="-0.05030782912888998" LOG_CI_START="-0.34200659433420155" LOG_EFFECT_SIZE="-0.19615721173154577" NO="2" P_CHI2="0.3166160258814342" P_Z="0.008388617573326384" STUDIES="7" TAU2="0.0" TOTAL_1="543" TOTAL_2="447" WEIGHT="100.00000000000003" Z="2.6360143830641545">
<NAME>Interstitial pneumonitis</NAME>
<DICH_DATA CI_END="5.191402094443973" CI_START="0.4661078148828928" EFFECT_SIZE="1.5555555555555556" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="3" LOG_CI_END="0.7152846679917867" LOG_CI_START="-0.33151361551396036" LOG_EFFECT_SIZE="0.19188552623891314" ORDER="113" O_E="0.0" SE="0.6148944934663492" STUDY_ID="STD-Cordonnier-2003" TOTAL_1="150" TOTAL_2="50" VAR="0.3780952380952381" WEIGHT="6.107279249012675"/>
<DICH_DATA CI_END="3.2229063532708806" CI_START="0.3102789502354341" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.508247686570799" LOG_CI_START="-0.508247686570799" LOG_EFFECT_SIZE="0.0" ORDER="114" O_E="0.0" SE="0.5970944139166224" STUDY_ID="STD-Emanuel-1992" TOTAL_1="46" TOTAL_2="46" VAR="0.35652173913043483" WEIGHT="6.785865832236305"/>
<DICH_DATA CI_END="0.9479000001178588" CI_START="0.3330386636908239" EFFECT_SIZE="0.5618606138107417" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="34" LOG_CI_END="-0.023237476678540606" LOG_CI_START="-0.4775053447133569" LOG_EFFECT_SIZE="-0.25037141069594876" ORDER="115" O_E="0.0" SE="0.2668391943458639" STUDY_ID="STD-Sullivan-1990" TOTAL_1="184" TOTAL_2="185" VAR="0.07120315563914972" WEIGHT="46.01883647313857"/>
<DICH_DATA CI_END="1.042546606978355" CI_START="0.15347035703634673" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.018095479186391133" LOG_CI_START="-0.8139754965304663" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="116" O_E="0.0" SE="0.4887626099538393" STUDY_ID="STD-Winston-1984" TOTAL_1="18" TOTAL_2="18" VAR="0.23888888888888885" WEIGHT="13.57173166447261"/>
<DICH_DATA CI_END="0.8529126852017203" CI_START="0.18846465705144" EFFECT_SIZE="0.40092879256965946" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="17" LOG_CI_END="-0.0690954263659058" LOG_CI_START="-0.7247700814617587" LOG_EFFECT_SIZE="-0.3969327539138322" ORDER="117" O_E="0.0" SE="0.3851465380451917" STUDY_ID="STD-Winston-1987" TOTAL_1="38" TOTAL_2="37" VAR="0.14833785576819633" WEIGHT="23.379569747331484"/>
<DICH_DATA CI_END="7.533035597908136" CI_START="0.25280645169509575" EFFECT_SIZE="1.38" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8769700197276257" LOG_CI_START="-0.5972118469251526" LOG_EFFECT_SIZE="0.13987908640123647" ORDER="118" O_E="0.0" SE="0.8659417257897716" STUDY_ID="STD-Winston-1993" TOTAL_1="25" TOTAL_2="23" VAR="0.749855072463768" WEIGHT="2.8274440967651273"/>
<DICH_DATA CI_END="23.226535498709673" CI_START="0.19834131861072427" EFFECT_SIZE="2.1463414634146343" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.365984434681748" LOG_CI_START="-0.7025868038208817" LOG_EFFECT_SIZE="0.33169881543043317" ORDER="119" O_E="0.0" SE="1.2150889850892173" STUDY_ID="STD-Wolff-1993" TOTAL_1="82" TOTAL_2="88" VAR="1.476441241685144" WEIGHT="1.30927293704324"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="17.927603702104822" CI_END="1.0972246003481876" CI_START="0.8673575163779308" CI_STUDY="95" CI_TOTAL="95" DF="10.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9755439530163527" ESTIMABLE="YES" EVENTS_1="305" EVENTS_2="251" I2="44.220096750432226" I2_Q="0.0" ID="CMP-001.21" LOG_CI_END="0.04029553615059403" LOG_CI_START="-0.06180185363582006" LOG_EFFECT_SIZE="-0.010753158742613018" METHOD="MH" NO="21" P_CHI2="0.05619729885350355" P_Q="0.0" P_Z="0.679711490972675" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="813" TOTAL_2="623" WEIGHT="200.0" Z="0.4128568595074516">
<NAME>acute GVHD and VOD</NAME>
<GROUP_LABEL_1>polyvalent IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="10.902617618901552" CI_END="1.044426259571552" CI_START="0.8269627770285628" DF="6.0" EFFECT_SIZE="0.9293554971144493" ESTIMABLE="YES" EVENTS_1="277" EVENTS_2="247" I2="44.967344451318056" ID="CMP-001.21.01" LOG_CI_END="0.01887778257225225" LOG_CI_START="-0.08251403832521995" LOG_EFFECT_SIZE="-0.03181812787648387" NO="1" P_CHI2="0.09143326518948847" P_Z="0.2186497479004248" STUDIES="7" TAU2="0.0" TOTAL_1="545" TOTAL_2="444" WEIGHT="100.00000000000001" Z="1.2301265356790345">
<NAME>Acute GVHD</NAME>
<DICH_DATA CI_END="1.1756305614022722" CI_START="0.6352653604555504" EFFECT_SIZE="0.8641975308641975" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="27" LOG_CI_END="0.07027086735961569" LOG_CI_START="-0.1970448250884016" LOG_EFFECT_SIZE="-0.06338697886439294" ORDER="120" O_E="0.0" SE="0.15702256097798384" STUDY_ID="STD-Cordonnier-2003" TOTAL_1="150" TOTAL_2="50" VAR="0.02465608465608465" WEIGHT="15.54831766043461"/>
<DICH_DATA CI_END="1.0368240423622626" CI_START="0.731416965135806" EFFECT_SIZE="0.8708333333333333" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="88" LOG_CI_END="0.015705059267452543" LOG_CI_START="-0.13583497046855658" LOG_EFFECT_SIZE="-0.06006495560055201" ORDER="121" O_E="0.0" SE="0.089015363602177" STUDY_ID="STD-Feinstein-1999" TOTAL_1="120" TOTAL_2="121" VAR="0.007923734957227778" WEIGHT="33.64381629920383"/>
<DICH_DATA CI_END="2.7408529251926943" CI_START="0.5200365162717657" EFFECT_SIZE="1.1938775510204083" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.43788573182153046" LOG_CI_START="-0.2839661597141969" LOG_EFFECT_SIZE="0.07695978605366682" ORDER="122" O_E="0.0" SE="0.4240193743125776" STUDY_ID="STD-Lum-1994" TOTAL_1="28" TOTAL_2="26" VAR="0.1797924297924298" WEIGHT="2.786895529442326"/>
<DICH_DATA CI_END="1.401990695259398" CI_START="0.9336724913275977" EFFECT_SIZE="1.1441154422788606" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="87" LOG_CI_END="0.14674513131187475" LOG_CI_START="-0.029805436567057274" LOG_EFFECT_SIZE="0.05846984737240875" ORDER="123" O_E="0.0" SE="0.10370667751149037" STUDY_ID="STD-Sullivan-1990" TOTAL_1="184" TOTAL_2="185" VAR="0.010755074960472264" WEIGHT="33.30957464060186"/>
<DICH_DATA CI_END="4.334593955143529" CI_START="0.05767552914693294" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6369484210048898" LOG_CI_START="-1.2390084123328524" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="124" O_E="0.0" SE="1.1019463300386796" STUDY_ID="STD-Ustun-1998" TOTAL_1="7" TOTAL_2="7" VAR="1.2142857142857144" WEIGHT="0.7678181560708449"/>
<DICH_DATA CI_END="1.3206325080361108" CI_START="0.425932268497982" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.12078198344656102" LOG_CI_START="-0.37065945666316086" LOG_EFFECT_SIZE="-0.12493873660829993" ORDER="125" O_E="0.0" SE="0.28867513459481287" STUDY_ID="STD-Winston-1984" TOTAL_1="18" TOTAL_2="18" VAR="0.08333333333333331" WEIGHT="4.60690893642507"/>
<DICH_DATA CI_END="0.8701151238792503" CI_START="0.31968610382828855" EFFECT_SIZE="0.5274122807017544" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="24" LOG_CI_END="-0.06042328260232113" LOG_CI_START="-0.49527624130684766" LOG_EFFECT_SIZE="-0.2778497619545844" ORDER="126" O_E="0.0" SE="0.2554347804999005" STUDY_ID="STD-Winston-1987" TOTAL_1="38" TOTAL_2="37" VAR="0.06524692708903235" WEIGHT="9.336668777821474"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.487809447240542" CI_END="6.707699152648129" CI_START="1.1090748787212197" DF="3.0" EFFECT_SIZE="2.727515467274503" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="4" I2="0.0" ID="CMP-001.21.02" LOG_CI_END="0.8265735758072136" LOG_CI_START="0.044960868347217485" LOG_EFFECT_SIZE="0.4357672220772155" NO="2" P_CHI2="0.47749848666934136" P_Z="0.028855809143928244" STUDIES="4" TAU2="0.0" TOTAL_1="268" TOTAL_2="179" WEIGHT="100.0" Z="2.1854508064228813">
<NAME>VOD</NAME>
<DICH_DATA CI_END="7.821345722213828" CI_START="0.7639744941851261" EFFECT_SIZE="2.4444444444444446" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="3" LOG_CI_END="0.8932814831685563" LOG_CI_START="-0.1169211404027935" LOG_EFFECT_SIZE="0.3881801713828814" ORDER="127" O_E="0.0" SE="0.5933980216694459" STUDY_ID="STD-Cordonnier-2003" TOTAL_1="150" TOTAL_2="50" VAR="0.3521212121212121" WEIGHT="65.52914360143275"/>
<DICH_DATA CI_END="9.196087501391645" CI_START="0.01644553380754024" EFFECT_SIZE="0.3888888888888889" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9636030949581328" LOG_CI_START="-1.7839520251362313" LOG_EFFECT_SIZE="-0.4101744650890492" ORDER="128" O_E="0.0" SE="1.6139274781606219" STUDY_ID="STD-Poynton-1992" TOTAL_1="29" TOTAL_2="34" VAR="2.604761904761905" WEIGHT="20.16281341582546"/>
<DICH_DATA CI_END="63.149196457537265" CI_START="0.1425196281959308" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8003678287428493" LOG_CI_START="-0.8461253193035243" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="129" O_E="0.0" SE="1.5545631755148024" STUDY_ID="STD-Ustun-1998" TOTAL_1="7" TOTAL_2="7" VAR="2.4166666666666665" WEIGHT="7.28101595571475"/>
<DICH_DATA CI_END="210.03210045415952" CI_START="0.6624048799437582" EFFECT_SIZE="11.795180722891565" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.3222856756134767" LOG_CI_START="-0.1788764767593484" LOG_EFFECT_SIZE="1.071704599427064" ORDER="130" O_E="0.0" SE="1.4691950292561289" STUDY_ID="STD-Wolff-1993" TOTAL_1="82" TOTAL_2="88" VAR="2.1585340339909176" WEIGHT="7.027027027027026"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.662777802629591" CI_END="1.097841614887431" CI_START="0.8670570526602088" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9756491761345468" ESTIMABLE="YES" EVENTS_1="306" EVENTS_2="284" I2="17.208072425892784" I2_Q="0.0" ID="CMP-001.22" LOG_CI_END="0.04053968916506361" LOG_CI_START="-0.06195232485331741" LOG_EFFECT_SIZE="-0.010706317844126907" METHOD="MH" NO="22" P_CHI2="0.28949672965383544" P_Q="0.0" P_Z="0.6821905572243262" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="777" TOTAL_2="682" WEIGHT="200.0" Z="0.4094757544283198">
<NAME>All-cause Mortality -sensitivity analysis by ITT</NAME>
<GROUP_LABEL_1>Polyvalent IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.953418928967421" CI_END="1.2423371089308661" CI_START="0.8655022884831431" DF="5.0" EFFECT_SIZE="1.0369405049698832" ESTIMABLE="YES" EVENTS_1="174" EVENTS_2="137" I2="16.014645371727354" ID="CMP-001.22.01" LOG_CI_END="0.09423945790432699" LOG_CI_START="-0.06273177946474326" LOG_EFFECT_SIZE="0.015753839219791836" NO="1" P_CHI2="0.31077814717285834" P_Z="0.694017342233062" STUDIES="6" TAU2="0.0" TOTAL_1="543" TOTAL_2="443" WEIGHT="100.0" Z="0.3934091112046061">
<NAME>ITT</NAME>
<DICH_DATA CI_END="1.7431481714047472" CI_START="0.6296112326755309" EFFECT_SIZE="1.0476190476190477" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="14" LOG_CI_END="0.24133430465929537" LOG_CI_START="-0.2009275324827214" LOG_EFFECT_SIZE="0.02020338608828699" ORDER="131" O_E="0.0" SE="0.25978679236862195" STUDY_ID="STD-Cordonnier-2003" TOTAL_1="150" TOTAL_2="50" VAR="0.06748917748917749" WEIGHT="14.400384466920546"/>
<DICH_DATA CI_END="1.7956645992446418" CI_START="0.6392948795428534" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="13" LOG_CI_END="0.25422522080559784" LOG_CI_START="-0.19429877405071144" LOG_EFFECT_SIZE="0.029963223377443202" ORDER="132" O_E="0.0" SE="0.263465214808178" STUDY_ID="STD-Lum-1994" TOTAL_1="28" TOTAL_2="26" VAR="0.0694139194139194" WEIGHT="9.244691262714424"/>
<DICH_DATA CI_END="1.163219761020434" CI_START="0.7305092071417054" EFFECT_SIZE="0.921814919251474" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="94" LOG_CI_END="0.06566177146306576" LOG_CI_START="-0.13637430596426628" LOG_EFFECT_SIZE="-0.03535626725060022" ORDER="133" O_E="0.0" SE="0.11867699197552743" STUDY_ID="STD-Sullivan-2000" TOTAL_1="249" TOTAL_2="248" VAR="0.014084228424359403" WEIGHT="64.5885597073378"/>
<DICH_DATA CI_END="63.149196457537265" CI_START="0.1425196281959308" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8003678287428493" LOG_CI_START="-0.8461253193035243" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="134" O_E="0.0" SE="1.5545631755148024" STUDY_ID="STD-Ustun-1998" TOTAL_1="7" TOTAL_2="7" VAR="2.4166666666666665" WEIGHT="0.34286629683144154"/>
<DICH_DATA CI_END="1.7732552129951322" CI_START="0.674958343971265" EFFECT_SIZE="1.0940170940170941" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="13" LOG_CI_END="0.24877124525633185" LOG_CI_START="-0.17072302945291837" LOG_EFFECT_SIZE="0.03902410790170677" ORDER="135" O_E="0.0" SE="0.2464130134943632" STUDY_ID="STD-Winston-1993" TOTAL_1="27" TOTAL_2="24" VAR="0.06071937321937323" WEIGHT="9.438907465712626"/>
<DICH_DATA CI_END="13.606525523365265" CI_START="1.1379764111245112" EFFECT_SIZE="3.934959349593496" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" LOG_CI_END="1.1337472406573357" LOG_CI_START="0.05613325975269332" LOG_EFFECT_SIZE="0.5949402502050145" ORDER="136" O_E="0.0" SE="0.6329957866586224" STUDY_ID="STD-Wolff-1993" TOTAL_1="82" TOTAL_2="88" VAR="0.4006836659275683" WEIGHT="1.9845908004831674"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.4765727237179265" CI_END="1.0616897477447604" CI_START="0.7872468420100295" DF="2.0" EFFECT_SIZE="0.914227488706442" ESTIMABLE="YES" EVENTS_1="132" EVENTS_2="147" I2="42.47207928786963" ID="CMP-001.22.02" LOG_CI_END="0.02599762359304865" LOG_CI_START="-0.10388907283224914" LOG_EFFECT_SIZE="-0.03894572461960024" NO="2" P_CHI2="0.17582175890463636" P_Z="0.2398482532057543" STUDIES="3" TAU2="0.0" TOTAL_1="234" TOTAL_2="239" WEIGHT="100.0" Z="1.1753662185123412">
<NAME>PER PROTOCOL</NAME>
<DICH_DATA CI_END="1.258328438015756" CI_START="0.40795117345534293" EFFECT_SIZE="0.7164750957854407" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="18" LOG_CI_END="0.09979401169835539" LOG_CI_START="-0.3893918133019193" LOG_EFFECT_SIZE="-0.14479890080178195" ORDER="137" O_E="0.0" SE="0.2873501751140487" STUDY_ID="STD-Poynton-1992" TOTAL_1="29" TOTAL_2="34" VAR="0.08257012313807446" WEIGHT="11.38773751057524"/>
<DICH_DATA CI_END="1.1452298351980588" CI_START="0.8383914163838789" EFFECT_SIZE="0.9798728813559322" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="118" LOG_CI_END="0.058892653611788165" LOG_CI_START="-0.07655317672986092" LOG_EFFECT_SIZE="-0.008830261559036367" ORDER="138" O_E="0.0" SE="0.07956155121035804" STUDY_ID="STD-Sullivan-1990" TOTAL_1="184" TOTAL_2="185" VAR="0.0063300404309984265" WEIGHT="80.86879253374765"/>
<DICH_DATA CI_END="1.1376372913410278" CI_START="0.23721093899940981" EFFECT_SIZE="0.5194805194805194" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="0.05600381963585647" LOG_CI_START="-0.6248652873248954" LOG_EFFECT_SIZE="-0.2844307338445195" ORDER="139" O_E="0.0" SE="0.3999458837851816" STUDY_ID="STD-Winston-1984" TOTAL_1="21" TOTAL_2="20" VAR="0.15995670995670996" WEIGHT="7.743469955677107"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="22.650038793429275" CI_END="1.0016363007746538" CI_START="0.6858899600141297" CI_STUDY="95" CI_TOTAL="95" DF="16.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8288620405634632" ESTIMABLE="YES" EVENTS_1="197" EVENTS_2="172" I2="29.359944387196528" I2_Q="0.0" ID="CMP-001.23" LOG_CI_END="7.100556231835448E-4" LOG_CI_START="-0.16374555425242518" LOG_EFFECT_SIZE="-0.08151774931462079" METHOD="MH" NO="23" P_CHI2="0.12341488501999676" P_Q="0.0" P_Z="0.05201141566279577" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1354" TOTAL_2="1069" WEIGHT="300.0" Z="1.9430392539150232">
<NAME>CMV Infections, Interstitial pneumonitis and VOD</NAME>
<GROUP_LABEL_1>polyvalent IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.080695275465664" CI_END="1.066430346801584" CI_START="0.6609937682730591" DF="5.0" EFFECT_SIZE="0.8395855010260268" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="96" I2="1.5882722952375452" ID="CMP-001.23.01" LOG_CI_END="0.02793249505260472" LOG_CI_START="-0.17980263494307513" LOG_EFFECT_SIZE="-0.07593506994523518" NO="1" P_CHI2="0.40611189434969897" P_Z="0.15189145758416941" STUDIES="6" TAU2="0.0" TOTAL_1="543" TOTAL_2="443" WEIGHT="100.00000000000001" Z="1.4328823657249115">
<NAME>CMV infections</NAME>
<DICH_DATA CI_END="1.4080965589264984" CI_START="0.6140017241774663" EFFECT_SIZE="0.9298245614035088" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="19" LOG_CI_END="0.14863243717192903" LOG_CI_START="-0.21183040931533378" LOG_EFFECT_SIZE="-0.031598986071702355" ORDER="140" O_E="0.0" SE="0.21173766034648542" STUDY_ID="STD-Cordonnier-2003" TOTAL_1="150" TOTAL_2="50" VAR="0.04483283680900363" WEIGHT="27.0326621208816"/>
<DICH_DATA CI_END="2.371723402122864" CI_START="0.7210196475976105" EFFECT_SIZE="1.3076923076923077" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="13" LOG_CI_END="0.3750640388506784" LOG_CI_START="-0.14205290070780402" LOG_EFFECT_SIZE="0.11650556907143717" ORDER="141" O_E="0.0" SE="0.3037570500667868" STUDY_ID="STD-Emanuel-1992" TOTAL_1="46" TOTAL_2="46" VAR="0.09226834546527643" WEIGHT="12.330687984963538"/>
<DICH_DATA CI_END="1.0720598207282825" CI_START="0.08535554474734167" EFFECT_SIZE="0.3025" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="0.030219019580024386" LOG_CI_START="-1.068768261603049" LOG_EFFECT_SIZE="-0.5192746210115123" ORDER="142" O_E="0.0" SE="0.6455505690417155" STUDY_ID="STD-Feinstein-1999" TOTAL_1="120" TOTAL_2="121" VAR="0.4167355371900826" WEIGHT="9.445787157329233"/>
<DICH_DATA CI_END="1.1567742386182183" CI_START="0.5072949958791901" EFFECT_SIZE="0.7660455486542443" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="42" LOG_CI_END="0.0632486083127206" LOG_CI_START="-0.29473942168175477" LOG_EFFECT_SIZE="-0.11574540668451712" ORDER="143" O_E="0.0" SE="0.21028394088808292" STUDY_ID="STD-Sullivan-1990" TOTAL_1="184" TOTAL_2="185" VAR="0.044219335795422754" WEIGHT="39.72964634054543"/>
<DICH_DATA CI_END="1.5500603737061573" CI_START="0.4128871435309164" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.1903486139488756" LOG_CI_START="-0.3841686399649884" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="144" O_E="0.0" SE="0.3374742788552765" STUDY_ID="STD-Winston-1984" TOTAL_1="18" TOTAL_2="18" VAR="0.1138888888888889" WEIGHT="9.485144603818105"/>
<DICH_DATA CI_END="6.007403904090159" CI_START="0.1408928071947561" EFFECT_SIZE="0.92" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7786868324501918" LOG_CI_START="-0.8511111777590813" LOG_EFFECT_SIZE="-0.03621217265444471" ORDER="145" O_E="0.0" SE="0.9573514188271905" STUDY_ID="STD-Winston-1993" TOTAL_1="25" TOTAL_2="23" VAR="0.9165217391304348" WEIGHT="1.9760717924621054"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.045981204469275" CI_END="0.8906194408358926" CI_START="0.4549811516566809" DF="6.0" EFFECT_SIZE="0.6365650468564416" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="72" I2="14.84507514447821" ID="CMP-001.23.02" LOG_CI_END="-0.05030782912888998" LOG_CI_START="-0.34200659433420155" LOG_EFFECT_SIZE="-0.19615721173154577" NO="2" P_CHI2="0.3166160258814342" P_Z="0.008388617573326384" STUDIES="7" TAU2="0.0" TOTAL_1="543" TOTAL_2="447" WEIGHT="100.00000000000001" Z="2.6360143830641545">
<NAME>Interstitial pneumonitis</NAME>
<DICH_DATA CI_END="5.191402094443973" CI_START="0.4661078148828928" EFFECT_SIZE="1.5555555555555556" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="3" LOG_CI_END="0.7152846679917867" LOG_CI_START="-0.33151361551396036" LOG_EFFECT_SIZE="0.19188552623891314" ORDER="146" O_E="0.0" SE="0.6148944934663492" STUDY_ID="STD-Cordonnier-2003" TOTAL_1="150" TOTAL_2="50" VAR="0.3780952380952381" WEIGHT="6.107279249012675"/>
<DICH_DATA CI_END="3.2229063532708806" CI_START="0.3102789502354341" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.508247686570799" LOG_CI_START="-0.508247686570799" LOG_EFFECT_SIZE="0.0" ORDER="147" O_E="0.0" SE="0.5970944139166224" STUDY_ID="STD-Emanuel-1992" TOTAL_1="46" TOTAL_2="46" VAR="0.35652173913043483" WEIGHT="6.785865832236305"/>
<DICH_DATA CI_END="0.9479000001178588" CI_START="0.3330386636908239" EFFECT_SIZE="0.5618606138107417" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="34" LOG_CI_END="-0.023237476678540606" LOG_CI_START="-0.4775053447133569" LOG_EFFECT_SIZE="-0.25037141069594876" ORDER="148" O_E="0.0" SE="0.2668391943458639" STUDY_ID="STD-Sullivan-1990" TOTAL_1="184" TOTAL_2="185" VAR="0.07120315563914972" WEIGHT="46.01883647313857"/>
<DICH_DATA CI_END="1.042546606978355" CI_START="0.15347035703634673" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.018095479186391133" LOG_CI_START="-0.8139754965304663" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="149" O_E="0.0" SE="0.4887626099538393" STUDY_ID="STD-Winston-1984" TOTAL_1="18" TOTAL_2="18" VAR="0.23888888888888885" WEIGHT="13.57173166447261"/>
<DICH_DATA CI_END="0.8529126852017203" CI_START="0.18846465705144" EFFECT_SIZE="0.40092879256965946" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="17" LOG_CI_END="-0.0690954263659058" LOG_CI_START="-0.7247700814617587" LOG_EFFECT_SIZE="-0.3969327539138322" ORDER="150" O_E="0.0" SE="0.3851465380451917" STUDY_ID="STD-Winston-1987" TOTAL_1="38" TOTAL_2="37" VAR="0.14833785576819633" WEIGHT="23.379569747331484"/>
<DICH_DATA CI_END="7.533035597908136" CI_START="0.25280645169509575" EFFECT_SIZE="1.38" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8769700197276257" LOG_CI_START="-0.5972118469251526" LOG_EFFECT_SIZE="0.13987908640123647" ORDER="151" O_E="0.0" SE="0.8659417257897716" STUDY_ID="STD-Winston-1993" TOTAL_1="25" TOTAL_2="23" VAR="0.749855072463768" WEIGHT="2.8274440967651273"/>
<DICH_DATA CI_END="23.226535498709673" CI_START="0.19834131861072427" EFFECT_SIZE="2.1463414634146343" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.365984434681748" LOG_CI_START="-0.7025868038208817" LOG_EFFECT_SIZE="0.33169881543043317" ORDER="152" O_E="0.0" SE="1.2150889850892173" STUDY_ID="STD-Wolff-1993" TOTAL_1="82" TOTAL_2="88" VAR="1.476441241685144" WEIGHT="1.30927293704324"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.487809447240542" CI_END="6.707699152648129" CI_START="1.1090748787212197" DF="3.0" EFFECT_SIZE="2.727515467274503" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="4" I2="0.0" ID="CMP-001.23.03" LOG_CI_END="0.8265735758072136" LOG_CI_START="0.044960868347217485" LOG_EFFECT_SIZE="0.4357672220772155" NO="3" P_CHI2="0.47749848666934136" P_Z="0.028855809143928244" STUDIES="4" TAU2="0.0" TOTAL_1="268" TOTAL_2="179" WEIGHT="100.0" Z="2.1854508064228813">
<NAME>VOD</NAME>
<DICH_DATA CI_END="7.821345722213828" CI_START="0.7639744941851261" EFFECT_SIZE="2.4444444444444446" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="3" LOG_CI_END="0.8932814831685563" LOG_CI_START="-0.1169211404027935" LOG_EFFECT_SIZE="0.3881801713828814" ORDER="153" O_E="0.0" SE="0.5933980216694459" STUDY_ID="STD-Cordonnier-2003" TOTAL_1="150" TOTAL_2="50" VAR="0.3521212121212121" WEIGHT="65.52914360143275"/>
<DICH_DATA CI_END="9.196087501391645" CI_START="0.01644553380754024" EFFECT_SIZE="0.3888888888888889" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9636030949581328" LOG_CI_START="-1.7839520251362313" LOG_EFFECT_SIZE="-0.4101744650890492" ORDER="154" O_E="0.0" SE="1.6139274781606219" STUDY_ID="STD-Poynton-1992" TOTAL_1="29" TOTAL_2="34" VAR="2.604761904761905" WEIGHT="20.16281341582546"/>
<DICH_DATA CI_END="63.149196457537265" CI_START="0.1425196281959308" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8003678287428493" LOG_CI_START="-0.8461253193035243" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="155" O_E="0.0" SE="1.5545631755148024" STUDY_ID="STD-Ustun-1998" TOTAL_1="7" TOTAL_2="7" VAR="2.4166666666666665" WEIGHT="7.28101595571475"/>
<DICH_DATA CI_END="210.03210045415952" CI_START="0.6624048799437582" EFFECT_SIZE="11.795180722891565" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.3222856756134767" LOG_CI_START="-0.1788764767593484" LOG_EFFECT_SIZE="1.071704599427064" ORDER="156" O_E="0.0" SE="1.4691950292561289" STUDY_ID="STD-Wolff-1993" TOTAL_1="82" TOTAL_2="88" VAR="2.1585340339909176" WEIGHT="7.027027027027026"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.4866501220310468" CI_END="1.104965036877188" CI_START="0.8996776632637041" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9970518353454655" ESTIMABLE="YES" EVENTS_1="267" EVENTS_2="181" I2="0.0" I2_Q="0.0" ID="CMP-001.24" LOG_CI_END="0.043348536363632416" LOG_CI_START="-0.04591306182795536" LOG_EFFECT_SIZE="-0.0012822627321614482" METHOD="MH" NO="24" P_CHI2="0.9747875188902902" P_Q="0.0" P_Z="0.9550943443430022" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="388" TOTAL_2="300" WEIGHT="200.0" Z="0.0563106380497502">
<NAME>Clinically Documented Infections- sensitivity analysis by randomization generation</NAME>
<GROUP_LABEL_1>IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.11418916941310056" CI_END="1.139454757459382" CI_START="0.8628447072519021" DF="1.0" EFFECT_SIZE="0.991550556767948" ESTIMABLE="YES" EVENTS_1="171" EVENTS_2="84" I2="0.0" ID="CMP-001.24.01" LOG_CI_END="0.056697086009759666" LOG_CI_START="-0.06406736054471013" LOG_EFFECT_SIZE="-0.00368513726747522" NO="1" P_CHI2="0.7354243657864881" P_Z="0.9047866059053853" STUDIES="2" TAU2="0.0" TOTAL_1="232" TOTAL_2="138" WEIGHT="100.0" Z="0.11961693244012883">
<NAME>randomization generation A</NAME>
<DICH_DATA CI_END="1.1197236422163708" CI_START="0.9063572887417918" EFFECT_SIZE="1.0074074074074073" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="45" LOG_CI_END="0.04911084814310333" LOG_CI_START="-0.04270056839268063" LOG_EFFECT_SIZE="0.003205139875211354" ORDER="157" O_E="0.0" SE="0.05393048054696102" STUDY_ID="STD-Cordonnier-2003" TOTAL_1="150" TOTAL_2="50" VAR="0.002908496732026141" WEIGHT="64.21017290582508"/>
<DICH_DATA CI_END="1.3573826675095535" CI_START="0.6833484518054647" EFFECT_SIZE="0.9631019387116948" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="39" LOG_CI_END="0.13270229936184452" LOG_CI_START="-0.16535778518138775" LOG_EFFECT_SIZE="-0.016327742909771636" ORDER="158" O_E="0.0" SE="0.17508196908190843" STUDY_ID="STD-Wolff-1993" TOTAL_1="82" TOTAL_2="88" VAR="0.03065369589759834" WEIGHT="35.789827094174925"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.42950989700242326" CI_END="1.1679006848304676" CI_START="0.8614710521202492" DF="2.0" EFFECT_SIZE="1.0030516595534162" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="97" I2="0.0" ID="CMP-001.24.02" LOG_CI_END="0.06740591309833119" LOG_CI_START="-0.0647593115016893" LOG_EFFECT_SIZE="0.001323300798320921" NO="2" P_CHI2="0.8067392219651128" P_Z="0.9686925254253166" STUDIES="3" TAU2="0.0" TOTAL_1="156" TOTAL_2="162" WEIGHT="100.0" Z="0.0392481745976877">
<NAME>Randomization Generation B</NAME>
<DICH_DATA CI_END="1.1457727361680978" CI_START="0.8483793519680012" EFFECT_SIZE="0.9859259259259259" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="90" LOG_CI_END="0.05909848393504327" LOG_CI_START="-0.07140990997570523" LOG_EFFECT_SIZE="-0.006155713020331018" ORDER="159" O_E="0.0" SE="0.07666127661014252" STUDY_ID="STD-Feinstein-1999" TOTAL_1="120" TOTAL_2="121" VAR="0.005876951331496785" WEIGHT="92.98473623575812"/>
<DICH_DATA CI_END="6.41946023225646" CI_START="0.38066311635842387" EFFECT_SIZE="1.5632183908045978" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.80749851280288" LOG_CI_START="-0.4194592012996821" LOG_EFFECT_SIZE="0.194019655751599" ORDER="160" O_E="0.0" SE="0.7207210348024826" STUDY_ID="STD-Poynton-1992" TOTAL_1="29" TOTAL_2="34" VAR="0.5194388100067613" WEIGHT="2.8653894248311884"/>
<DICH_DATA CI_END="2.4775917649219226" CI_START="0.40361774452035826" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.3940297488328639" LOG_CI_START="-0.39402974883286385" LOG_EFFECT_SIZE="0.0" ORDER="161" O_E="0.0" SE="0.46291004988627577" STUDY_ID="STD-Ustun-1998" TOTAL_1="7" TOTAL_2="7" VAR="0.2142857142857143" WEIGHT="4.149874339410687"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.48665012203104685" CI_END="1.104965036877188" CI_START="0.8996776632637042" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9970518353454655" ESTIMABLE="YES" EVENTS_1="267" EVENTS_2="181" I2="0.0" I2_Q="0.0" ID="CMP-001.25" LOG_CI_END="0.043348536363632416" LOG_CI_START="-0.04591306182795531" LOG_EFFECT_SIZE="-0.0012822627321614482" METHOD="MH" NO="25" P_CHI2="0.9747875188902902" P_Q="0.0" P_Z="0.9550943443430022" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="388" TOTAL_2="300" WEIGHT="200.0" Z="0.05631063804975021">
<NAME>Clinically documented infections - sensitivity analysis by blinding</NAME>
<GROUP_LABEL_1>IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1197236422163708" CI_START="0.9063572887417918" DF="0.0" EFFECT_SIZE="1.0074074074074073" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="45" I2="0.0" ID="CMP-001.25.01" LOG_CI_END="0.04911084814310333" LOG_CI_START="-0.04270056839268063" LOG_EFFECT_SIZE="0.003205139875211354" NO="1" P_CHI2="1.0" P_Z="0.8911534498746887" STUDIES="1" TAU2="0.0" TOTAL_1="150" TOTAL_2="50" WEIGHT="100.0" Z="0.136844827317941">
<NAME>Double blind</NAME>
<DICH_DATA CI_END="1.1197236422163708" CI_START="0.9063572887417918" EFFECT_SIZE="1.0074074074074073" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="45" LOG_CI_END="0.04911084814310333" LOG_CI_START="-0.04270056839268063" LOG_EFFECT_SIZE="0.003205139875211354" ORDER="162" O_E="0.0" SE="0.05393048054696102" STUDY_ID="STD-Cordonnier-2003" TOTAL_1="150" TOTAL_2="50" VAR="0.002908496732026141" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.43304338350312516" CI_END="1.1469983395283374" CI_START="0.8576633205993311" DF="3.0" EFFECT_SIZE="0.9918358758392403" ESTIMABLE="YES" EVENTS_1="131" EVENTS_2="136" I2="0.0" ID="CMP-001.25.02" LOG_CI_END="0.059562789187926436" LOG_CI_START="-0.0666831628522011" LOG_EFFECT_SIZE="-0.0035601868321373563" NO="2" P_CHI2="0.9333350368465197" P_Z="0.9119783121635874" STUDIES="4" TAU2="0.0" TOTAL_1="238" TOTAL_2="250" WEIGHT="100.00000000000001" Z="0.11054355179649712">
<NAME>no blinding</NAME>
<DICH_DATA CI_END="1.1457727361680978" CI_START="0.8483793519680012" EFFECT_SIZE="0.9859259259259259" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="90" LOG_CI_END="0.05909848393504327" LOG_CI_START="-0.07140990997570523" LOG_EFFECT_SIZE="-0.006155713020331018" ORDER="163" O_E="0.0" SE="0.07666127661014252" STUDY_ID="STD-Feinstein-1999" TOTAL_1="120" TOTAL_2="121" VAR="0.005876951331496785" WEIGHT="66.87950525124498"/>
<DICH_DATA CI_END="6.41946023225646" CI_START="0.38066311635842387" EFFECT_SIZE="1.5632183908045978" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.80749851280288" LOG_CI_START="-0.4194592012996821" LOG_EFFECT_SIZE="0.194019655751599" ORDER="164" O_E="0.0" SE="0.7207210348024826" STUDY_ID="STD-Poynton-1992" TOTAL_1="29" TOTAL_2="34" VAR="0.5194388100067613" WEIGHT="2.0609385458595733"/>
<DICH_DATA CI_END="2.4775917649219226" CI_START="0.40361774452035826" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.3940297488328639" LOG_CI_START="-0.39402974883286385" LOG_EFFECT_SIZE="0.0" ORDER="165" O_E="0.0" SE="0.46291004988627577" STUDY_ID="STD-Ustun-1998" TOTAL_1="7" TOTAL_2="7" VAR="0.2142857142857143" WEIGHT="2.9848075491759336"/>
<DICH_DATA CI_END="1.3573826675095535" CI_START="0.6833484518054647" EFFECT_SIZE="0.9631019387116948" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="39" LOG_CI_END="0.13270229936184452" LOG_CI_START="-0.16535778518138775" LOG_EFFECT_SIZE="-0.016327742909771636" ORDER="166" O_E="0.0" SE="0.17508196908190843" STUDY_ID="STD-Wolff-1993" TOTAL_1="82" TOTAL_2="88" VAR="0.03065369589759834" WEIGHT="28.074748653719517"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.487809447240542" CI_END="6.707699152648129" CI_START="1.1090748787212197" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.727515467274503" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.26" LOG_CI_END="0.8265735758072136" LOG_CI_START="0.044960868347217485" LOG_EFFECT_SIZE="0.4357672220772155" METHOD="MH" NO="26" P_CHI2="0.47749848666934136" P_Q="0.0" P_Z="0.028855809143928244" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="268" TOTAL_2="179" WEIGHT="100.0" Z="2.1854508064228813">
<NAME>VOD - sensitivity analysis according to randomization generation</NAME>
<GROUP_LABEL_1>IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.0160760421690793" CI_END="9.465822667119202" CI_START="1.1856223485858441" DF="1.0" EFFECT_SIZE="3.3500583430571758" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="3" I2="1.5821691981596981" ID="CMP-001.26.01" LOG_CI_END="0.9761583641280682" LOG_CI_START="0.07394637701854723" LOG_EFFECT_SIZE="0.5250523705733078" NO="1" P_CHI2="0.313451878423307" P_Z="0.022533895065128953" STUDIES="2" TAU2="0.0" TOTAL_1="232" TOTAL_2="138" WEIGHT="72.55617062845978" Z="2.2812459843678385">
<NAME>Randomization A</NAME>
<DICH_DATA CI_END="7.821345722213828" CI_START="0.7639744941851261" EFFECT_SIZE="2.4444444444444446" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="3" LOG_CI_END="0.8932814831685563" LOG_CI_START="-0.1169211404027935" LOG_EFFECT_SIZE="0.3881801713828814" ORDER="167" O_E="0.0" SE="0.5933980216694459" STUDY_ID="STD-Cordonnier-2003" TOTAL_1="150" TOTAL_2="50" VAR="0.3521212121212121" WEIGHT="65.52914360143275"/>
<DICH_DATA CI_END="210.03210045415952" CI_START="0.6624048799437582" EFFECT_SIZE="11.795180722891565" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.3222856756134767" LOG_CI_START="-0.1788764767593484" LOG_EFFECT_SIZE="1.071704599427064" ORDER="168" O_E="0.0" SE="1.4691950292561289" STUDY_ID="STD-Wolff-1993" TOTAL_1="82" TOTAL_2="88" VAR="2.1585340339909176" WEIGHT="7.027027027027026"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8323519526912194" CI_END="7.508705169648478" CI_START="0.15580971282469908" DF="1.0" EFFECT_SIZE="1.0816326530612244" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-001.26.02" LOG_CI_END="0.8755650520295041" LOG_CI_START="-0.8074054728849535" LOG_EFFECT_SIZE="0.03407978957227533" NO="2" P_CHI2="0.3615933868123008" P_Z="0.936732209794084" STUDIES="2" TAU2="0.0" TOTAL_1="36" TOTAL_2="41" WEIGHT="27.44382937154021" Z="0.07937769458649127">
<NAME>Randomization B</NAME>
<DICH_DATA CI_END="9.196087501391645" CI_START="0.01644553380754024" EFFECT_SIZE="0.3888888888888889" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9636030949581328" LOG_CI_START="-1.7839520251362313" LOG_EFFECT_SIZE="-0.4101744650890492" ORDER="169" O_E="0.0" SE="1.6139274781606219" STUDY_ID="STD-Poynton-1992" TOTAL_1="29" TOTAL_2="34" VAR="2.604761904761905" WEIGHT="20.16281341582546"/>
<DICH_DATA CI_END="63.149196457537265" CI_START="0.1425196281959308" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8003678287428493" LOG_CI_START="-0.8461253193035243" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="170" O_E="0.0" SE="1.5545631755148024" STUDY_ID="STD-Ustun-1998" TOTAL_1="7" TOTAL_2="7" VAR="2.4166666666666665" WEIGHT="7.28101595571475"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.487809447240542" CI_END="6.707699152648129" CI_START="1.10907487872122" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.7275154672745034" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.27" LOG_CI_END="0.8265735758072136" LOG_CI_START="0.044960868347217575" LOG_EFFECT_SIZE="0.4357672220772156" METHOD="MH" NO="27" P_CHI2="0.47749848666934136" P_Q="0.0" P_Z="0.028855809143928192" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="268" TOTAL_2="179" WEIGHT="100.0" Z="2.185450806422882">
<NAME>VOD - sensitivity analysis by blinding</NAME>
<GROUP_LABEL_1>IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.821345722213828" CI_START="0.7639744941851261" DF="0.0" EFFECT_SIZE="2.4444444444444446" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="3" I2="0.0" ID="CMP-001.27.01" LOG_CI_END="0.8932814831685563" LOG_CI_START="-0.1169211404027935" LOG_EFFECT_SIZE="0.3881801713828814" NO="1" P_CHI2="1.0" P_Z="0.13199777324627324" STUDIES="1" TAU2="0.0" TOTAL_1="150" TOTAL_2="50" WEIGHT="65.52914360143276" Z="1.5062704009485228">
<NAME>double blind</NAME>
<DICH_DATA CI_END="7.821345722213828" CI_START="0.7639744941851261" EFFECT_SIZE="2.4444444444444446" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="3" LOG_CI_END="0.8932814831685563" LOG_CI_START="-0.1169211404027935" LOG_EFFECT_SIZE="0.3881801713828814" ORDER="171" O_E="0.0" SE="0.5933980216694459" STUDY_ID="STD-Cordonnier-2003" TOTAL_1="150" TOTAL_2="50" VAR="0.3521212121212121" WEIGHT="65.52914360143276"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.505409730607358" CI_END="13.588300179681285" CI_START="0.7848196125102441" DF="2.0" EFFECT_SIZE="3.265633856036274" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" I2="20.17273759389596" ID="CMP-001.27.02" LOG_CI_END="1.133165132320686" LOG_CI_START="-0.10523015254637033" LOG_EFFECT_SIZE="0.5139674898871577" NO="2" P_CHI2="0.2857309822963163" P_Z="0.10376344106667217" STUDIES="3" TAU2="0.0" TOTAL_1="118" TOTAL_2="129" WEIGHT="34.47085639856724" Z="1.6268759768597234">
<NAME>no blinding</NAME>
<DICH_DATA CI_END="9.196087501391645" CI_START="0.01644553380754024" EFFECT_SIZE="0.3888888888888889" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9636030949581328" LOG_CI_START="-1.7839520251362313" LOG_EFFECT_SIZE="-0.4101744650890492" ORDER="172" O_E="0.0" SE="1.6139274781606219" STUDY_ID="STD-Poynton-1992" TOTAL_1="29" TOTAL_2="34" VAR="2.604761904761905" WEIGHT="20.162813415825465"/>
<DICH_DATA CI_END="63.149196457537265" CI_START="0.1425196281959308" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8003678287428493" LOG_CI_START="-0.8461253193035243" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="173" O_E="0.0" SE="1.5545631755148024" STUDY_ID="STD-Ustun-1998" TOTAL_1="7" TOTAL_2="7" VAR="2.4166666666666665" WEIGHT="7.281015955714751"/>
<DICH_DATA CI_END="210.03210045415952" CI_START="0.6624048799437582" EFFECT_SIZE="11.795180722891565" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.3222856756134767" LOG_CI_START="-0.1788764767593484" LOG_EFFECT_SIZE="1.071704599427064" ORDER="174" O_E="0.0" SE="1.4691950292561289" STUDY_ID="STD-Wolff-1993" TOTAL_1="82" TOTAL_2="88" VAR="2.1585340339909176" WEIGHT="7.027027027027027"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.306721719856845" CI_END="0.8670595624859128" CI_START="0.42930282040041945" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6101074623624563" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="67" I2="20.71950813594017" I2_Q="0.0" ID="CMP-001.28" LOG_CI_END="-0.061951067725112496" LOG_CI_START="-0.36723625831693824" LOG_EFFECT_SIZE="-0.2145936630210254" METHOD="MH" NO="28" P_CHI2="0.2775071923751019" P_Q="0.0" P_Z="0.005861520450240515" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="497" TOTAL_2="401" WEIGHT="99.99999999999999" Z="2.7554291121450585">
<NAME>IP - sensitivity analysis by randomization generation</NAME>
<GROUP_LABEL_1>IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.05588651696499286" CI_END="4.854169635045651" CI_START="0.5675738400017003" DF="1.0" EFFECT_SIZE="1.6598493003229278" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="4" I2="0.0" ID="CMP-001.28.01" LOG_CI_END="0.6861149492264426" LOG_CI_START="-0.24597762978384985" LOG_EFFECT_SIZE="0.22006865972129636" NO="1" P_CHI2="0.8131197430232735" P_Z="0.35470499508196773" STUDIES="2" TAU2="0.0" TOTAL_1="232" TOTAL_2="138" WEIGHT="7.956467387990591" Z="0.9255017299627669">
<NAME>Randomization generation A</NAME>
<DICH_DATA CI_END="5.191402094443973" CI_START="0.4661078148828928" EFFECT_SIZE="1.5555555555555556" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="3" LOG_CI_END="0.7152846679917867" LOG_CI_START="-0.33151361551396036" LOG_EFFECT_SIZE="0.19188552623891314" ORDER="175" O_E="0.0" SE="0.6148944934663492" STUDY_ID="STD-Cordonnier-2003" TOTAL_1="150" TOTAL_2="50" VAR="0.3780952380952381" WEIGHT="6.551881110670401"/>
<DICH_DATA CI_END="23.226535498709673" CI_START="0.19834131861072427" EFFECT_SIZE="2.1463414634146343" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.365984434681748" LOG_CI_START="-0.7025868038208817" LOG_EFFECT_SIZE="0.33169881543043317" ORDER="176" O_E="0.0" SE="1.2150889850892173" STUDY_ID="STD-Wolff-1993" TOTAL_1="82" TOTAL_2="88" VAR="1.476441241685144" WEIGHT="1.4045862773201905"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.0974936597590177" CI_END="0.7588484896038399" CI_START="0.35545992867842124" DF="3.0" EFFECT_SIZE="0.5193652183120357" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="63" I2="0.0" ID="CMP-001.28.02" LOG_CI_END="-0.11984492594554336" LOG_CI_START="-0.44920935058743994" LOG_EFFECT_SIZE="-0.2845271382664917" NO="2" P_CHI2="0.5524200328032396" P_Z="7.084257030466214E-4" STUDIES="4" TAU2="0.0" TOTAL_1="265" TOTAL_2="263" WEIGHT="92.0435326120094" Z="3.38629737703393">
<NAME>Randomization generation B</NAME>
<DICH_DATA CI_END="0.9479000001178588" CI_START="0.3330386636908239" EFFECT_SIZE="0.5618606138107417" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="34" LOG_CI_END="-0.023237476678540606" LOG_CI_START="-0.4775053447133569" LOG_EFFECT_SIZE="-0.25037141069594876" ORDER="177" O_E="0.0" SE="0.2668391943458639" STUDY_ID="STD-Sullivan-1990" TOTAL_1="184" TOTAL_2="185" VAR="0.07120315563914972" WEIGHT="49.36894697784285"/>
<DICH_DATA CI_END="1.042546606978355" CI_START="0.15347035703634673" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.018095479186391133" LOG_CI_START="-0.8139754965304663" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="178" O_E="0.0" SE="0.4887626099538393" STUDY_ID="STD-Winston-1984" TOTAL_1="18" TOTAL_2="18" VAR="0.23888888888888885" WEIGHT="14.55973580148978"/>
<DICH_DATA CI_END="0.8529126852017203" CI_START="0.18846465705144" EFFECT_SIZE="0.40092879256965946" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="17" LOG_CI_END="-0.0690954263659058" LOG_CI_START="-0.7247700814617587" LOG_EFFECT_SIZE="-0.3969327539138322" ORDER="179" O_E="0.0" SE="0.3851465380451917" STUDY_ID="STD-Winston-1987" TOTAL_1="38" TOTAL_2="37" VAR="0.14833785576819633" WEIGHT="25.081571540699727"/>
<DICH_DATA CI_END="7.533035597908136" CI_START="0.25280645169509575" EFFECT_SIZE="1.38" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8769700197276257" LOG_CI_START="-0.5972118469251526" LOG_EFFECT_SIZE="0.13987908640123647" ORDER="180" O_E="0.0" SE="0.8659417257897716" STUDY_ID="STD-Winston-1993" TOTAL_1="25" TOTAL_2="23" VAR="0.749855072463768" WEIGHT="3.0332782919770374"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.045981204469275" CI_END="0.8906194408358926" CI_START="0.4549811516566809" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6365650468564416" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="72" I2="14.84507514447821" I2_Q="0.0" ID="CMP-001.29" LOG_CI_END="-0.05030782912888998" LOG_CI_START="-0.34200659433420155" LOG_EFFECT_SIZE="-0.19615721173154577" METHOD="MH" NO="29" P_CHI2="0.3166160258814342" P_Q="0.0" P_Z="0.008388617573326384" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="543" TOTAL_2="447" WEIGHT="100.00000000000001" Z="2.6360143830641545">
<NAME>IP - sensitivity analysis by blinding</NAME>
<GROUP_LABEL_1>IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.191402094443973" CI_START="0.4661078148828928" DF="0.0" EFFECT_SIZE="1.5555555555555556" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="3" I2="0.0" ID="CMP-001.29.01" LOG_CI_END="0.7152846679917867" LOG_CI_START="-0.33151361551396036" LOG_EFFECT_SIZE="0.19188552623891314" NO="1" P_CHI2="1.0" P_Z="0.4724179206649589" STUDIES="1" TAU2="0.0" TOTAL_1="150" TOTAL_2="50" WEIGHT="6.107279249012675" Z="0.7185505106547503">
<NAME>double blind</NAME>
<DICH_DATA CI_END="5.191402094443973" CI_START="0.4661078148828928" EFFECT_SIZE="1.5555555555555556" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="3" LOG_CI_END="0.7152846679917867" LOG_CI_START="-0.33151361551396036" LOG_EFFECT_SIZE="0.19188552623891314" ORDER="181" O_E="0.0" SE="0.6148944934663492" STUDY_ID="STD-Cordonnier-2003" TOTAL_1="150" TOTAL_2="50" VAR="0.3780952380952381" WEIGHT="6.107279249012675"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.4958650182996465" CI_END="0.8209707246758784" CI_START="0.40523442530225445" DF="5.0" EFFECT_SIZE="0.5767890427218646" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="69" I2="0.0" ID="CMP-001.29.02" LOG_CI_END="-0.08567232928544113" LOG_CI_START="-0.3922936677447645" LOG_EFFECT_SIZE="-0.23898299851510282" NO="2" P_CHI2="0.4804369215294957" P_Z="0.0022489427810943297" STUDIES="6" TAU2="0.0" TOTAL_1="393" TOTAL_2="397" WEIGHT="93.89272075098734" Z="3.0552216121718407">
<NAME>no blinding</NAME>
<DICH_DATA CI_END="3.2229063532708806" CI_START="0.3102789502354341" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.508247686570799" LOG_CI_START="-0.508247686570799" LOG_EFFECT_SIZE="0.0" ORDER="182" O_E="0.0" SE="0.5970944139166224" STUDY_ID="STD-Emanuel-1992" TOTAL_1="46" TOTAL_2="46" VAR="0.35652173913043483" WEIGHT="6.785865832236305"/>
<DICH_DATA CI_END="0.9479000001178588" CI_START="0.3330386636908239" EFFECT_SIZE="0.5618606138107417" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="34" LOG_CI_END="-0.023237476678540606" LOG_CI_START="-0.4775053447133569" LOG_EFFECT_SIZE="-0.25037141069594876" ORDER="183" O_E="0.0" SE="0.2668391943458639" STUDY_ID="STD-Sullivan-1990" TOTAL_1="184" TOTAL_2="185" VAR="0.07120315563914972" WEIGHT="46.01883647313857"/>
<DICH_DATA CI_END="1.042546606978355" CI_START="0.15347035703634673" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.018095479186391133" LOG_CI_START="-0.8139754965304663" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="184" O_E="0.0" SE="0.4887626099538393" STUDY_ID="STD-Winston-1984" TOTAL_1="18" TOTAL_2="18" VAR="0.23888888888888885" WEIGHT="13.57173166447261"/>
<DICH_DATA CI_END="0.8529126852017203" CI_START="0.18846465705144" EFFECT_SIZE="0.40092879256965946" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="17" LOG_CI_END="-0.0690954263659058" LOG_CI_START="-0.7247700814617587" LOG_EFFECT_SIZE="-0.3969327539138322" ORDER="185" O_E="0.0" SE="0.3851465380451917" STUDY_ID="STD-Winston-1987" TOTAL_1="38" TOTAL_2="37" VAR="0.14833785576819633" WEIGHT="23.379569747331484"/>
<DICH_DATA CI_END="7.533035597908136" CI_START="0.25280645169509575" EFFECT_SIZE="1.38" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8769700197276257" LOG_CI_START="-0.5972118469251526" LOG_EFFECT_SIZE="0.13987908640123647" ORDER="186" O_E="0.0" SE="0.8659417257897716" STUDY_ID="STD-Winston-1993" TOTAL_1="25" TOTAL_2="23" VAR="0.749855072463768" WEIGHT="2.8274440967651273"/>
<DICH_DATA CI_END="23.226535498709673" CI_START="0.19834131861072427" EFFECT_SIZE="2.1463414634146343" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.365984434681748" LOG_CI_START="-0.7025868038208817" LOG_EFFECT_SIZE="0.33169881543043317" ORDER="187" O_E="0.0" SE="1.2150889850892173" STUDY_ID="STD-Wolff-1993" TOTAL_1="82" TOTAL_2="88" VAR="1.476441241685144" WEIGHT="1.30927293704324"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.23307138470898" CI_END="1.2510470067051067" CI_START="0.724805045114763" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9522421867023032" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="83" I2="44.69845813417285" I2_Q="0.0" ID="CMP-001.30" LOG_CI_END="0.09727362813395124" LOG_CI_START="-0.13977879234852192" LOG_EFFECT_SIZE="-0.021252582107285332" METHOD="MH" NO="30" P_CHI2="0.12407232071247154" P_Q="0.0" P_Z="0.7252617963139605" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="563" TOTAL_2="468" WEIGHT="100.0" Z="0.35143531058641425">
<NAME>Fungal Infections</NAME>
<GROUP_LABEL_1>Polyvalent IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.489917024445268" CI_START="0.5245646486033343" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="7" LOG_CI_END="0.39618487463550084" LOG_CI_START="-0.2802009806801273" LOG_EFFECT_SIZE="0.05799194697768673" ORDER="188" O_E="0.0" SE="0.3973123995763823" STUDY_ID="STD-Cordonnier-2003" TOTAL_1="150" TOTAL_2="50" VAR="0.15785714285714286" WEIGHT="12.163510838251428"/>
<DICH_DATA CI_END="3.7045592748592036" CI_START="1.0082422220083482" EFFECT_SIZE="1.9326388888888888" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="12" LOG_CI_END="0.568736548109742" LOG_CI_START="0.003564880367844669" LOG_EFFECT_SIZE="0.2861507142387933" ORDER="189" O_E="0.0" SE="0.3319846352764656" STUDY_ID="STD-Feinstein-1999" TOTAL_1="120" TOTAL_2="121" VAR="0.11021379805964787" WEIGHT="13.843474101625809"/>
<DICH_DATA CI_END="1.1059681550267104" CI_START="0.5345078040264374" EFFECT_SIZE="0.7688618925831202" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="51" LOG_CI_END="0.043742622180899804" LOG_CI_START="-0.2720459495368195" LOG_EFFECT_SIZE="-0.11415166367795983" ORDER="190" O_E="0.0" SE="0.1854957702056289" STUDY_ID="STD-Sullivan-1990" TOTAL_1="184" TOTAL_2="185" VAR="0.03440868076417948" WEIGHT="58.91980162919158"/>
<DICH_DATA CI_END="1.9995479625023824" CI_START="0.1422543743779317" EFFECT_SIZE="0.5333333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.3009318258740424" LOG_CI_START="-0.8469343700015177" LOG_EFFECT_SIZE="-0.27300127206373764" ORDER="191" O_E="0.0" SE="0.6742622854866122" STUDY_ID="STD-Winston-1993" TOTAL_1="27" TOTAL_2="24" VAR="0.4546296296296296" WEIGHT="6.132862607521728"/>
<DICH_DATA CI_END="1.967386467561412" CI_START="0.2286693695510198" EFFECT_SIZE="0.6707317073170732" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.2938896798192904" LOG_CI_START="-0.640792005598236" LOG_EFFECT_SIZE="-0.1734511628894728" ORDER="192" O_E="0.0" SE="0.549036648763217" STUDY_ID="STD-Wolff-1993" TOTAL_1="82" TOTAL_2="88" VAR="0.30144124168514413" WEIGHT="8.940350823409453"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.1779918101716056" CI_END="1.1309072395497257" CI_START="0.9326347138339923" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0269972491347037" ESTIMABLE="YES" EVENTS_1="207" EVENTS_2="205" I2="0.0" I2_Q="0.0" ID="CMP-001.31" LOG_CI_END="0.053426984232430245" LOG_CI_START="-0.030288423595261692" LOG_EFFECT_SIZE="0.011569280318584275" METHOD="MH" NO="31" P_CHI2="0.7582875338164838" P_Q="0.0" P_Z="0.5880078338558173" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="322" TOTAL_2="331" WEIGHT="100.0" Z="0.5417251934827837">
<NAME>Bacteremia</NAME>
<GROUP_LABEL_1>Polyvalent IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8804900359214143" CI_START="0.3581680823833743" EFFECT_SIZE="0.8206896551724138" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.27427103658542584" LOG_CI_START="-0.4459131182703141" LOG_EFFECT_SIZE="-0.08582104084244414" ORDER="193" O_E="0.0" SE="0.42303973753132323" STUDY_ID="STD-Poynton-1992" TOTAL_1="29" TOTAL_2="34" VAR="0.17896261953057085" WEIGHT="4.534967803366417"/>
<DICH_DATA CI_END="1.1005553959529077" CI_START="0.9416423166221286" EFFECT_SIZE="1.0180027173913044" ESTIMABLE="YES" EVENTS_1="162" EVENTS_2="160" LOG_CI_END="0.04161190745381864" LOG_CI_START="-0.026114032893451558" LOG_EFFECT_SIZE="0.007748937280183537" ORDER="194" O_E="0.0" SE="0.03978255260879802" STUDY_ID="STD-Sullivan-1990" TOTAL_1="184" TOTAL_2="185" VAR="0.0015826514920717818" WEIGHT="78.60102312176208"/>
<DICH_DATA CI_END="4.115975374102722" CI_START="0.6219667921502269" EFFECT_SIZE="1.6" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.61447276771253" LOG_CI_START="-0.20623280240068048" LOG_EFFECT_SIZE="0.2041199826559248" ORDER="195" O_E="0.0" SE="0.482086514442592" STUDY_ID="STD-Winston-1993" TOTAL_1="27" TOTAL_2="24" VAR="0.23240740740740742" WEIGHT="2.6078364548770367"/>
<DICH_DATA CI_END="1.5668104755865655" CI_START="0.6868701755017389" EFFECT_SIZE="1.0373983739837398" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="30" LOG_CI_END="0.19501646654842927" LOG_CI_START="-0.16312534065693815" LOG_EFFECT_SIZE="0.01594556294574557" ORDER="196" O_E="0.0" SE="0.21037427038297035" STUDY_ID="STD-Wolff-1993" TOTAL_1="82" TOTAL_2="88" VAR="0.04425733363916712" WEIGHT="14.25617261999447"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2008-06-17 21:39:26 +0200" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Hyperimmune CMV-IVIG vs. placebo / no intervention - HSCT</NAME>
<DICH_OUTCOME CHI2="1.5307190435554525" CI_END="1.1563935595994508" CI_START="0.6325350057726253" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8552540013917884" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="54" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.06310566425233122" LOG_CI_START="-0.1989154347478743" LOG_EFFECT_SIZE="-0.06790488524777158" METHOD="MH" MODIFIED="2008-06-17 21:39:26 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6751987889003426" P_Q="0.0" P_Z="0.3096860664723735" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="143" TOTAL_2="145" WEIGHT="100.0" Z="1.0158810108635805">
<NAME>All-cause Mortality</NAME>
<GROUP_LABEL_1>CMV-IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.5639184979939795" CI_START="0.21910996010107084" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.659337880227438" LOG_CI_START="-0.659337880227438" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-06-17 21:37:03 +0200" MODIFIED_BY="[Empty name]" ORDER="345" O_E="0.0" SE="0.7745966692414834" STUDY_ID="STD-Bordigoni-1987" TOTAL_1="30" TOTAL_2="30" VAR="0.6" WEIGHT="5.6367432150313155"/>
<DICH_DATA CI_END="1.763402512262695" CI_START="0.6283495873982091" EFFECT_SIZE="1.0526315789473684" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="19" LOG_CI_END="0.24635145518204069" LOG_CI_START="-0.20179866575973626" LOG_EFFECT_SIZE="0.02227639471115221" MODIFIED="2008-06-17 21:38:43 +0200" MODIFIED_BY="[Empty name]" ORDER="347" O_E="0.0" SE="0.26324559942007597" STUDY_ID="STD-Bowden-1991" TOTAL_1="60" TOTAL_2="60" VAR="0.0692982456140351" WEIGHT="35.69937369519833"/>
<DICH_DATA CI_END="1.5214869439065046" CI_START="0.3476373043837393" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.1822682299681336" LOG_CI_START="-0.4588736263006965" LOG_EFFECT_SIZE="-0.13830269816628143" MODIFIED="2008-06-17 21:37:58 +0200" MODIFIED_BY="[Empty name]" ORDER="346" O_E="0.0" SE="0.3766099000756842" STUDY_ID="STD-Ringden-1987" TOTAL_1="27" TOTAL_2="27" VAR="0.14183501683501684" WEIGHT="20.668058455114824"/>
<DICH_DATA CI_END="1.0874345761561044" CI_START="0.4740058601283737" EFFECT_SIZE="0.717948717948718" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="21" LOG_CI_END="0.03640313774705149" LOG_CI_START="-0.32421628911561146" LOG_EFFECT_SIZE="-0.14390657568427997" MODIFIED="2008-06-17 21:39:26 +0200" MODIFIED_BY="[Empty name]" ORDER="344" O_E="0.0" SE="0.21182963643408084" STUDY_ID="STD-Winston-1982" TOTAL_1="26" TOTAL_2="28" VAR="0.044871794871794865" WEIGHT="37.995824634655534"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.450785002321229" CI_END="1.2360097945189255" CI_START="0.638832902234536" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8885964912280702" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="43" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.0920219122484834" LOG_CI_START="-0.19461272420086778" LOG_EFFECT_SIZE="-0.05129540597619217" METHOD="MH" NO="2" P_CHI2="0.4841345882539799" P_Q="0.0" P_Z="0.48299082389493087" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="116" TOTAL_2="118" WEIGHT="100.00000000000001" Z="0.7015003457438922">
<NAME>All-cause Mortality - 100d (3-4mo)</NAME>
<GROUP_LABEL_1>CMV-IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.5639184979939795" CI_START="0.21910996010107084" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.659337880227438" LOG_CI_START="-0.659337880227438" LOG_EFFECT_SIZE="0.0" ORDER="197" O_E="0.0" SE="0.7745966692414834" STUDY_ID="STD-Bordigoni-1987" TOTAL_1="30" TOTAL_2="30" VAR="0.6" WEIGHT="7.105263157894738"/>
<DICH_DATA CI_END="1.763402512262695" CI_START="0.6283495873982091" EFFECT_SIZE="1.0526315789473684" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="19" LOG_CI_END="0.24635145518204069" LOG_CI_START="-0.20179866575973626" LOG_EFFECT_SIZE="0.02227639471115221" ORDER="198" O_E="0.0" SE="0.26324559942007597" STUDY_ID="STD-Bowden-1991" TOTAL_1="60" TOTAL_2="60" VAR="0.0692982456140351" WEIGHT="45.00000000000001"/>
<DICH_DATA CI_END="1.0874345761561044" CI_START="0.4740058601283737" EFFECT_SIZE="0.717948717948718" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="21" LOG_CI_END="0.03640313774705149" LOG_CI_START="-0.32421628911561146" LOG_EFFECT_SIZE="-0.14390657568427997" ORDER="199" O_E="0.0" SE="0.21182963643408084" STUDY_ID="STD-Winston-1982" TOTAL_1="26" TOTAL_2="28" VAR="0.044871794871794865" WEIGHT="47.89473684210527"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="14.886560166474018" CI_END="1.2558119037351552" CI_START="0.8219072308943188" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0159531900255465" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="96" I2="52.977720025848" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.09892459538261848" LOG_CI_START="-0.08517719874258894" LOG_EFFECT_SIZE="0.006873698320014759" METHOD="MH" NO="3" P_CHI2="0.03748139227604241" P_Q="0.0" P_Z="0.8836403596779662" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="274" TOTAL_2="279" WEIGHT="100.00000000000001" Z="0.1463560006227856">
<NAME>CMV infection</NAME>
<GROUP_LABEL_1>CMV-IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.5639184979939795" CI_START="0.21910996010107084" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.659337880227438" LOG_CI_START="-0.659337880227438" LOG_EFFECT_SIZE="0.0" ORDER="200" O_E="0.0" SE="0.7745966692414834" STUDY_ID="STD-Bordigoni-1987" TOTAL_1="30" TOTAL_2="30" VAR="0.6" WEIGHT="3.222781546013313"/>
<DICH_DATA CI_END="1.438541147339936" CI_START="0.23819491243820237" EFFECT_SIZE="0.5853658536585366" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="0.15792228875474487" LOG_CI_START="-0.6230675187710039" LOG_EFFECT_SIZE="-0.23257261500812948" ORDER="201" O_E="0.0" SE="0.45875727890252144" STUDY_ID="STD-Bowden-1986" TOTAL_1="41" TOTAL_2="44" VAR="0.21045824094604582" WEIGHT="11.399799821584347"/>
<DICH_DATA CI_END="2.1917512963458234" CI_START="0.854374390199907" EFFECT_SIZE="1.368421052631579" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="19" LOG_CI_END="0.34079127209676224" LOG_CI_START="-0.06835177806078423" LOG_EFFECT_SIZE="0.136219747017989" ORDER="202" O_E="0.0" SE="0.2403326529533046" STUDY_ID="STD-Bowden-1991" TOTAL_1="60" TOTAL_2="60" VAR="0.057759784075573556" WEIGHT="20.41094979141765"/>
<DICH_DATA CI_END="1.4458876640404827" CI_START="0.40148268821311334" EFFECT_SIZE="0.7619047619047619" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="0.16013455244502747" LOG_CI_START="-0.39633317660101647" LOG_EFFECT_SIZE="-0.11809931207799451" ORDER="203" O_E="0.0" SE="0.3268718986013299" STUDY_ID="STD-Meyers-1983" TOTAL_1="30" TOTAL_2="32" VAR="0.1068452380952381" WEIGHT="14.554497304576254"/>
<DICH_DATA CI_END="1.6298671834140095" CI_START="0.8351055380230756" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="18" LOG_CI_END="0.21215221553245636" LOG_CI_START="-0.0782586362712299" LOG_EFFECT_SIZE="0.06694678963061322" ORDER="204" O_E="0.0" SE="0.17058877190638633" STUDY_ID="STD-Ringden-1987" TOTAL_1="27" TOTAL_2="27" VAR="0.0291005291005291" WEIGHT="19.33668927607988"/>
<DICH_DATA CI_END="4.254162342032459" CI_START="0.8011645418402873" EFFECT_SIZE="1.8461538461538463" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.6288140588867885" LOG_CI_START="-0.09627828007725006" LOG_EFFECT_SIZE="0.26626788940476925" ORDER="205" O_E="0.0" SE="0.42592282917244106" STUDY_ID="STD-Ruutu-1997" TOTAL_1="13" TOTAL_2="15" VAR="0.18141025641025643" WEIGHT="4.987638106925366"/>
<DICH_DATA CI_END="14.003443300239491" CI_START="0.673668130553749" EFFECT_SIZE="3.0714285714285716" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.146234837280102" LOG_CI_START="-0.17155399747740463" LOG_EFFECT_SIZE="0.4873404199013485" ORDER="206" O_E="0.0" SE="0.7740756846964955" STUDY_ID="STD-Serrano-1999" TOTAL_1="49" TOTAL_2="43" VAR="0.5991931656383482" WEIGHT="2.2886419674587297"/>
<DICH_DATA CI_END="0.8946727275804478" CI_START="0.38033771153170703" EFFECT_SIZE="0.5833333333333334" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="24" LOG_CI_END="-0.04833580110740116" LOG_CI_START="-0.4198306109593347" LOG_EFFECT_SIZE="-0.23408320603336794" ORDER="207" O_E="0.0" SE="0.21821789023599242" STUDY_ID="STD-Winston-1982" TOTAL_1="24" TOTAL_2="28" VAR="0.04761904761904763" WEIGHT="23.799002185944467"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.174515288961075" CI_END="1.555081161371982" CI_START="0.5797982697948159" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9495437676874026" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="27" I2="22.69807360443399" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.19175306025428104" LOG_CI_START="-0.23672308497909866" LOG_EFFECT_SIZE="-0.02248501236240881" METHOD="MH" NO="4" P_CHI2="0.26985534418567103" P_Q="0.0" P_Z="0.8370214559909657" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="174" TOTAL_2="171" WEIGHT="100.0" Z="0.20570486787895967">
<NAME>Interstitial Pneumonitis</NAME>
<GROUP_LABEL_1>CMV-IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1876520922627805" CI_START="0.37311302308189653" EFFECT_SIZE="0.9034608378870674" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.3399782562243235" LOG_CI_START="-0.4281595921441123" LOG_EFFECT_SIZE="-0.04409066795989443" ORDER="208" O_E="0.0" SE="0.451207974475292" STUDY_ID="STD-Bowden-1991" TOTAL_1="61" TOTAL_2="62" VAR="0.20358863623009577" WEIGHT="32.999932797204366"/>
<DICH_DATA CI_END="4.521215975389076" CI_START="0.22117943611706017" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6552552534796292" LOG_CI_START="-0.6552552534796292" LOG_EFFECT_SIZE="0.0" ORDER="209" O_E="0.0" SE="0.769800358919501" STUDY_ID="STD-Ringden-1987" TOTAL_1="27" TOTAL_2="27" VAR="0.5925925925925926" WEIGHT="11.090141349880154"/>
<DICH_DATA CI_END="22.62194860474717" CI_START="0.23541048032726553" EFFECT_SIZE="2.3076923076923075" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.354530011369287" LOG_CI_START="-0.6281742065436359" LOG_EFFECT_SIZE="0.36317790241282566" ORDER="210" O_E="0.0" SE="1.1646502721462166" STUDY_ID="STD-Ruutu-1997" TOTAL_1="13" TOTAL_2="15" VAR="1.3564102564102565" WEIGHT="3.4326627987724287"/>
<DICH_DATA CI_END="8.2674362904401" CI_START="0.6623863264041151" EFFECT_SIZE="2.3401360544217686" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.9173708568888046" LOG_CI_START="-0.1788886412420966" LOG_EFFECT_SIZE="0.369241107823354" ORDER="211" O_E="0.0" SE="0.6439482557741257" STUDY_ID="STD-Serrano-1999" TOTAL_1="49" TOTAL_2="43" VAR="0.4146693561145388" WEIGHT="11.813411437915816"/>
<DICH_DATA CI_END="1.1101683716543946" CI_START="0.18610831971373606" EFFECT_SIZE="0.45454545454545453" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="0.04538885025972793" LOG_CI_START="-0.7302342119041405" LOG_EFFECT_SIZE="-0.3424226808222063" ORDER="212" O_E="0.0" SE="0.455604826111135" STUDY_ID="STD-Winston-1982" TOTAL_1="24" TOTAL_2="24" VAR="0.20757575757575758" WEIGHT="40.663851616227234"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8131764046270815" CI_END="1.3201196615177686" CI_START="0.33666981668423723" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.12061329937363115" LOG_CI_START="-0.47279581748499366" LOG_EFFECT_SIZE="-0.17609125905568127" METHOD="MH" NO="5" P_CHI2="0.6659186131039674" P_Q="0.0" P_Z="0.24474048015009142" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="117" TOTAL_2="117" WEIGHT="100.0" Z="1.1632194920378116">
<NAME>Infection-related Mortality</NAME>
<GROUP_LABEL_1>CMV-IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.5639184979939795" CI_START="0.21910996010107084" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.659337880227438" LOG_CI_START="-0.659337880227438" LOG_EFFECT_SIZE="0.0" ORDER="213" O_E="0.0" SE="0.7745966692414834" STUDY_ID="STD-Bordigoni-1987" TOTAL_1="30" TOTAL_2="30" VAR="0.6" WEIGHT="16.666666666666664"/>
<DICH_DATA CI_END="2.03094066338857" CI_START="0.2769652556276479" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.30769723510379193" LOG_CI_START="-0.5575747083203917" LOG_EFFECT_SIZE="-0.12493873660829993" ORDER="214" O_E="0.0" SE="0.5082650227325635" STUDY_ID="STD-Bowden-1991" TOTAL_1="60" TOTAL_2="60" VAR="0.2583333333333333" WEIGHT="44.44444444444444"/>
<DICH_DATA CI_END="1.4852263972650719" CI_START="0.1236669841890606" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.17179265943688432" LOG_CI_START="-0.9077462300260731" LOG_EFFECT_SIZE="-0.36797678529459443" ORDER="215" O_E="0.0" SE="0.6341264874742278" STUDY_ID="STD-Ringden-1987" TOTAL_1="27" TOTAL_2="27" VAR="0.4021164021164021" WEIGHT="38.888888888888886"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.1734143622317958" CI_END="1.43734073327429" CI_START="0.7224953941589547" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0190544929628294" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="43" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="0.15755973336712592" LOG_CI_START="-0.14116491714958246" LOG_EFFECT_SIZE="0.008197408108771747" METHOD="MH" NO="6" P_CHI2="0.8824560859667294" P_Q="0.0" P_Z="0.9143382860775949" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="173" TOTAL_2="169" WEIGHT="100.0" Z="0.10756812088977957">
<NAME>Acute GVHD</NAME>
<GROUP_LABEL_1>CMV-IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.676841393350012" CI_START="0.37357461763863437" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.4276226393850946" LOG_CI_START="-0.4276226393850946" LOG_EFFECT_SIZE="0.0" ORDER="216" O_E="0.0" SE="0.5023753102820165" STUDY_ID="STD-Bowden-1991" TOTAL_1="60" TOTAL_2="60" VAR="0.2523809523809524" WEIGHT="16.268495128112594"/>
<DICH_DATA CI_END="1.5420084873859228" CI_START="0.464314131353907" EFFECT_SIZE="0.8461538461538461" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" LOG_CI_END="0.18808676412656455" LOG_CI_START="-0.333188098423788" LOG_EFFECT_SIZE="-0.07255066714861173" ORDER="217" O_E="0.0" SE="0.3061994346142621" STUDY_ID="STD-Ringden-1987" TOTAL_1="27" TOTAL_2="27" VAR="0.09375809375809377" WEIGHT="30.212919523637677"/>
<DICH_DATA CI_END="2.9911052174958446" CI_START="0.6058396631837345" EFFECT_SIZE="1.3461538461538463" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.4758316903880975" LOG_CI_START="-0.21764229762918205" LOG_EFFECT_SIZE="0.1290946963794577" ORDER="218" O_E="0.0" SE="0.4073500533129534" STUDY_ID="STD-Ruutu-1997" TOTAL_1="13" TOTAL_2="15" VAR="0.16593406593406596" WEIGHT="12.948394081559004"/>
<DICH_DATA CI_END="3.0065928499956365" CI_START="0.5227259381679017" EFFECT_SIZE="1.2536443148688046" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.47807462032789877" LOG_CI_START="-0.28172594925426675" LOG_EFFECT_SIZE="0.098174335536816" ORDER="219" O_E="0.0" SE="0.4463106156460413" STUDY_ID="STD-Serrano-1999" TOTAL_1="49" TOTAL_2="43" VAR="0.19919316563834838" WEIGHT="17.32948394081559"/>
<DICH_DATA CI_END="1.8134816410046115" CI_START="0.4466546457847158" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.2585131633072724" LOG_CI_START="-0.35002814442862273" LOG_EFFECT_SIZE="-0.045757490560675115" ORDER="220" O_E="0.0" SE="0.3574601764921203" STUDY_ID="STD-Winston-1982" TOTAL_1="24" TOTAL_2="24" VAR="0.1277777777777778" WEIGHT="23.240707325875135"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="129.33809770163077" CI_START="0.37885202326879575" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="2.111726469076227" LOG_CI_START="-0.4215303890477134" LOG_EFFECT_SIZE="0.8450980400142568" METHOD="MH" NO="7" P_CHI2="1.0" P_Q="0.0" P_Z="0.19097730008968364" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0" Z="1.307693467025676">
<NAME>Adverse Events</NAME>
<GROUP_LABEL_1>CMV-IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="129.33809770163077" CI_START="0.37885202326879575" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.111726469076227" LOG_CI_START="-0.4215303890477134" LOG_EFFECT_SIZE="0.8450980400142568" ORDER="221" O_E="0.0" SE="1.4880476182856899" STUDY_ID="STD-Ringden-1987" TOTAL_1="27" TOTAL_2="27" VAR="2.2142857142857144" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.430037983285483" CI_END="1.9342496815796593" CI_START="0.5423166857631574" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0241952337092393" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="12" I2="58.84837986573483" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="0.2865125340351522" LOG_CI_START="-0.26574703317585724" LOG_EFFECT_SIZE="0.010382750429647463" METHOD="MH" NO="8" P_CHI2="0.1190302295057627" P_Q="0.0" P_Z="0.9412518310638708" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="168" TOTAL_2="103" WEIGHT="100.0" Z="0.073696566291631">
<NAME>Fungal Infections</NAME>
<GROUP_LABEL_1>CMV-IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.556679755725247" CI_START="0.39005133877812576" EFFECT_SIZE="0.7792207792207793" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="11" LOG_CI_END="0.19219927754795899" LOG_CI_START="-0.4088782271256355" LOG_EFFECT_SIZE="-0.10833947478883822" ORDER="222" O_E="0.0" SE="0.3530759016269039" STUDY_ID="STD-Boeckh-2001" TOTAL_1="119" TOTAL_2="60" VAR="0.12466259230965113" WEIGHT="93.21124776507558"/>
<DICH_DATA CI_END="36.10484583643048" CI_START="0.5332357579563234" EFFECT_SIZE="4.387755102040816" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.5575654949468172" LOG_CI_START="-0.2730807351726339" LOG_EFFECT_SIZE="0.6422423798870917" ORDER="223" O_E="0.0" SE="1.0753306574171524" STUDY_ID="STD-Serrano-1999" TOTAL_1="49" TOTAL_2="43" VAR="1.1563360227812054" WEIGHT="6.788752234924419"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.524461654139847" CI_START="1.233604339406043" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7647058823529411" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="0.4021687782709791" LOG_CI_START="0.09117588841179787" LOG_EFFECT_SIZE="0.2466723333413885" METHOD="MH" NO="9" P_CHI2="1.0" P_Q="0.0" P_Z="0.001875973694467172" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="119" TOTAL_2="60" WEIGHT="100.0" Z="3.1091957732570474">
<NAME>Bacteremia</NAME>
<GROUP_LABEL_1>CMV-IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.5244616541398477" CI_START="1.233604339406043" EFFECT_SIZE="1.7647058823529411" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="22" LOG_CI_END="0.4021687782709792" LOG_CI_START="0.09117588841179787" LOG_EFFECT_SIZE="0.2466723333413885" ORDER="224" O_E="0.0" SE="0.18267876294291566" STUDY_ID="STD-Boeckh-2001" TOTAL_1="119" TOTAL_2="60" VAR="0.03337153043035397" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Polyvalent immunoglobulins or hyperimmune CMV-IVIG vs. placebo / no intervention - HSCT</NAME>
<DICH_OUTCOME CHI2="9.921920592238179" CI_END="1.0860642491814319" CI_START="0.8696405840494837" CI_STUDY="95" CI_TOTAL="95" DF="11.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.971846463168645" ESTIMABLE="YES" EVENTS_1="345" EVENTS_2="327" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.03585551792281367" LOG_CI_START="-0.060660200962390505" LOG_EFFECT_SIZE="-0.01240234151978842" METHOD="MH" NO="1" P_CHI2="0.5374240220354781" P_Q="0.0" P_Z="0.6144626141102361" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="899" TOTAL_2="807" WEIGHT="100.0" Z="0.5037136537658322">
<NAME>All-cause Mortality</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.2371510892009185" CI_END="1.1201187551781746" CI_START="0.8820847875302142" DF="7.0" EFFECT_SIZE="0.9940018682929868" ESTIMABLE="YES" EVENTS_1="300" EVENTS_2="273" I2="3.276856960396875" ID="CMP-003.01.01" LOG_CI_END="0.04926406908491544" LOG_CI_START="-0.05448966771770894" LOG_EFFECT_SIZE="-0.0026127993163967524" NO="1" P_CHI2="0.40461277362558123" P_Z="0.9213650562812918" STUDIES="8" TAU2="0.0" TOTAL_1="756" TOTAL_2="662" WEIGHT="84.031894962307" Z="0.0987143734150108">
<NAME>Polyvalent IVIG</NAME>
<DICH_DATA CI_END="1.7431481714047472" CI_START="0.6296112326755309" EFFECT_SIZE="1.0476190476190477" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="14" LOG_CI_END="0.24133430465929537" LOG_CI_START="-0.2009275324827214" LOG_EFFECT_SIZE="0.02020338608828699" ORDER="225" O_E="0.0" SE="0.25978679236862195" STUDY_ID="STD-Cordonnier-2003" TOTAL_1="150" TOTAL_2="50" VAR="0.06748917748917749" WEIGHT="6.3005675409686335"/>
<DICH_DATA CI_END="1.7956645992446418" CI_START="0.6392948795428534" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="13" LOG_CI_END="0.25422522080559784" LOG_CI_START="-0.19429877405071144" LOG_EFFECT_SIZE="0.029963223377443202" ORDER="226" O_E="0.0" SE="0.263465214808178" STUDY_ID="STD-Lum-1994" TOTAL_1="28" TOTAL_2="26" VAR="0.0694139194139194" WEIGHT="4.04480879173295"/>
<DICH_DATA CI_END="1.258328438015756" CI_START="0.40795117345534293" EFFECT_SIZE="0.7164750957854407" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="18" LOG_CI_END="0.09979401169835539" LOG_CI_START="-0.3893918133019193" LOG_EFFECT_SIZE="-0.14479890080178195" ORDER="227" O_E="0.0" SE="0.2873501751140487" STUDY_ID="STD-Poynton-1992" TOTAL_1="29" TOTAL_2="34" VAR="0.08257012313807446" WEIGHT="4.971876426886813"/>
<DICH_DATA CI_END="1.1452298351980588" CI_START="0.8383914163838789" EFFECT_SIZE="0.9798728813559322" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="118" LOG_CI_END="0.058892653611788165" LOG_CI_START="-0.07655317672986092" LOG_EFFECT_SIZE="-0.008830261559036367" ORDER="228" O_E="0.0" SE="0.07956155121035804" STUDY_ID="STD-Sullivan-1990" TOTAL_1="184" TOTAL_2="185" VAR="0.0063300404309984265" WEIGHT="35.30724543799483"/>
<DICH_DATA CI_END="1.163219761020434" CI_START="0.7305092071417054" EFFECT_SIZE="0.921814919251474" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="94" LOG_CI_END="0.06566177146306576" LOG_CI_START="-0.13637430596426628" LOG_EFFECT_SIZE="-0.03535626725060022" ORDER="229" O_E="0.0" SE="0.11867699197552743" STUDY_ID="STD-Sullivan-2000" TOTAL_1="249" TOTAL_2="248" VAR="0.014084228424359403" WEIGHT="28.25928597564661"/>
<DICH_DATA CI_END="63.149196457537265" CI_START="0.1425196281959308" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8003678287428493" LOG_CI_START="-0.8461253193035243" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="230" O_E="0.0" SE="1.5545631755148024" STUDY_ID="STD-Ustun-1998" TOTAL_1="7" TOTAL_2="7" VAR="2.4166666666666665" WEIGHT="0.15001351288020556"/>
<DICH_DATA CI_END="1.7732552129951322" CI_START="0.674958343971265" EFFECT_SIZE="1.0940170940170941" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="13" LOG_CI_END="0.24877124525633185" LOG_CI_START="-0.17072302945291837" LOG_EFFECT_SIZE="0.03902410790170677" ORDER="231" O_E="0.0" SE="0.2464130134943632" STUDY_ID="STD-Winston-1993" TOTAL_1="27" TOTAL_2="24" VAR="0.06071937321937323" WEIGHT="4.129783766349188"/>
<DICH_DATA CI_END="13.606525523365265" CI_START="1.1379764111245112" EFFECT_SIZE="3.934959349593496" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" LOG_CI_END="1.1337472406573357" LOG_CI_START="0.05613325975269332" LOG_EFFECT_SIZE="0.5949402502050145" ORDER="232" O_E="0.0" SE="0.6329957866586224" STUDY_ID="STD-Wolff-1993" TOTAL_1="82" TOTAL_2="88" VAR="0.4006836659275683" WEIGHT="0.8683135098477781"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5307190435554525" CI_END="1.1563935595994508" CI_START="0.6325350057726253" DF="3.0" EFFECT_SIZE="0.8552540013917884" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="54" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="0.06310566425233122" LOG_CI_START="-0.1989154347478743" LOG_EFFECT_SIZE="-0.06790488524777158" NO="2" P_CHI2="0.6751987889003426" P_Z="0.3096860664723735" STUDIES="4" TAU2="0.0" TOTAL_1="143" TOTAL_2="145" WEIGHT="15.968105037692993" Z="1.0158810108635805">
<NAME>CMV-IVIG</NAME>
<DICH_DATA CI_END="4.5639184979939795" CI_START="0.21910996010107084" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.659337880227438" LOG_CI_START="-0.659337880227438" LOG_EFFECT_SIZE="0.0" ORDER="233" O_E="0.0" SE="0.7745966692414834" STUDY_ID="STD-Bordigoni-1987" TOTAL_1="30" TOTAL_2="30" VAR="0.6" WEIGHT="0.9000810772812333"/>
<DICH_DATA CI_END="1.763402512262695" CI_START="0.6283495873982091" EFFECT_SIZE="1.0526315789473684" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="19" LOG_CI_END="0.24635145518204069" LOG_CI_START="-0.20179866575973626" LOG_EFFECT_SIZE="0.02227639471115221" ORDER="234" O_E="0.0" SE="0.26324559942007597" STUDY_ID="STD-Bowden-1991" TOTAL_1="60" TOTAL_2="60" VAR="0.0692982456140351" WEIGHT="5.700513489447811"/>
<DICH_DATA CI_END="1.5214869439065046" CI_START="0.3476373043837393" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.1822682299681336" LOG_CI_START="-0.4588736263006965" LOG_EFFECT_SIZE="-0.13830269816628143" ORDER="235" O_E="0.0" SE="0.3766099000756842" STUDY_ID="STD-Ringden-1987" TOTAL_1="27" TOTAL_2="27" VAR="0.14183501683501684" WEIGHT="3.3002972833645225"/>
<DICH_DATA CI_END="1.0874345761561044" CI_START="0.4740058601283737" EFFECT_SIZE="0.717948717948718" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="21" LOG_CI_END="0.03640313774705149" LOG_CI_START="-0.32421628911561146" LOG_EFFECT_SIZE="-0.14390657568427997" ORDER="236" O_E="0.0" SE="0.21182963643408084" STUDY_ID="STD-Winston-1982" TOTAL_1="26" TOTAL_2="28" VAR="0.044871794871794865" WEIGHT="6.067213187599425"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.840442972183155" CI_END="1.140911144449711" CI_START="0.8156015029983261" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.964639230075537" ESTIMABLE="YES" EVENTS_1="191" EVENTS_2="172" I2="20.818447423666328" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.05725182235175046" LOG_CI_START="-0.08852198257109488" LOG_EFFECT_SIZE="-0.015635080109672198" METHOD="MH" NO="2" P_CHI2="0.26431566081088964" P_Q="0.0" P_Z="0.6741678148210706" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="633" TOTAL_2="545" WEIGHT="100.0" Z="0.4204348500963574">
<NAME>All-cause Mortality - 100d (3-4 mo)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.92297368532887" CI_END="1.2004906514139164" CI_START="0.8137710421283362" DF="4.0" EFFECT_SIZE="0.9883949253544496" ESTIMABLE="YES" EVENTS_1="154" EVENTS_2="129" I2="42.2213606202667" ID="CMP-003.02.01" LOG_CI_END="0.079358782422902" LOG_CI_START="-0.08949776848571968" LOG_EFFECT_SIZE="-0.005069493031408816" NO="1" P_CHI2="0.14001529457725204" P_Z="0.9063164813310526" STUDIES="5" TAU2="0.0" TOTAL_1="517" TOTAL_2="427" WEIGHT="76.19632463488377" Z="0.1176859731881535">
<NAME>Polyvalent IVIG</NAME>
<DICH_DATA CI_END="1.7431481714047472" CI_START="0.6296112326755309" EFFECT_SIZE="1.0476190476190477" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="14" LOG_CI_END="0.24133430465929537" LOG_CI_START="-0.2009275324827214" LOG_EFFECT_SIZE="0.02020338608828699" ORDER="237" O_E="0.0" SE="0.25978679236862195" STUDY_ID="STD-Cordonnier-2003" TOTAL_1="150" TOTAL_2="50" VAR="0.06748917748917749" WEIGHT="11.839196431597285"/>
<DICH_DATA CI_END="1.258328438015756" CI_START="0.40795117345534293" EFFECT_SIZE="0.7164750957854407" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="18" LOG_CI_END="0.09979401169835539" LOG_CI_START="-0.3893918133019193" LOG_EFFECT_SIZE="-0.14479890080178195" ORDER="238" O_E="0.0" SE="0.2873501751140487" STUDY_ID="STD-Poynton-1992" TOTAL_1="29" TOTAL_2="34" VAR="0.08257012313807446" WEIGHT="9.34249514330126"/>
<DICH_DATA CI_END="1.163219761020434" CI_START="0.7305092071417054" EFFECT_SIZE="0.921814919251474" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="94" LOG_CI_END="0.06566177146306576" LOG_CI_START="-0.13637430596426628" LOG_EFFECT_SIZE="-0.03535626725060022" ORDER="239" O_E="0.0" SE="0.11867699197552743" STUDY_ID="STD-Sullivan-2000" TOTAL_1="249" TOTAL_2="248" VAR="0.014084228424359403" WEIGHT="53.10112708210521"/>
<DICH_DATA CI_END="63.149196457537265" CI_START="0.1425196281959308" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8003678287428493" LOG_CI_START="-0.8461253193035243" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="240" O_E="0.0" SE="1.5545631755148024" STUDY_ID="STD-Ustun-1998" TOTAL_1="7" TOTAL_2="7" VAR="2.4166666666666665" WEIGHT="0.2818856293237449"/>
<DICH_DATA CI_END="13.606525523365265" CI_START="1.1379764111245112" EFFECT_SIZE="3.934959349593496" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" LOG_CI_END="1.1337472406573357" LOG_CI_START="0.05613325975269332" LOG_EFFECT_SIZE="0.5949402502050145" ORDER="241" O_E="0.0" SE="0.6329957866586224" STUDY_ID="STD-Wolff-1993" TOTAL_1="82" TOTAL_2="88" VAR="0.4006836659275683" WEIGHT="1.6316203485562646"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.450785002321229" CI_END="1.2360097945189255" CI_START="0.638832902234536" DF="2.0" EFFECT_SIZE="0.8885964912280702" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="43" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="0.0920219122484834" LOG_CI_START="-0.19461272420086778" LOG_EFFECT_SIZE="-0.05129540597619217" NO="2" P_CHI2="0.4841345882539799" P_Z="0.48299082389493087" STUDIES="3" TAU2="0.0" TOTAL_1="116" TOTAL_2="118" WEIGHT="23.803675365116234" Z="0.7015003457438922">
<NAME>CMV-IVIG</NAME>
<DICH_DATA CI_END="4.5639184979939795" CI_START="0.21910996010107084" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.659337880227438" LOG_CI_START="-0.659337880227438" LOG_EFFECT_SIZE="0.0" ORDER="242" O_E="0.0" SE="0.7745966692414834" STUDY_ID="STD-Bordigoni-1987" TOTAL_1="30" TOTAL_2="30" VAR="0.6" WEIGHT="1.6913137759424695"/>
<DICH_DATA CI_END="1.763402512262695" CI_START="0.6283495873982091" EFFECT_SIZE="1.0526315789473684" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="19" LOG_CI_END="0.24635145518204069" LOG_CI_START="-0.20179866575973626" LOG_EFFECT_SIZE="0.02227639471115221" ORDER="243" O_E="0.0" SE="0.26324559942007597" STUDY_ID="STD-Bowden-1991" TOTAL_1="60" TOTAL_2="60" VAR="0.0692982456140351" WEIGHT="10.711653914302305"/>
<DICH_DATA CI_END="1.0874345761561044" CI_START="0.4740058601283737" EFFECT_SIZE="0.717948717948718" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="21" LOG_CI_END="0.03640313774705149" LOG_CI_START="-0.32421628911561146" LOG_EFFECT_SIZE="-0.14390657568427997" ORDER="244" O_E="0.0" SE="0.21182963643408084" STUDY_ID="STD-Winston-1982" TOTAL_1="26" TOTAL_2="28" VAR="0.044871794871794865" WEIGHT="11.400707674871459"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="18.07265255702695" CI_END="1.0597754893290965" CI_START="0.7645890803709254" CI_STUDY="95" CI_TOTAL="95" DF="12.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9001626335200664" ESTIMABLE="YES" EVENTS_1="200" EVENTS_2="187" I2="33.601335154677116" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.025213870856534835" LOG_CI_START="-0.11657190873461513" LOG_EFFECT_SIZE="-0.04567901893904014" METHOD="MH" NO="3" P_CHI2="0.11350238258053769" P_Q="0.0" P_Z="0.20663223559418042" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="804" TOTAL_2="707" WEIGHT="100.0" Z="1.2628802723066592">
<NAME>CMV infection</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.080695275465663" CI_END="1.066430346801584" CI_START="0.6609937682730591" DF="5.0" EFFECT_SIZE="0.8395855010260268" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="96" I2="1.5882722952375279" ID="CMP-003.03.01" LOG_CI_END="0.02793249505260472" LOG_CI_START="-0.17980263494307513" LOG_EFFECT_SIZE="-0.07593506994523518" NO="1" P_CHI2="0.4061118943496991" P_Z="0.15189145758416947" STUDIES="6" TAU2="0.0" TOTAL_1="543" TOTAL_2="443" WEIGHT="54.3800925759714" Z="1.4328823657249112">
<NAME>Polyvalent IVIG</NAME>
<DICH_DATA CI_END="1.4080965589264984" CI_START="0.6140017241774663" EFFECT_SIZE="0.9298245614035088" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="19" LOG_CI_END="0.14863243717192903" LOG_CI_START="-0.21183040931533378" LOG_EFFECT_SIZE="-0.031598986071702355" ORDER="245" O_E="0.0" SE="0.21173766034648542" STUDY_ID="STD-Cordonnier-2003" TOTAL_1="150" TOTAL_2="50" VAR="0.04483283680900363" WEIGHT="14.700386687084967"/>
<DICH_DATA CI_END="2.371723402122864" CI_START="0.7210196475976105" EFFECT_SIZE="1.3076923076923077" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="13" LOG_CI_END="0.3750640388506784" LOG_CI_START="-0.14205290070780402" LOG_EFFECT_SIZE="0.11650556907143717" ORDER="246" O_E="0.0" SE="0.3037570500667868" STUDY_ID="STD-Emanuel-1992" TOTAL_1="46" TOTAL_2="46" VAR="0.09226834546527643" WEIGHT="6.705439541477354"/>
<DICH_DATA CI_END="1.0720598207282825" CI_START="0.08535554474734167" EFFECT_SIZE="0.3025" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="0.030219019580024386" LOG_CI_START="-1.068768261603049" LOG_EFFECT_SIZE="-0.5192746210115123" ORDER="247" O_E="0.0" SE="0.6455505690417155" STUDY_ID="STD-Feinstein-1999" TOTAL_1="120" TOTAL_2="121" VAR="0.4167355371900826" WEIGHT="5.136627800684854"/>
<DICH_DATA CI_END="1.1567742386182183" CI_START="0.5072949958791901" EFFECT_SIZE="0.7660455486542443" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="42" LOG_CI_END="0.0632486083127206" LOG_CI_START="-0.29473942168175477" LOG_EFFECT_SIZE="-0.11574540668451712" ORDER="248" O_E="0.0" SE="0.21028394088808292" STUDY_ID="STD-Sullivan-1990" TOTAL_1="184" TOTAL_2="185" VAR="0.044219335795422754" WEIGHT="21.605018460094637"/>
<DICH_DATA CI_END="1.5500603737061573" CI_START="0.4128871435309164" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.1903486139488756" LOG_CI_START="-0.3841686399649884" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="249" O_E="0.0" SE="0.3374742788552765" STUDY_ID="STD-Winston-1984" TOTAL_1="18" TOTAL_2="18" VAR="0.1138888888888889" WEIGHT="5.158030416521041"/>
<DICH_DATA CI_END="6.007403904090159" CI_START="0.1408928071947561" EFFECT_SIZE="0.92" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7786868324501918" LOG_CI_START="-0.8511111777590813" LOG_EFFECT_SIZE="-0.03621217265444471" ORDER="250" O_E="0.0" SE="0.9573514188271905" STUDY_ID="STD-Winston-1993" TOTAL_1="25" TOTAL_2="23" VAR="0.9165217391304348" WEIGHT="1.0745896701085502"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="12.634303730373198" CI_END="1.211511902327115" CI_START="0.7804360297932381" DF="6.0" EFFECT_SIZE="0.9723721196637771" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="91" I2="52.510244109646955" ID="CMP-003.03.02" LOG_CI_END="0.0833276851591182" LOG_CI_START="-0.10766268907353714" LOG_EFFECT_SIZE="-0.012167501957209477" NO="2" P_CHI2="0.04922516316792025" P_Z="0.8027973509385523" STUDIES="7" TAU2="0.0" TOTAL_1="261" TOTAL_2="264" WEIGHT="45.61990742402859" Z="0.24972845583202918">
<NAME>CMV-IVIG</NAME>
<DICH_DATA CI_END="4.5639184979939795" CI_START="0.21910996010107084" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.659337880227438" LOG_CI_START="-0.659337880227438" LOG_EFFECT_SIZE="0.0" ORDER="251" O_E="0.0" SE="0.7745966692414834" STUDY_ID="STD-Bordigoni-1987" TOTAL_1="30" TOTAL_2="30" VAR="0.6" WEIGHT="1.5474091249563124"/>
<DICH_DATA CI_END="1.438541147339936" CI_START="0.23819491243820237" EFFECT_SIZE="0.5853658536585366" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="0.15792228875474487" LOG_CI_START="-0.6230675187710039" LOG_EFFECT_SIZE="-0.23257261500812948" ORDER="252" O_E="0.0" SE="0.45875727890252144" STUDY_ID="STD-Bowden-1986" TOTAL_1="41" TOTAL_2="44" VAR="0.21045824094604582" WEIGHT="5.473580512590563"/>
<DICH_DATA CI_END="2.1917512963458234" CI_START="0.854374390199907" EFFECT_SIZE="1.368421052631579" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="19" LOG_CI_END="0.34079127209676224" LOG_CI_START="-0.06835177806078423" LOG_EFFECT_SIZE="0.136219747017989" ORDER="253" O_E="0.0" SE="0.2403326529533046" STUDY_ID="STD-Bowden-1991" TOTAL_1="60" TOTAL_2="60" VAR="0.057759784075573556" WEIGHT="9.800257791389978"/>
<DICH_DATA CI_END="1.4458876640404827" CI_START="0.40148268821311334" EFFECT_SIZE="0.7619047619047619" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="0.16013455244502747" LOG_CI_START="-0.39633317660101647" LOG_EFFECT_SIZE="-0.11809931207799451" ORDER="254" O_E="0.0" SE="0.3268718986013299" STUDY_ID="STD-Meyers-1983" TOTAL_1="30" TOTAL_2="32" VAR="0.1068452380952381" WEIGHT="6.988299273996249"/>
<DICH_DATA CI_END="1.6298671834140095" CI_START="0.8351055380230756" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="18" LOG_CI_END="0.21215221553245636" LOG_CI_START="-0.0782586362712299" LOG_EFFECT_SIZE="0.06694678963061322" ORDER="255" O_E="0.0" SE="0.17058877190638633" STUDY_ID="STD-Ringden-1987" TOTAL_1="27" TOTAL_2="27" VAR="0.0291005291005291" WEIGHT="9.284454749737874"/>
<DICH_DATA CI_END="14.003443300239491" CI_START="0.673668130553749" EFFECT_SIZE="3.0714285714285716" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.146234837280102" LOG_CI_START="-0.17155399747740463" LOG_EFFECT_SIZE="0.4873404199013485" ORDER="256" O_E="0.0" SE="0.7740756846964955" STUDY_ID="STD-Serrano-1999" TOTAL_1="49" TOTAL_2="43" VAR="0.5991931656383482" WEIGHT="1.0988847409110045"/>
<DICH_DATA CI_END="0.8946727275804478" CI_START="0.38033771153170703" EFFECT_SIZE="0.5833333333333334" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="24" LOG_CI_END="-0.04833580110740116" LOG_CI_START="-0.4198306109593347" LOG_EFFECT_SIZE="-0.23408320603336794" ORDER="257" O_E="0.0" SE="0.21821789023599242" STUDY_ID="STD-Winston-1982" TOTAL_1="24" TOTAL_2="28" VAR="0.04761904761904763" WEIGHT="11.427021230446615"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="13.674253570432896" CI_END="0.9500909109600201" CI_START="0.5465607214365048" CI_STUDY="95" CI_TOTAL="95" DF="11.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.720612499006626" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="99" I2="19.55685227466668" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="-0.02223483656455658" LOG_CI_START="-0.2623615820768035" LOG_EFFECT_SIZE="-0.14229820932068002" METHOD="MH" NO="4" P_CHI2="0.2515453319884987" P_Q="0.0" P_Z="0.02018266489467092" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="717" TOTAL_2="618" WEIGHT="100.00000000000003" Z="2.322934621365202">
<NAME>Interstitial Pneumonitis</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.045981204469275" CI_END="0.8906194408358926" CI_START="0.4549811516566809" DF="6.0" EFFECT_SIZE="0.6365650468564416" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="72" I2="14.84507514447821" ID="CMP-003.04.01" LOG_CI_END="-0.05030782912888998" LOG_CI_START="-0.34200659433420155" LOG_EFFECT_SIZE="-0.19615721173154577" NO="1" P_CHI2="0.3166160258814342" P_Z="0.008388617573326384" STUDIES="7" TAU2="0.0" TOTAL_1="543" TOTAL_2="447" WEIGHT="73.1459532050493" Z="2.6360143830641545">
<NAME>Polyvalent IVIG</NAME>
<DICH_DATA CI_END="5.191402094443973" CI_START="0.4661078148828928" EFFECT_SIZE="1.5555555555555556" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="3" LOG_CI_END="0.7152846679917867" LOG_CI_START="-0.33151361551396036" LOG_EFFECT_SIZE="0.19188552623891314" ORDER="258" O_E="0.0" SE="0.6148944934663492" STUDY_ID="STD-Cordonnier-2003" TOTAL_1="150" TOTAL_2="50" VAR="0.3780952380952381" WEIGHT="4.467227621584495"/>
<DICH_DATA CI_END="3.2229063532708806" CI_START="0.3102789502354341" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.508247686570799" LOG_CI_START="-0.508247686570799" LOG_EFFECT_SIZE="0.0" ORDER="259" O_E="0.0" SE="0.5970944139166224" STUDY_ID="STD-Emanuel-1992" TOTAL_1="46" TOTAL_2="46" VAR="0.35652173913043483" WEIGHT="4.963586246204995"/>
<DICH_DATA CI_END="0.9479000001178588" CI_START="0.3330386636908239" EFFECT_SIZE="0.5618606138107417" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="34" LOG_CI_END="-0.023237476678540606" LOG_CI_START="-0.4775053447133569" LOG_EFFECT_SIZE="-0.25037141069594876" ORDER="260" O_E="0.0" SE="0.2668391943458639" STUDY_ID="STD-Sullivan-1990" TOTAL_1="184" TOTAL_2="185" VAR="0.07120315563914972" WEIGHT="33.66091659215009"/>
<DICH_DATA CI_END="1.042546606978355" CI_START="0.15347035703634673" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.018095479186391133" LOG_CI_START="-0.8139754965304663" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="261" O_E="0.0" SE="0.4887626099538393" STUDY_ID="STD-Winston-1984" TOTAL_1="18" TOTAL_2="18" VAR="0.23888888888888885" WEIGHT="9.92717249240999"/>
<DICH_DATA CI_END="0.8529126852017203" CI_START="0.18846465705144" EFFECT_SIZE="0.40092879256965946" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="17" LOG_CI_END="-0.0690954263659058" LOG_CI_START="-0.7247700814617587" LOG_EFFECT_SIZE="-0.3969327539138322" ORDER="262" O_E="0.0" SE="0.3851465380451917" STUDY_ID="STD-Winston-1987" TOTAL_1="38" TOTAL_2="37" VAR="0.14833785576819633" WEIGHT="17.101209146924944"/>
<DICH_DATA CI_END="7.533035597908136" CI_START="0.25280645169509575" EFFECT_SIZE="1.38" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8769700197276257" LOG_CI_START="-0.5972118469251526" LOG_EFFECT_SIZE="0.13987908640123647" ORDER="263" O_E="0.0" SE="0.8659417257897716" STUDY_ID="STD-Winston-1993" TOTAL_1="25" TOTAL_2="23" VAR="0.749855072463768" WEIGHT="2.068160935918748"/>
<DICH_DATA CI_END="23.226535498709673" CI_START="0.19834131861072427" EFFECT_SIZE="2.1463414634146343" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.365984434681748" LOG_CI_START="-0.7025868038208817" LOG_EFFECT_SIZE="0.33169881543043317" ORDER="264" O_E="0.0" SE="1.2150889850892173" STUDY_ID="STD-Wolff-1993" TOTAL_1="82" TOTAL_2="88" VAR="1.476441241685144" WEIGHT="0.9576801698560226"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.174515288961075" CI_END="1.5550811613719815" CI_START="0.5797982697948157" DF="4.0" EFFECT_SIZE="0.9495437676874023" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="27" I2="22.69807360443399" ID="CMP-003.04.02" LOG_CI_END="0.1917530602542809" LOG_CI_START="-0.2367230849790987" LOG_EFFECT_SIZE="-0.02248501236240891" NO="2" P_CHI2="0.26985534418567103" P_Z="0.8370214559909649" STUDIES="5" TAU2="0.0" TOTAL_1="174" TOTAL_2="171" WEIGHT="26.854046794950726" Z="0.20570486787896058">
<NAME>CMV-IVIG</NAME>
<DICH_DATA CI_END="2.1876520922627805" CI_START="0.37311302308189653" EFFECT_SIZE="0.9034608378870674" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.3399782562243235" LOG_CI_START="-0.4281595921441123" LOG_EFFECT_SIZE="-0.04409066795989443" ORDER="265" O_E="0.0" SE="0.451207974475292" STUDY_ID="STD-Bowden-1991" TOTAL_1="61" TOTAL_2="62" VAR="0.20358863623009577" WEIGHT="8.861817395663554"/>
<DICH_DATA CI_END="4.521215975389076" CI_START="0.22117943611706017" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6552552534796292" LOG_CI_START="-0.6552552534796292" LOG_EFFECT_SIZE="0.0" ORDER="266" O_E="0.0" SE="0.769800358919501" STUDY_ID="STD-Ringden-1987" TOTAL_1="27" TOTAL_2="27" VAR="0.5925925925925926" WEIGHT="2.978151747722997"/>
<DICH_DATA CI_END="22.62194860474717" CI_START="0.23541048032726553" EFFECT_SIZE="2.3076923076923075" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.354530011369287" LOG_CI_START="-0.6281742065436359" LOG_EFFECT_SIZE="0.36317790241282566" ORDER="267" O_E="0.0" SE="1.1646502721462166" STUDY_ID="STD-Ruutu-1997" TOTAL_1="13" TOTAL_2="15" VAR="1.3564102564102565" WEIGHT="0.9218088742952134"/>
<DICH_DATA CI_END="8.2674362904401" CI_START="0.6623863264041151" EFFECT_SIZE="2.3401360544217686" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.9173708568888046" LOG_CI_START="-0.1788886412420966" LOG_EFFECT_SIZE="0.369241107823354" ORDER="268" O_E="0.0" SE="0.6439482557741257" STUDY_ID="STD-Serrano-1999" TOTAL_1="49" TOTAL_2="43" VAR="0.4146693561145388" WEIGHT="3.172379035617975"/>
<DICH_DATA CI_END="1.1101683716543946" CI_START="0.18610831971373606" EFFECT_SIZE="0.45454545454545453" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="0.04538885025972793" LOG_CI_START="-0.7302342119041405" LOG_EFFECT_SIZE="-0.3424226808222063" ORDER="269" O_E="0.0" SE="0.455604826111135" STUDY_ID="STD-Winston-1982" TOTAL_1="24" TOTAL_2="24" VAR="0.20757575757575758" WEIGHT="10.919889741650989"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.328264506891146" CI_END="1.116497116378225" CI_START="0.3863281997269702" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6567604745801571" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="0.047857605739170105" LOG_CI_START="-0.4130435897096352" LOG_EFFECT_SIZE="-0.18259299198523252" METHOD="MH" NO="5" P_CHI2="0.503184542062286" P_Q="0.0" P_Z="0.12043774226516817" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="254" TOTAL_2="255" WEIGHT="100.0" Z="1.5529388582816888">
<NAME>Infection-related Mortality</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.519189638523394" CI_END="1.4914842096109595" CI_START="0.2766812431267061" DF="2.0" EFFECT_SIZE="0.6423906173186319" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" I2="43.1687346965714" ID="CMP-003.05.01" LOG_CI_END="0.17361865983342947" LOG_CI_START="-0.5580202817071924" LOG_EFFECT_SIZE="-0.19220081093688143" NO="1" P_CHI2="0.17211463615166966" P_Z="0.30312217163126365" STUDIES="3" TAU2="0.0" TOTAL_1="137" TOTAL_2="138" WEIGHT="40.80644236831547" Z="1.0297611180794821">
<NAME>Polyvalent IVIG</NAME>
<DICH_DATA CI_END="2.1025707802411278" CI_START="0.14763268194458018" EFFECT_SIZE="0.5571428571428572" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.3227506246605525" LOG_CI_START="-0.8308174906360677" LOG_EFFECT_SIZE="-0.2540334329877576" ORDER="270" O_E="0.0" SE="0.6776116211794992" STUDY_ID="STD-Lum-1994" TOTAL_1="28" TOTAL_2="26" VAR="0.4591575091575092" WEIGHT="17.051642116123116"/>
<DICH_DATA CI_END="1.4165296650786792" CI_START="0.022311525872526987" EFFECT_SIZE="0.17777777777777778" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.15122567398181586" LOG_CI_START="-1.651470727548616" LOG_EFFECT_SIZE="-0.7501225267834001" ORDER="271" O_E="0.0" SE="1.0589127897500796" STUDY_ID="STD-Winston-1993" TOTAL_1="27" TOTAL_2="24" VAR="1.1212962962962962" WEIGHT="17.40986989167192"/>
<DICH_DATA CI_END="11.407509778352972" CI_START="0.40383762688634794" EFFECT_SIZE="2.1463414634146343" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0571908497158287" LOG_CI_START="-0.3937932188549624" LOG_EFFECT_SIZE="0.33169881543043317" ORDER="272" O_E="0.0" SE="0.8523152243654598" STUDY_ID="STD-Wolff-1993" TOTAL_1="82" TOTAL_2="88" VAR="0.7264412416851441" WEIGHT="6.344930360520434"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8131764046270815" CI_END="1.3201196615177686" CI_START="0.33666981668423723" DF="2.0" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="18" I2="0.0" ID="CMP-003.05.02" LOG_CI_END="0.12061329937363115" LOG_CI_START="-0.47279581748499366" LOG_EFFECT_SIZE="-0.17609125905568127" NO="2" P_CHI2="0.6659186131039674" P_Z="0.24474048015009142" STUDIES="3" TAU2="0.0" TOTAL_1="117" TOTAL_2="117" WEIGHT="59.19355763168453" Z="1.1632194920378116">
<NAME>CMV-IVIG</NAME>
<DICH_DATA CI_END="4.5639184979939795" CI_START="0.21910996010107084" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.659337880227438" LOG_CI_START="-0.659337880227438" LOG_EFFECT_SIZE="0.0" ORDER="273" O_E="0.0" SE="0.7745966692414834" STUDY_ID="STD-Bordigoni-1987" TOTAL_1="30" TOTAL_2="30" VAR="0.6" WEIGHT="9.865592938614089"/>
<DICH_DATA CI_END="2.03094066338857" CI_START="0.2769652556276479" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.30769723510379193" LOG_CI_START="-0.5575747083203917" LOG_EFFECT_SIZE="-0.12493873660829993" ORDER="274" O_E="0.0" SE="0.5082650227325635" STUDY_ID="STD-Bowden-1991" TOTAL_1="60" TOTAL_2="60" VAR="0.2583333333333333" WEIGHT="26.308247836304236"/>
<DICH_DATA CI_END="1.4852263972650719" CI_START="0.1236669841890606" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.17179265943688432" LOG_CI_START="-0.9077462300260731" LOG_EFFECT_SIZE="-0.36797678529459443" ORDER="275" O_E="0.0" SE="0.6341264874742278" STUDY_ID="STD-Ringden-1987" TOTAL_1="27" TOTAL_2="27" VAR="0.4021164021164021" WEIGHT="23.019716856766205"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.347631910932444" CI_END="1.053383545781829" CI_START="0.8425229478748983" CI_STUDY="95" CI_TOTAL="95" DF="11.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.942072083354039" ESTIMABLE="YES" EVENTS_1="321" EVENTS_2="290" I2="10.914092035244968" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="0.02258653024325178" LOG_CI_START="-0.07441826137684424" LOG_EFFECT_SIZE="-0.025915865566796245" METHOD="MH" NO="6" P_CHI2="0.3380881567918671" P_Q="0.0" P_Z="0.29498402838221505" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="718" TOTAL_2="613" WEIGHT="100.0" Z="1.0472506005276465">
<NAME>Acute GVHD</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="10.902617618901552" CI_END="1.0444262595715519" CI_START="0.8269627770285627" DF="6.0" EFFECT_SIZE="0.9293554971144492" ESTIMABLE="YES" EVENTS_1="277" EVENTS_2="247" I2="44.967344451318056" ID="CMP-003.06.01" LOG_CI_END="0.018877782572252158" LOG_CI_START="-0.08251403832522" LOG_EFFECT_SIZE="-0.03181812787648393" NO="1" P_CHI2="0.09143326518948847" P_Z="0.2186497479004239" STUDIES="7" TAU2="0.0" TOTAL_1="545" TOTAL_2="444" WEIGHT="85.82304504156886" Z="1.2301265356790367">
<NAME>Polyvalent IVIG</NAME>
<DICH_DATA CI_END="1.1756305614022722" CI_START="0.6352653604555504" EFFECT_SIZE="0.8641975308641975" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="27" LOG_CI_END="0.07027086735961569" LOG_CI_START="-0.1970448250884016" LOG_EFFECT_SIZE="-0.06338697886439294" ORDER="276" O_E="0.0" SE="0.15702256097798384" STUDY_ID="STD-Cordonnier-2003" TOTAL_1="150" TOTAL_2="50" VAR="0.02465608465608465" WEIGHT="13.344039668921"/>
<DICH_DATA CI_END="1.0368240423622626" CI_START="0.731416965135806" EFFECT_SIZE="0.8708333333333333" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="88" LOG_CI_END="0.015705059267452543" LOG_CI_START="-0.13583497046855658" LOG_EFFECT_SIZE="-0.06006495560055201" ORDER="277" O_E="0.0" SE="0.089015363602177" STUDY_ID="STD-Feinstein-1999" TOTAL_1="120" TOTAL_2="121" VAR="0.007923734957227778" WEIGHT="28.874147616168386"/>
<DICH_DATA CI_END="2.7408529251926943" CI_START="0.5200365162717657" EFFECT_SIZE="1.1938775510204083" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.43788573182153046" LOG_CI_START="-0.2839661597141969" LOG_EFFECT_SIZE="0.07695978605366682" ORDER="278" O_E="0.0" SE="0.4240193743125776" STUDY_ID="STD-Lum-1994" TOTAL_1="28" TOTAL_2="26" VAR="0.1797924297924298" WEIGHT="2.3917986054947566"/>
<DICH_DATA CI_END="1.401990695259398" CI_START="0.9336724913275977" EFFECT_SIZE="1.1441154422788606" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="87" LOG_CI_END="0.14674513131187475" LOG_CI_START="-0.029805436567057274" LOG_EFFECT_SIZE="0.05846984737240875" ORDER="279" O_E="0.0" SE="0.10370667751149037" STUDY_ID="STD-Sullivan-1990" TOTAL_1="184" TOTAL_2="185" VAR="0.010755074960472264" WEIGHT="28.58729124695873"/>
<DICH_DATA CI_END="4.334593955143529" CI_START="0.05767552914693294" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6369484210048898" LOG_CI_START="-1.2390084123328524" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="280" O_E="0.0" SE="1.1019463300386796" STUDY_ID="STD-Ustun-1998" TOTAL_1="7" TOTAL_2="7" VAR="1.2142857142857144" WEIGHT="0.6589649219220247"/>
<DICH_DATA CI_END="1.3206325080361108" CI_START="0.425932268497982" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.12078198344656102" LOG_CI_START="-0.37065945666316086" LOG_EFFECT_SIZE="-0.12493873660829993" ORDER="281" O_E="0.0" SE="0.28867513459481287" STUDY_ID="STD-Winston-1984" TOTAL_1="18" TOTAL_2="18" VAR="0.08333333333333331" WEIGHT="3.9537895315321485"/>
<DICH_DATA CI_END="0.8701151238792503" CI_START="0.31968610382828855" EFFECT_SIZE="0.5274122807017544" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="24" LOG_CI_END="-0.06042328260232113" LOG_CI_START="-0.49527624130684766" LOG_EFFECT_SIZE="-0.2778497619545844" ORDER="282" O_E="0.0" SE="0.2554347804999005" STUDY_ID="STD-Winston-1987" TOTAL_1="38" TOTAL_2="37" VAR="0.06524692708903235" WEIGHT="8.01301345057182"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.1734143622317958" CI_END="1.43734073327429" CI_START="0.7224953941589547" DF="4.0" EFFECT_SIZE="1.0190544929628294" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="43" I2="0.0" ID="CMP-003.06.02" LOG_CI_END="0.15755973336712592" LOG_CI_START="-0.14116491714958246" LOG_EFFECT_SIZE="0.008197408108771747" NO="2" P_CHI2="0.8824560859667294" P_Z="0.9143382860775949" STUDIES="5" TAU2="0.0" TOTAL_1="173" TOTAL_2="169" WEIGHT="14.176954958431136" Z="0.10756812088977957">
<NAME>CMV-IVIG</NAME>
<DICH_DATA CI_END="2.676841393350012" CI_START="0.37357461763863437" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.4276226393850946" LOG_CI_START="-0.4276226393850946" LOG_EFFECT_SIZE="0.0" ORDER="283" O_E="0.0" SE="0.5023753102820165" STUDY_ID="STD-Bowden-1991" TOTAL_1="60" TOTAL_2="60" VAR="0.2523809523809524" WEIGHT="2.3063772267270863"/>
<DICH_DATA CI_END="1.5420084873859228" CI_START="0.464314131353907" EFFECT_SIZE="0.8461538461538461" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" LOG_CI_END="0.18808676412656455" LOG_CI_START="-0.333188098423788" LOG_EFFECT_SIZE="-0.07255066714861173" ORDER="284" O_E="0.0" SE="0.3061994346142621" STUDY_ID="STD-Ringden-1987" TOTAL_1="27" TOTAL_2="27" VAR="0.09375809375809377" WEIGHT="4.283271992493161"/>
<DICH_DATA CI_END="2.9911052174958446" CI_START="0.6058396631837345" EFFECT_SIZE="1.3461538461538463" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.4758316903880975" LOG_CI_START="-0.21764229762918205" LOG_EFFECT_SIZE="0.1290946963794577" ORDER="285" O_E="0.0" SE="0.4073500533129534" STUDY_ID="STD-Ruutu-1997" TOTAL_1="13" TOTAL_2="15" VAR="0.16593406593406596" WEIGHT="1.835687996782783"/>
<DICH_DATA CI_END="3.0065928499956365" CI_START="0.5227259381679017" EFFECT_SIZE="1.2536443148688046" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.47807462032789877" LOG_CI_START="-0.28172594925426675" LOG_EFFECT_SIZE="0.098174335536816" ORDER="286" O_E="0.0" SE="0.4463106156460413" STUDY_ID="STD-Serrano-1999" TOTAL_1="49" TOTAL_2="43" VAR="0.19919316563834838" WEIGHT="2.4567931328179835"/>
<DICH_DATA CI_END="1.8134816410046115" CI_START="0.4466546457847158" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.2585131633072724" LOG_CI_START="-0.35002814442862273" LOG_EFFECT_SIZE="-0.045757490560675115" ORDER="287" O_E="0.0" SE="0.3574601764921203" STUDY_ID="STD-Winston-1982" TOTAL_1="24" TOTAL_2="24" VAR="0.1277777777777778" WEIGHT="3.2948246096101235"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.769582141371091" CI_END="19.775618984706238" CI_START="3.253102834003924" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="RR" EFFECT_SIZE="8.020730774893872" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="1.2961300859717444" LOG_CI_START="0.5122977920044389" LOG_EFFECT_SIZE="0.9042139389880915" METHOD="MH" NO="7" P_CHI2="0.7354573970214495" P_Q="0.0" P_Z="6.127140180825551E-6" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="442" TOTAL_2="340" WEIGHT="100.0" Z="4.521953913804116">
<NAME>Adverse Events</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.7826306494346964" CI_END="20.96979314178891" CI_START="3.146032219814102" DF="4.0" EFFECT_SIZE="8.122293079352943" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="2" I2="0.0" ID="CMP-003.07.01" LOG_CI_END="1.3215941463536263" LOG_CI_START="0.4977631660990349" LOG_EFFECT_SIZE="0.9096786562263307" NO="1" P_CHI2="0.5948349436660892" P_Z="1.5019253483374046E-5" STUDIES="5" TAU2="0.0" TOTAL_1="415" TOTAL_2="313" WEIGHT="90.95046504985781" Z="4.328405817313192">
<NAME>Polyvalent IVIG</NAME>
<DICH_DATA CI_END="13.761098541212323" CI_START="0.8074290782698115" EFFECT_SIZE="3.3333333333333335" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="2" LOG_CI_END="1.1386531047819934" LOG_CI_START="-0.09289561422131816" LOG_EFFECT_SIZE="0.5228787452803376" ORDER="288" O_E="0.0" SE="0.7234178138070235" STUDY_ID="STD-Cordonnier-2003" TOTAL_1="150" TOTAL_2="50" VAR="0.5233333333333333" WEIGHT="54.29720970085311"/>
<DICH_DATA CI_END="485.1818815553855" CI_START="1.7521603689061844" EFFECT_SIZE="29.156756756756756" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="0" LOG_CI_END="2.6859045743721146" LOG_CI_START="0.2435738530556026" LOG_EFFECT_SIZE="1.4647392137138586" ORDER="289" O_E="0.0" SE="1.4346371554333703" STUDY_ID="STD-Sullivan-1990" TOTAL_1="184" TOTAL_2="185" VAR="2.0581837677499526" WEIGHT="9.02514267264854"/>
<DICH_DATA CI_END="155.8552614005574" CI_START="0.5197129649144481" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.192721467881129" LOG_CI_START="-0.2842364490024794" LOG_EFFECT_SIZE="0.9542425094393249" ORDER="290" O_E="0.0" SE="1.4549773415168654" STUDY_ID="STD-Winston-1984" TOTAL_1="18" TOTAL_2="18" VAR="2.116959064327485" WEIGHT="9.049534950142185"/>
<DICH_DATA CI_END="307.0366023917386" CI_START="1.1162334414534598" EFFECT_SIZE="18.512820512820515" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" LOG_CI_END="2.487190151598393" LOG_CI_START="0.04775502948788675" LOG_EFFECT_SIZE="1.2674725905431399" ORDER="291" O_E="0.0" SE="1.4329362661263156" STUDY_ID="STD-Winston-1987" TOTAL_1="38" TOTAL_2="37" VAR="2.053306342780027" WEIGHT="9.167061378066109"/>
<DICH_DATA CI_END="91.34475988701922" CI_START="0.23320193927135308" EFFECT_SIZE="4.615384615384615" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9606836385257036" LOG_CI_START="-0.6322678423720901" LOG_EFFECT_SIZE="0.6642078980768068" ORDER="292" O_E="0.0" SE="1.5231125351961998" STUDY_ID="STD-Winston-1993" TOTAL_1="25" TOTAL_2="23" VAR="2.319871794871795" WEIGHT="9.411516348147872"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="129.33809770163077" CI_START="0.37885202326879575" DF="0.0" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-003.07.02" LOG_CI_END="2.111726469076227" LOG_CI_START="-0.4215303890477134" LOG_EFFECT_SIZE="0.8450980400142568" NO="2" P_CHI2="1.0" P_Z="0.19097730008968364" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="27" WEIGHT="9.049534950142185" Z="1.307693467025676">
<NAME>CMV-IVIG</NAME>
<DICH_DATA CI_END="129.33809770163077" CI_START="0.37885202326879575" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.111726469076227" LOG_CI_START="-0.4215303890477134" LOG_EFFECT_SIZE="0.8450980400142568" ORDER="293" O_E="0.0" SE="1.4880476182856899" STUDY_ID="STD-Ringden-1987" TOTAL_1="27" TOTAL_2="27" VAR="2.2142857142857144" WEIGHT="9.049534950142185"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2008-07-21 22:43:21 +0200" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Polyvalent immunoglobulins vs. hyperimmune CMV-IVIG - HSCT</NAME>
<DICH_OUTCOME CHI2="3.260695804604645E-4" CI_END="2.316842942515391" CI_START="0.9233628774393544" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4626300851466416" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.3648965942082808" LOG_CI_START="-0.034627589658521016" LOG_EFFECT_SIZE="0.16513450227487989" METHOD="MH" NO="1" P_CHI2="0.9855930649072308" P_Q="0.0" P_Z="0.1051859506119248" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="105" TOTAL_2="107" WEIGHT="100.00000000000001" Z="1.6202156972385788">
<NAME>All-cause Mortality</NAME>
<GROUP_LABEL_1>Polyvalent IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>CMV-IVIG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="294" O_E="0.0" SE="0.0" STUDY_ID="STD-Condie-1984" TOTAL_1="18" TOTAL_2="17" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.2767023932930264" CI_START="0.6446781699480653" EFFECT_SIZE="1.453416149068323" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.5154369983491257" LOG_CI_START="-0.19065703559253944" LOG_EFFECT_SIZE="0.16238998137829314" ORDER="295" O_E="0.0" SE="0.4147631307591723" STUDY_ID="STD-Jacobsen-1985" TOTAL_1="23" TOTAL_2="26" VAR="0.17202845463715027" WEIGHT="30.4635761589404"/>
<DICH_DATA CI_END="2.5609138024420175" CI_START="0.8399779442243898" EFFECT_SIZE="1.4666666666666666" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="15" LOG_CI_END="0.40839496083711735" LOG_CI_START="-0.0757321173040674" LOG_EFFECT_SIZE="0.16633142176652496" ORDER="296" O_E="0.0" SE="0.28437864216781844" STUDY_ID="STD-Zikos-1998" TOTAL_1="64" TOTAL_2="64" VAR="0.08087121212121212" WEIGHT="69.53642384105962"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.7885787671209026" CI_START="0.8855363112628108" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5714285714285714" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.4453829162268381" LOG_CI_START="-0.052793625938901696" LOG_EFFECT_SIZE="0.1962946451439682" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.12245403489666065" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="64" TOTAL_2="64" WEIGHT="100.0" Z="1.5445545997316381">
<NAME>Clinically documented Infection</NAME>
<GROUP_LABEL_1>Polyvalent IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>CMV-IVIG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.7885787671209026" CI_START="0.8855363112628108" EFFECT_SIZE="1.5714285714285714" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="14" LOG_CI_END="0.4453829162268381" LOG_CI_START="-0.052793625938901696" LOG_EFFECT_SIZE="0.1962946451439682" ORDER="297" O_E="0.0" SE="0.2926313668818107" STUDY_ID="STD-Zikos-1998" TOTAL_1="64" TOTAL_2="64" VAR="0.08563311688311688" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.124358689512011" CI_END="1.8858678692049344" CI_START="1.0727208755075506" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4223255013340217" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="38" I2="71.9272977798793" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.27551126120862957" LOG_CI_START="0.030486732220730912" LOG_EFFECT_SIZE="0.15299899671468023" METHOD="MH" NO="3" P_CHI2="0.028376960603284984" P_Q="0.0" P_Z="0.014377373943877642" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="105" TOTAL_2="107" WEIGHT="100.0" Z="2.4476939061586407">
<NAME>CMV Infection</NAME>
<GROUP_LABEL_1>Polyvalent IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>CMV-IVIG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="203.19187778380652" CI_START="0.7464799873619702" EFFECT_SIZE="12.31578947368421" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.307906343847246" LOG_CI_START="-0.1269818309326178" LOG_EFFECT_SIZE="1.0904622564573139" ORDER="298" O_E="0.0" SE="1.4302653667565435" STUDY_ID="STD-Condie-1984" TOTAL_1="18" TOTAL_2="17" VAR="2.04565901934323" WEIGHT="1.335456292853659"/>
<DICH_DATA CI_END="52.23060500295229" CI_START="0.8807820762508144" EFFECT_SIZE="6.782608695652174" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.7179250564309425" LOG_CI_START="-0.05513153175720511" LOG_EFFECT_SIZE="0.8313967623368688" ORDER="299" O_E="0.0" SE="1.0415022166733794" STUDY_ID="STD-Jacobsen-1985" TOTAL_1="23" TOTAL_2="26" VAR="1.084726867335563" WEIGHT="2.4414034483747886"/>
<DICH_DATA CI_END="1.4933956770400967" CI_START="0.8628200783144928" EFFECT_SIZE="1.135135135135135" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="37" LOG_CI_END="0.1741748898338407" LOG_CI_START="-0.06407975717202985" LOG_EFFECT_SIZE="0.05504756633090544" ORDER="300" O_E="0.0" SE="0.13995195903077182" STUDY_ID="STD-Zikos-1998" TOTAL_1="64" TOTAL_2="64" VAR="0.019586550836550837" WEIGHT="96.22314025877155"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.03694376868737809" CI_END="1.7515481280057232" CI_START="0.3971674922394066" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8340611353711791" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="0.24342207510512162" LOG_CI_START="-0.4010263052894425" LOG_EFFECT_SIZE="-0.07880211509216042" METHOD="MH" NO="4" P_CHI2="0.8475796509045118" P_Q="0.0" P_Z="0.6317092127613471" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="82" TOTAL_2="81" WEIGHT="100.0" Z="0.4793225095597353">
<NAME>Interstitial Pneumonitis</NAME>
<GROUP_LABEL_1>Polyvalent IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>CMV-IVIG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.0528059593900325" CI_START="0.22008833326336258" EFFECT_SIZE="0.9444444444444444" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6077558110489953" LOG_CI_START="-0.6574029784990596" LOG_EFFECT_SIZE="-0.024823583725032152" ORDER="301" O_E="0.0" SE="0.7431605356175383" STUDY_ID="STD-Condie-1984" TOTAL_1="18" TOTAL_2="17" VAR="0.5522875816993463" WEIGHT="23.580786026200876"/>
<DICH_DATA CI_END="1.895674329555127" CI_START="0.33761073303672046" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.277763729085581" LOG_CI_START="-0.4715837551016938" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="302" O_E="0.0" SE="0.44017042154147523" STUDY_ID="STD-Zikos-1998" TOTAL_1="64" TOTAL_2="64" VAR="0.19375" WEIGHT="76.41921397379913"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.22930927759209077" CI_END="11.258847565796435" CI_START="0.9535682592129671" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.2765957446808507" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="1.051493939233854" LOG_CI_START="-0.020648213432362943" LOG_EFFECT_SIZE="0.5154228629007456" METHOD="MH" NO="5" P_CHI2="0.6320364834839314" P_Q="0.0" P_Z="0.059501331522482055" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="87" TOTAL_2="90" WEIGHT="100.0" Z="1.8844707216888794">
<NAME>Infection-related Mortality</NAME>
<GROUP_LABEL_1>Polyvalent IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>CMV-IVIG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="17.17180605207287" CI_START="0.9116143185371036" EFFECT_SIZE="3.9565217391304346" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.2348159746717036" LOG_CI_START="-0.04018886206470204" LOG_EFFECT_SIZE="0.5973135563035007" ORDER="303" O_E="0.0" SE="0.748944152474695" STUDY_ID="STD-Jacobsen-1985" TOTAL_1="23" TOTAL_2="26" VAR="0.5609173435260392" WEIGHT="65.2482269503546"/>
<DICH_DATA CI_END="21.50889698600391" CI_START="0.18596955495220638" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3326181395750694" LOG_CI_START="-0.730558148247107" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="304" O_E="0.0" SE="1.2119199643540823" STUDY_ID="STD-Zikos-1998" TOTAL_1="64" TOTAL_2="64" VAR="1.46875" WEIGHT="34.75177304964539"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.3741203842976732" CI_END="1.7473035119287283" CI_START="0.8693372912036493" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.232475598935226" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-004.06" LOG_CI_END="0.24236834980661043" LOG_CI_START="-0.060811690423592524" LOG_EFFECT_SIZE="0.09077832969150895" METHOD="MH" NO="6" P_CHI2="0.5407671214446368" P_Q="0.0" P_Z="0.24051245505416474" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="82" TOTAL_2="81" WEIGHT="99.99999999999999" Z="1.1737069276523957">
<NAME>Acute GVHD</NAME>
<GROUP_LABEL_1>Polyvalent IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>CMV-IVIG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.921339362494975" CI_START="0.753980497196565" EFFECT_SIZE="1.4841269841269842" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" LOG_CI_END="0.46558201048196607" LOG_CI_START="-0.12263988764409389" LOG_EFFECT_SIZE="0.17147106141893606" ORDER="305" O_E="0.0" SE="0.34552445470460336" STUDY_ID="STD-Condie-1984" TOTAL_1="18" TOTAL_2="17" VAR="0.1193871487989135" WEIGHT="22.360248447204967"/>
<DICH_DATA CI_END="1.7435884115204943" CI_START="0.7717417660665518" EFFECT_SIZE="1.16" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="25" LOG_CI_END="0.24144397388692426" LOG_CI_START="-0.11252799543308734" LOG_EFFECT_SIZE="0.06445798922691845" ORDER="306" O_E="0.0" SE="0.20792488696808192" STUDY_ID="STD-Zikos-1998" TOTAL_1="64" TOTAL_2="64" VAR="0.04323275862068965" WEIGHT="77.63975155279502"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2008-08-11 15:34:16 +0200" MODIFIED_BY="Nicole Skoetz" NO="5">
<NAME>Polyvalent immunoglobulins 250mg/kg vs. Polyvalent immunoglobulins or hyperimmune CMV-IVIG 500mg/kg - HSCT</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2454363322624353" CI_START="0.8366818078262379" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0208006279434851" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="98" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.09532153094611263" LOG_CI_START="-0.07743967388099278" LOG_EFFECT_SIZE="0.008940928532559933" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.8392378639998933" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="208" TOTAL_2="204" WEIGHT="100.0" Z="0.20286843831288917">
<NAME>All-cause Mortality</NAME>
<GROUP_LABEL_1>Polyvalent IVIG 250</GROUP_LABEL_1>
<GROUP_LABEL_2>Polyvalent IVIG 500</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2454363322624353" CI_START="0.8366818078262379" EFFECT_SIZE="1.0208006279434851" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="98" LOG_CI_END="0.09532153094611263" LOG_CI_START="-0.07743967388099278" LOG_EFFECT_SIZE="0.008940928532559933" ORDER="307" O_E="0.0" SE="0.10148078689719782" STUDY_ID="STD-Winston-2001" TOTAL_1="208" TOTAL_2="204" VAR="0.010298350109274476" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.22633156176542907" CI_END="0.9720586997565199" CI_START="0.80798027768896" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8862303640472055" ESTIMABLE="YES" EVENTS_1="188" EVENTS_2="208" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="-0.012307508519602741" LOG_CI_START="-0.09259923996228389" LOG_EFFECT_SIZE="-0.052453374240943325" METHOD="MH" NO="2" P_CHI2="0.6342573826676012" P_Q="0.0" P_Z="0.010442253590617016" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="257" TOTAL_2="252" WEIGHT="100.0" Z="2.5608296777917126">
<NAME>Clinically documented Infection</NAME>
<GROUP_LABEL_1>Polyvalent IVIG 250</GROUP_LABEL_1>
<GROUP_LABEL_2>Polyvalent IVIG 500</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.047116440589004" CI_START="0.7983050737669" EFFECT_SIZE="0.9142857142857143" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="45" LOG_CI_END="0.01999497842523714" LOG_CI_START="-0.09783111048597654" LOG_EFFECT_SIZE="-0.03891806603036967" ORDER="308" O_E="0.0" SE="0.06921162787499353" STUDY_ID="STD-Cordonnier-2003" TOTAL_1="49" TOTAL_2="48" VAR="0.004790249433106582" WEIGHT="21.64469778049285"/>
<DICH_DATA CI_END="0.9827466601950989" CI_START="0.785276482033824" EFFECT_SIZE="0.8784804152902312" ESTIMABLE="YES" EVENTS_1="146" EVENTS_2="163" LOG_CI_END="-0.007558423428813235" LOG_CI_START="-0.10497740888395375" LOG_EFFECT_SIZE="-0.056267916156383505" ORDER="309" O_E="0.0" SE="0.05722439428810488" STUDY_ID="STD-Winston-2001" TOTAL_1="208" TOTAL_2="204" VAR="0.0032746313016404904" WEIGHT="78.35530221950715"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.3945413899874906" CI_END="1.567928642562658" CI_START="1.0378762989273678" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.275662955692115" ESTIMABLE="YES" EVENTS_1="121" EVENTS_2="93" I2="81.46274302657044" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="0.195326293777973" LOG_CI_START="0.01614559446172775" LOG_EFFECT_SIZE="0.10573594411985038" METHOD="MH" NO="3" P_CHI2="0.020199907186568833" P_Q="0.0" P_Z="0.020712721806939685" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="257" TOTAL_2="252" WEIGHT="100.0" Z="2.313180416608155">
<NAME>Microbiologically documented Infection</NAME>
<GROUP_LABEL_1>Polyvalent IVIG 250</GROUP_LABEL_1>
<GROUP_LABEL_2>Polyvalent IVIG 500</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.8011166296362484" CI_START="1.299138248079133" EFFECT_SIZE="1.9076262083780882" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="19" LOG_CI_END="0.44733119184854075" LOG_CI_START="0.1136553690739385" LOG_EFFECT_SIZE="0.2804932804612396" ORDER="310" O_E="0.0" SE="0.19600283001976274" STUDY_ID="STD-Cordonnier-2003" TOTAL_1="49" TOTAL_2="48" VAR="0.038417109375756" WEIGHT="20.43977499685601"/>
<DICH_DATA CI_END="1.423308128401655" CI_START="0.8708229538530519" EFFECT_SIZE="1.1133056133056134" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="74" LOG_CI_END="0.15329892958428393" LOG_CI_START="-0.060070131996198484" LOG_EFFECT_SIZE="0.0466143987940427" ORDER="311" O_E="0.0" SE="0.1253340429662643" STUDY_ID="STD-Winston-2001" TOTAL_1="208" TOTAL_2="204" VAR="0.015708622326269385" WEIGHT="79.560225003144"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4127960315524821" CI_START="0.339249212288432" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6923076923076923" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="0.15007946633168184" LOG_CI_START="-0.4694811520667057" LOG_EFFECT_SIZE="-0.1597008428675119" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.31229461781571377" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="208" TOTAL_2="204" WEIGHT="100.00000000000001" Z="1.0104189679781894">
<NAME>CMV Infection</NAME>
<GROUP_LABEL_1>Polyvalent IVIG 250</GROUP_LABEL_1>
<GROUP_LABEL_2>Polyvalent IVIG 500</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.412796031552482" CI_START="0.33924921228843213" EFFECT_SIZE="0.6923076923076923" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="17" LOG_CI_END="0.1500794663316818" LOG_CI_START="-0.4694811520667056" LOG_EFFECT_SIZE="-0.1597008428675119" ORDER="312" O_E="0.0" SE="0.36393297412173575" STUDY_ID="STD-Winston-2001" TOTAL_1="208" TOTAL_2="204" VAR="0.13244720965309198" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.44303920080088666" CI_END="2.917679690885371" CI_START="0.32908846329327474" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9798850574712645" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-005.05" LOG_CI_END="0.465037612397556" LOG_CI_START="-0.48268734230572213" LOG_EFFECT_SIZE="-0.008824864954083122" METHOD="MH" NO="5" P_CHI2="0.5056592230059594" P_Q="0.0" P_Z="0.9708829432897943" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="257" TOTAL_2="252" WEIGHT="100.00000000000001" Z="0.03650092232476446">
<NAME>Interstitial Pneumonitis</NAME>
<GROUP_LABEL_1>Polyvalent IVIG 250</GROUP_LABEL_1>
<GROUP_LABEL_2>Polyvalent IVIG 500</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.287106516712772" CI_START="0.34974061280331387" EFFECT_SIZE="1.2244897959183674" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.632164274050848" LOG_CI_START="-0.456253933340588" LOG_EFFECT_SIZE="0.08795517035512998" ORDER="313" O_E="0.0" SE="0.6393422427787487" STUDY_ID="STD-Cordonnier-2003" TOTAL_1="49" TOTAL_2="48" VAR="0.40875850340136055" WEIGHT="66.67987845157882"/>
<DICH_DATA CI_END="5.366139562781302" CI_START="0.044813793639253835" EFFECT_SIZE="0.49038461538461536" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7296619636317832" LOG_CI_START="-1.3485882900334714" LOG_EFFECT_SIZE="-0.309463163200844" ORDER="314" O_E="0.0" SE="1.2207744865076409" STUDY_ID="STD-Winston-2001" TOTAL_1="208" TOTAL_2="204" VAR="1.490290346907994" WEIGHT="33.3201215484212"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4324145263870698" CI_START="0.4663397721818547" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8173076923076923" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-005.06" LOG_CI_END="0.15606871662481175" LOG_CI_START="-0.331297543793787" LOG_EFFECT_SIZE="-0.08761441358448763" METHOD="MH" NO="6" P_CHI2="1.0" P_Q="0.0" P_Z="0.4810031039411278" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="208" TOTAL_2="204" WEIGHT="100.0" Z="0.7046901236236641">
<NAME>Infection related Mortality</NAME>
<GROUP_LABEL_1>Polyvalent IVIG 250</GROUP_LABEL_1>
<GROUP_LABEL_2>Polyvalent IVIG 500</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4324145263870698" CI_START="0.4663397721818547" EFFECT_SIZE="0.8173076923076923" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="24" LOG_CI_END="0.15606871662481175" LOG_CI_START="-0.331297543793787" LOG_EFFECT_SIZE="-0.08761441358448763" ORDER="315" O_E="0.0" SE="0.28628135387178233" STUDY_ID="STD-Winston-2001" TOTAL_1="208" TOTAL_2="204" VAR="0.08195701357466065" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.3487392597923726" CI_END="1.5533984007436732" CI_START="1.1295735207944844" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.324642480341225" ESTIMABLE="YES" EVENTS_1="206" EVENTS_2="153" I2="14.847934198673078" I2_Q="0.0" ID="CMP-005.07" LOG_CI_END="0.191282853703442" LOG_CI_START="0.05291450319460257" LOG_EFFECT_SIZE="0.1220986784490223" METHOD="MH" MODIFIED="2008-08-11 15:34:16 +0200" MODIFIED_BY="Nicole Skoetz" NO="7" P_CHI2="0.3090137615471843" P_Q="0.0" P_Z="5.421572606221177E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="424" TOTAL_2="417" WEIGHT="100.0" Z="3.4590137331258095">
<NAME>Acute GVHD</NAME>
<GROUP_LABEL_1>Polyvalent IVIG 250</GROUP_LABEL_1>
<GROUP_LABEL_2>Polyvalent IVIG 500</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9204094238320555" CI_START="1.2050456165753451" EFFECT_SIZE="1.5212432278300543" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="63" LOG_CI_END="0.28339382847199696" LOG_CI_START="0.0810034872859754" LOG_EFFECT_SIZE="0.18219865787898618" ORDER="316" O_E="0.0" SE="0.11888508826101558" STUDY_ID="STD-Abdel_x002d_Mageed-1999" TOTAL_1="167" TOTAL_2="165" VAR="0.014133664210829466" WEIGHT="41.08506919924267"/>
<DICH_DATA CI_END="1.8613371837590884" CI_START="0.7017118985082513" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="18" LOG_CI_END="0.2698250532927894" LOG_CI_START="-0.15384115933741588" LOG_EFFECT_SIZE="0.05799194697768673" ORDER="317" O_E="0.0" SE="0.248863630480558" STUDY_ID="STD-Cordonnier-2003" TOTAL_1="49" TOTAL_2="48" VAR="0.06193310657596372" WEIGHT="11.788591989510458"/>
<DICH_DATA CI_END="1.5305136361014515" CI_START="0.9388513023893886" EFFECT_SIZE="1.1987179487179487" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="72" LOG_CI_END="0.1848372032944992" LOG_CI_START="-0.02740318693042452" LOG_EFFECT_SIZE="0.07871700818203736" ORDER="318" O_E="0.0" SE="0.1246710558249958" STUDY_ID="STD-Winston-2001" TOTAL_1="208" TOTAL_2="204" VAR="0.015542872160519219" WEIGHT="47.126338811246875"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" NO="6">
<NAME>Polyvalent immunoglobulins vs. placebo / no intervention - MM/CLL</NAME>
<DICH_OUTCOME CHI2="0.2741242177804907" CI_END="3.1940084432245834" CI_START="0.5825428746589153" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3640552995391704" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="0.5043360598428521" LOG_CI_START="-0.23467210542203412" LOG_EFFECT_SIZE="0.13483197721040902" METHOD="MH" NO="1" P_CHI2="0.6005785890852218" P_Q="0.0" P_Z="0.4744913274766831" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="82" TOTAL_2="81" WEIGHT="100.0" Z="0.7151905262156474">
<NAME>All-cause Mortality</NAME>
<GROUP_LABEL_1>Polyvalent IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.482109737226686" CI_START="0.5711595989579685" EFFECT_SIZE="1.6" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.651482485329026" LOG_CI_START="-0.24324252001717644" LOG_EFFECT_SIZE="0.2041199826559248" ORDER="319" O_E="0.0" SE="0.5255658971005652" STUDY_ID="STD-Chapel-1994" TOTAL_1="41" TOTAL_2="41" VAR="0.2762195121951219" WEIGHT="62.21198156682027"/>
<DICH_DATA CI_END="4.550290767904632" CI_START="0.2091766097468634" EFFECT_SIZE="0.975609756097561" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6580391493739782" LOG_CI_START="-0.6794868801575243" LOG_EFFECT_SIZE="-0.010723865391773113" ORDER="320" O_E="0.0" SE="0.7856694106074307" STUDY_ID="STD-Cooperative-CLL-1988" TOTAL_1="41" TOTAL_2="40" VAR="0.6172764227642276" WEIGHT="37.78801843317972"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.4457526089813757" CI_END="0.6101480487829363" CI_START="0.3866709425044341" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.48572267920094014" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="88" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="-0.21456477323802475" LOG_CI_START="-0.41265846300357" LOG_EFFECT_SIZE="-0.31361161812079735" METHOD="MH" NO="2" P_CHI2="0.800213966715978" P_Q="0.0" P_Z="5.441038341114042E-10" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="106" TOTAL_2="99" WEIGHT="100.00000000000001" Z="6.205825913764186">
<NAME>Clinically-documented infections</NAME>
<GROUP_LABEL_1>Polyvalent IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9846943341001941" CI_START="0.23132991458359423" EFFECT_SIZE="0.4772727272727273" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="-0.00669856098993951" LOG_CI_START="-0.6357682025145969" LOG_EFFECT_SIZE="-0.3212333817522681" ORDER="321" O_E="0.0" SE="0.3695186213765303" STUDY_ID="STD-Boughton-1995" TOTAL_1="24" TOTAL_2="18" VAR="0.13654401154401155" WEIGHT="13.960047003525267"/>
<DICH_DATA CI_END="0.6500883228203642" CI_START="0.3078635581190527" EFFECT_SIZE="0.4473684210526316" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="38" LOG_CI_END="-0.187027634883803" LOG_CI_START="-0.5116417155932693" LOG_EFFECT_SIZE="-0.34933467523853623" ORDER="322" O_E="0.0" SE="0.19067991787435526" STUDY_ID="STD-Chapel-1994" TOTAL_1="41" TOTAL_2="41" VAR="0.036358831080570864" WEIGHT="42.197414806110466"/>
<DICH_DATA CI_END="0.711115757149746" CI_START="0.3880800723971427" EFFECT_SIZE="0.525328330206379" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="39" LOG_CI_END="-0.14805969800525748" LOG_CI_START="-0.4110786573634486" LOG_EFFECT_SIZE="-0.279569177684353" ORDER="323" O_E="0.0" SE="0.1544986386918481" STUDY_ID="STD-Cooperative-CLL-1988" TOTAL_1="41" TOTAL_2="40" VAR="0.023869829357634223" WEIGHT="43.84253819036428"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.7893233539778475" CI_END="0.9547835806175221" CI_START="0.5323531643698709" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7129390299528661" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="57" I2="58.24044750833396" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="-0.02009505814928026" LOG_CI_START="-0.27380016009153346" LOG_EFFECT_SIZE="-0.14694760912040686" METHOD="MH" NO="3" P_CHI2="0.09120378324990708" P_Q="0.0" P_Z="0.023180462324765606" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="106" TOTAL_2="99" WEIGHT="100.0" Z="2.2704472183284876">
<NAME>Microbiologically-documented infections</NAME>
<GROUP_LABEL_1>Polyvalent IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.6257226530281987" CI_START="0.6205659437631841" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.55939457999496" LOG_CI_START="-0.2072120618835976" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="324" O_E="0.0" SE="0.4503085362035432" STUDY_ID="STD-Boughton-1995" TOTAL_1="24" TOTAL_2="18" VAR="0.2027777777777778" WEIGHT="9.852516344838072"/>
<DICH_DATA CI_END="0.8099989184315315" CI_START="0.33029506383653634" EFFECT_SIZE="0.5172413793103449" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="29" LOG_CI_END="-0.09151556102200614" LOG_CI_START="-0.48109791666454343" LOG_EFFECT_SIZE="-0.2863067388432748" ORDER="325" O_E="0.0" SE="0.22884260416818866" STUDY_ID="STD-Chapel-1994" TOTAL_1="41" TOTAL_2="41" VAR="0.05236893748247828" WEIGHT="50.00152045005321"/>
<DICH_DATA CI_END="1.1816140257056764" CI_START="0.4933623112940977" EFFECT_SIZE="0.7635206786850477" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="23" LOG_CI_END="0.07247563739057916" LOG_CI_START="-0.306834030002699" LOG_EFFECT_SIZE="-0.11717919630605993" ORDER="326" O_E="0.0" SE="0.22280837623994693" STUDY_ID="STD-Cooperative-CLL-1988" TOTAL_1="41" TOTAL_2="40" VAR="0.04964357252268175" WEIGHT="40.14596320510871"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.3760616885326464" CI_END="3.07312226598392" CI_START="0.13902273311745925" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6536312849162011" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="57.9135506108195" I2_Q="0.0" ID="CMP-006.04" LOG_CI_END="0.4875798392625059" LOG_CI_START="-0.8569141777299689" LOG_EFFECT_SIZE="-0.1846671692337315" METHOD="MH" NO="4" P_CHI2="0.12320798324808535" P_Q="0.0" P_Z="0.5902976313301476" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="65" TOTAL_2="59" WEIGHT="100.0" Z="0.5384047771885364">
<NAME>Bacteremia</NAME>
<GROUP_LABEL_1>Polyvalent IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="74.60377781899123" CI_START="0.19355588178168812" EFFECT_SIZE="3.8" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.8727608200249466" LOG_CI_START="-0.7131936267913266" LOG_EFFECT_SIZE="0.5797835966168101" ORDER="327" O_E="0.0" SE="1.5190024427408375" STUDY_ID="STD-Boughton-1995" TOTAL_1="24" TOTAL_2="18" VAR="2.3073684210526313" WEIGHT="13.966480446927374"/>
<DICH_DATA CI_END="2.681155551998083" CI_START="0.00761170430790459" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4283220110790027" LOG_CI_START="-2.1185180911075165" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="328" O_E="0.0" SE="1.4960264830861913" STUDY_ID="STD-Chapel-1994" TOTAL_1="41" TOTAL_2="41" VAR="2.238095238095238" WEIGHT="86.03351955307262"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.950938032119094" CI_START="0.013974591508858441" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-006.05" LOG_CI_END="0.9004183686742377" LOG_CI_START="-1.8546608781135625" LOG_EFFECT_SIZE="-0.4771212547196625" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.49723397076143483" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="41" TOTAL_2="41" WEIGHT="100.0" Z="0.6788483319304867">
<NAME>Infection-related Mortality</NAME>
<GROUP_LABEL_1>Polyvalent IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.950938032119094" CI_START="0.013974591508858441" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9004183686742377" LOG_CI_START="-1.8546608781135625" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="329" O_E="0.0" SE="1.618347187425374" STUDY_ID="STD-Chapel-1994" TOTAL_1="41" TOTAL_2="41" VAR="2.619047619047619" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.021583613474934" CI_END="3.237450729372239" CI_START="1.741829764844979" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.3746764079848126" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="30" I2="1.0676587073157788" I2_Q="0.0" ID="CMP-006.06" LOG_CI_END="0.5102031676299776" LOG_CI_START="0.2410057076170173" LOG_EFFECT_SIZE="0.37560443762349743" METHOD="MH" NO="6" P_CHI2="0.36393082552453837" P_Q="0.0" P_Z="4.516207363416002E-8" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="106" TOTAL_2="99" WEIGHT="100.0" Z="5.469376792337">
<NAME>Adverse Events</NAME>
<GROUP_LABEL_1>Polyvalent IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.46818925001847" CI_START="1.6374732106215295" EFFECT_SIZE="3.9375" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="4" LOG_CI_END="0.9762669300151047" LOG_CI_START="0.21417420358020908" LOG_EFFECT_SIZE="0.5952205667976569" ORDER="330" O_E="0.0" SE="0.4476570399276944" STUDY_ID="STD-Boughton-1995" TOTAL_1="24" TOTAL_2="18" VAR="0.20039682539682538" WEIGHT="14.911120059828567"/>
<DICH_DATA CI_END="2.8740223209989693" CI_START="1.4659929284848023" EFFECT_SIZE="2.0526315789473686" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="19" LOG_CI_END="0.4584901367449846" LOG_CI_START="0.166131875402356" LOG_EFFECT_SIZE="0.3123110060736703" ORDER="331" O_E="0.0" SE="0.17173268990939378" STUDY_ID="STD-Chapel-1994" TOTAL_1="41" TOTAL_2="41" VAR="0.029492116783516" WEIGHT="61.97434274866249"/>
<DICH_DATA CI_END="4.8357081152618875" CI_START="1.0283384526089985" EFFECT_SIZE="2.229965156794425" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="7" LOG_CI_END="0.684460078839522" LOG_CI_START="0.012136075660267826" LOG_EFFECT_SIZE="0.3482980772498948" ORDER="332" O_E="0.0" SE="0.39492644752498385" STUDY_ID="STD-Cooperative-CLL-1988" TOTAL_1="41" TOTAL_2="40" VAR="0.15596689895470384" WEIGHT="23.114537191508948"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.40977715033443524" CI_END="42.241112666231565" CI_START="0.6968660317288768" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="5.425531914893615" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.07" LOG_CI_END="1.6257353493562539" LOG_CI_START="-0.15685070435977871" LOG_EFFECT_SIZE="0.7344423224982376" METHOD="MH" NO="7" P_CHI2="0.5220826516955028" P_Q="0.0" P_Z="0.10630042680189587" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="106" TOTAL_2="99" WEIGHT="100.0" Z="1.6150474170015106">
<NAME>Adverse Events requiring discontinuation</NAME>
<GROUP_LABEL_1>Polyvalent IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="52.91582277553271" CI_START="0.09823904698697497" EFFECT_SIZE="2.28" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.723585553256599" LOG_CI_START="-1.0077158592556916" LOG_EFFECT_SIZE="0.35793484700045375" ORDER="333" O_E="0.0" SE="1.6043799698697618" STUDY_ID="STD-Boughton-1995" TOTAL_1="24" TOTAL_2="18" VAR="2.574035087719298" WEIGHT="53.191489361702125"/>
<DICH_DATA CI_END="161.98317625369413" CI_START="0.5000519305359206" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.2094699105944775" LOG_CI_START="-0.30098489171582765" LOG_EFFECT_SIZE="0.9542425094393249" ORDER="334" O_E="0.0" SE="1.4746535778287642" STUDY_ID="STD-Chapel-1994" TOTAL_1="41" TOTAL_2="41" VAR="2.174603174603175" WEIGHT="46.80851063829787"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="335" O_E="0.0" SE="0.0" STUDY_ID="STD-Cooperative-CLL-1988" TOTAL_1="41" TOTAL_2="40" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.693113792984962" CI_END="0.6882805801812618" CI_START="0.47991844525492783" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5747334564298052" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="145" I2="42.48321005489627" I2_Q="0.0" ID="CMP-006.08" LOG_CI_END="-0.16223448388095776" LOG_CI_START="-0.3188325580098816" LOG_EFFECT_SIZE="-0.24053352094541966" METHOD="MH" NO="8" P_CHI2="0.12194897906140412" P_Q="0.0" P_Z="1.7336278673686549E-9" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="212" TOTAL_2="198" WEIGHT="100.0" Z="6.020981301973222">
<NAME>Clinically and microbiologically documented infections</NAME>
<GROUP_LABEL_1>Polyvalent IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.4457526089813757" CI_END="0.6101480487829363" CI_START="0.3866709425044341" DF="2.0" EFFECT_SIZE="0.48572267920094014" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="88" I2="0.0" ID="CMP-006.08.01" LOG_CI_END="-0.21456477323802475" LOG_CI_START="-0.41265846300357" LOG_EFFECT_SIZE="-0.31361161812079735" NO="1" P_CHI2="0.800213966715978" P_Z="5.441038341114042E-10" STUDIES="3" TAU2="0.0" TOTAL_1="106" TOTAL_2="99" WEIGHT="60.825540532491516" Z="6.205825913764186">
<NAME>Clinically-documented infections</NAME>
<DICH_DATA CI_END="0.9846943341001941" CI_START="0.23132991458359423" EFFECT_SIZE="0.4772727272727273" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="-0.00669856098993951" LOG_CI_START="-0.6357682025145969" LOG_EFFECT_SIZE="-0.3212333817522681" ORDER="336" O_E="0.0" SE="0.3695186213765303" STUDY_ID="STD-Boughton-1995" TOTAL_1="24" TOTAL_2="18" VAR="0.13654401154401155" WEIGHT="8.491274048484126"/>
<DICH_DATA CI_END="0.6500883228203642" CI_START="0.3078635581190527" EFFECT_SIZE="0.4473684210526316" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="38" LOG_CI_END="-0.187027634883803" LOG_CI_START="-0.5116417155932693" LOG_EFFECT_SIZE="-0.34933467523853623" ORDER="337" O_E="0.0" SE="0.19067991787435526" STUDY_ID="STD-Chapel-1994" TOTAL_1="41" TOTAL_2="41" VAR="0.036358831080570864" WEIGHT="25.66680564655429"/>
<DICH_DATA CI_END="0.711115757149746" CI_START="0.3880800723971427" EFFECT_SIZE="0.525328330206379" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="39" LOG_CI_END="-0.14805969800525748" LOG_CI_START="-0.4110786573634486" LOG_EFFECT_SIZE="-0.279569177684353" ORDER="338" O_E="0.0" SE="0.1544986386918481" STUDY_ID="STD-Cooperative-CLL-1988" TOTAL_1="41" TOTAL_2="40" VAR="0.023869829357634223" WEIGHT="26.667460837453095"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.7893233539778475" CI_END="0.9547835806175221" CI_START="0.5323531643698709" DF="2.0" EFFECT_SIZE="0.7129390299528661" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="57" I2="58.24044750833396" ID="CMP-006.08.02" LOG_CI_END="-0.02009505814928026" LOG_CI_START="-0.27380016009153346" LOG_EFFECT_SIZE="-0.14694760912040686" NO="2" P_CHI2="0.09120378324990708" P_Z="0.023180462324765606" STUDIES="3" TAU2="0.0" TOTAL_1="106" TOTAL_2="99" WEIGHT="39.174459467508484" Z="2.2704472183284876">
<NAME>Microbiologically-documented infections</NAME>
<DICH_DATA CI_END="3.6257226530281987" CI_START="0.6205659437631841" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.55939457999496" LOG_CI_START="-0.2072120618835976" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="339" O_E="0.0" SE="0.4503085362035432" STUDY_ID="STD-Boughton-1995" TOTAL_1="24" TOTAL_2="18" VAR="0.2027777777777778" WEIGHT="3.859670022038239"/>
<DICH_DATA CI_END="0.8099989184315315" CI_START="0.33029506383653634" EFFECT_SIZE="0.5172413793103449" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="29" LOG_CI_END="-0.09151556102200614" LOG_CI_START="-0.48109791666454343" LOG_EFFECT_SIZE="-0.2863067388432748" ORDER="340" O_E="0.0" SE="0.22884260416818866" STUDY_ID="STD-Chapel-1994" TOTAL_1="41" TOTAL_2="41" VAR="0.05236893748247828" WEIGHT="19.587825361844065"/>
<DICH_DATA CI_END="1.1816140257056764" CI_START="0.4933623112940977" EFFECT_SIZE="0.7635206786850477" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="23" LOG_CI_END="0.07247563739057916" LOG_CI_START="-0.306834030002699" LOG_EFFECT_SIZE="-0.11717919630605993" ORDER="341" O_E="0.0" SE="0.22280837623994693" STUDY_ID="STD-Cooperative-CLL-1988" TOTAL_1="41" TOTAL_2="40" VAR="0.04964357252268175" WEIGHT="15.726964083626182"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.299004746291743" CI_START="0.2580529180189465" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4634146341463414" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-006.09" LOG_CI_END="0.9190260129652039" LOG_CI_START="-0.5882912256373876" LOG_EFFECT_SIZE="0.16536739366390812" METHOD="MH" NO="9" P_CHI2="1.0" P_Q="0.0" P_Z="0.6671561379235085" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="41" TOTAL_2="40" WEIGHT="100.0" Z="0.4300543077434686">
<NAME>Fungal infections</NAME>
<GROUP_LABEL_1>Polyvalent IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.29900474629174" CI_START="0.25805291801894653" EFFECT_SIZE="1.4634146341463414" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9190260129652037" LOG_CI_START="-0.5882912256373874" LOG_EFFECT_SIZE="0.16536739366390812" ORDER="342" O_E="0.0" SE="0.8854056072958281" STUDY_ID="STD-Cooperative-CLL-1988" TOTAL_1="41" TOTAL_2="40" VAR="0.7839430894308942" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.681155551998083" CI_START="0.00761170430790459" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-006.10" LOG_CI_END="0.4283220110790027" LOG_CI_START="-2.1185180911075165" LOG_EFFECT_SIZE="-0.8450980400142569" METHOD="MH" NO="10" P_CHI2="1.0" P_Q="0.0" P_Z="0.19335463843690395" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="41" TOTAL_2="41" WEIGHT="100.0" Z="1.3007190521394016">
<NAME>Bacteremia</NAME>
<GROUP_LABEL_1>Polyvalent IVIG</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.681155551998083" CI_START="0.00761170430790459" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4283220110790027" LOG_CI_START="-2.1185180911075165" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="343" O_E="0.0" SE="1.4960264830861913" STUDY_ID="STD-Chapel-1994" TOTAL_1="41" TOTAL_2="41" VAR="2.238095238095238" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2008-08-11 15:34:17 +0200" MODIFIED_BY="Nicole Skoetz">
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-01" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Flow diagram</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2008-06-25 17:41:39 +0200" MODIFIED_BY="[Empty name]" NO="2" REF_ID="CMP-001.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Polyvalent immunoglobulins vs. placebo / no intervention - HSCT, outcome: 1.1 All-cause Mortality.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArkAAAGwCAMAAACaZ43TAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2008-06-25 17:58:17 +0200" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-001.02" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Polyvalent immunoglobulins vs. placebo / no intervention - HSCT, outcome: 1.2 All cause mortality 100 days.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAswAAADACAMAAAAnUsV6AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2008-06-25 17:50:11 +0200" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.03" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Polyvalent immunoglobulins vs. placebo / no intervention - HSCT, outcome: 1.3 All-cause Mortality at 1-2years and more.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArkAAADQCAMAAAA05Ik9AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2008-06-13 16:09:24 +0200" MODIFIED_BY="Nicole Skoetz" NO="5" REF_ID="CMP-001.04" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Polyvalent immunoglobulins vs. placebo / no intervention - HSCT, outcome: 1.4 All-cause Mortality - by type of HSCT.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArkAAAHwCAMAAACVP4e/AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2008-06-13 16:09:27 +0200" MODIFIED_BY="Nicole Skoetz" NO="6" REF_ID="CMP-001.05" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Polyvalent immunoglobulins vs. placebo / no intervention - HSCT, outcome: 1.5 All cause mortality -by use of antifungal prophylaxis.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqoAAAGACAMAAABShLCVAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2008-06-13 16:09:31 +0200" MODIFIED_BY="Nicole Skoetz" NO="7" REF_ID="CMP-001.06" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Polyvalent immunoglobulins vs. placebo / no intervention - HSCT, outcome: 1.6 All-cause Mortality - high dose IVIG.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArkAAACwCAMAAAA8EIZnAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-08" MODIFIED="2008-06-25 14:10:29 +0200" MODIFIED_BY="[Empty name]" NO="8" REF_ID="CMP-001.07" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Polyvalent immunoglobulins vs. placebo / no intervention - HSCT, outcome: 1.7 All-cause Mortality -sensitivity analysis by randomization generation.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArkAAAGwCAMAAACaZ43TAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-09" MODIFIED="2008-06-25 14:10:29 +0200" MODIFIED_BY="[Empty name]" NO="9" REF_ID="CMP-001.08" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Polyvalent immunoglobulins vs. placebo / no intervention - HSCT, outcome: 1.8 All-cause Mortality -sensitivity analysis by double blinding.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArkAAAGwCAMAAACaZ43TAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-10" MODIFIED="2008-06-13 16:09:40 +0200" MODIFIED_BY="Nicole Skoetz" NO="10" REF_ID="CMP-001.09" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Polyvalent immunoglobulins vs. placebo / no intervention - HSCT, outcome: 1.9 Clinically documented infections.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArkAAADQCAMAAAA05Ik9AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-11" MODIFIED="2008-06-13 16:09:44 +0200" MODIFIED_BY="Nicole Skoetz" NO="11" REF_ID="CMP-001.10" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Polyvalent immunoglobulins vs. placebo / no intervention - HSCT, outcome: 1.10 Microbiologically documented infections - bacterial.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArkAAADwCAMAAAAzSIwLAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-12" MODIFIED="2008-06-13 16:09:47 +0200" MODIFIED_BY="Nicole Skoetz" NO="12" REF_ID="CMP-001.11" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Polyvalent immunoglobulins vs. placebo / no intervention - HSCT, outcome: 1.11 Microbiologically documented infections - patient months.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArkAAADgCAMAAAAwno6QAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-13" MODIFIED="2008-06-13 16:09:50 +0200" MODIFIED_BY="Nicole Skoetz" NO="13" REF_ID="CMP-001.12" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Polyvalent immunoglobulins vs. placebo / no intervention - HSCT, outcome: 1.12 CMV infections.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArkAAADgCAMAAAAwno6QAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-14" MODIFIED="2008-06-13 16:09:54 +0200" MODIFIED_BY="Nicole Skoetz" NO="14" REF_ID="CMP-001.13" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Polyvalent immunoglobulins vs. placebo / no intervention - HSCT, outcome: 1.13 CMV infections - patient months.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArkAAADACAMAAAA3MoumAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-15" MODIFIED="2008-06-13 16:09:57 +0200" MODIFIED_BY="Nicole Skoetz" NO="15" REF_ID="CMP-001.14" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Polyvalent immunoglobulins vs. placebo / no intervention - HSCT, outcome: 1.14 Interstitial Pneumonitis.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArkAAADwCAMAAAAzSIwLAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-16" MODIFIED="2008-06-13 16:10:01 +0200" MODIFIED_BY="Nicole Skoetz" NO="16" REF_ID="CMP-001.15" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Polyvalent immunoglobulins vs. placebo / no intervention - HSCT, outcome: 1.15 Infection-related Mortality.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArkAAACwCAMAAAA8EIZnAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-17" MODIFIED="2008-06-13 16:10:05 +0200" MODIFIED_BY="Nicole Skoetz" NO="17" REF_ID="CMP-001.16" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Polyvalent immunoglobulins vs. placebo / no intervention - HSCT, outcome: 1.16 Acute GVHD.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArkAAADwCAMAAAAzSIwLAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-18" MODIFIED="2008-06-13 16:10:08 +0200" MODIFIED_BY="Nicole Skoetz" NO="18" REF_ID="CMP-001.17" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Polyvalent immunoglobulins vs. placebo / no intervention - HSCT, outcome: 1.17 VOD.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAsAAAADACAMAAAA9biX0AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-19" MODIFIED="2008-06-13 16:10:12 +0200" MODIFIED_BY="Nicole Skoetz" NO="19" REF_ID="CMP-001.18" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Polyvalent immunoglobulins vs. placebo / no intervention - HSCT, outcome: 1.18 Adverse Events.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAsAAAADQCAMAAAA+uCdvAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-20" MODIFIED="2008-06-13 16:10:15 +0200" MODIFIED_BY="Nicole Skoetz" NO="20" REF_ID="CMP-001.19" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Polyvalent immunoglobulins vs. placebo / no intervention - HSCT, outcome: 1.19 VOD according to type of transplant.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAsIAAAFwCAMAAACFJu0IAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD////AwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID/gAAAAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///80TKWtAAAjYklEQVR42u1dTYwlx12vmXm7tYs39tozY+9nNo7xShBHPjgHIgHK
JSCRQkLKASkHOCCTS5ACl0ggoShCwAVuCFAUBAaZC5aQUjnlEohEOMAhklGcjRJ7s+vNeteznvVu
slue2Xm8113dXd9d1a+7X/d7v9/uvP6oz6761b/+Vf3vqg1KAGDM2EQRAKAwAIDCANAUk4Hkg2W/
vLrkTk/mXcaLwOoJU6OqSdTyx3hNmp2XQZWkeqaVzzyXPeZs0FkdjhTmnMunTy1JWZhlMc4OUVE5
/bHllwHnteWTNT6OrA5JCluSkUlxmv3ySl6yovXndxl3y2oexeAiKSNKVjYKvpwiUBM3JFjmIHO5
xDwOKKubg2OwS4Kysl2X7vPuibdSKK4oCxHDll4MJi2ykuAkrb9Z6awOTgqXnRHLGm/+6+jfudO7
IgDSyc0H0IDLXDDObRWTk6UzdnhZHY4UZiyg9KvsZKNgY0MFs8p/8ZxMd2MDebbhZHVQw7kYBgf9
jR+F6OKOiZW5GxtO6xxKVjcHXZmcuCZknHK48hjbgWX+GBvkw1c90mA0h8FmdXN4xHW0Xl5STXd3
F5o7Dq8/T5SxsXQi27zFIEtC5nJJeRxWVjeGa+bDyAorDMDqz0gwAgYDI5fCADDu4RwAgMIAKAwA
oDAAdIuJPgmQvy807I38MwNFiHqfETDtTDU3nhaYuTOVmkRkrKpNnelenLmfoAhGKisDJQ6SWXo5
86WbI5R+8/lY1WnRqcnh53BipMpyU8PYx8tDtNWeeJig4aBqSbCWkoiNtT4Z1rQ8eG0N5BXAC4rY
Th1iCDmcOCqtNPDkSqtjmmktUV9nVT5Lr6WJb9XQirs8pllUwSu74CiD08pG1e8/PYmaWItmzxwP
TIqkfHVVIzNkLIrFLXM1EKuniLWajpFUw86hpgvLF4KaasCMjHDNDN8wMWDSvKO0/zCtRFnse3Tb
iDfK4DT3lPuv+wwkPomYWE175qoY2rJsllGbdVJUxABMKZaTw029U2Auu1yv2ZEVgtd11zWdDmPM
TIwbJZTQxzHWfhI8xTCIRzyz3hXr9SyvLPMCV1Xk3WcXVBl6Die2EpH0dKkh4jVI8zF5qvmeUxgs
nIRbxCyq9WpamS0RWPV1q5ljdUSdDcVTBjMrkcOJqzdMJXFnIwUrqYTmEsH3Bkm4YuW5wZsURMkN
mikjf68P5oma9/HB6rBzuGlowpY0CU18KCGYJoFYoBji5xb0DLVoq9dxEow1EMiqIb9VE6X+zVgR
rzxjunLDdKPRVnvsoeZwU1fzKitz2ah0mWToPEoIXvUnXM+m7SGoCztTklmqZ1iVXkAXTk6iNlZX
Cell5++teGyzMcuyuMeNR2nd3nngOYyzVEtKifH4pUxWGP5iiAvbhp9un24gOZxEETipJviyFzcY
BhYoBjC4fSkMAACwLvhsz+lNIIWBltEzpWBsCYwcoDAwcugzEoaZqzqm1ueHYmzOAKB3KWy8bFMN
txiKChi+FGaOM6cTd14AwNKlsNP+UL+h2csOYXlbAFI4icEElAWGLIUt3jpMWjCKA4YrhR0cduym
AgYDA5fCleQ1TT0BYISKBA8pF8td3hYA5oClGtAy+jYDxQtmYIUVCQAAhQEAFAYAUBhYZUxQBEDP
OGyXf5DCABQJABiOIiGc3+4Jz+sP+74M7zwsgKSI8lzN/M49p6Zd4z8Ya5VL6Vr6pv4yDKQvgxSH
mYNQYzYzUtwzyksQuk4UFvFlXZWXHd55WITBKREJNXOpadf6D8Ra3qWWb0FjGazELPTnIWoBSIJq
GaGlZ628qFgnKZxXgChbd1byshWXd7SD5tMjwBYXAjQhIpFXWcM2Q2MEfDi8oNG+Fyor4SgVPcU+
pS/zXjjw7wl+dfC4GQlate68KQti3ikO2v1hgMZpBItpNF5XXd1RztLzUrZFEWKwpiYssRK0T4P5
oqRcRBd28kEtRJ9ADIqeFtQxXS+Mo3KjGg3nNRirbNeVn/xs3mOJ+DJIynUpSvRcVjrzOhhxTRaX
SxF06r0oafOAgbzSiDSp5Zt6ubZwm6XNNPpVp3Daw9NFAncnhIcFET+mEoomJMcaInKSyD3CXH1s
Gh2Qe6YsVhC71YglMLhhomLxWMVCeajmFyidiwd5WKjY1koKF0pUpUxJTU6941G78krLLuVN/bCQ
siJnOONjaph2jf9grLqjoJU3qRAnPCkNJV+5WjeImrDoaEw7NOCrjdEoIw2lbe+yGF9tAH3qRpiR
AAYwx0I7mZsZ5XAOAEBhAACFgU7xp6AwMGqc/JOVHs4Jv/rvnpkRihFbe9bBocE1TfSbnJuaCaqQ
8YGVZHmjib2wGZtmL+x8PLerPiF95mqzoj8c8NB/Yo5ek1+BtW0dHGSXoEl+k3Mj4nIgYpJUbP3S
7YXtB6BBV29Y7d32yatk9TDxygIh7YDz5i+objJMPG/+BzKHQ5u2EtE4VtpqUdAFPPnD7pOGE8Vb
JD7kaz3X7qRO3GXNmSpNvjS6WsEZR9oK01PVkx6f76u/06zaDhNKZ6lv58QM6gt4af5aW836NzID
qS9BCSFtv50SwYezHLMCzMII0TQpEd84RG2befni6skdjcJ0bhiV3LKF/GBpgIZRrWcqUy0T46TN
vmGjuXlVdGJxXm+90kzfnGNMunCj3pcOq9PsUtmJNeItv+Rs/g1mwtd8cZ8gvbzaUths1jSyPtVO
bFAMFq1TV3ZWJIXBCyQl4hkshqd6L08Ku+xh854wYDLcvZFqivGvbrncSw70JIVi3xxvL2wZG2sp
Wq6aebGVMF0Pc+GgvbCALfFwAHvhBooEGDwsDvcabOSKRNxIAuh3cqVhRcFeGABAYQAAhQGgwi4o
DIwb15/2DucqUz312hri9mskbCedOhxPNLaki8XqWuY3wuQz1lBYeeNnhrU8Zesbr+L6wtcu3I6b
kQhUUX9GwnbSqcN4kdhG6h8kGKtrmd96e+FYQ+HqJagV1uGpWNZmyDhsQsLrF2/VUbhYPYeWxRM0
Eu4HzZLupmnFGKzRxLa2SBloJoXRayx3U5Vp9sJbjfJxTXnciV8mqKJjCEbClIyKwZ3kgjqpbCgL
0Wssd1OZaW/nDtPzIcjpBzGKBK17WMUQZV3exqdrPpTEri8sFlr+T1BHFKNYo7WJqaTGYHcM9ZSs
VgukYu0WtE2QmcVHA/XrCyctQOzekcCIYmUrRGewpxHQ2MWZh15MQ9Ej2tY6xTrLDJ3B7vWFRa3O
H2fOuu5qRGeTLS6LZdHPYG3gqoi5vnBmJOyUIG0vITyUnr+1B0lcXzjWUNgl8K2FjVt/mGED6wsP
Xpg3NRTuVJdqbUZiceAF80opJG2HHp0iAQxyWqOJ0xDnJY498+jg6IBsTSbf+Hl6AooEMFTYisTD
k+cODg+me/nVdnZ8ZvP41uTGASgMDJvCxw6feXT46LbX79PH//zLk6vtUTjbD5dXV9zMEXM5sjxQ
HpjNz0tvudPMb58aPityw/Mc8DajltExZ6xKSXDt+dUyiYneSojJeMqrMiXuqjylCNotgAQKv/7r
dx775LfejQrx4q3JhP9iU9ViU6t7zq19nZnztLozDyXLb3aib8ZbOiXuFr0ozcqUmeOBFmoceXQs
5Fw9dXHGE6N3JcT1gs6prD+dvKsXQd/8nWkN/3n+5O4Tp57/0f7b/zaV97bDx+9+cO3Nj+088eTu
2QsPFx/O8bwNMynDOKskLVOFbuVdF8uKrM5u5eec9cpgW6x1l4YFHqcfRgYMdDXMU/5Lw8P/+8zv
/83hxvaPyP5c35397SUc97Zvzc43dreObR37yUFTChvlwDib/ZeELk7nHGfczReeouN3BJ6QqXbS
cFG8nURZSkLlBetPYChzDV/50sEGIfM15PcW+sv15p2tGZNvxRF5U5cCjNWIBa57UV3yrjuLhC1N
EvAql7zMVCdpBNy53RnElUmsLJX+tIQ6edRoTH843WgzuumnCDmXrAsTziO0VrOUJaelHjbTx2by
dul9GuukQv3NN+gcXyZWL5iQN1OPq8lsuzi4fvMv33t/euLZV87t7kgdt+Hf7ucuPHtiev/uazff
jpypmJi1kCwnOFlm6+9bxLPmzukymHl4HBbWMlT/9XKC3Hh5rlT83HvHz9zM9du5bhB7fPHmsa3/
+KX3X8tiajgjwYwBS1QJMKY3+arIc8VihejNwsNDvSTUB48Tp8UEGtOmGLgrFftGlaoMxToay9ZL
5F++8eDOe/Thc48ufCn7XF6+0Qgc2bmLH304fWP/9s2XGrzrcM0LZxMR8r82+C1OpUteN6ycgc2P
yjxSOS/cp+mHOi/ccjUqD8b9zspTO8qkbqKDM30KmBvPVM0XKTeMC0bUelnOvHA5zjs4OvDPDj+9
NZlMriz2snmxt3OJww+gi3IOi4flUljOtl0+eHQwf0e3Xb5j3p5M/uLLW1fasJRY8AVzpHRlYHA7
4r8BgwdA4Ryvf+bHzxwdHE6Pbc7+fR9mPsBw2xvshQEAFAZAYQAAhQEAFAYAUBhYeSg2EsXGgMVl
zTrDSsCuJ+b6XMUYC2uNmMKDXRitz1WMsT7RSigSYr5te7aFpFA3cJe3SeUgiNtnyxjJ+m3A0qWw
LvSoKffUi+I880P7W+e9B4EPMbxSwzkHJ+dL5VK3B9optfJ+AJIYiJDCPs1QBFTGfpago11LejSR
VaOwvlBrcPnlbhWJ3qglQOPVUiQscZst7E5rJHRnakT3peFatxcYnxT2rC6s6gqG3pD57K7uRT4j
jB09gHoKU+OXqttBqQfTS6fcoj2MF3sZlALLUCQAABQGAFAYAEBhABQGAFAYANqHOqkmaPWrn0XC
sU1rOccsPWRbNtvBNM9mJPlLQuqKt4rUng2rvMhE8+2izR3jPRkm2JR3hBReGO4t4DWzIGq/ZROm
Z+FsHL54lW2OvUkrB5XDjtxUtsmCgsEjViRMi2HVJFiI3GhYsRhWvVX+C1rRIpi0NKY+dlIXXbX4
Ao0l3DkY8VatBjRdTSlsWwxXp/P/xLAYriQeLQxuTZugQscQqqClTjZSUzcpRKdwsdcgvJPg2odL
87gUzcXITUDyAyOgsIhTEVSzcLuaqbMHNl4S07DAJM7kqNer8LaHUl+gLms66n+IzDIar5vHRuHS
IEzUs1qQOPL3AhrjSlNjFBSSeLTDOVpPDhrPIQcP3F13DWOEX2OuibdOWXZrKPgGadwzEoG5NeFW
QytLTErUU6dyEK1GKBKe1pOdxg3nkoQ4MEIKaxbDZT9cjIbyM814V7nS+RJv45uN21TfeQyaybJK
68Krd+pLJi2oknNCSc2XqlSZm6bQhceARusL12iI7SiQsbGkpibwzqJb9L2+cPKrDVHb8fbMj8Q3
EGDv2ujCzfXGljhCW/dY+QaNVwgw8wFAYQAAhQEAFAYwnDPXF9ZH8GlTpNarWWFNsqpGwiRoYyOM
tYXr7YOrtVPwinitKByaL12QCCFrA5etr2pzIYr04+2DhXIDVr/rqEgIxQZYGgcbpsPEs9qwvc5w
EYlhcZybFnsbiHWj6dQv6LtWUtgQZ6oQM0yHSWC1YcMKUrU8Vu2LVatdW6PQYhABdju1EKqoL8mv
PoAVoHCN8NOM2TXbYBot9ZyWvwk7etTYB0eoL8BKU1iKtvhV+ITz1L4W6Xq225E2aCjAGlGY1g/v
fFyxvt5MWAfe+9GQoKRd+2BgDRSJ2D6YCssCXQQFqbC+shfBhStpkMEgLxBYX5jqS0D4LYSJblSs
Db+0QIrFcT5Oo9UMBw1rEUn2wb4bwEpiY3QV3MQ+GOgRfdsLj+8Fc+InbWDwqmOENhK0Q98AKAwA
oDAAgMIAKAwAoDAAgMIAAAoDoDAAgMIAAAoDACgMgMIAAAoDACgMAKAwAAoDACgMAKAwAMyhf8HM
CFfP2OyEy0tCXF/19f2pHwAEpTDTz2Y05uaZwWAUIDAkKcy81OS6J54JaSbFsE9CA0DvUpi7OGtq
Doo85pLNHOIYGIQUDjJYqslgKzBkKWypD4xZAz0GpQEY8IyErQIzMBgYmxRWJC8rRLGLuFAogFEo
EuU8McupzUti82pqAqIZWB42sOYY0C6wsiUAgMIAKAwAoDAAgMIAAAoDoDAADA27oDAwblx/WrtU
bCSqLQrLXYLyzTzlRnHFtodyOzrt0AvKnZfj/DbJXo3/iFiVXfRK3+7d7+StqrCNyOfhqpRcSRcX
WsUYfsUKbphz7cJtN4XzwjDLutoHVFSspsahJ8Qn1DB7Nf5jYqWOkhKu/R6FdnBFrl64ki4uhJF3
zW/iHmcjkcMXb3kprMhe2cCVTZDFIqRqQQjTDjnfe0ZlcYoEilHjoagW03Ie3pH0a33IYeXpFAqr
oqJs0rSUwsvvj8Q4dpHz6wwhPkY8PVUOS2+n/sQ7t5EQ5PQDryIxK2paL0O0LrBHXStBK6j2fm5T
zTF2p44OREVEMdXEqitvcQJfrOjGkRqDwybv/hqp9gunvenCKcl0o6M307ApsZjXIMs0vRB6rJsl
Mjidwo3KclC9+jL0CLEqTzcE6AzW5oVpqf3GahGkz+GuQB0nPZ1YE0ZPUhUzXR+kPQ6xUtKSfkXi
ELAmiYSHzkYV1bQtrVFLK+9a5MVjmK6imi2q9bvywFcbY5SxqXPdvQJfbQCtagKrr06AwoMFrZ2e
WDCWEeHhsUsfPn/+zJmv7m4/9cXTH3pcQJEABq1IXLpx9tpZMt0/NZ1Oj8jR9N35ze293DE7KrTd
mqDMgVZx+UpqiLv/+v7G//DHHv3td06e/Pz3jh+/t/fBncP9/f2H79+7d/+nP/3ZzzJfxVzaA2Ma
QpXCcqGI8oqbjYq5HOXClnlgVi4xUUSYLTXR+zLESqZ4z7HmS8Rw9fnVMjFKkOkLODMlqLZmKMvP
mFZBRInDWgtaSXxgUvjSNz5Ozk2nj6a/+q2j6ZkbR3tNtCynLjxfotJe9Y85T6s71cKW89BaeSlr
XrK+GZyl3PKim3Gx8qwc1OfnXqKX0Tii1tYMZfkZU1IuXd1rQcvDANaouXtsY+PsuTMnv7rz1FOn
n/jQKXHl+cce/ujNt65df1XcfOe7t2cM3pZeU4/EEMiF9GCkeHaWidVC0jLHasKWWFZaISMlpfly
Vq9aVv3ZzDElEyNJLdsl/jkJxrE07t69tEHObMz0WHJ0dHR2JmPP3yfk3oynf7iX67Gzv72Fj/c9
MxKMmeXOlCWE81OuCQItMKupBMBiWDTRZOm6Cpl7g/TB4weXNjb+69zJuYx98ouPz2TsiXcePnzr
zbf2r1+/cfPWXMbO9YQu/hwU5iaJubPofUyVXV0tmfshCDN0zRZjrV1EznR1lInJ4No4peDQVRil
n/MH6Rg/JB8+f42cfuLa5tbmta2tjRd7r+xN/ZnrxaVZ0sU6gbxQBBlfvgKm6Im89VhTNeyYMmmk
tQ9C033h6tXrv33jJze/cuv23mvv7d97g352evnUcyc++uxHLl08ffb8mbNP7+7sSP21zT+3IlEQ
ManYOB/uspZLqeS+Eh3seqInrh5cn749o/WtB3fefe/O3ffv3aPTU0+9/txzpz5y8TS9cO7M5MXd
nb1tqRM0PDpnJMztYqKkQrUIsTlwyRULtm4MdowraqaZasrIcmbM+3DG4tADovXBj1+6fv3mT249
2Lu9997+G+/fo/d/8PD5507877OnTr9y8dz5L52Z7LLs8/qCn3XHAq554WwiQv4n5eZGyql0yeum
mrHMj8o8krI7Eu+bvNW2ILzlWOtmm8vZHGeZGM2LKdtHcfdcr+XMSKXx8Rq/S2jGi9X165+ZPvrr
P5pOX/478uhT/nlj6qZwd2IOa2i3WrIpJBkbhV04Rt79+NHbZzbeI4+Ro+nv/uOjjdutUTg2u9gk
tIHA5+0weAUoHAbMfICRUxjGlsDIAQoDoDAAgMIAAAoDoDAAjBLq+sL5QV360zxzo6/PvFPWF26e
BGYZx0thOvjFbzrPnaDrusjTiikSQohiYWEhrNukcpj5cfrsjl8AEJDCuiiivjXF1fPMD+1rtXf0
8kDqcM5BmPlSudTtoXN60dVcdR9oXQoTa4RnXwib2Z1TGBIYSKZwtReJSSHq4Bd0VWBwioQlboWy
/LAgAanckSoMADFSuFAKsg2fKu1T1RUMvSHfGqpzRaL7NChGjGOnMDV+afFfUR6oy0svFU9XIgmg
Z0UCAEBhAACFAQAUBkBhAACFAaBbCgvlVz+LhHC8ComNUdiuS9ieEVhzKUxdxFwkOAA0pLBpMaya
BAuRGw0rFsOqt8p/xkphxWiGLaKQtshKdKR06cMcGRgpnGY+tsVwdTr/TwyL4cpcmBY7ZlNfjFZY
bZd4PbrSBV9TAHEUFnF9vGq1a/NqzmKqXnkjo84oqOUBAGIpTMvuvJ7VIlLndXG4VikQC+nUABQJ
QuuHWLT5SEw3Q47yAHkMJM9IiHqR6BHEhtx1fiwklBDCFbuwXCCIgXgprFkMlyprfiptiHXLWuVK
8lcYjmWMpIwiO1aHwi+1PMCOFwig0frCNZMDkXMHNtmBVUDf6wsn7yJev6QOOAkMmsK0BR+aPxAe
6GY4BwCgMACAwgAACgPrM5wTzuFVMfWVNOxSLXeK4EYMlWWPc1CnOlOiLQkoLYms/Chz00oYzI+s
EYVD1mALEkEEqERd0Qs1YX3lTEHdYSovWhgKDq+hIiEUo11pHGyYDhPPasO2YW8RiWFxnJsWexuI
6HfJTGBFpLBT8NHCDFg14iWB1YZ1/mmWx6p98fwWdUleapLWp4AEtBBdykMMrx2Fa+Qf1emhrzYc
yRbqkrk0oIOYi7i5uO4KjApeTwpL0RZvWiP8pIkwNgtLSUpMoR+rWmiLGgJrRWFaP7zzCVXL0jdB
qRXx7IwLAwVinRUJETkbRQU1RakIStlKk7acmzCOhqdBgPWkcGUYrE1eeS2EiW5UrHXeWiDF4jiL
V9BqhoN6SGhkJjA6k16sMGDyimNjdBWcSklQuGf0bS88vhfMiUM0MHjVMUIbCdqhbwAUBgBQGABA
YQAUBgBQGABAYQAAhQFQGABAYQAAhQEAFAZAYQAAhQEAFAYAUBgAhQFgUTz88NndJx//9JO7Z88/
XCymDZiEA+2i7sOj13/j8ODR4W2yvZdfb+89s/mFr906AIWB4VP40uGdP/j7W2637cnkr/54cnUh
CrPsl9s5YfLm7A7LfWReOZufl95yp5nfvj//08tPPgIr88lbipeXBeSIlSmpVc5FkajFFJF3OyFW
PBTXq4Qp+WBG4DLPfAgUPvYvXzw4PNyrDbzza9+efJ2+0FAX5jz/UwltlDCbe8j5m/nWK7GoZLZM
Bue5YNlByVMLLWP+zFx/Us1Z3q+cizOelndnQlwrV2bXETMCF3levtJ74dzuZz90/7feevudve1C
4nqP77567c0Xnj/91Mlz0RryxCMMmCp0CTEEtC2rs1v5OV8ihbkhz1qU7eaTu5wb64cW2+YJcV8q
LgZb9cOWTl5ybGd6cLgx03lf3c50XrI3138jju9s7+9v7EwmW8evnGgwI5G3fZ73foq80YqEMRZT
40sUx4x10DQaOi/wFGrUljDhwSdepgA+tvFPO6dP3X/r6o1bZK49NPl79+b1qz/Y+PT2mQt3Eyms
FYKPCLK7bp8r7WitMoPc4MDCDPbExutleFwxMcK1E01jCTNY8StLYKm1cP6HU7LXRkTXpmR6rTmF
rSqTnJbK1kxGMz4Abcub5fZ04biG7WvuscXEhlaYjXFw/St7+/Tys6+c292Rum7yHztz4dnnpm/c
ufn2C6m6cKhIh6FjLYsFhWzsqBBYnbQfQBEk4Sp5eaZTvM4effAL38v03ExHiDh+8vFvT77+sbka
XK8KJ+7+KQdtVX9XFhZnjA+g8PrIgTJyje0NeELea4jMnPN5A5bjBy/NfvZPfec3PzjziSxzhX7h
PO783quT7RvfnJ291HxGgrNsHmjOSa72mNk0cK5bSi/a2E29t/SJ4eoZOsgM9yjYVqKuYqrPuxVh
dKaGrIYcfGL2883Ljz74lW8euXXk7cnmF742+f6J5KgT3s7FtvDV0ejGoR6FZTwbxqsNdbbi3Af7
n/+H2xltczbvHt88tnXlRMP0tuI1iSuXr0T5uwwGt43LxF/2dQwmV/rObE2CR3fvH/63OPznJx57
7OgjW08+uXPw4Gc/vXf3z5qmBxsJoGcp3DZgbAmMHKAwAAoDACgMAKAwAAoDwCihTAvLnYSKWTZl
M8S6nY67npgrdsDrY/MX7JA0YgoPdptBuQGzoP20FmD8ioQQQu7KmZ0Zt0nlMPPj9NkyIBeBOCms
Cz1qyj31ojjP/NC+JGQvAh9ieAUoHBR/VKibICfsc7+4LkEFBDKQSGFdMxQBlbEPevUg6TGWWzUK
Z6RxSlnqENgd1n9v1BKg8UoM5/wjdJFpEjUSesQMppRCV1kBKVwoBfOBmrLvvKorGHpD5rO7uhf5
jDB0YaCewtT4pcV/RXmgLi+dcov2MF7sZVAKLEORAABQGABAYQAAhYFVBT7/XCeEZydj5y5r/PWd
CKQwsEKKhFB+9bPYRm6HkRZsovAgbJM29Y4wbxQ3zVCKnzxSO7PueFXTu0BupCUeMHxM2oyMOuW9
ZhZELWJoFnCOMM5uRfEjaPEmJipe1UrJn5vsP141j5jC2XswkVWkNH8oT4nI3zGXDsoHFfMrUfov
aJWfy/v5Mcx7IytZYgadFiRXZUG6Zq8yxAKu0f56SaSGwrbFcHWac9lwKCUeLQxuTZsg6amwoxFO
IjqsdWXTKcLagXRuR8Q7j4sqmk8gN6tH4dUZznkoLOIeXSOE7dXZAxsviWk4u8KZHLWks+qf1lWR
w8aC+h+CFD0KMCZFgpaDp3pWi2ZSP6LhacZFgUblM733xZtkb6z2HMAIdeEIciTopg4eaF23MPp1
Gmw1tL5/cQj1IBc9GgomJMY9IxH4Bl+41VCqKJvqqYs91BnQMxvhCORjJPXcDEvTtRG1lLRRDHRY
iUxCWqNmByxPZTevK5bKldJrk6gPkqQ1sMp7hXUeraKK1zv1pUVj3PAzuoxYZAbKK0du4VooRLkb
ri/Nn89jXYdHI/NpexTUFUWjF8wLDUlbSqRxaqvysXXjQi2EDKH23XDhGLPxPvLRFgrf5UmU8/+a
a/IL5vkLrT4YHN85ik5axjqQuXk3H6b54mqEk8E0URdunomWOEJb91j5Bo0Xfjnki6GlonXET0lL
FAbWUjwnD5H7ix+WakD/MrzV+EFhoNexQvvxg8JAA4aJAcW/Qc1gbjOatClS69WssCZZ1VdyjlTN
6UvthnD2NdbkpjHfDJDKpJA45oWlBVegppWZ9cBLVFpDTRqdT2fM4Xlh4Q1GU9uaoCFKE8vdctTa
jj4jKcL2wZZpHbDK8K4vrC4zrC4hLIqPO1yrDTu+uJCRqI5FvMLbcmgbqhOoux7wri+sfeRgmA6T
wGrDOus0y2PVvli12g1pFDTcTUVY/uDji/WjcI0gozo9dJPHSLY4zYUTbIij7IMJ7H3XlsJStMWv
wif8Q8mI9S9jpKRh7RPdUiCB15PC1bcMkQzQVVfhlbcx35JQN69pRBggDDb/id/j27kdeGiPcM0t
MbH6DHhTnsRNKdQqmop5cVDK2hMcwrVwZd0XzDGNAhLYBF/JxDZdtBT51hZC+eiyuravlHNqmLFp
gaqIaTW14VwFQphrPlTxeA3TpBdhPgCYbEk3xnIpyeR5eVHdyS/UGzJU9i+7W94s7uSSt1FivvgM
TxFSmBqKBDFWEibu7zipdupYlFhfhJiqY7+QzR+18hSSvWZOoV/4++eiV1bP88vyDpdn2qG8Sbjq
OTvlrq4+MjF5YceneYqWwgMH7IMXE7+yh+fMwQtu6gCus+yU1yoNyYlxEk42ZTg3dA536HstdOFg
tzxjm8EbFgjF2k6spRkJYPUViSD1dInJA6F424m1M5wDVp/Fha5ry9OAsGUkURCnJcYaPgyk8Pqp
EyzrwNWeXLml9O057QwvGhcNRcAhUGMTm9/0xFenbWCJbGDkgCIBgMIAAAoDACgMgMIAAAoDACgM
AKAwAAoDACgMAH3h/wG9TK1mMlS7eAAAAABJRU5ErkJggg==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-21" MODIFIED="2008-06-17 21:40:02 +0200" MODIFIED_BY="[Empty name]" NO="21" REF_ID="CMP-002.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Hyperimmune CMV-IVIG vs. placebo / no intervention - HSCT, outcome: 2.1 All-cause Mortality.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqkAAADACAMAAAAQnApOAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-22" MODIFIED="2008-06-25 13:49:44 +0200" MODIFIED_BY="[Empty name]" NO="22" REF_ID="CMP-001.20" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Polyvalent immunoglobulins vs. placebo / no intervention - HSCT, outcome: 1.20 CMV Infections and Interstitial pneumonitis.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArkAAAHgCAMAAACW6YUkAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD////AwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID/gAAAAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///80TKWtAAApAElEQVR42u1dS88kt3XlzLRxR4YByx5EkmM5RuRtAC+8CYKssubC
gBdZxf8hvyLLbAP4NwjwgstskkV2ARIgD8CADAd6TSRNoAS2pQt/tvN114NvFllF1qvPkebr6iry
ksU6vHXJOs16QgIADoinaAIAzAUAMBcAkrjsslZSqKy9UnX7hTA3xu/TxQQSSpVRlfonLG510aWZ
W8Kqp1QrVWrf1Ty0z5XDhrptyoG/SulD6f7hJ5QbnYu61UWp+DGzuylx99W87IaESpr+cvii+kND
b5ZDn+/2ShX2zCqvyKEsx6YcO4NavxmEebLKu0X0Fdymenuq5n587u3uEvaXcuzN4/FralWnTUI2
B88iN2GFPlm/FZQovLOctZr7iXNtEip567Ld38A93KHsmHDs9mppDTaIfNR47f0QUolNibq/ah4j
zjVJKffOwbkBpK77cI7SPiZ3cF77qebTgxH3Ogw4IC/zXL4cCeBGh30khWruMs71G0iJ0MxK0Ovq
hNl3q1tCKXfXTccz3kV4sNtq7oe5qmdqoM+qkWD28XCbhW3EE0ZsZpup7M2iTdC3Ql/B9au3s2o+
2YniJuBaxUmjAuBkcwte7ADiAgfwuQBwwrkFAABzATAXAMBcACjExR7Pd0/1HOmPSs0ACFMtsGg6
wBV4WsdUWWYZrlRpEZlWTVmbe3zYsswPqYV+8m9kFf3kdqA6tkRgTNvNo5qHls4p7r+GF6dU2Wn8
ck+vy1GrG6k0L9NZzZaQlYrItTpdjCxsBjXZ8F27q4EZ/qGG2EMNL4FrNSorldHZpCVlFeZDJ51y
TDpqanX/GvaqnN6gs2shbpbSU4tD4+nLi5iwOvR2GThhMRTl/tYi7SH6zIbCVYa6g3c7yFYnZ/il
fdfQinP7x3bW/V86FVGW2t157D9obEdNhivPlLkPuX3RbJbSs0vUpVcT6fOLyLHqCoh1MyyUEvcW
3UsxtP8ulI9b1PCpfQuQISFsVAHk5VBT9+SJW4yU0i1MOS1UcEeTsn4RqkSjo+LnbN9v7cvbf/Me
+YeuQHePbMGQvdfw4kcKRWdXmiM/OnRPU5UK6II+YHERYc8yM6K1Ii6//0v9w1C3oubY+DaoLhmf
nKKGl9Atr5S7zUYBXlEFvSSD5jOKCFlVneSs9z8qu356DB9NISMW1Ro/9dx3DZ86Ua7nO1JTGEYO
afkbmWiG/FkCu0IV1XKNi5Ay3/2aOnnvAowhtZSDuX5L2oGLtEWaVW/Le63hUzuE02ruvi/ZHsgJ
bIwcSt89lF1NP0Eyzg2W1Fdpmli6vEScW1zEpNVQC9ltp3zlvMruZm6rDtNKVn2ry4p3XsM8rVhR
SVLlL/VxYsSbIZmlRpq2J7WTGl6yeFt0AdSWKwHsB+XNAOLW97kAAADnxI9WLu8CnwvUwcpMgsoR
OCbAXOCYsOcWpLVioqWLstSZSus3gwrO0HzEhsu+Amf3ufrZj3IXVjTWRbXFUubStUpZqYRrW4G4
QAufayyk7EJaXnlQ+furJquA2jW0nqq7XC4ALPG5CQ4VKF0ctashbhWOKHbzRWCBczBXBSLeOHHV
+C+qdtX7VKwrSIQQQM25hcqiqYQnl3C5wPK5hTLiTnJu2kih5hYA4j5Xuj8McH6v46krU7NdUiad
r8Q8GVA5WuiEtwFmmQLUjJ9sKVPcKgKiWHAXmAVoxYA6WDvow9Nf4FTRAgCAuQAA5gIAmAuAuQAA
5gIAmAucGLZugYO/g+PI0wp/f58/+LEAjxauJvIMdbUqymJlo7kV4eHYcHQ8f4q3odvubptdM3tH
bWvGFx6P8no/aHzYAXN5soktUOjqP/4LfiwC5deOy7PobJPpE1b7veQau/0/QVyySGe1GflHx3O0
TliXe8vG9+Rzb81DPDqVW4P3nXfcY31YKSPuannfH69hVlpO3SYmsuVVZKof8+JTpuQhq7Jezbk5
aR351E/Du9WKzDWaxvIYwt0zfFj7G6Ig3qDyLAXdK8tqoC2qNc/NY1Ck5h1n20cJqmj3esz1WsXs
wxS50JS6RotjrqFrFBia3Zt4gdXgsev9iQuqzok2Gz0GsPiN1ZzFomXNTeWGZpbXsayyVSqg3FiB
cPrJaPmumVvWAHSu1ltUfaZosMBrVIC3af/LNpfqqd3hI1NduW43HCtUCHNLDfGikuYdrsEaXlB9
IhJ35HYvzr1KkPGpb18UGZvY+7kbwvQ77Y8ljrDc0MyyJ9InrbI1fmPSybrtabtMwRK8o6Gecn/h
L34TsW8kGMn7inrxmwhghbgHcwvAdkNGajbUPATgcwEwFwDAXAAAc4Gzj9C4LLYf5l0sZWs1Ta5f
FJeNPLisHln63LRV10S+PlcfdhW4lj53aAFnEt0ubxA50h0xVyyQqNTX5Aa7FJflqa7PTVl1TeTr
c/Vp+QpcszH7FrDK98rrO8uG02IPYo05q0vQAXQ9XbsXU5Dr9PngM/m6/V0XMac3lMh6F6jqfRM0
4wQp0ahjC0RUjjUFwvmdfcS749azhIuhpswVvaDccJ6W1snq8ys0Es24IsO1z7xr0nKrlBMMZJZO
Mw2tSVy3kvoZ2sMqtLh4vajv1PbvECi/D/KqzTd9Ecsqwpk/dcuS6XKvQSjR5+YlDGsW+H4VN5O3
hOhOrczZxS+gmGbeEShHKUBFxqioBy0RM+9Ed37ZQyne7/WiV865qC2asMRmG61qltXQjyu5bgsk
ZWJ3Iht7mnO1At84GSps3noztapcwao5wVW7AhOxwl0hGOd6QYAXEngX0BaWcu0J3bkErqvPzUnV
n3qRPldzMNG0xgh5LCJc3n0A+tx9A/rc+dECsC11V8121GgB2B2gz4XPBcBcAABzgXXwBpgLHBE/
ef/UIzR7OtebVuHYoRUEukKI4vVzq+pz7cNJ1YLbhvXXz2VnITzLSkif+wd/ffK5BZo1ql1BoGuW
ME1vIcqrMaHPtQ9zZi0HNW/l9XPZeS5hWwnoc3/y46KGfjjElNMl6gG6Ftd9nPsVSe1Da6zXOt2V
TBIUCm1FzknYVhueMc3ozxy5QWj8WBRN8D6bNR38rlh3Lu6S9BpsiHTJ7u2j+mlfM4fUJBvNKmOZ
In5+zb3S6LXPSxrmYVYzyi3Xz+X4NcoRP3Poo26gW6IWa8KWHKv2mbfR55bV+ovXP7+LONdtFuLo
IfcCtdXpHmHdY33mppq3qj53RuN+8foXyyLIY8S5If86/a4GCn1sh81crvWr3GFkxZV7cHEdvxBn
w9OMuxHn3KiahwplNjcjrqEJnaER5uoNcVpcgjcjT6Tb3/ISEtDai+Zm1Ct5cc2VfGsVkSM79tS0
9dfPDRQBfS6wM0CfWxgtALuh7qrZjh0tAHuaqpg5ToM+FwDAXAAAc4F7B+JcYB4eNmaQt96CtSIg
ZyxW1F6XW2bbEdpyvj5G5Opzwy+G9qW1ohfM5utzhzenjoMsT587PEx2q+ZU8r7Wz2UKXGlKNbdY
Q5dbZtsR2nJB78jW50bXfebwarf5+lzbB/Q0JndFs8gTTrOSdPppsUuyIW9fhktirqQrVtTlFkkh
ltWKsqyGaRhfxby8n0aycqDlTSklT7ubhbc+A8+cve+2LDqHuTThF3aqy41UP5vI6YQUubnnkbBw
4d9EDh4XiQ1UzfiVBK3Qtg/O3i31uRSO3+jmdhMr6TZU2TjXggvf+zszNJmySrF3cwdu5qX63Cnu
ZK0leQ/LOXr63OhJc/Rqtl84t/haeOusL+CrZ5VStfQbgqqxiSqmOt8ILXnVlkahFYZqxaFZ9i8o
mUSN4SWFggUuPEWGEGoKOfrcYWScWr+85Wht/q+5siWyQ0Ke/1OaFRtiHz6vxx587hDnBu/8sXCg
vS53zqK8M+sxUUTyJOPi2QJ9bvqoXXBkUvdeZLrQ5+4b0OcWRgvAbqh7gsCi/dwCsDtAnwufC4C5
AADmAgCYC9wTjBGafoYUUOVFFCDBtWpbTchw2fvLy7Lkpc9I5alpK66fay5H6l+asTyR9/61U80t
DJylXCoJX5jaakKmSPvLhVny0mek8tS0FdfPHSvg18mcUCAhVnr78oPYyW8idEMmF89dX6E7g+Xc
IH2Z1WbPAqL63DbFJs75mfD0uRZoHeaSv4h+cPHcCYXuLvhMTdJT8SWnuiRmX4hKXnm1n/5S2ufu
QZ/bPxv3lbiTCx/3oVXb2GpGAW3qNGWVdUONssfMuHNRhXvPQuL+9Lnz2rLX4pRKYtvGubOzLLWq
lUmmB8htmHSFOeexGe2JPZuWPX3xvRee3LW6lBoGUAzl7oinwg10nXCXc5rTNDJj1dgzgQtarrhT
JNt2BYHwIaOF+OK5LaW5K8e5eemTqQJq2mrr5yZih0jeEwP63J27cOhzM6IFYNfRxxrZzhQtAHsb
72Ucgj4XAMBcAABzAQDMBQ4/Qqukz203nVhiObnS7ewick4xoLWtp89lX8Lj5e2XI4I+N93gYpUV
dM1yytJW1TnknGJIa1tNn8tWw4fz9stG3+v6ufP1ue26OpWnLe1ClHW4/XQUxRjO08mnRRLVSf1M
/Dasz215tevrc3eFnTwJrXQTCq+wx1HBbsvOZeLhavK4+lwdPQjaAwM4sdLt/CKYpk+R3bcmF62f
y4WnuoPlci+7LDRbnzsKU3e08DA1s1twiiX63KxliJnWOMcjxrlew+fpc9s3YbHLrV4E0xwTBfrc
rPX5IdMVNfW5K6y5X0xcbkJcbhfTZi0VfO8S6MJoIVef204eWrJ+bp+2tDI8NVU7bbVPs0yfa9Uj
rc+Nra57ekCfu/PJEehzM6IFYI/UXTXbqUZowE5nR3ahz/3K1598/pvNR2gAUIhvP//wg++9DeYC
x8L/vvj5Z0L863s/+XLjEZq8/lH6m3Ijbxk6KLtMXWZ53R6TdYce064XvY/nIIdKqUp2lUhYNffr
w8P5m20SrrKyt8bShDJLk8OpmcVLt7DxOrTGa5fP+q03Xv+vLUdoj02ghlN3qOBt6j3XXD1fHjes
9tKHAlmb4VaNrkCjAjU6RNyquV8fHrbUVJ9w0hvGldWI3Za0ipe2GdWd/gos+u7XP//sRb/92599
a/MRmuo6sRz8ltR+VZouVie3e77hmW+71OgDVnK5yj6ZFl0jxutUvVSd3uN5fDnVBo3w5R/97JG2
r168EuLx36sXv3jrH7eMc6V0m1sq3e+7TdMvSzuznHZaK3D3Vo2x99S5jNIOnDyrdakSpXnfxFZL
r3yP7vH2m++LR9Ia/15++k+bMVe53FVBhxMjaH8rm+Rw82DB7CW1ooVUGZPsyW0TNdXR+nLN4tU2
Lvdvfufv+9F2PlcHiNn345HKSg1B5qPHUFvyttbNOe5yywPvvDYZAuXtmi8bf/Xp29cY1/j35psf
bzkrppQoJO4wItoZpKwaoPTmKlttUnm5jt94/unr3+8DhVu8+52Xf75dnCvdAavMbWYzhtAeQw0X
e2XG6mmOWoX35oqsmqlyvKhO783RBIYgzo4twrMP/uX1buORvm/86pPnYjvmqlswpvTko+q/DQHY
uGkGWdcdyonRpB+3reSX7VBR1RqhZYWjupX6w6E2SZkLGvYOR4pvc65Jt/vFv7/Zj9d+/fv1e84y
rVhuW0lxgNhthzFPqtnSjnylFn/rV58J+R8fNhhbFMa55e6ndkLAm5aYR9x18PLLb731tx9u0jTQ
5wJVJ2AO4nMBYCuAuQCYCwBgLgCAuQCYCwB7gbl+bvfhr7Iy9QPohj+Qtt4fXroYblFBrRf/Bdox
d4dvOnbWzWnbQ5ou/gusES0wc7/Mym3L2S30gcc0wZRNPO5alAJxD+dzbf9Drgsyv1hL6VIzZ+Us
tbfGrZzB3DOM0AIXkdhk6LrLYRK1XEOeuy5JDFIc1ef6cab/hX1CN2duS/vDurVwuOdg7vi+DI85
FKDVoYc2oOypogXPubKxvC6LhA9uONFwONvAWj7XWjFXh33kL+mqffMq0ULDMpov/gu0ZS45f2n4
3x3pu0laXW/y67VCQcAJogUAAHMBAMwFwFwAAHMBAMwFgBTMWTH9snnzewEC7wgd54b7BIFHrHpX
RCTbPcqjSKbhDY/+mx+NffrUjArGatPVAYLH4zB3MSjEZVuhQ4HnVY4aLaQ7Y4qWxWR1jmDRrP9a
r9j0a6PrwATiHi9acBW6pgSXuRPpGgpdM5lOP7CJhmy9sneSlE5VDHu5mWJ3BNNj99ZpqvMBB/K5
vkJXb17/F45CV/s3Gl7O7MpzhkCCTR0PeXf1YAAyOMpgptBbiv33jBphwdWWofh1a7OsdwDbMJfz
4gBTwupfXQreZsn+dIhtZXDFAxT6MQ95PpRmuMzgM1+mQfUImflRmDv+TpGnycwij/PlwXHO7yuK
7vFznCeFB5zAzkdoNM0JyqdO4PLznKAyI1Pkvj/BXisX21MWwNHmFhKTYxw8wFoCScLcDJGGCjwi
F2SiyE7OfkkuvOyRmWspdPXIZpCw3rasYNT4Zv9QN0Pw2ie5jpsskWxnwZIIh2Lh6NyVZSY7GGFj
BpoQ5+4Ys9bP5fpx5XwrpaVhTYU2WHv93OInEdO/M1yZFoUPDEDas8e52VMBM1JUKmhWeVSxisCG
gOIGAHMBAMwFADAXOPkIjYMDnmF+tmhU4z03ZW9ylMkqNiF3YUezm6HHNdbbxVzC+ZmbmudceP1T
CoCQttbUQfBQvvGMY0KPa0p0QN07ihbY0Nz2YlxHqisiq+n66+gORhyFbyfljfYLb8ecKVtQ9l58
ruO8tEi3c1yGIlckVtO1GWMpfU09r6mS9cMGywInSB0MNez1duF074a5E67Ols6SvZpuJkkoRMaJ
J3MWnUXOIwU85r035vaOLH91OA5u+t+5PIbWCrToitMl3Q44NXOp1GXZ8wAcpQ9l8L9MW8vgKJib
PRkg7HDBdZyc9KnuL+Mtrxq/4xfpcevMhwCHY66zlizb+lzhf7NFvNaIyspkKHy7oRfpuQpKc2+O
Hjcm0AVOgSeHu65z9LhAe6ytzz3e09/Cn4eBuCfFAXUL1DA1AOYCAJgLAGAuAOYCAJgLAGAuAOYC
AJgLAGAuAIC5AJgLAGAuAIC5AJgLAGAuAIC5AJgLAGAuADSE/dtfKVT/Ka5b/YcwtoYUIvqTucfd
10T9h213BjxbAOAxV5pskar/0DtEKLHHNIf0C1HTFnBS5kqDLR59LC94+79zhdeDxt/bbtn5Xjke
MjMOH2MuNVrsXet4YDAQsAUgzo0RNHUHv93AO3b1hBq2VWdFDcGF6hMYkUT/MeY1jtkHxp4xBioq
5umBu/a5KhDxBneoGKEDzloGuoaKhAXOAZVRAACfG+VpcowlzRBDymlDwbzZES9cLhCcWygmrrn7
dqdX+cQtjllDBQDwuYYntPnm7Qh7TpkxcSWDeTMdqcTMGDAdLUjZzYQNZLnt8DygmaLf7iNb/WFm
Uwb5dHrlGbY5atoCd4EOa67lCN6dGVjLEQDmj9DaAB4XgM8FwFwAAHMBAMwFADAXAHMBYB+wZ8XC
L0yNvd7G3z+8Qi30sQT++wKn0vZvBi4teyJ9jlXj4FCV6beyMUVKuGY2ixtf8klOnaxTJ/s1yedn
Lpe9+I5C7W+9Uz30+vU5xHU+c9LSjBOaTj9t1TjIww6eet87x0uwG3AkLQcuAxsVKHz3VhM8NH1c
cHE7PvHY5W8N3nfecY/1YaWMv/90scfl0rQzuwrluf48M/nV1ilz38rNFNpqyNZp0+96e57l+ZqZ
hLmEMjKZ/pOFu0e/FphJ1HCqeaeSc2ko77Y///pRRiJyr8BE85BfQvhuP7QAB3K0DQ+mjfu6hYem
dbpMV5f8OxNFTyx0jbaIueb2pnRdc6y6L/vuXoWc2wa2h5h5pjuIFCa5tbl1zmrbKi65xAjNZ3yi
GJpVNImCd9cnSwqZ8ItjQTuh7srMLWMZLclc3kuO+RbfahEo58Rmd/K+2Kd2b41MdeW63XCsUCsA
IMq+KjybGQ2sVqtAqAV4/Uru0OdSH+2THon09x6KjE3s/dwNF/qd9sfKYe68sifS51gl9kJPvjVJ
xtCOgiUELBpuwju6SXtvgCd4F/nOA42Zcf/qcRV+EwGsEPeccoQG7Ak0cyR2/lspfC4A5gIAmAsA
YC5w9hEal8X27KtCa2pyw+PlfKs8px6TRUxb1QfHtijT51ol2PpcNlSQifLuT59Lc/kk6mtylw6Y
2ahVvSKmreqDhtouW5/rtx/5Fq0pr1B5G+hzH8RPLxsyd2wMHnuto8s1Rbk68SKKlTnRxnSnKlap
+My4pFCmkK48quOb7Y1KME+LS5WZK3pBudH5La2T5XNWvClxUSjD4922XhFZVjn8Y5F6F7B9k5eX
8LD6FLI1QuMr+orbamXK76i8yEMm27P8Hlh628wrIml1PEiPjXnTINx6ep27Nwealb0fSGygqLtc
frizOJczbyZamdMswppz26/rzbKseremEn3udAWZcvbd2dxCbLyRdYGdi7p1Y7bR8s60yiuNl7Zz
uRvgac7VCnzjZKjQpPFKrn6Jlje/iJlWm7YA3ylxnV+tew7VvvsnxLq2sJRbTOjOEJ5W1ufmpNJ6
WTJmX+vocx01tKPP5WEm9z4EutDn7hvQ586PFoCtA/YVs51nhAZsDOhz4XMBMBcAEC0Ax8HDrkgD
nwucwOfa6lSmiYeWqwlz7ZLK0mbODk2ld881smCdmKfPtfIk1s8NNXLoaN788XmYyxS4ckkJtVhH
mGuVVJaW87tGKr1jleKJ5uhzzTNLrZ8bamRfvTsu9nJ/ca7TMkN7mUpdsd7D+Fnr55aCSqxOdh9a
cKopI1kyokqOI9CMzxLHaHvmTmn9xwBivbrS/LSlRI6kp9jNPZS3XJ8bML3gbl8nYKPECG0XgYjJ
XArHb3RzuwmlLkd7YpuwIafdiy8fFwgWkmFL0/VzOc1rFmL+0sFHjhYo5R44ejVbC3Ptkkri1qKX
Xkyn762mF7dtuH7uqMUNWhuuxB3OLTBNXbVEY6/QYPNki0wN0+flXWlIcF/iqacZDpasd83sP1Qw
ap4rqOWS9LysrPnnmG7r5lfiMmB3PneIc4O35di9er3FcktsNxXmVtfnennS+lxrydx03hMD+tx9
A/rcwmgB2A11V8121LkFYHeAPhc+FwBzAQDMBQAwF7hT5rLxJ/P9cL3EpFs0i7n5XDiXJuXs9bzy
0idTuQfHdpmsuWnQaUu2jo5FcKBRzAvA96ZyHJSkVHK1HdXonoibrT7JS59M5R6cp891V+i15Lgc
mDlgz0ovLa+BhwBH9sncoQm65jaXwN5UoVvO8TrqxpJU/UGbotTirKxuMO8i5OZ5lp/43ZVn4gzm
uo6ByVwCm3IVuu34XGC5tBFpeaqg/NN6IcHic3SW5I8Um9NMufV5yE+89jO0i0tWCqzpTNOXaJ/P
y9vUacKqyddessB139tA4j4XHp2MFgovfq/FKZfEFrvcWVka/CwubZV0iDp+5DZMkYi3WjMtoMeO
mZvRwcn1v43Yy0d1NQVhToVz5PvwyE+FG+g64S7ntJRppNkas1uvXlt9/mPuOfIJmmnFaKF7/QHF
U5whzt1o/VxLcOuVEDvqTDHc1U95BPS5+w80Zga00OcCh4w+oM8FNo53Zk4xQJ8LAGAuAIC5AJgL
AAcfoelFSAOqvPAkS2AFXW42PiiyXLycrxZo0pTVSKpAkVy8fq67CK+9fm5oIeGm6+c+7HcYX12f
206hW2K5eDlfzikieYqBIgdNYmV9LtbPjXWnpfrcHYhuqNhwzntfKVWRFdZX47wXwRffyOJ4lpOI
tmZuJX3uvtRipUzP9NBUrzsUkLPwxQEVuvjDhtQs8rkn0udyEy1FOnzk0OK2DfS5YS+YtbrvuaOF
YHskUxj63L2Amry2IkdmS0bcOQbPVfW54cUJk6v73iFzy/W5BwwWisOArN2sx0519bm0I3pshur6
3L3ECutbHWeshuacIZStoM89v9amMFo4lj63TZ2S5rgbGgXEs031uVg/F9gloM/NiRaA88Q90OcC
W0+RzBunQZ8LAGAuAIC5AJgLAAcfodXR54p204kllk2tar0ick4xoJedfgzJFCnB1ucGzsoQC/e7
e3Ef3Q9zhaihz20nXyixbGlVqxWRc4pz1s/11sCN6HNDZ2WKhY1E0OcW63PbdXUqT1vahSjrcPXp
KN2QNOesBtk5Lb0Ai9j+rvnlmfht6+veQJ+7J+zkSWiRZKn0rJhqneyi3NYztIf2zV5Pn6ujh2a1
LrLM87SqWQFpjkzX0BGU6HMndMWpsyLzh2/7u5WvXUS2PndUjbZbQ7fYcrOXZ+dUZLhHlehzs3TF
NLGboCy3evKy8G9vN+hFLrfURL0XEIRerHKnmql6+tw9vVLKF8vWjRUadJmsc0yW3/wCHMznlupz
28lDSyzbYtkC4kxM1U5b7dMUrZ9rjjL8RtQK3LgEGPpcYG+TI9DnZkQLwB6pu2q2U43QgC0BfS58
LgDmAgCYCwCZeAPMBQ6J91+LjdBMfa6xi8fJyHXVuMHx8gx9bk3ZQpZVX2sbfwwZWhpXjNKIkDCX
4pUxd5xQn/vi1etfxOcWfCWpfuK+rho3zIhCfW5x9Xi51YDWNqrP9ZbG9dQHrtTXWzg3kuiE+txX
4nOTupdYe45dn/UPJbadfKH2WSoIDHK1tk6SPluE4RTfR/EdVXprNt6dOF5Dsvu5cXYRfa5W3x9J
jbtF58gykb/I3QaPbiuVN/UMbbFkl8V3PolGC5Y+d6qTtlbjzmLA2AvHH2fVX1csWxnAGfpc9sTP
nE1+Tyycox7eCoufeb346ieL7K2nxl0rJi62mm2civW5c6pMPvtPqXy0iTujJ2yoxp1xQXgfP+bh
pfWLu9y9nWwz2MSd1ucmQ4V1hR0HIy7PqB8XE5cTO06Ny1ScmI711hSDcsHwZZCw1h3xFJx0nj5X
i3lD7Z4W5nr7ZmqSjwroc3eK2cLcre420OcCNQIx6HOBjTBXmLtgkiIXb//qyVc/2LyB4HOBInz5
rW+89/Lj977xBMwFDsXbN37x8rrx8stvbsxdc4Qmr3+U/qbcyFuGDsouU5dZXrfHZN2hx7TrRe/j
OcihUqqSXTV83IpwzJql6UKH8zfbJFxlNW4qqzShrHOQuqW9zFbpstZ5W/i3v/jafxpf3/q7v9zH
CO2xWdRwXRwqeJt6zzVX35iPG1Z76UOBrM1wq0ZXoFGBGh1CjOepQof70nShw5aa6hNjK/VbusrK
OgdpnaKd2S69BYu+8saf/ron7ovb35c//Obb+xmhqcGv9H5Lar8qTRerk9tO2Oh8t13dtpKruVxl
n8waxWR0jiyHlHeHkEJtQZTv/pLfv2pkb/9e9Z8fv/jG3/9gD3GulG5zS6X7fbdp+mVpZ5bTTmsF
7t6qMfaeOtdZqjT/VJPKx+ifbuk2QeWLn330SFbh/Xv5J1vFu0/t5rfaRAWvUazZOkbLbVrWrUb4
WyOXO0Xc/DbJq24wlarVS4P49u9fxA797g+397k6QCy6ardr0kdejx750TOoLXnbYLQgF1ktbZMJ
l6tUKlyOe5ZF+OB//uHtPr61/731xy8/3MOsmFKl7sYcLuwIUlYNUHpzw0fjrhmrfNZJtbocP/j0
a2+/uAUIL/pA4fHz2Tsff/R8+zjX6KwFEwJS2jGE9hhquNgrM1ZPc9QqvDfnTZ5k1CTbWev0wWKk
dE7KOjf9RdabCHTxm08//c6LPr694tVb//zfHz7fzDk9te/7V3cyTj6q/tsQQ3l3I9XnUk6YJf3Q
ayW/bEd7bWO/SNm60FCbpKocrK6309rhZe4vRxu89sln3/3+8OXNdz7+s+14u1QrlssLKXYYUewf
yWZLE7RZi3/5zi8/FS9evfnVnz8vqU/rOLfczdROCHjTEvOI2wrPP/q/d9569r2XHz3fuGmgzwWq
TsAcxOcCwA5GaAAA5gIAmAsAYC4A5gLApjDXz+0+7PVc7a0wmv9AWi8qSw1LELSbN1wDRcyl/S7v
Q1bfalQAi1WXAwbqRwvMPCycy+ztFvrAY5pgytoOcRUuDYvXAYfzueYlvC56HV4j29q+paHma5eP
L3BlcfDuAawzQgtczOtSsBRO0O7S04qLx4PBx/W5whu0+V/YJ3Q75hI4BZQxt39hRMCnUoBda0wx
tJtcQPc4U7TgOVc2ltdlkfDBtRnbxwzNh1Ag7pF9Lo0DonFJfTcgcIKD7iVG7aKF1WZZGRO6B2Uu
OX9p+N+IECiUpO3lphUGgY3tA2tHCwAA5gIAmAuAuQAA5gIAmAsAKZizYuxoYLn8VeWhV9ORNtVp
ZshNMb6jd5QbWmm6R3kUsquN+jNabKojafhg9/3m4Rc59kdYQPd4AOYuBoW4bCt0yHveNnDVfMF7
0E7ErvFq3UgS63W91is2/dqM32nsiiDugaIFV6FrSnCZO5GuodA1k+n0A5toyNYre6d46Xwz7U30
k3SHIp+efm24/hvagfV8rq/Q1Zu313Q6Cl3DWw4aWleeMwQSbOp4IioX8wlsVxyx9sxjBBDiGE9z
+mqLdHKnNuSHGiDx/pnLeXGAKZalEDMCF5ui/i9YmHVL50BZdkjNLvG8ECDsSuO1ofF1vSwYT4X3
ztxxbMLTZGaRx/ka0fJkIppMXeg5KXC7AA4wQqNpThRQJxTZGrmyaZERCqSTMJXnYmKw5FBzC4nJ
MU4PrMh86X1kUokKiM4FzphSBqNdhLI5DuybuZZCdwwGu81es2trZskb0PQf+dLaLqrsS9ChriUR
FoECo5NW2sywpSd0J4k52u+DXRBld5i1fu7Eha/jsHKtlJaGNRXaYO31c4ufRPDkbXtlWhQ+KQBp
zx7nzh/5V6IGVU+oU4O9xwcUNwCYCwBgLgCAucDJR2gcHPAM87NFoxrvgSl7s6JMVrFR0Q17j9rK
9Li+LBc4G3NT85wLL3zq0X+WttYUJpbpcUOyXOCk0QIbmttejOtIdUVkNV1/Hd3BiKPw7aS80X5R
pqcB7tznOs7L9FWOVFckVtO1eWgpfU09r6mSTYUNQ5wyCl+K9bgD/eF0T8/cCW9HNh3s1XQz2UGh
UCS4MxxoTOlxbcrCa98Lc7n0inNw0//OM2LooBKycLSI8dmdMJemR2wxF8rubxILVjWf+oVPqDJc
TGTg3NFC7u8AyNe+ctKnsvd2KKYArwM/u+Gp0AW4d+baMtmRMVFFrrBFvJac1spkKHy7MRfpuQp3
NYVhEtaLWfL1uCG5L3AaPDncBZ1JQTC3MdbW5x7v6e+834WBuGfDAXULtFomAMwFADAXAMBcAMwF
ADAXAMBcAMwFADAXAMBcAMwFADAXAMBcAABzATAXAMBcAABzATAXAMBcAKiKJ/iZy/nBNP9odrq1
C4HPBRAtAACYCwCIcxHnnudUNF0vuK53gPOM0BAtAIhzAQDMBQCM0IBzAyO0u4CxCrExBgq8dW4i
N8eHe8mxVe6bG4L2+9XCnSNg7l0Ql4xXMgb2pt+lYR6ljFF/2kIa0TcqeCYQ594fh7P4UuhXc15T
M89+zDJ87n1h4bAmetevNFwK2CfEucA8d+rQqOnbDgrsI1oAVvPYVe2DuUC+S9yTfTAXyCcW78g+
nkTcBzN1COnN517f2pi+VevciXlZpglGUnY9g5bdQ2AucEwgWgDAXAAAcwEAzAXOCDxDOz3k9U/+
66SDb55OvY7aOlZY2HQFoiWDueeHOmVhiBbux/dK2flE2W+PX/Se7ou5o891+++2d9w57On87KzC
YvacRPC5901cpW+95nb3ddyj+i3rY9wplJn4tqlC9/PMwvovvj0rEXzuXTvb/jauZIAOyr3Rh7Zu
m2oyMiguTIl0sfC5dx/nJu+9jyRz6CITuWTtwjC3AKSjhSTjbP+oErlU7cIwQgOSfBriWN97Jlyr
FIVut6wwOfNk4HPvJmaQt7u0ebs2dhk38I5tThKLgs7dPuA+cwu77ozYmwopoBUDjglECwCYCwBg
LgCAuQCYCwBgLgCAuQCYCwBgLgCAuQBg4/8ByfhfLvcbm4wAAAAASUVORK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-23" MODIFIED="2008-06-13 16:10:25 +0200" MODIFIED_BY="Nicole Skoetz" NO="23" REF_ID="CMP-001.22" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Polyvalent immunoglobulins vs. placebo / no intervention - HSCT, outcome: 1.22 All-cause Mortality -sensitivity analysis by ITT.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArkAAAGgCAMAAACZsY9IAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-24" MODIFIED="2008-06-25 14:00:25 +0200" MODIFIED_BY="[Empty name]" NO="24" REF_ID="CMP-001.23" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Polyvalent immunoglobulins vs. placebo / no intervention - HSCT, outcome: 1.23 CMV Infections, Interstitial pneumonitis and VOD.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAsAAAAKACAMAAAClqT6xAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-25" MODIFIED="2008-06-13 16:10:34 +0200" MODIFIED_BY="Nicole Skoetz" NO="25" REF_ID="CMP-001.24" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Polyvalent immunoglobulins vs. placebo / no intervention - HSCT, outcome: 1.24 Clinically Documented Infections- sensitivity analysis by randomization generation.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqkAAAFgCAMAAACv9xAUAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-26" MODIFIED="2008-06-13 16:10:37 +0200" MODIFIED_BY="Nicole Skoetz" NO="26" REF_ID="CMP-001.25" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Polyvalent immunoglobulins vs. placebo / no intervention - HSCT, outcome: 1.25 Clinically documented infections - sensitivity analysis by blinding.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqsAAAFgCAMAAACrAsApAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-27" MODIFIED="2008-06-13 16:10:40 +0200" MODIFIED_BY="Nicole Skoetz" NO="27" REF_ID="CMP-001.26" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Polyvalent immunoglobulins vs. placebo / no intervention - HSCT, outcome: 1.26 VOD - sensitivity analysis according to randomization generation.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArAAAAFwCAMAAAB3mritAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-28" MODIFIED="2008-06-13 16:10:44 +0200" MODIFIED_BY="Nicole Skoetz" NO="28" REF_ID="CMP-001.27" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Polyvalent immunoglobulins vs. placebo / no intervention - HSCT, outcome: 1.27 VOD - sensitivity analysis by blinding.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArAAAAFwCAMAAAB3mritAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-29" MODIFIED="2008-06-13 16:10:47 +0200" MODIFIED_BY="Nicole Skoetz" NO="29" REF_ID="CMP-001.28" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Polyvalent immunoglobulins vs. placebo / no intervention - HSCT, outcome: 1.28 IP - sensitivity analysis by randomization generation.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqkAAAGQCAMAAAC6ZQkNAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-30" MODIFIED="2008-06-13 16:10:49 +0200" MODIFIED_BY="Nicole Skoetz" NO="30" REF_ID="CMP-001.29" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Polyvalent immunoglobulins vs. placebo / no intervention - HSCT, outcome: 1.29 IP - sensitivity analysis by blinding.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqkAAAGgCAMAAAC+Hw6gAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-31" MODIFIED="2008-06-13 16:10:52 +0200" MODIFIED_BY="Nicole Skoetz" NO="31" REF_ID="CMP-001.30" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Polyvalent immunoglobulins vs. placebo / no intervention - HSCT, outcome: 1.30 Fungal Infections.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArkAAADQCAMAAAA05Ik9AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-32" MODIFIED="2008-06-16 13:10:16 +0200" MODIFIED_BY="Nicole Skoetz" NO="32" REF_ID="CMP-001.31" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Polyvalent immunoglobulins vs. placebo / no intervention - HSCT, outcome: 1.31 Bacteremia.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArkAAADACAMAAAA3MoumAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-33" MODIFIED="2008-06-16 13:10:16 +0200" MODIFIED_BY="Nicole Skoetz" NO="33" REF_ID="CMP-002.02" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Hyperimmune CMV-IVIG vs. placebo / no intervention - HSCT, outcome: 2.2 All-cause Mortality - 100d (3-4mo).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqkAAACwCAMAAAAbvgePAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-34" MODIFIED="2008-06-16 13:10:14 +0200" MODIFIED_BY="Nicole Skoetz" NO="34" REF_ID="CMP-002.03" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Hyperimmune CMV-IVIG vs. placebo / no intervention - HSCT, outcome: 2.3 CMV infection.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqkAAAEACAMAAACnAx9OAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-35" MODIFIED="2008-06-16 13:10:12 +0200" MODIFIED_BY="Nicole Skoetz" NO="35" REF_ID="CMP-002.04" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Hyperimmune CMV-IVIG vs. placebo / no intervention - HSCT, outcome: 2.4 Interstitial Pneumonitis.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqkAAADQCAMAAAATSgjVAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-36" MODIFIED="2008-06-16 13:10:09 +0200" MODIFIED_BY="Nicole Skoetz" NO="36" REF_ID="CMP-002.05" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Hyperimmune CMV-IVIG vs. placebo / no intervention - HSCT, outcome: 2.5 Infection-related Mortality.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqkAAACwCAMAAAAbvgePAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-37" MODIFIED="2008-06-16 13:10:05 +0200" MODIFIED_BY="Nicole Skoetz" NO="37" REF_ID="CMP-002.06" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Hyperimmune CMV-IVIG vs. placebo / no intervention - HSCT, outcome: 2.6 Acute GVHD.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqkAAADQCAMAAAATSgjVAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-38" MODIFIED="2008-08-11 15:33:48 +0200" MODIFIED_BY="Nicole Skoetz" NO="38" REF_ID="CMP-002.08" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Hyperimmune CMV-IVIG vs. placebo / no intervention - HSCT, outcome: 2.8 Fungal Infections.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqkAAACgCAMAAAAYaAUUAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-39" MODIFIED="2008-08-11 15:33:48 +0200" MODIFIED_BY="Nicole Skoetz" NO="39" REF_ID="CMP-003.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 Polyvalent immunoglobulins or hyperimmune CMV-IVIG vs. placebo / no intervention - HSCT, outcome: 3.1 All-cause Mortality.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqoAAAHwCAMAAABZpr1UAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-40" MODIFIED="2008-08-11 15:33:48 +0200" MODIFIED_BY="Nicole Skoetz" NO="40" REF_ID="CMP-003.02" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 Polyvalent immunoglobulins or hyperimmune CMV-IVIG vs. placebo / no intervention - HSCT, outcome: 3.2 All-cause Mortality - 100d (3-4 mo).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqoAAAGwCAMAAABW/rc4AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-41" MODIFIED="2008-08-11 15:33:48 +0200" MODIFIED_BY="Nicole Skoetz" NO="41" REF_ID="CMP-003.03" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 Polyvalent immunoglobulins or hyperimmune CMV-IVIG vs. placebo / no intervention - HSCT, outcome: 3.3 CMV infection.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqoAAAIACAMAAAB93L7QAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-42" MODIFIED="2008-08-11 15:33:48 +0200" MODIFIED_BY="Nicole Skoetz" NO="42" REF_ID="CMP-003.04" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 Polyvalent immunoglobulins or hyperimmune CMV-IVIG vs. placebo / no intervention - HSCT, outcome: 3.4 Interstitial Pneumonitis.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqoAAAHwCAMAAABZpr1UAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-43" MODIFIED="2008-08-11 15:33:48 +0200" MODIFIED_BY="Nicole Skoetz" NO="43" REF_ID="CMP-003.05" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 Polyvalent immunoglobulins or hyperimmune CMV-IVIG vs. placebo / no intervention - HSCT, outcome: 3.5 Infection-related Mortality.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqoAAAGQCAMAAABRUrIOAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-44" MODIFIED="2008-08-11 15:33:48 +0200" MODIFIED_BY="Nicole Skoetz" NO="44" REF_ID="CMP-003.06" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 Polyvalent immunoglobulins or hyperimmune CMV-IVIG vs. placebo / no intervention - HSCT, outcome: 3.6 Acute GVHD.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqoAAAHwCAMAAABZpr1UAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-45" MODIFIED="2008-08-11 15:33:48 +0200" MODIFIED_BY="Nicole Skoetz" NO="45" REF_ID="CMP-003.07" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 Polyvalent immunoglobulins or hyperimmune CMV-IVIG vs. placebo / no intervention - HSCT, outcome: 3.7 Adverse Events.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArEAAAGQCAMAAACOHMgRAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-46" MODIFIED="2008-08-11 15:33:48 +0200" MODIFIED_BY="Nicole Skoetz" NO="46" REF_ID="CMP-004.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 4 Polyvalent immunoglobulins vs. hyperimmune CMV-IVIG - HSCT, outcome: 4.1 All-cause Mortality.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArkAAACwCAMAAAA8EIZnAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-47" MODIFIED="2008-08-11 15:33:48 +0200" MODIFIED_BY="Nicole Skoetz" NO="47" REF_ID="CMP-004.03" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 4 Polyvalent immunoglobulins vs. hyperimmune CMV-IVIG - HSCT, outcome: 4.3 CMV Infection.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAsAAAACwCAMAAAA2TCg1AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-48" MODIFIED="2008-08-11 15:33:48 +0200" MODIFIED_BY="Nicole Skoetz" NO="48" REF_ID="CMP-004.04" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 4 Polyvalent immunoglobulins vs. hyperimmune CMV-IVIG - HSCT, outcome: 4.4 Interstitial Pneumonitis.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArkAAACgCAMAAAA/xoT8AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-49" MODIFIED="2008-08-11 15:33:48 +0200" MODIFIED_BY="Nicole Skoetz" NO="49" REF_ID="CMP-004.05" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 4 Polyvalent immunoglobulins vs. hyperimmune CMV-IVIG - HSCT, outcome: 4.5 Infection-related Mortality.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArkAAACgCAMAAAA/xoT8AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-50" MODIFIED="2008-08-11 15:33:48 +0200" MODIFIED_BY="Nicole Skoetz" NO="50" REF_ID="CMP-004.06" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 4 Polyvalent immunoglobulins vs. hyperimmune CMV-IVIG - HSCT, outcome: 4.6 Acute GVHD.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArkAAACgCAMAAAA/xoT8AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-51" MODIFIED="2008-08-11 15:33:48 +0200" MODIFIED_BY="Nicole Skoetz" NO="51" REF_ID="CMP-005.02" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 5 Polyvalent immunoglobulins 250mg/kg vs. Polyvalent immunoglobulins or hyperimmune CMV-IVIG 500mg/kg - HSCT, outcome: 5.2 Clinically documented Infection.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvkAAACgCAMAAAChfINcAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-52" MODIFIED="2008-08-11 15:33:48 +0200" MODIFIED_BY="Nicole Skoetz" NO="52" REF_ID="CMP-005.03" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 5 Polyvalent immunoglobulins 250mg/kg vs. Polyvalent immunoglobulins or hyperimmune CMV-IVIG 500mg/kg - HSCT, outcome: 5.3 Microbiologically documented Infection.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvkAAACgCAMAAAChfINcAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-53" MODIFIED="2008-08-11 15:33:48 +0200" MODIFIED_BY="Nicole Skoetz" NO="53" REF_ID="CMP-005.05" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 5 Polyvalent immunoglobulins 250mg/kg vs. Polyvalent immunoglobulins or hyperimmune CMV-IVIG 500mg/kg - HSCT, outcome: 5.5 Interstitial Pneumonitis.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvkAAACgCAMAAAChfINcAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-54" MODIFIED="2008-08-11 15:34:17 +0200" MODIFIED_BY="Nicole Skoetz" NO="54" REF_ID="CMP-005.07" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 5 Polyvalent immunoglobulins 250mg/kg vs. Polyvalent immunoglobulins or hyperimmune CMV-IVIG 500mg/kg - HSCT, outcome: 5.8 Acute GVHD.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAv4AAACwCAMAAABAdpq+AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-55" MODIFIED="2008-08-11 15:33:48 +0200" MODIFIED_BY="Nicole Skoetz" NO="55" REF_ID="CMP-006.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 6 Polyvalent immunoglobulins vs. placebo / no intervention - MM/CLL, outcome: 6.1 All-cause Mortality.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAssAAACgCAMAAADNetFZAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-56" MODIFIED="2008-08-11 15:33:48 +0200" MODIFIED_BY="Nicole Skoetz" NO="56" REF_ID="CMP-006.02" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 6 Polyvalent immunoglobulins vs. placebo / no intervention - MM/CLL, outcome: 6.2 Clinically-documented infections.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAssAAACwCAMAAADOrNPCAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-57" MODIFIED="2008-08-11 15:33:48 +0200" MODIFIED_BY="Nicole Skoetz" NO="57" REF_ID="CMP-006.03" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 6 Polyvalent immunoglobulins vs. placebo / no intervention - MM/CLL, outcome: 6.3 Microbiologically-documented infections.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAssAAACwCAMAAADOrNPCAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-58" MODIFIED="2008-08-11 15:33:48 +0200" MODIFIED_BY="Nicole Skoetz" NO="58" REF_ID="CMP-006.04" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 6 Polyvalent immunoglobulins vs. placebo / no intervention - MM/CLL, outcome: 6.4 Bacteremia.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArkAAACgCAMAAAA/xoT8AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD////AwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID/gAAAAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///80TKWtAAARP0lEQVR42u1dS6glRxmuc+4Za2aSycw4STQZJBu5ElACEcQHogt1
IaUuFNxJslFwIWaZrSsFNxLIZgRBMVkNKNRWSUSMCzeiScw1WYjiZOJc55Fx7lTmPjynu+v96Ko+
1X2q+/5fcqf7dD3+v6u/+uuvqv/0mWEEAIwQc2gCADAXAADmAgBBLArRg1T/UvmROjOZVwnlhdUT
olbVItTKR2iLzD5vX0pTz7SmWSk4jFJlq1mOzaWUNnef2pJNY4pmXB6iqnLmIxu9fUpbm6bqbhQd
ezUXqDBwO0ga41n9S6V1JLzT11cJdVtmGkVcLsqokoi+QAe/e1WuYbOqhEbBzahXkprz4ojrspdE
dGeRvhqMaJZGcVXJLQvZZAuYjKgagaK0gWWyahZnc8XQQ6o+W//rGMSpM7vS79M5TTfbZYUChFLb
haRoo0QtT81ybC4hAYdeJSUpnYQdHUipOr9FoqeRAm6rHDWLmqHFEDeYb9Tgxoo6VkdWaaSM/liK
mvOiHyRFrqUVp9WVGWOHqyofIaXdtxx6inAPilVzXh5fHZ2WCobp6e5Gc9fhzeepMraW3NbM2wJN
IzQKDq9eYWrOyo24IWiaXgFg2msLBAFxAeO0uQDAKGdoAAAwFwDMBQCAuQBAdyz06Xy9q2eE/tDQ
AkBrUG00zABPLY2mFSZupVJFRNaqRrWZ6fxMq57nRnLnXymKqlgrpzp6iIDIW6+jqknrLimWr+HC
kErqGL/Y26tL5OpGNMzLcFG1JUgmEbG1toshic1AWxu+bnfKmWEn9YgSNFw4npWIrKRKZyNaKCtS
N51kTpFVhNTK/sWv0pjeIIvLONyoSE8ZHOrPny6ipVbe24njhhEXZX7XImwhmsJKhCtxdQdrOIgN
To6xS2VrqPm5zbadNv4TQxGqRbsb2/6kCbkQMRlmeCaJ3eS2g2ajIj3rTHX+ti9ZxIuIqdWMH5bN
sGYkcVOj+Sh4+xcR+bgJDef6EEBccbDeCCCrBG0bk1uGGEKIKYwaLZQwohGSXwRNidGh/nvWx1v9
8TafrC1/1xOox8g+GFK6hgvbU0i6u9QS8d6heZs0NYDOaQPWFuG2LB09Ws3jsvs/kd8LNRVV58bV
pDplfjIJDReuIS+Vu73NAixRCb0kguYdRLhqpXXIWWN/aLR+cg7vzUE8NdIhvupZtoZzw8u1bEdo
CUMpQTR7QwLNEL9KoCuUMVquZxGExJtfNUzeegDCpSaEV9ecEd1xIXqQZtZhuVQN57oLJ4O5m76k
WyDDsVFKUDl6UF1NO0PQz3VKalRqJ5aUF/Bzk0W01upqIb3trLGJxnYSswn5NWrcQfaw4sI1jIsV
S5JEaPybPiYMfzMEi+TI0+9NFaLhIoq3SQ+AbvJNAOUgvRmAuPltLgAAAEwTXx9Y3gJsLiAPBmYS
RDkCxglgLgCYCwD0iEeAuYBR4o5OXXU9l4X8bIbVgzOR1aXlIbPTzhIqFHkZzilCu1FPE8kjbwjs
VUPWpDdeXUqRYwuWT4s5qmBoclPv+Z1HrniYW9837kSppuTyj/HnlLvpGI7XTuRlWUWwUC5mHkV7
MOwjrqjJbLyKffKDQ7C4O1ve8g+zsRByH0W+r+ZoplF34bcEvJ2W3ZdhYQUYFslMmDXmN0CbWXXp
x+CwEB9YB7Lg9QTbbZx+3/mCczrW9KvYor8/mu8pG3SLVstTU7XpzlixC82pr7kYKmDAYlltD45J
dIlctxvjkOsi5XVxEbLt1a6z6xtV9OwMv009NtfnmmJnAvaNpsIFY304DH3kTeRRUqdcDU3MSyp+
PbZOFr5jNuGNpfnJKyi3n6s+InEo4Wb7eZBBb9g9gntJhXU/N6qFffLGydrodzLiK93KxY9puAgi
isn40GbIITKbz4Jdqz1o0pZW4m3DBMeMTSz2kSWX6Zm4GOOhLVGSSJbcKdaTNyW4/NxmsNdHf0kJ
ny8giymHrMYsvkrWbYIYp3RMrmXPEdnq80CTycxa1TLVd8ElrxhXrWfExecyiCgryEWPehqDP7Kh
Y97b/dz8e2GA/q0Fm3z7tDMXWLsR4PWeiDPPfsdZfZGAiBsAMBcAAOYC8uJhYC5gjLj0z4nP0Fj7
DrAehGpFlfY5n0tbqGS4g0KtIgK1mm0RE59rizWCfPUwXWZE5CLkC/HV148fembi3gLD0XGdTC0g
yvW6FpOgnVQws4hArWZbKBdYG3GlWDPItwpsMGrU5Lvkmfsel/61Oz3mLkx7ImNxkRGIqwXkjyNy
OVVNnKdW3K/CWiYcIflbDdu3XN0wFy5nb+cUb4HXykP59cB+IyB/faL0zlm8iVodG73RPguOaUmc
ILkucOpGlbKfnz8SZeyhYe3O2ly03v2EIRnf+Xli5g5oDMfn5ulP4qiGSyjYO3dj4jM0FBpOmPNp
KUE5BUU3dFYFdw4Y4GNSWnxuTvWxpodB3b3pM1f7Hg9i4cFFD8ktiL39qNKx1nQvKkVQVMbJEVdb
W6jnrdiys8xrdnVXoaBQ0Y6qsF5q7Vf94xrHt3C5arov0ASXuvynQUNCB5Cyjgi9LeLic/WiHg46
alQo20QiQ3wudOrCZoxdw3Rdqb3Gig29tgC7v8UvdgxZbCprC/6ZGWAoh73jc8EdH/Y4Z2gAADAX
AADmAgDAXAAwFwAA5gIAwFwAMBcAAOYCAMBcAACYCwDmAgDAXAAAmAsA5gIAwFzACHH3sYsXTz38
/vMPnPniA+ceuvTBR2c3725MmRnEjQNacOKPXzk6ODz4wJ/rjxd21eOD6Eu/u312ga6evjmsVlsL
eDIAp4H9+a0/vHDu1Hdeu/Xe8zdu3Hr39tUmYU873rnzl1t3b16//t7/zp/+3hv3n33gpZ8dDm1z
6x9fFd+Dk9+II83F5RVS56iyUrI6F9nqpGXeob9K5wRR9MxZaX2PVqWES5MHpUnUZnLXSp1aE1Na
8ySI8pRsYeLRdMJfP/bowVOXjvYffL17Oz3x9tbsuz+d/xp/dBibu7OzjeiObBJxul2fLq8sm2xn
e3sHrTIu/6Wr0x3RqKukZd7t7Z3NE1fVMxvq6ngj6OQT12UybxK1mVzEFdWZWm/XpkBIq8SIg164
OVthu3qUSfd988X7z5w6jU999vXn9q/ffPl979y5VjkEjX1NPF49+c67v71x/fnnzn/u+ukz9507
e/5Ofju88NgAoprYBpYRVixzdYmKDr95i1sbL5q3VhqwxS09KYPWDjE0RU2HA/vm94/uff43h/+5
uFv7ra/U/uvuhd0sx2uvNPVeuP3w07+cbaETszdO9sbc1Y0TQkkzxBHJTWswXus5DeEtIIKyktdX
Xa7O2qJ1LYZo0tLv8O5HLn/tv2eeunRwuFuN5i8s/3Z7/3vnR417+hBazBezrVfxmhQOroqtKOxJ
qezxKpGQzZtYr4L8kLnWGMtn2Mq4ZgprTaNUaje5R28dVX+beR300exodnh09FYP3oLeCkTv9Oqc
h1b9nxbJ3BhGdayOJvbV1GZq6wfr3tVJ9E2E9i4jhE88+uI3rp/ZP9pH15pBvbe/C/PF0tbO51ff
bUztk70y1+6+FKFyiTpgh9hkI5AgfVN8+3v/+HSzuPX3Lx/uH9x3ePD465WPWg3wOY5PXJ3PH5tf
eVmuMuRycxNfe9LMw0TryAakhNDcM6L+plRrVadMRiNlx5hJYi59+ZKbORxpPGKa5UYrYi05fBPv
vfbVMz949uDwE5Q7E8nHC5/602zrx8/OXnny3t/qSx/v4eFqe2i8NZTmqecFlLe/nELURypnCGI9
t5AJmr60mrlW6iKWJpQoS7FqM/lqVfILrYlenUZUcWoVzsNldHf74Iffvv/gaP9aZIHHd7/w0tb8
Jx/+5L1BHnHC7m9sY5RmeccL0n0BJ+dDOLF/cf/w4Oj2+3b1jd/q+OD86V/MF5c/86FbA7/QPyVu
IdKWEiBuz4twMcTtw3zcffXNZw6r9d/Hr83ne+j8bPHve5t67BBxA8jUzeD9uQAAMBcAzAUAgLkA
ADAXAMwFAEYEZfeX/x4f/6j9FmUIQ/3s1AA/9MXgB11GyFxc+E+fsf4VZBh+/m3M3gJjrPltw+rM
uIxkwjKPM2c/GIBRQNpR2lzd8ODm58EZdtgjfl7lsXICABueoTmoiJnKUDywweq/czDof+O1ucia
tNkfmE3oaQy1GIaOKTC38gGcNhU7zPMABhFIBYjyFizjurKswtdFARs8Vl8BCDFmm8tH/tXcq/pg
OwSGc1DlHGCttXchGNZzR8pcbPyL+f+Kh4BdWaayZAW0nYy3AAAAcwEAYC4AmAsAjBHwDcpjgPBy
YuxiY0u+oYWAzQWMEwuL0PFxua4eYZYRa8NNhtXysDuLktnIUm/lYV/vqyu1F7SYGWvMjM1dnzYI
K6pAKNEImLs2sNO6axE62NqokllE9JlNFos8TEvCyF2EdxjlAlbzYce2maEKw0DcETG3tk7Vg2tC
EsTpygwxYZRWZkuaydUnJvJzNtXn3HpZxhMHiC/KmbxkOGGj1jbKMnQTtXWRaTi6a6RG5xtESAtz
7QhdeVpT2EgQ9g1zSpnhOdyRYGocD45hnQyWUAphD9Wc9eofV3VJ4lraWPu/U+DydGZoHuayuFtX
7Z0tCDvHV6wfPeSoTKAZPCDE4eAN4Yi+wNycNrrZitq1DnXgBoNN4dK9BT6PUb3IOKvOctmGbt+v
wLmtE9cBu+edgFL9XNzOCbzWcMRMmsS7QLh7Fp+gUKkkjxpQwNpCYHGMuV1MrDiS6qmLL9jpK+Cw
dY8geDdfC098hoazDFi4LCFO5moRusIZVF0/wxlVPomVWzPBbyb5OquUIFdRtRBht67Yl2B8U0MK
CvBT14H7vKOnM3O9R8NeSW8tzfzkCvb52LhnZ/3KaryCTru/a80yMwnpLO04fk1ZW9vG9tVwm6il
/ZmC1I9tc1cmJpbrtdTk3V/G2CDEjR8KWS8dYsIc7j6Wh9m9vq/gJC5O9HO7K5GJGjh7Rpn7+LJ3
zTv3jvqZWtRRP0aZmAs4TsbYQdCOg1b2+iFWDDCYxc5aPzAXMIT7n79+YC4gnlisoPpn2CzmDp5K
W9O0NkyZtSqqxCq4pNoriMqGRVs8rhpjCxu3sm2YEQ0qrrLwUC1Ls/QNSvGMcbSezprD67nMWwyn
djGGQ0xGVrqVaKwgMmWrg+GYMkqMG2B68L4/V32NrvqKXMbjtF1v07Xfo8srURN5vSyiu3bhHXD1
OMD7/lztKwRGqC4KvE1XJ44W6avG86pRsiG3QX4diLloGSzTeD9A5OPC3JZVCj10Futv040kiTM8
17vEzVwubWhLASu+EeAYMbcxZPFvh2P+2WHEGx+DNtEdCBkVl9QarAOYGnNxwNq1mFBmficx4a3m
wdha5ovGCJQBL6ECWf0T/3PSzl+eDv0ctZaWKKxdAa/kRdzigJezzDKKLGhT7aUKhkNEk54Ew7Hk
bI1rOmagkxQ2d7GxigZrDoKJWAsSUz8p59gIJNMKyYqxXKRgVfQZc6rATKkoEBpmleEXgMCN9SKk
tomkORcf5JX6g3qhKVX9V10VF/mV2s52Euarz8gUYXOx4S0g4025yP1VSKydOl66q79kF6vTuVDo
kfZiXtzmBlhlgLLmsMuHXvW8/iiu0OZMO4iLiKqZq1PqGs8jhTUf7Pq0TNE2t3BAPG4nY9sM45Q4
6EDNgd51Vp3SVs8gWRhFYbHdVsXKpG6Puafs5wbH3iXJDLqQQCmSW1imtQXAZL2FION0+0gDpWhu
YXlmaIDJkpf7sbb1DJhWghLNbpow0vFmwOYeG5+BVKO0Olwrl5QBvGabkUWjoDHaO8xnrLDVRU99
bS4FvPkZME6AtwAA5gIAwFwAAJgLAOYCAMBcAACYCwDmAgDAXAAAmAsA6Pg/juYnkHOT8/0AAAAA
SUVORK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-59" MODIFIED="2008-08-11 15:33:48 +0200" MODIFIED_BY="Nicole Skoetz" NO="59" REF_ID="CMP-006.06" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 6 Polyvalent immunoglobulins vs. placebo / no intervention - MM/CLL, outcome: 6.6 Adverse Events.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAssAAACwCAMAAADOrNPCAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-60" MODIFIED="2008-08-11 15:33:48 +0200" MODIFIED_BY="Nicole Skoetz" NO="60" REF_ID="CMP-006.07" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 6 Polyvalent immunoglobulins vs. placebo / no intervention - MM/CLL, outcome: 6.7 Adverse Events requiring discontinuation.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAssAAACwCAMAAADOrNPCAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-61" MODIFIED="2008-08-11 15:33:48 +0200" MODIFIED_BY="Nicole Skoetz" NO="61" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Funnel plot: all cause mortality, IVIG vs. no treatment, HSCT</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAAAAAFUAAKoAAP8AJAAA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==
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-05-27 13:27:38 +0200" MODIFIED_BY="Nicole Skoetz">
<APPENDIX ID="APP-01" MODIFIED="2008-05-27 13:27:38 +0200" MODIFIED_BY="Nicole Skoetz" NO="1">
<TITLE MODIFIED="2008-05-27 13:27:35 +0200" MODIFIED_BY="Nicole Skoetz">Search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-05-27 13:27:38 +0200" MODIFIED_BY="Nicole Skoetz">
<P>The following search strategy was modified to search the different databases:</P>
<P>Part 1<BR/>"Immunoglobulins"[MeSH] OR "Immunoglobulins, Intravenous"[MeSH] OR "gamma-Globulins"[MeSH] OR immunoglobulin* OR gammaglobulin* OR gamma globulin* OR immune globulin* OR immune globulin, intravenous OR intravenous immune globulin OR omrigam OR sandoglobulin* OR ivig OR hyperimmune* OR Alphaglobin OR Endobulin OR Gamimune OR Gamimmune OR Gamimune N OR Gamimmune N OR Intraglobin F OR Venimmune OR Venoglobulin-I OR Venoglobulin I OR VenoglobulinI OR Venoglobulin OR Iveegam OR Intraglobin OR Gammagard OR Gammonativ OR Globulin-N OR Globulin N OR GlobulinN OR (cytomegalovirus AND "Antibodies, Monoclonal"[MESH])</P>
<P>Part 2:<BR/>(randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized controlled trials [mh] OR random allocation [mh] OR double-blind method [mh] OR single-blind method [mh] OR random* OR placebo) NOT (animals [mh] NOT humans [mh])</P>
<P>Part 3:<BR/>hematologic neoplasms [mh] OR (hematological OR hematologic) malignan*[tw] OR (hematological OR hematologic) neoplas*[tw] OR myeloma OR leukemia OR lymphoma</P>
<P>Part 4:<BR/>autograft* OR autotransplant* OR allograft* or allotransplant* OR homograft* OR homotransplant* OR bone marrow transplant* OR stem cell transplant* OR peripheral blood stem cell transplant* OR ((autologous OR allogeneic OR allogenic) AND (transplant* OR graft*)).</P>
<P>(Part 3 OR part 4) AND part 1 AND part 2</P>
<P>We did not limit the search strategy for prophylaxis and by outcome to enhance the sensitivity of our search.</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>